

2021

# Prescription Drug Guide

## NC State Health Plan Formulary

List of covered drugs

PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN.

42

This formulary was updated on 09/18/2020. For more recent information or other questions, please contact the NC State Health Plan Humana Customer Care Team at 1-888-700-2263 or, for TTY users, 711, or visit [our.humana.com/ncshp](http://our.humana.com/ncshp).

**Humana**<sup>®</sup>



*Dale R. Folwell, CPA*   
STATE TREASURER OF NORTH CAROLINA  
DALE R. FOLWELL, CPA



## Welcome to Humana Group Medicare Plan!

When this drug list (formulary) refers to "we," "us", or "our," it means Humana. When it refers to "plan" or "our plan," it means Humana Group Medicare Plan. This document includes a list of the drugs (formulary) for our plan which is current as of January 1, 2021. For an updated formulary, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages. You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network, and/or copayments/coinsurance may change on January 1 of each year, and from time to time during the year.

### What is the formulary?

A formulary is the entire list of covered drugs or medicines selected by Humana Group Medicare Plan. The terms formulary and Drug List may be used interchangeably throughout communications regarding changes to your pharmacy benefits. Humana Group Medicare Plan worked with a team of doctors and pharmacists to make a formulary that represents the prescription drugs we think you need for a quality treatment program. Humana Group Medicare Plan will generally cover the drugs listed in the formulary as long as the drug is medically necessary, the prescription is filled at a Humana Group Medicare Plan network pharmacy, and other plan rules are followed. For more information on how to fill your medicines, please review your Evidence of Coverage.

### Can the formulary change?

Most changes in drug coverage happen on January 1, but we may add or remove drugs on the Drug List during the year, move them to different cost sharing tiers, or add new restrictions. We must follow Medicare rules in making these changes.

**Changes that can affect you this year:** In the below cases, you will be affected by coverage changes during the year:

- **New generic drugs.** We may immediately remove a brand name drug on our Drug List if we are replacing it with a new generic drug that will appear on the same or lower cost sharing tier and with the same or fewer restrictions. Also, when adding the new generic drug, we may decide to keep the brand name drug on our Drug List, but immediately move it to a different cost sharing tier or add new restrictions. If you are currently taking that brand name drug, we may not tell you in advance before we make that change, but we will later provide you with information about the specific change(s) we have made.
  - If we make such a change, you or your prescriber can ask us to make an exception and continue to cover the brand name drug for you. The notice we provide you will also include information on how to request an exception, and you can also find information in the section below entitled "How do I request an exception to the Formulary?"
- **Drugs removed from the market.** If the Food and Drug Administration deems a drug on our formulary to be unsafe or the drug's manufacturer removes the drug from the market, we will immediately remove the drug from our formulary and provide notice to members who take the drug.
- **Other changes.** We may make other changes that affect members currently taking a drug. For instance, we may add a generic drug that is not new to market to replace a brand name drug currently on the formulary or add new restrictions to the brand name drug or move it to a different cost sharing tier or both. Or we may make changes based on new clinical guidelines. If we remove drugs from our formulary, or add prior authorization, quantity limits and/or step therapy restrictions on a drug or move a drug to a higher cost sharing tier, we must notify affected members of the change at least 30 days before the change becomes effective, or at the time the member requests a refill of the drug, at which time the member will receive a 30-day supply of the drug.

We'll notify members who are affected by the following changes to the formulary:

- When a drug is removed from the formulary
- When prior authorization, quantity limits, or step-therapy restrictions are added to a drug or made more restrictive
- When a drug is moved to a higher cost sharing tier

If we make these other changes, you or your prescriber can ask us to make an exception and continue to cover the brand name drug for you. The notice we provide you will also include information on how to request an exception, and you can also find information in the section below entitled "How do I request an exception to the Formulary?"

**Changes that will not affect you if you are currently taking the drug.** Generally, if you are taking a drug on our 2021 formulary that was covered at the beginning of the year, we will not discontinue or reduce coverage of the drug during the 2021 coverage year except as described above. This means these drugs will remain available at the same cost share and with no new restrictions for those members taking them for the remainder of the coverage year. You will not get direct notice this year about changes that do not affect you. However, on January 1 of the next year, such changes would affect you, and it is important to check the Drug List for the new benefit year for any changes to drugs.

### **What if you're affected by a Drug List change?**

We'll notify you by mail at least 30 days before one of these changes happens or we will provide a 30-day refill of the affected medicine with notice of the change.

The enclosed formulary is current as of January 1, 2021. We'll update the printed formularies each month and they'll be available on [our.humana.com/ncshp](http://our.humana.com/ncshp).

### **How do I use the formulary?**

There are two ways to find your drug in the formulary:

#### **Medical condition**

The formulary starts on page 10. We've put the drugs into groups depending on the type of medical conditions that they're used to treat. For example, drugs that treat a heart condition are listed under the category "Cardiovascular Agents." If you know what medical condition your drug is used for, look for the category name in the list that begins on page 10. Then look under the category name for your drug. The formulary also lists the Tier and Utilization Management Requirements for each drug (see page 5 for more information on Utilization Management Requirements).

#### **Alphabetical listing**

If you're not sure about your drug's group, you should look for your drug in the Index that begins on page 181. The Index is an alphabetical list of all of the drugs included in this document. Both brand-name drugs and generic drugs are listed. Look in the Index to search for your drug. Next to each drug, you'll see the page number where you can find coverage information. Turn to the page listed in the Index and find the name of the drug in the first column of the list.

Prescription drugs are grouped into one of four tiers.

Humana Group Medicare Plan covers both brand-name drugs and generic drugs. A generic drug is approved by the FDA as having the same active ingredient as the brand-name drug. Generally, generic drugs cost less than brand-name drugs.

- **Tier 1 - Generic or Preferred Generic:** Generic or brand drugs that are available at the lowest cost share for the plan
- **Tier 2 - Preferred Brand:** Generic or brand drugs that the plan offers at a higher cost to you than Tier 1 Generic or Preferred Generic, and at a lower cost to you than Tier 3 Non-Preferred Drug
- **Tier 3 - Non-Preferred Drug:** Generic or brand drugs that the plan offers at a higher cost to you than Tier 2 Preferred Brand drug
- **Tier 4 - Specialty Tier:** Some injectables and other high-cost drugs

### **How much will I pay for covered drugs?**

Humana Group Medicare Plan pays part of the costs for your covered drugs and you pay part of the costs, too.

## The amount of money you pay depends on:

- Which tier your drug is on
- Whether you fill your prescription at a network pharmacy
- Your current drug payment stage - please read your Evidence of Coverage (EOC) for more information

**If you qualified for extra help with your drug costs, your costs may be different from those described above. Please refer to your Evidence of Coverage (EOC) or call to find out what your costs are.**

## Are there any restrictions on my coverage?

Some covered drugs may have additional requirements or limits on coverage. These are called Utilization Management Requirements. These requirements and limits may include:

- **Prior Authorization (PA):** Humana Group Medicare Plan requires you to get prior authorization for certain drugs to be covered under your plan. This means that you'll need to get approval from Humana Group Medicare Plan before you fill your prescriptions. If you don't get approval, Humana Group Medicare Plan may not cover the drug.
- **Quantity Limits (QL):** For some drugs, Humana Group Medicare Plan limits the amount of the drug that is covered. Humana Group Medicare Plan might limit how many refills you can get or how much of a drug you can get each time you fill your prescription. For example, if it's normally considered safe to take only one pill per day for a certain drug, we may limit coverage for your prescription to no more than one pill per day. Some drugs are limited to a 30-day supply regardless of tier placement.
- **Step Therapy (ST):** In some cases, Humana Group Medicare Plan requires that you first try certain drugs to treat your medical condition before coverage is available for another drug for that condition. For example, if Drug A and Drug B both treat your medical condition, Humana Group Medicare Plan may not cover Drug B unless you try Drug A first. If Drug A does not work for you, Humana Group Medicare Plan will then cover Drug B.
- **Part B versus Part D (B vs D):** Some drugs may be covered under Medicare Part B or Part D depending upon the circumstances. Information may need to be submitted to Humana Group Medicare Plan that describes the use and the place where you receive and take the drug so a determination can be made.

For drugs that need prior authorization or step therapy, or drugs that fall outside of quantity limits, your health care provider can fax information about your condition and need for those drugs to Humana Group Medicare Plan at **1-888-700-2263**. Representatives are available Monday - Friday, 8 a.m. - 9 p.m. Eastern Time.

You can find out if your drug has any additional requirements or limits by looking in the formulary that begins on page 10.

You can also visit [our.humana.com/ncshp](https://our.humana.com/ncshp) to get more information about the restrictions applied to specific covered drugs.

You can ask Humana Group Medicare Plan to make an exception to these restrictions or limits. See the section "**How do I request an exception to the formulary?**" on page 6 for information about how to request an exception.

## What if my drug isn't on the formulary?

If your drug isn't included in this list of covered drugs, visit [our.humana.com/ncshp](https://our.humana.com/ncshp) to see if your plan covers your drug. You can also call and ask if your drug is covered.

If Humana Group Medicare Plan doesn't cover your drug, you have two options:

- You can ask for a list of similar drugs that Humana Group Medicare Plan covers. Show the list to your doctor and ask him or her to prescribe a similar drug that is covered by Humana Group Medicare Plan.
- You can ask Humana Group Medicare Plan to make an exception and cover your drug. See below for information about how to request an exception.

Talk to your health care provider to decide if you should switch to another drug that is covered or if you should request a formulary exception so that it can be considered for coverage.

## How do I request an exception to the formulary?

You can ask Humana Group Medicare Plan to make an exception to the coverage rules. There are several types of exceptions that you can ask to be made.

- **Formulary exception:** You can request that your drug be covered if it's not on the formulary. If approved, this drug will be covered at a pre-determined cost sharing level, and you would not be able to ask us to provide the drug at a lower cost sharing level.
- **Utilization restriction exception:** You can request coverage restrictions or limits not be applied to your drug. For example, if your drug has a quantity limit, you can ask for the limit not to be applied and to cover more doses of the drug.
- **Tier exception:** You can request a higher level of coverage for your drug. For example, if your drug is usually considered a non-preferred drug, you can request it to be covered as a preferred drug instead. This would lower how much money you must pay for your drug. Please remember a higher level of coverage cannot be requested for the drug if approval was granted to cover a drug that was not on the formulary.

Generally, Humana Group Medicare Plan will only approve your request for an exception if the alternative drugs included on the plan's formulary, the lower cost sharing drug, or other restrictions wouldn't be as effective in treating your health condition and/or would cause adverse medical effects.

You should contact us to ask for an initial coverage decision for a formulary, tier, or utilization restriction exception.

**When you ask for an exception, you should submit a statement from your health care provider that supports your request. This is called a supporting statement.**

Generally, we must make the decision within 72 hours of receiving your health care provider's supporting statement. You can request a fast, or expedited, exception if you or your health care provider thinks your health would seriously suffer if you wait as long as 72 hours for a decision. If your request to expedite is granted, we must give you a decision no later than 24 hours after we get your health care provider's supporting statement.

## Will my plan cover my drugs if they are not on the formulary?

You may take drugs that your plan doesn't cover. Or, you may talk to your provider about taking a different drug that your plan covers, but that drug might have a Utilization Management Requirement, such as a Prior Authorization or Step Therapy, that keeps you from getting the drug right away. In certain cases, we may cover as much as a 30-day supply of your drug during the first 90 days you're a member of the plan.

Here is what we'll do for each of your current Part D drugs that aren't on the formulary, or if you have limited ability to get your drugs:

- We'll temporarily cover a 30-day supply of your drug unless you have a prescription written for fewer days (in which case we will allow multiple fills to provide up to a total of 30 days of a drug) when you go to a pharmacy.
- There will be no coverage for the drugs after your first 30-day supply, even if you've been a member of the plan for less than 90 days, unless a formulary exception has been approved.

If you're a resident of a long-term care facility and you take Part D drugs that aren't on the formulary, we'll cover a 31-day supply unless you have a prescription written for fewer days (in which case we will allow multiple fills to provide up to a total of 31 days of a drug) during the first 90 days you're a member of our plan. We'll cover a 31-day emergency supply of your drug unless you have a prescription for fewer days (in which we will allow multiple fills to provide up to a total of 31 days of a drug) while you request a formulary exception if:

- You need a drug that's not on the formulary *or*
- You have limited ability to get your drugs *and*
- You're past the first 90 days of membership in the plan

Throughout the plan year, your treatment setting (the place where you receive and take your medicine) may change. These changes include:

- Members who are discharged from a hospital or skilled-nursing facility to a home setting
- Members who are admitted to a hospital or skilled-nursing facility from a home setting

- Members who transfer from one skilled-nursing facility to another and use a different pharmacy
- Members who end their skilled-nursing facility Medicare Part A stay (where payments include all pharmacy charges) and who now need to use their Part D plan benefit
- Members who give up Hospice Status and go back to standard Medicare Part A and B coverage
- Members discharged from chronic psychiatric hospitals with highly individualized drug regimens

For these changes in treatment settings, Humana Group Medicare Plan will cover as much as a 31-day temporary supply of a Part D-covered drug when you fill your prescription at a pharmacy. If you change treatment settings multiple times within the same month, you may have to request an exception or prior authorization and receive approval for continued coverage of your drug. Humana Group Medicare Plan will review requests for continuation of therapy on a case-by-case basis understanding when you're on a stabilized drug regimen that, if changed, is known to have risks.

### **Transition extension**

Humana Group Medicare Plan will consider on a case-by-case basis an extension of the transition period if your exception request or appeal hasn't been processed by the end of your initial transition period. We'll continue to provide necessary drugs to you if your transition period is extended.

A Transition Policy is available on [our.humana.com/ncshp](https://www.humana.com/ncshp) in the same area where the Prescription Drug Guides are displayed.

### **Humana Pharmacy® makes it easy to manage your prescriptions with mail delivery solutions**

You may be able to fill your medicines through Humana Pharmacy – Humana's mail-delivery pharmacy. You can have your maintenance medicines, specialty medicines, or supplies mailed to a place that's most convenient for you. You should get your new prescription by mail in 7 – 10 days after Humana Pharmacy has received your prescription and all the necessary information. Refills should arrive within 5 – 7 days. To get started or learn more, visit [hprxweb.com](https://hprxweb.com). You can also call Humana Pharmacy at 1-855-899-3134 (TTY: 711) Monday – Friday, 8 a.m. to 11 p.m., and Saturday, 8 a.m. to 6:30 p.m., Eastern time.

Other pharmacies are available in our network.

## For More Information

For more detailed information about your Humana Group Medicare Plan prescription drug coverage, please read your Evidence of Coverage (EOC) and other plan materials.

If you have questions about Humana, please visit our website at [our.humana.com/ncshp](https://our.humana.com/ncshp). The Drug List Search tool lets you search for your drug by name or drug type.

If you have general questions about Medicare prescription drug coverage, please call Medicare at **1-800-MEDICARE (1-800-633-4227)** 24 hours a day, seven days a week. TTY users should call **1-877-486-2048**. You can also visit [www.medicare.gov](https://www.medicare.gov).



# Humana Group Medicare Plan Formulary

The formulary that begins on the next page provides coverage information about the drugs covered by Humana Group Medicare Plan. If you have trouble finding your drug in the list, turn to the Index that begins on page 181.

Your plan has additional coverage of some drugs. These drugs aren't normally covered under Medicare Part D and aren't subject to the Medicare appeals process. These drugs are listed separately on page 177.

## How to read your formulary

The first column of the chart lists categories of medical conditions in alphabetical order. The drug names are then listed in alphabetical order within each category. Brand-name drugs are CAPITALIZED and generic drugs are listed in lower-case italics. Next to the drug name you may see an indicator to tell you about additional coverage information for that drug. You might see the following indicators:

**DL** - Dispensing Limit; Drugs that may be limited to a 30 day supply, regardless of tier placement.

**MO** - Drugs that are typically available through mail-order. Please contact your mail-order pharmacy to make sure your drug is available.

**LA** - The health plan has authorized certain pharmacies to dispense this medicine, as it requires extra handling, doctor coordination or patient education. Please call the number on the back of your ID card for additional information.

The second column lists the tier of the drug. See page 4 for more details on the drug tiers in your plan.

The third column shows the Utilization Management Requirements for the drug. Humana Group Medicare Plan may have special requirements for covering that drug. If the column is blank, then there are no utilization requirements for that drug. The supply for each drug is based on benefits and whether your health care provider prescribes a supply for 30, 60, or 90 days. The amount of any quantity limits will also be in this column (Example: "QL - 30 for 30 days" means you can only get 30 doses every 30 days). See page 5 for more information about these requirements.

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<b>Analgesics</b>		
ABSTRAL 100 MCG, 200 MCG, 300 MCG, 400 MCG, 600 MCG, 800 MCG TAB SUBLINGUAL <b>DL</b>	4	PA,QL (128 per 30 days)
acetamin-caf-dihydrocodein 325 <b>DL</b>	1	QL (300 per 30 days)
acetamn-caf-dihydrcodein 320.5 <b>DL</b>	1	QL (300 per 30 days)
acetamin-codein 300-30 mg/12.5; acetaminop-codeine 120-12 mg/5 <b>DL</b>	1	QL (2700 per 30 days)
acetaminophen-cod #2 tablet <b>DL</b>	1	QL (390 per 30 days)
acetaminophen-cod #3 tablet <b>DL</b>	1	QL (360 per 30 days)
acetaminophen-cod #4 tablet <b>DL</b>	1	QL (180 per 30 days)
ACTIQ 1,200 MCG, 1,600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG LOZENGE ON A HANDLE <b>DL</b>	4	PA,QL (120 per 30 days)
ALLZITAL 25 MG-325 MG TABLET <b>DL</b>	4	QL (360 per 30 days)
ANAPROX DS 550 MG TABLET <b>MO</b>	3	
ARTHROTEC 50 MG-200 MCG TABLET,FILM-COATED <b>MO</b>	3	PA
ARTHROTEC 75 75 MG-200 MCG TABLET,FILM-COATED <b>MO</b>	3	PA
ARYMO ER 15 MG, 30 MG, 60 MG TABLET,CRUSH RESISTANT, EXTENDED RELEASE <b>DL</b>	4	ST,QL (90 per 30 days)
ascomp with codeine 30 mg-50 mg-325 mg-40 mg capsule <b>DL</b>	1	QL (360 per 30 days)
BELBUCA 150 MCG, 300 MCG, 450 MCG, 600 MCG, 75 MCG, 750 MCG, 900 MCG BUCCAL FILM <b>DL</b>	3	QL (60 per 30 days)
bupap 50 mg-300 mg tablet <b>MO</b>	1	QL (180 per 30 days)
BUPRENEX 0.3 MG/ML INJECTION SOLUTION <b>DL</b>	4	QL (240 per 30 days)
buprenorphine 10 mcg/hr patch; buprenorphine 15 mcg/hr patch; buprenorphine 20 mcg/hr patch; buprenorphine 5 mcg/hr patch; buprenorphine 7.5 mcg/hr patch <b>DL</b>	1	QL (4 per 28 days)
buprenorphine 0.3 mg/ml crpjt <b>DL</b>	1	QL (240 per 30 days)
butalbital compound with codeine 30 mg-50 mg-325 mg-40 mg capsule <b>DL</b>	1	QL (360 per 30 days)
butalb-acetaminoph-caff-codein <b>DL</b>	1	QL (180 per 30 days)
butalb-caff-acetaminoph-codein <b>DL</b>	1	QL (360 per 30 days)
butalbital-acetaminophn 25-325 <b>DL</b>	4	QL (360 per 30 days)
butalbital-acetaminophn 50-300 <b>DL</b>	4	QL (180 per 30 days)
butalbital-acetaminophn 50-300; butalbital-acetaminophn 50-325 <b>MO</b>	1	QL (180 per 30 days)
butalb-acetamin-caff 50-300-40; butalb-acetamin-caff 50-325-40 <b>MO</b>	1	QL (180 per 30 days)
butalb-acetamin-caff 50-325-40 <b>MO</b>	1	QL (180 per 30 days)
butalb-aspirin-caffe 50-325-40 <b>MO</b>	1	QL (180 per 30 days)
butalbital-asa-caffeine cap <b>MO</b>	1	QL (180 per 30 days)
butorphanol 1 mg/ml vial <b>DL</b>	1	QL (960 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>butorphanol 10 mg/ml spray</i> <b>DL</b>	1	QL (5 per 28 days)
<i>butorphanol 2 mg/ml vial</i> <b>DL</b>	1	QL (480 per 30 days)
BUTRANS 10 MCG/HOUR, 15 MCG/HOUR, 20 MCG/HOUR, 5 MCG/HOUR, 7.5 MCG/HOUR TRANSDERMAL PATCH <b>DL</b>	3	PA,QL (4 per 28 days)
CALDOLOR 800 MG/200 ML (4 MG/ML) INTRAVENOUS PIGGYBACK <b>MO</b>	3	B vs D
CALDOLOR 800 MG/8 ML (100 MG/ML) INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D
CAMBIA 50 MG ORAL POWDER PACKET <b>DL</b>	4	ST,QL (9 per 30 days)
CELEBREX 100 MG, 200 MG, 400 MG, 50 MG CAPSULE <b>MO</b>	3	PA,QL (60 per 30 days)
<i>celecoxib 100 mg, 200 mg, 400 mg, 50 mg capsule</i> <b>MO</b>	1	QL (60 per 30 days)
<i>codeine sulfate 15 mg, 30 mg tablet</i> <b>DL</b>	1	QL (360 per 30 days)
<i>codeine sulfate 60 mg tablet</i> <b>DL</b>	1	QL (180 per 30 days)
<i>asa-butalb-caff-cod #3 capsule</i> <b>DL</b>	1	QL (360 per 30 days)
CONZIP 100 MG, 200 MG, 300 MG CAPSULE, EXTENDED RELEASE; CONZIP 100 MG, 200 MG, 300 MG CAPSULE, EXTENDED RELEASE <b>DL</b>	3	ST,QL (30 per 30 days)
DAYPRO 600 MG TABLET <b>MO</b>	3	
DEMEROL 100 MG TABLET <b>DL</b>	3	QL (360 per 30 days)
DEMEROL 100 MG/ML INJECTION SOLUTION <b>DL</b>	3	B vs D,QL (360 per 30 days)
DEMEROL 50 MG/ML INJECTION SOLUTION <b>DL</b>	3	B vs D,QL (720 per 30 days)
DEMEROL (PF) 100 MG/2 ML, 100 MG/ML INJECTION SOLUTION; DEMEROL 100 MG/2 ML, 100 MG/ML AMPUL <b>DL</b>	3	B vs D,QL (360 per 30 days)
DEMEROL (PF) 100 MG/ML INJECTION SYRINGE <b>DL</b>	3	B vs D,QL (360 per 30 days)
DEMEROL (PF) 25 MG/ML INJECTION SYRINGE <b>DL</b>	3	B vs D,QL (1440 per 30 days)
DEMEROL (PF) 50 MG/ML INJECTION SYRINGE <b>DL</b>	3	B vs D,QL (720 per 30 days)
DEMEROL (PF) 75 MG/ML INJECTION SYRINGE <b>DL</b>	3	B vs D,QL (480 per 30 days)
DEMEROL 25 MG/0.5 ML, 50 MG/ML, 75 MG/1.5 ML AMPUL <b>DL</b>	3	B vs D,QL (720 per 30 days)
<i>diclofenac epolamine 1.3% ptch</i> <b>MO</b>	1	PA,QL (60 per 30 days)
<i>diclofenac pot 50 mg tablet</i> <b>MO</b>	1	
<i>diclofenac 1.5% topical soln</i> <b>MO</b>	1	PA,QL (300 per 30 days)
<i>diclofenac sod ec 25 mg, 50 mg, 75 mg tab</i> <b>MO</b>	1	
<i>diclofenac sod er 100 mg tab</i> <b>MO</b>	1	
<i>diclofenac sodium 1% gel</i> <b>MO</b>	1	
<i>diclofenac-misoprost 50-0.2 tb; diclofenac-misoprost 75-0.2 tb</i> <b>MO</b>	1	
<i>diflunisal 500 mg tablet</i> <b>MO</b>	1	
DILAUDID 1 MG/ML ORAL LIQUID <b>DL</b>	3	PA,QL (2400 per 30 days)
DILAUDID 2 MG, 4 MG TABLET <b>DL</b>	4	PA,QL (360 per 30 days)
DILAUDID 8 MG TABLET <b>DL</b>	4	PA,QL (240 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
DOLOPHINE 10 MG TABLET <b>DL</b>	3	QL (240 per 30 days)
DOLOPHINE 5 MG TABLET <b>DL</b>	3	QL (480 per 30 days)
DUEXIS 800 MG-26.6 MG TABLET <b>DL</b>	4	PA,QL (90 per 30 days)
DURAGESIC 100 MCG/HR, 12 MCG/HR, 25 MCG/HR, 50 MCG/HR, 75 MCG/HR TRANSDERMAL PATCH <b>DL</b>	4	PA,QL (20 per 30 days)
DURAMORPH (PF) 0.5 MG/ML INJECTION SOLUTION <b>DL</b>	3	B vs D,QL (7200 per 30 days)
DURAMORPH (PF) 1 MG/ML INJECTION SOLUTION <b>DL</b>	3	B vs D,QL (3600 per 30 days)
<i>divorah 325 mg-30 mg-16 mg tablet</i> <b>DL</b>	1	QL (300 per 30 days)
EC-NAPROSYN 375 MG, 500 MG TABLET,DELAYED RELEASE <b>MO</b>	3	PA
<i>ec-naproxen 375 mg tablet,delayered release</i> <b>MO</b>	3	PA
<i>ec-naproxen 500 mg tablet,delayered release</i> <b>MO</b>	1	
EMBEDA ER 100-4 MG, 20-0.8 MG, 30-1.2 MG, 50-2 MG, 60-2.4 MG, 80-3.2 MG CAPSULE <b>DL</b>	3	ST,QL (60 per 30 days)
<i>endocet 10 mg-325 mg tablet; endocet 2.5 mg-325 mg tablet; endocet 5 mg-325 mg tablet; endocet 7.5 mg-325 mg tablet</i> <b>DL</b>	1	QL (360 per 30 days)
ESGIC 50 MG-325 MG-40 MG CAPSULE <b>MO</b>	1	QL (180 per 30 days)
ESGIC 50 MG-325 MG-40 MG TABLET <b>MO</b>	1	QL (180 per 30 days)
<i>etodolac 200 mg, 300 mg capsule</i> <b>MO</b>	1	
<i>etodolac 400 mg, 500 mg tablet</i> <b>MO</b>	1	
<i>etodolac er 400 mg, 500 mg, 600 mg tablet</i> <b>MO</b>	1	
EXALGO ER 12 MG TABLET <b>DL</b>	4	ST,QL (180 per 30 days)
EXALGO ER 16 MG TABLET <b>DL</b>	4	ST,QL (120 per 30 days)
EXALGO ER 32 MG TABLET <b>DL</b>	4	ST,QL (60 per 30 days)
EXALGO ER 8 MG TABLET <b>DL</b>	4	ST,QL (240 per 30 days)
FELDENE 10 MG, 20 MG CAPSULE <b>MO</b>	3	
<i>fenoprofen 200 mg, 400 mg capsule</i> <b>MO</b>	1	
<i>fenoprofen 600 mg tablet</i> <b>MO</b>	1	
<i>fentanyl 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 37.5 mcg/hour, 50 mcg/hr, 62.5 mcg/hour, 75 mcg/hr, 87.5 mcg/hour patch; fentanyl 37.5 mcg/hr patch; fentanyl 62.5 mcg/hr patch; fentanyl 87.5 mcg/hr patch</i> <b>DL</b>	1	QL (20 per 30 days)
<i>fentanyl cit 100 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg buccal tb</i> <b>DL</b>	4	PA,QL (120 per 30 days)
<i>fentanyl cit otfc 1,200 mcg, 1,600 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg; fentanyl citrate otfc 1,200 mcg, 1,600 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg</i> <b>DL</b>	4	PA,QL (120 per 30 days)
<i>fentanyl 100 mcg/2 ml ampul</i> <b>DL</b>	1	B vs D,QL (720 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
FENTORA 100 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG BUCCAL TABLET, EFFERVESCENT <b>DL</b>	4	PA,QL (120 per 30 days)
<i>fioricet 50 mg-300 mg-40 mg capsule</i> <b>MO</b>	1	QL (180 per 30 days)
FIORICET WITH CODEINE 50 MG-300 MG-40 MG-30 MG CAPSULE <b>DL</b>	4	QL (180 per 30 days)
FIORINAL 50 MG-325 MG-40 MG CAPSULE <b>MO</b>	3	QL (180 per 30 days)
FIORINAL-CODEINE #3 30 MG-50 MG-325 MG-40 MG CAPSULE <b>DL</b>	3	QL (360 per 30 days)
FLECTOR 1.3 % TRANSDERMAL 12 HOUR PATCH <b>MO</b>	3	PA,QL (60 per 30 days)
<i>flurbiprofen 100 mg, 50 mg tablet</i> <b>MO</b>	1	
<i>hydrocodone er 10 mg, 15 mg, 20 mg, 30 mg, 40 mg capsule</i> <b>DL</b>	1	ST,QL (90 per 30 days)
<i>hydrocodone er 50 mg capsule</i> <b>DL</b>	1	ST,QL (120 per 30 days)
<i>hydrocodone-acetamin 10-300 mg, 5-300 mg, 7.5-300 mg;</i> <i>hydrocodone-acetamin 7.5-300</i> <b>DL</b>	1	QL (390 per 30 days)
<i>hydrocodone-acetamin 10-325 mg, 2.5-325 mg, 5-325 mg, 7.5-325 mg;</i> <i>hydrocodone-acetamin 2.5-325; hydrocodone-acetamin 7.5-325</i> <b>DL</b>	1	QL (360 per 30 days)
<i>hydrocodone-acetamin 10-325/15</i> <b>DL</b>	1	QL (2700 per 30 days)
<i>hydrocodone-acetamin 7.5-325/15</i> <b>DL</b>	1	QL (5520 per 30 days)
<i>hydrocodone-ibuprofen 10-200; hydrocodone-ibuprofen 10-200 mg, 5-200 mg,</i> <i>7.5-200 mg; hydrocodone-ibuprofen 7.5-200</i> <b>DL</b>	1	QL (150 per 30 days)
<i>hydromorphone 0.5 mg/0.5 ml, 1 mg/ml; hydromorphone 0.5 mg/0.5 ml, 1</i> <i>mg/ml carpuct</i> <b>DL</b>	1	B vs D,QL (720 per 30 days)
<i>hydromorphone 1 mg/ml solution</i> <b>DL</b>	1	QL (2400 per 30 days)
<i>hydromorphone 2 mg, 4 mg tablet</i> <b>DL</b>	1	QL (360 per 30 days)
<i>hydromorphone 2 mg/ml carpuct</i> <b>DL</b>	1	QL (360 per 30 days)
<i>hydromorphone 2 mg/ml vial</i> <b>DL</b>	1	B vs D,QL (360 per 30 days)
<i>hydromorphone 4 mg/ml carpuct</i> <b>DL</b>	1	B vs D,QL (180 per 30 days)
<i>hydromorphone 8 mg tablet</i> <b>DL</b>	1	QL (240 per 30 days)
<i>hydromorphone hcl 1 mg/ml amp</i> <b>DL</b>	1	B vs D,QL (720 per 30 days)
<i>hydromorphone hcl 4 mg/ml amp</i> <b>DL</b>	1	B vs D,QL (180 per 30 days)
<i>hydromorphone hcl er 12 mg tab</i> <b>DL</b>	1	ST,QL (180 per 30 days)
<i>hydromorphone hcl er 16 mg tab</i> <b>DL</b>	1	ST,QL (120 per 30 days)
<i>hydromorphone hcl er 32 mg tab</i> <b>DL</b>	1	ST,QL (60 per 30 days)
<i>hydromorphone hcl er 8 mg tab</i> <b>DL</b>	1	ST,QL (240 per 30 days)
<i>hydromorphone 1 mg/ml vial</i> <b>DL</b>	1	B vs D,QL (720 per 30 days)
<i>hydromorphone 4 mg/ml vial</i> <b>DL</b>	1	B vs D,QL (180 per 30 days)
<i>hydromorphone 500 mg/50 ml vl</i> <b>DL</b>	1	QL (144 per 30 days)
HYSINGLA ER 100 MG, 120 MG, 20 MG, 30 MG, 40 MG, 60 MG, 80 MG TABLET, CRUSH RESISTANT, EXTENDED RELEASE <b>DL</b>	3	ST,QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>ibu 400 mg, 600 mg, 800 mg tablet</i> <b>MO</b>	1	
IBUDONE 10 MG-200 MG TABLET <b>DL</b>	1	QL (150 per 30 days)
<i>ibudone 5-200 mg tablet</i> <b>DL</b>	1	QL (150 per 30 days)
<i>ibuprofen 100 mg/5 ml susp</i> <b>MO</b>	1	
<i>ibuprofen 400 mg, 600 mg, 800 mg tablet</i> <b>MO</b>	1	
<i>oxycodone-ibuprofen 5-400 tab</i> <b>DL</b>	1	QL (240 per 30 days)
INDOCIN 25 MG/5 ML ORAL SUSPENSION <b>DL</b>	4	
INDOCIN 50 MG RECTAL SUPPOSITORY <b>DL</b>	4	
<i>indomethacin 25 mg, 50 mg, 75 mg capsule; indomethacin er 25 mg, 50 mg, 75 mg capsule</i> <b>MO</b>	1	
<i>indomethacin 1 mg vial</i> <b>MO</b>	1	
INFUMORPH P/F 10 MG/ML INJECTION SOLUTION <b>DL</b>	3	B vs D,QL (360 per 30 days)
INFUMORPH P/F 25 MG/ML INJECTION SOLUTION <b>DL</b>	3	B vs D,QL (150 per 30 days)
KADIAN 10 MG, 100 MG, 20 MG, 200 MG, 30 MG, 40 MG, 50 MG, 60 MG, 80 MG CAPSULE,EXTENDED RELEASE <b>DL</b>	4	ST,QL (60 per 30 days)
<i>ketoprofen 25 mg, 50 mg, 75 mg capsule</i> <b>MO</b>	1	
<i>ketoprofen er 200 mg capsule</i> <b>MO</b>	1	
<i>ketorolac 10 mg tablet</i> <b>MO</b>	1	QL (20 per 30 days)
<i>ketorolac 15 mg/ml, 30 mg/ml, 30 mg/ml (1 ml), 60 mg/2 ml vial; ketorolac 30 mg/ml vial; ketorolac 300 mg/10 ml vial</i> <b>MO</b>	1	
<i>ketorolac 15 mg/ml, 30 mg/ml, 60 mg/2 ml carpject</i> <b>MO</b>	1	
<i>ketorolac 15 mg/ml, 30 mg/ml, 60 mg/2 ml isecure syr; ketorolac 15 mg/ml, 30 mg/ml, 60 mg/2 ml syringe</i> <b>MO</b>	1	
<i>ketorolac 15.75 mg nasal spray</i> <b>DL</b>	4	PA,QL (5 per 30 days)
LAZANDA 100 MCG/SPRAY, 300 MCG/SPRAY, 400 MCG/SPRAY NASAL SPRAY <b>DL</b>	4	PA,QL (30 per 30 days)
<i>levorphanol 2 mg tablet</i> <b>DL</b>	4	QL (240 per 30 days)
<i>levorphanol 3 mg tablet</i> <b>DL</b>	4	QL (150 per 30 days)
LICART 1.3 % TRANSDERMAL 24 HOUR PATCH <b>DL</b>	4	PA,QL (30 per 30 days)
LODINE 400 MG TABLET <b>MO</b>	3	PA
<i>lorcet (hydrocodone) 5 mg-325 mg tablet</i> <b>DL</b>	1	QL (360 per 30 days)
<i>lorcet hd 10 mg-325 mg tablet</i> <b>DL</b>	1	QL (360 per 30 days)
<i>lorcet plus 7.5-325 mg tablet</i> <b>DL</b>	1	QL (360 per 30 days)
<i>lortab elixir 10 mg-300 mg/15 ml oral solution</i> <b>DL</b>	1	QL (6000 per 30 days)
<i>meclofenamate 100 mg, 50 mg capsule</i> <b>MO</b>	1	
<i>mefenamic acid 250 mg capsule</i> <b>MO</b>	1	
<i>meloxicam 15 mg tablet</i> <b>MO</b>	1	QL (30 per 30 days)
<i>meloxicam 7.5 mg tablet</i> <b>MO</b>	1	QL (60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
meperidine 10 mg/ml cartrdge <sup>DL</sup>	1	B vs D,QL (3600 per 30 days)
meperidine 100 mg tablet <sup>DL</sup>	1	QL (360 per 30 days)
meperidine 50 mg tablet <sup>DL</sup>	1	QL (480 per 30 days)
meperidine 50 mg/5 ml solution <sup>DL</sup>	1	QL (720 per 30 days)
meperidine 100 mg/ml vial <sup>DL</sup>	1	B vs D,QL (360 per 30 days)
meperidine 25 mg/ml vial <sup>DL</sup>	1	B vs D,QL (1440 per 30 days)
meperidine 50 mg/ml vial <sup>DL</sup>	1	B vs D,QL (720 per 30 days)
methadone 10 mg/5 ml solution <sup>DL</sup>	1	QL (1800 per 30 days)
methadone 10 mg/ml oral conc <sup>DL</sup>	1	QL (360 per 30 days)
methadone 5 mg/5 ml solution <sup>DL</sup>	1	QL (3600 per 30 days)
methadone hcl 10 mg tablet <sup>DL</sup>	1	QL (240 per 30 days)
methadone hcl 10 mg/ml vial <sup>DL</sup>	1	QL (360 per 30 days)
methadone hcl 5 mg tablet <sup>DL</sup>	1	QL (480 per 30 days)
methadone intensol 10 mg/ml oral concentrate <sup>DL</sup>	1	QL (360 per 30 days)
METHADOSE 10 MG/ML ORAL CONCENTRATE <sup>DL</sup>	3	QL (360 per 30 days)
mitigo (pf) 10 mg/ml injection solution <sup>DL</sup>	4	B vs D,QL (360 per 30 days)
mitigo (pf) 25 mg/ml injection solution <sup>DL</sup>	4	B vs D,QL (150 per 30 days)
MOBIC 15 MG TABLET <sup>MO</sup>	3	PA,QL (30 per 30 days)
MOBIC 7.5 MG TABLET <sup>MO</sup>	3	PA,QL (60 per 30 days)
MORPHABOND ER 100 MG TABLET <sup>DL</sup>	3	ST,QL (180 per 30 days)
MORPHABOND ER 15 MG, 30 MG TABLET <sup>DL</sup>	3	ST,QL (90 per 30 days)
MORPHABOND ER 60 MG TABLET <sup>DL</sup>	3	ST,QL (60 per 30 days)
morphine 10 mg/ml carpject <sup>DL</sup>	1	B vs D,QL (360 per 30 days)
morphine 2 mg/ml carpject <sup>DL</sup>	1	B vs D,QL (1800 per 30 days)
morphine 4 mg/ml carpject <sup>DL</sup>	1	B vs D,QL (900 per 30 days)
morphine 5 mg/ml syringe <sup>DL</sup>	1	B vs D
morphine 8 mg/ml isecure syrng <sup>DL</sup>	1	B vs D,QL (450 per 30 days)
morphine sulf 10 mg/5 ml soln <sup>DL</sup>	1	QL (2700 per 30 days)
morphine sulf 20 mg/5 ml soln <sup>DL</sup>	1	QL (1350 per 30 days)
morphine sulf er 100 mg tablet <sup>DL</sup>	1	QL (180 per 30 days)
morphine sulf er 15 mg, 30 mg, 60 mg tablet <sup>DL</sup>	1	QL (120 per 30 days)
morphine sulf er 200 mg tablet <sup>DL</sup>	1	QL (90 per 30 days)
morphine sulfate 10 mg/ml vial <sup>DL</sup>	1	B vs D,QL (360 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>morphine sulfate 2 mg/ml vial</i> <sup>DL</sup>	1	B vs D,QL (1800 per 30 days)
<i>morphine sulfate 4 mg/ml vial</i> <sup>DL</sup>	1	B vs D,QL (900 per 30 days)
<i>morphine sulfate 5 mg/ml vial</i> <sup>DL</sup>	1	B vs D,QL (720 per 30 days)
<i>morphine sulfate 8 mg/ml vial</i> <sup>DL</sup>	1	B vs D,QL (450 per 30 days)
<i>morphine sulfate er 10 mg, 100 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 80 mg cap</i> <sup>DL</sup>	1	ST,QL (60 per 30 days)
<i>morphine sulfate er 120 mg, 60 mg, 75 mg, 90 mg cap</i> <sup>DL</sup>	1	ST,QL (60 per 30 days)
<i>morphine sulfate er 30 mg, 45 mg cap</i> <sup>DL</sup>	1	ST,QL (30 per 30 days)
<i>morphine sulfate ir 15 mg, 30 mg tab</i> <sup>DL</sup>	1	QL (180 per 30 days)
<i>morphine 10 mg/10 ml vial; morphine sulfate 1 mg/ml vial</i> <sup>DL</sup>	1	B vs D,QL (3600 per 30 days)
<i>morphine 5 mg/10 ml vial</i> <sup>DL</sup>	1	B vs D,QL (7200 per 30 days)
<i>morphine 5 mg/ml vial</i> <sup>DL</sup>	1	B vs D,QL (720 per 30 days)
<i>morphine sulf 100 mg/5 ml conc</i> <sup>DL</sup>	1	QL (540 per 30 days)
MS CONTIN 100 MG TABLET,EXTENDED RELEASE <sup>DL</sup>	4	PA,QL (180 per 30 days)
MS CONTIN 15 MG, 30 MG, 60 MG TABLET,EXTENDED RELEASE <sup>DL</sup>	4	PA,QL (120 per 30 days)
MS CONTIN 200 MG TABLET,EXTENDED RELEASE <sup>DL</sup>	4	PA,QL (90 per 30 days)
<i>nabumetone 500 mg, 750 mg tablet</i> <sup>MO</sup>	1	
<i>nalbuphine 100 mg/10 ml vial</i> <sup>DL</sup>	1	QL (240 per 30 days)
<i>nalbuphine 200 mg/10 ml vial</i> <sup>DL</sup>	1	QL (120 per 30 days)
NALFON 400 MG CAPSULE <sup>MO</sup>	3	
NALFON 600 MG TABLET <sup>MO</sup>	1	
<i>nalocet 2.5 mg-300 mg tablet</i> <sup>DL</sup>	4	PA,QL (360 per 30 days)
NAPRELAN CR 375 MG TAB,EXTENDED RELEASE 24 HR MPHASE <sup>DL</sup>	4	ST,QL (120 per 30 days)
NAPRELAN CR 500 MG TAB,EXTENDED RELEASE 24 HR MPHASE <sup>DL</sup>	4	ST,QL (90 per 30 days)
NAPRELAN CR 750 MG TAB,EXTENDED RELEASE 24 HR MPHASE <sup>DL</sup>	4	ST,QL (60 per 30 days)
NAPROSYN 500 MG TABLET <sup>MO</sup>	3	PA
<i>naproxen 125 mg/5 ml suspen</i> <sup>MO</sup>	1	
<i>naproxen 250 mg, 375 mg, 500 mg tablet; naproxen dr 250 mg, 375 mg, 500 mg tablet</i> <sup>MO</sup>	1	
<i>naproxen sod cr 375 mg tablet</i> <sup>MO</sup>	1	ST,QL (120 per 30 days)
<i>naproxen sod cr 500 mg tablet</i> <sup>MO</sup>	1	ST,QL (90 per 30 days)
<i>naproxen sodium 275 mg, 550 mg tab</i> <sup>MO</sup>	1	
<i>naproxen-esomepraz dr 375-20mg; naproxen-esomepraz dr 500-20mg</i> <sup>DL</sup>	4	PA,QL (60 per 30 days)
NORCO 10 MG-325 MG TABLET; NORCO 5 MG-325 MG TABLET; NORCO 7.5 MG-325 MG TABLET <sup>DL</sup>	1	PA,QL (360 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
NUCYNTA 100 MG, 50 MG, 75 MG TABLET <b>DL</b>	3	ST,QL (180 per 30 days)
NUCYNTA ER 100 MG, 150 MG, 200 MG, 250 MG, 50 MG TABLET,EXTENDED RELEASE <b>DL</b>	4	ST,QL (60 per 30 days)
OPANA 10 MG, 5 MG TABLET <b>DL</b>	4	PA,QL (360 per 30 days)
oxaprozin 600 mg tablet <b>MO</b>	1	
OXAYDO 5 MG, 7.5 MG TABLET,ORAL ONLY (NOT FEEDING TUBES); OXAYDO 5 MG, 7.5 MG TABLET,ORAL ONLY (NOT FOR FEEDING TUBES) <b>DL</b>	4	PA,QL (360 per 30 days)
oxycodone hcl 10 mg, 15 mg, 20 mg, 30 mg, 5 mg tablet <b>DL</b>	1	QL (360 per 30 days)
oxycodone hcl 100 mg/5 ml conc <b>DL</b>	1	QL (270 per 30 days)
oxycodone hcl 5 mg capsule <b>DL</b>	1	QL (360 per 30 days)
oxycodone hcl 5 mg/5 ml soln <b>DL</b>	1	QL (5400 per 30 days)
oxycodone hcl er 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg tablet <b>DL</b>	3	PA,QL (90 per 30 days)
oxycodone hcl er 80 mg tablet <b>DL</b>	3	PA,QL (120 per 30 days)
oxycodon-acetaminophen 2.5-300 <b>DL</b>	4	PA,QL (360 per 30 days)
oxycodon-acetaminophen 2.5-325; oxycodon-acetaminophen 7.5-325; oxycodone-acetaminophen 10-325; oxycodone-acetaminophen 5-325 <b>DL</b>	1	QL (360 per 30 days)
oxycodone-aspirin 4.8355-325 <b>DL</b>	1	QL (360 per 30 days)
OXYCONTIN 10 MG, 15 MG, 20 MG, 30 MG, 40 MG, 60 MG TABLET,CRUSH RESISTANT,EXTENDED RELEASE <b>DL</b>	3	PA,QL (90 per 30 days)
OXYCONTIN 80 MG TABLET,CRUSH RESISTANT,EXTENDED RELEASE <b>DL</b>	3	PA,QL (120 per 30 days)
oxymorphone hcl 10 mg, 5 mg tablet <b>DL</b>	1	QL (360 per 30 days)
oxymorphone hcl er 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 5 mg, 7.5 mg tab; oxymorphone hcl er 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 5 mg, 7.5 mg tablet <b>DL</b>	1	ST,QL (60 per 30 days)
PENNSAID 2 % TOPICAL SOLUTION IN PACKET <b>DL</b>	4	PA
PENNSAID 20 MG/GRAM/ACTUATION (2 %) TOPICAL SOLN IN METERED-DOSE PUMP <b>DL</b>	4	PA,QL (224 per 28 days)
pentazocine-naloxone tablet <b>DL</b>	1	QL (360 per 30 days)
PERCOCET 10 MG-325 MG TABLET; PERCOCET 5 MG-325 MG TABLET; PERCOCET 7.5 MG-325 MG TABLET <b>DL</b>	4	PA,QL (360 per 30 days)
PERCOCET 2.5 MG-325 MG TABLET <b>DL</b>	1	PA,QL (360 per 30 days)
phrenilin forte 50-300-40 mg <b>MO</b>	1	QL (180 per 30 days)
piroxicam 10 mg, 20 mg capsule <b>MO</b>	1	
primlev 10 mg-300 mg tablet; primlev 5 mg-300 mg tablet; primlev 7.5 mg-300 mg tablet <b>DL</b>	4	QL (390 per 30 days)
profeno 600 mg tablet <b>MO</b>	1	
prolate 10 mg-300 mg tablet; prolate 5 mg-300 mg tablet; prolate 7.5 mg-300 mg tablet <b>DL</b>	4	QL (390 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
QMIIZ ODT 15 MG, 7.5 MG TABLET <b>MO</b>	3	ST,QL (30 per 30 days)
RELAFEN 500 MG, 750 MG TABLET <b>DL</b>	4	ST
RELAFEN DS 1,000 MG TABLET <b>DL</b>	4	ST,QL (60 per 30 days)
ROXICODONE 15 MG, 30 MG, 5 MG TABLET <b>DL</b>	3	PA,QL (360 per 30 days)
ROXYBOND 15 MG, 30 MG TABLET <b>DL</b>	4	PA,QL (180 per 30 days)
ROXYBOND 5 MG TABLET <b>DL</b>	4	PA,QL (360 per 30 days)
SPRIX 15.75 MG/SPRAY NASAL SPRAY <b>DL</b>	4	PA,QL (5 per 30 days)
SUBSYS 1,200 MCG (600 MCG/SPRAY X 2), 1,600 MCG (800 MCG/SPRAY X 2), 100 MCG/SPRAY, 200 MCG/SPRAY, 400 MCG/SPRAY, 600 MCG/SPRAY, 800 MCG/SPRAY SUBLINGUAL SPRAY; SUBSYS 1,200 MCG (600 MCG/SPRAY X2) SUBLINGUAL SPRAY; SUBSYS 1,600 MCG (800 MCG/SPRAY X2) SUBLINGUAL SPRAY <b>DL</b>	4	PA,QL (120 per 30 days)
<i>sulindac 150 mg, 200 mg tablet</i> <b>MO</b>	1	
TALWIN 30 MG/ML VIAL <b>DL</b>	3	QL (360 per 30 days)
<i>tencon 50 mg-325 mg tablet</i> <b>MO</b>	1	QL (180 per 30 days)
TIVORBEX 20 MG, 40 MG CAPSULE <b>DL</b>	4	ST,QL (90 per 30 days)
<i>tolmetin sodium 200 mg, 600 mg tab</i> <b>MO</b>	1	
<i>tolmetin sodium 400 mg cap</i> <b>MO</b>	1	
<i>tramadol er 100 mg, 200 mg, 300 mg tablet; tramadol hcl er 100 mg, 200 mg, 300 mg tablet</i> <b>DL</b>	1	QL (30 per 30 days)
<i>tramadol hcl 100 mg tablet</i> <b>DL</b>	1	QL (120 per 30 days)
<i>tramadol hcl 50 mg tablet</i> <b>DL</b>	1	QL (240 per 30 days)
<i>tramadol hcl er 100 mg, 150 mg, 200 mg, 300 mg capsule</i> <b>DL</b>	1	ST,QL (30 per 30 days)
<i>tramadol-acetaminophn 37.5-325</i> <b>DL</b>	1	QL (240 per 30 days)
TREZIX 320.5 MG-30 MG-16 MG CAPSULE <b>DL</b>	1	QL (300 per 30 days)
TYLENOL WITH CODEINE #3 TABLET <b>DL</b>	1	PA,QL (360 per 30 days)
TYLENOL WITH CODEINE #4 TABLET <b>DL</b>	1	PA,QL (180 per 30 days)
ULTRACET 37.5 MG-325 MG TABLET <b>DL</b>	3	QL (240 per 30 days)
ULTRAM 50 MG TABLET <b>DL</b>	3	QL (240 per 30 days)
<i>vanatol lq 50 mg-325 mg-40 mg/15 ml oral solution</i> <b>DL</b>	4	QL (450 per 30 days)
<i>vanatol s 50 mg-325 mg-40 mg/15 ml oral solution</i> <b>DL</b>	4	QL (450 per 30 days)
<i>vicodin 5-300 mg tablet</i> <b>DL</b>	1	QL (390 per 30 days)
<i>vicodin hp 10 mg-300 mg tablet</i> <b>DL</b>	1	QL (390 per 30 days)
VIMOVO 375 MG-20 MG TABLET,IMMEDIATE AND DELAY RELEASE; VIMOVO 500 MG-20 MG TABLET,IMMEDIATE AND DELAY RELEASE <b>DL</b>	4	PA,QL (60 per 30 days)
VIVLODEX 10 MG, 5 MG CAPSULE <b>DL</b>	4	PA,QL (30 per 30 days)
VOLTAREN 1 % TOPICAL GEL <b>MO</b>	3	PA

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
VOLTAREN-XR 100 MG TABLET,EXTENDED RELEASE <b>MO</b>	3	PA
<i>vtol lq 50 mg-325 mg-40 mg/15 ml oral solution</i> <b>DL</b>	4	QL (450 per 30 days)
XTAMPZA ER 13.5 MG, 18 MG, 27 MG, 36 MG, 9 MG CAPSULE SPRINKLE <b>DL</b>	2	QL (60 per 30 days)
ZEBUTAL 50 MG-325 MG-40 MG CAPSULE <b>MO</b>	1	QL (180 per 30 days)
ZIPSOR 25 MG CAPSULE <b>DL</b>	4	QL (120 per 30 days)
ZOHYDRO ER 10 MG, 15 MG, 20 MG, 30 MG, 40 MG CAPSULE, ORAL ONLY,EXTENDED RELEASE <b>DL</b>	3	ST,QL (90 per 30 days)
ZOHYDRO ER 50 MG CAPSULE, ORAL ONLY,EXTENDED RELEASE <b>DL</b>	3	ST,QL (120 per 30 days)
ZORVOLEX 18 MG, 35 MG CAPSULE <b>DL</b>	4	ST,QL (90 per 30 days)
<b>Anesthetics</b>		
<i>bupivacaine 0.25% vial; bupivacaine 0.5% vial</i> <b>MO</b>	1	
<i>bupivacaine 0.25% vial; bupivacaine 0.5% (5 mg/ml) amp; bupivacaine 0.75% vial</i> <b>MO</b>	1	
<i>bupivacain 0.75%-dextros 8.25%</i> <b>MO</b>	1	
<i>bupivacaine 0.25%-epi 1:200000; bupivacaine 0.5%-epi 1:200,000</i> <b>MO</b>	1	
<i>bupivacaine 0.25%-epi 1:200000; bupivacaine 0.5%-epi 1:200,000</i> <b>MO</b>	1	
<i>bupivacaine 0.5%-epi 1:200,000</i> <b>MO</b>	1	
CARBOCAINE 1 % (10 MG/ML), 2 % INJECTION SOLUTION <b>MO</b>	3	
CARBOCAINE (PF) 10 MG/ML (1 %), 15 MG/ML (1.5 %), 20 MG/ML (2 %) INJECTION SOLUTION <b>MO</b>	3	
CARBOCAINE WITH NEO-COBEFRIN 2 %-1:20,000 INJECTION CARTRIDGE <b>MO</b>	1	
<i>chloroprocaine 2% vial; chloroprocaine 3% vial</i> <b>MO</b>	1	
CLOTOTEKAL 10 MG/ML (1 %) INTRATHECAL SOLUTION <b>MO</b>	3	
<i>glydo 2 % mucosal jelly in applicator</i> <b>MO</b>	1	
<i>lidocaine 5% ointment</i> <b>MO</b>	1	PA
<i>lidocaine 5% patch</i> <b>MO</b>	1	PA,QL (90 per 30 days)
<i>lidocaine 5% in d7.5w ampul</i> <b>MO</b>	1	
<i>lidocaine hcl 0.5% vial; lidocaine hcl 1% 50 mg/5 ml vl; lidocaine hcl 1.5% ampul; lidocaine hcl 2% 100 mg/5 ml; lidocaine hcl 4% ampul</i> <b>MO</b>	1	
<i>lidocaine hcl 0.5% vial; lidocaine hcl 1% vial; lidocaine hcl 2% vial; lidocaine hcl 4% solution</i> <b>MO</b>	1	
<i>lidocaine hcl 2% jelly</i> <b>MO</b>	1	
<i>lidocaine hcl 2% jelly uro-jet</i> <b>MO</b>	1	
<i>lidocaine viscous 2 % mucosal solution</i> <b>MO</b>	1	
<i>lidocaine 0.5%-epi 1:200,000; lidocaine 2%-epi 1:100,000</i> <b>MO</b>	1	
<i>lidocaine 2%-epi 1:100,000; lidocaine 2%-epi 1:50,000 cart</i> <b>MO</b>	1	
<i>lidocaine-prilocaine cream</i> <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
LIDODERM 5 % TOPICAL PATCH <b>DL</b>	4	PA,QL (90 per 30 days)
MARCAINE 0.25 % (2.5 MG/ML), 0.5 % (5 MG/ML) INJECTION SOLUTION <b>MO</b>	3	
MARCAINE (PF) 0.25 % (2.5 MG/ML), 0.5 % (5 MG/ML), 0.75 % (7.5 MG/ML) INJECTION SOLUTION <b>MO</b>	3	
MARCAINE SPINAL (PF) 0.75 % (7.5 MG/ML) INJECTION SOLUTION <b>MO</b>	3	
MARCAINE-EPINEPHRINE 0.25 %-1:200,000, 0.5 %-1:200,000 INJECTION SOLUTION <b>MO</b>	3	
<i>marcaine-epinephrine 0.5 %-1:200,000 injection cartridge</i> <b>MO</b>	1	
MARCAINE-EPINEPHRINE (PF) 0.25 %-1:200,000, 0.5 %-1:200,000 INJECTION SOLUTION <b>MO</b>	3	
<i>mepivacaine hcl 3% cartridge</i> <b>MO</b>	1	
NAROPIN (PF) 10 MG/ML (1 %), 2 MG/ML (0.2 %), 5 MG/ML (0.5 %), 7.5 MG/ML (0.75 %) INJECTION SOLUTION <b>MO</b>	3	
NESACAINE 10 MG/ML (1 %), 20 MG/ML (2 %) INJECTION SOLUTION <b>MO</b>	3	
NESACAINE-MPF 20 MG/ML (2 %), 30 MG/ML (3 %) INJECTION SOLUTION <b>MO</b>	3	
PLIAGLIS 7 %-7 % TOPICAL CREAM <b>MO</b>	3	
<i>polocaine 1 % (10 mg/ml), 2 % injection solution</i> <b>MO</b>	1	
<i>polocaine-mpf 10 mg/ml (1 %), 15 mg/ml (1.5 %), 20 mg/ml (2 %) injection solution</i> <b>MO</b>	1	
<i>ropivacaine 0.2% 200 mg/100 ml; ropivacaine 0.5% 100 mg/20 ml; ropivacaine 0.75% 150 mg/20 ml; ropivacaine 1% 200 mg/20 ml v1</i> <b>MO</b>	1	
SENSORCAINE 0.25 % (2.5 MG/ML), 0.5 % (5 MG/ML) INJECTION SOLUTION <b>MO</b>	1	
<i>sensorcaine-epinephrine 0.25 %-1:200,000, 0.5 %-1:200,000 injection solution</i> <b>MO</b>	1	
SENSORCAINE-MPF 0.25 % (2.5 MG/ML), 0.5 % (5 MG/ML) INJECTION SOLUTION <b>MO</b>	1	
<i>sensorcaine-mpf 0.75 % (7.5 mg/ml) injection solution</i> <b>MO</b>	1	
<i>sensorcaine-mpf spinal 0.75 % (7.5 mg/ml) injection solution</i> <b>MO</b>	1	
<i>sensorcaine-mpf/epinephrine 0.25 %-1:200,000 injection solution</i> <b>MO</b>	1	
SENSORCAINE-MPF/EPINEPHRINE 0.5 %-1:200,000, 0.75 %-1:200,000 INJECTION SOLUTION <b>MO</b>	1	
SYNERA 70 MG-70 MG PATCH <b>DL</b>	4	PA
<i>vivacaine 0.5 %-1:200,000 injection cartridge</i> <b>MO</b>	1	
ZTLIDO 1.8 % TOPICAL PATCH <b>MO</b>	3	PA,QL (90 per 30 days)
<b>Anti-Addiction/Substance Abuse Treatment Agents</b>		
<i>acamprosate calc dr 333 mg tab</i> <b>MO</b>	1	
ANTABUSE 250 MG, 500 MG TABLET <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
BUNAVAIL 2.1 MG-0.3 MG BUCCAL FILM; BUNAVAIL 4.2 MG-0.7 MG BUCCAL FILM; BUNAVAIL 6.3 MG-1 MG BUCCAL FILM <b>MO</b>	3	PA,QL (60 per 30 days)
<i>buprenorphine 2 mg, 8 mg tablet sl</i> <b>MO</b>	1	QL (90 per 30 days)
<i>bupreno-nalox 2-0.5 mg, 4-1 mg, 8-2 mg sl film; buprenorp-nalox 2-0.5 mg, 4-1 mg, 8-2 mg sl film</i> <b>MO</b>	1	QL (90 per 30 days)
<i>buprenor-nalox 12-3 mg sl film</i> <b>MO</b>	1	QL (60 per 30 days)
<i>buprenorphin-naloxon 2-0.5 mg, 8-2 mg sl; buprenorphn-naloxn 2-0.5 mg, 8-2 mg sl</i> <b>MO</b>	3	PA,QL (90 per 30 days)
<i>bupropion hcl sr 150 mg tablet</i> <b>MO</b>	1	QL (90 per 30 days)
CHANTIX 0.5 MG, 1 MG TABLET <b>MO</b>	3	QL (56 per 28 days)
CHANTIX CONTINUING MONTH BOX 1 MG TABLET <b>MO</b>	3	QL (56 per 28 days)
CHANTIX STARTING MONTH BOX 0.5 MG (11)-1 MG (42) TABLETS IN DOSE PACK <b>MO</b>	3	QL (56 per 28 days)
<i>disulfiram 250 mg, 500 mg tablet</i> <b>MO</b>	1	
EVZIO 2 MG AUTO-INJECTOR <b>DL</b>	4	PA,QL (0.8 per 30 days)
LUCEMYRA 0.18 MG TABLET <b>DL</b>	4	PA,QL (224 per 365 days)
<i>naloxone 0.4 mg/ml vial</i> <b>MO</b>	1	
<i>naloxone 0.4 mg/ml, 1 mg/ml carpject; naloxone 2 mg/2 ml syringe</i> <b>MO</b>	1	
<i>naloxone 2 mg auto-injector</i> <b>MO</b>	3	QL (0.8 per 30 days)
<i>naltrexone 50 mg tablet</i> <b>MO</b>	1	
NARCAN 4 MG/ACTUATION NASAL SPRAY <b>MO</b>	2	QL (2 per 30 days)
NICOTROL 10 MG INHALATION CARTRIDGE <b>MO</b>	3	
NICOTROL NS 10 MG/ML NASAL SPRAY <b>MO</b>	3	
SUBOXONE 12 MG-3 MG SUBLINGUAL FILM <b>MO</b>	3	PA,QL (60 per 30 days)
SUBOXONE 2 MG-0.5 MG SUBLINGUAL FILM; SUBOXONE 4 MG-1 MG SUBLINGUAL FILM; SUBOXONE 8 MG-2 MG SUBLINGUAL FILM <b>MO</b>	3	PA,QL (90 per 30 days)
VIVITROL 380 MG INTRAMUSCULAR SUSPENSION,EXTENDED RELEASE <b>DL</b>	4	QL (1 per 28 days)
ZUBSOLV 0.7 MG-0.18 MG SUBLINGUAL TABLET; ZUBSOLV 1.4 MG-0.36 MG SUBLINGUAL TABLET; ZUBSOLV 2.9 MG-0.71 MG SUBLINGUAL TABLET; ZUBSOLV 5.7 MG-1.4 MG SUBLINGUAL TABLET <b>MO</b>	1	QL (90 per 30 days)
ZUBSOLV 11.4 MG-2.9 MG SUBLINGUAL TABLET <b>MO</b>	1	QL (30 per 30 days)
ZUBSOLV 8.6 MG-2.1 MG SUBLINGUAL TABLET <b>MO</b>	1	QL (60 per 30 days)
ZYBAN SR 150 MG TABLET <b>MO</b>	3	QL (90 per 30 days)
<b>Antibacterials</b>		
<i>acetic acid 2% ear solution</i> <b>MO</b>	1	
ACTICLATE 150 MG TABLET <b>DL</b>	4	ST,QL (30 per 30 days)
ACTICLATE 75 MG TABLET <b>DL</b>	4	ST,QL (60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
amikacin sulf 1 gram/4 ml vial; amikacin sulf 1,000 mg/4 ml, 500 mg/2 ml vial <b>MO</b>	1	
amoxicillin 125 mg, 250 mg tab chew <b>MO</b>	1	
amoxicillin 125 mg/5 ml, 200 mg/5 ml, 250 mg/5 ml, 400 mg/5 ml susp <b>MO</b>	1	
amoxicillin 250 mg, 500 mg capsule <b>MO</b>	1	
amoxicillin 500 mg, 875 mg tablet <b>MO</b>	1	
amox-clav 200-28.5 mg, 400-57 mg tab chew <b>MO</b>	1	
amox-clav 200-28.5 mg/5 ml, 250-62.5 mg/5 ml, 400-57 mg/5 ml, 600-42.9 mg/5 ml sus; amox-clav 200-28.5 mg/5 ml, 250-62.5 mg/5 ml, 400-57 mg/5 ml, 600-42.9 mg/5 ml susp <b>MO</b>	1	
amox-clav 250-125 mg, 500-125 mg, 875-125 mg tablet <b>MO</b>	1	
amox-clav er 1,000-62.5 mg tab <b>MO</b>	1	
ampicillin 250 mg, 500 mg capsule <b>MO</b>	1	
ampicillin 1 gm add-vantage vl; ampicillin 1 gm vial; ampicillin 1 gram, 10 gram, 125 mg, 2 gram, 250 mg, 500 mg vial; ampicillin 10 gm vial; ampicillin 2 gm add-vantage vl; ampicillin 2 gm vial <b>MO</b>	1	
ampicillin-sulb 1.5 g add vial; ampicillin-sulbactam 1.5 gm vl; ampicillin-sulbactam 15 gm vl; ampicillin-sulbactam 3 gm vial <b>MO</b>	1	
ARIKAYCE 590 MG/8.4 ML SUSPENSION FOR INHALATION VIA NEBULIZATION <b>DL</b>	4	PA,QL (235.2 per 28 days)
AUGMENTIN 125 MG-31.25 MG/5 ML ORAL SUSPENSION; AUGMENTIN 250 MG-62.5 MG/5 ML ORAL SUSPENSION <b>DL</b>	4	
AUGMENTIN 500 MG-125 MG TABLET; AUGMENTIN 875 MG-125 MG TABLET <b>MO</b>	3	PA
AUGMENTIN ES-600 600 MG-42.9 MG/5 ML ORAL SUSPENSION <b>MO</b>	3	
AUGMENTIN XR 1,000 MG-62.5 MG TABLET,EXTENDED RELEASE <b>MO</b>	3	
AVC 15% CREAM <b>MO</b>	3	
AVELOX 400 MG TABLET <b>MO</b>	3	PA
AVELOX 400 MG/250 ML IN SODIUM CHLORIDE(ISO-OSM) INTRAVENOUS PIGGYBACK <b>MO</b>	3	PA
avidoxy 100 mg tablet <b>MO</b>	1	ST
AVYCAZ 2.5 GRAM INTRAVENOUS SOLUTION <b>DL</b>	4	B vs D
AZACTAM 1 GRAM, 2 GRAM SOLUTION FOR INJECTION <b>MO</b>	3	PA
AZACTAM-ISO-OSMOT 1 GM/50 ML; AZACTAM-ISO-OSMOT 2 GM/50 ML <b>MO</b>	3	
azithromycin 1 gm pwd packet <b>MO</b>	1	
azithromycin 100 mg/5 ml, 200 mg/5 ml susp <b>MO</b>	1	
azithromycin 250 mg, 500 mg, 600 mg tablet <b>MO</b>	1	
azithromycin i.v. 500 mg vial <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
aztreonam 1 gm vial <b>MO</b>	1	
aztreonam 2 gm vial <b>DL</b>	4	
baciim 50,000 unit vial <b>MO</b>	1	
bacitracin 50,000 unit vial <b>MO</b>	1	
BACTRIM 400 MG-80 MG TABLET <b>MO</b>	3	
BACTRIM DS 800 MG-160 MG TABLET <b>MO</b>	3	
BAXDELA 300 MG INTRAVENOUS SOLUTION <b>DL</b>	4	QL (28 per 14 days)
BAXDELA 450 MG TABLET <b>DL</b>	4	QL (28 per 14 days)
BETHKIS 300 MG/4 ML SOLUTION FOR NEBULIZATION <b>DL</b>	4	PA
BICILLIN C-R 1,200,000 UNIT/2 ML INTRAMUSCULAR SYRINGE; BICILLIN C-R 900,000 UNIT-300K UNIT/2 ML INTRAMUSCULAR SYRINGE <b>MO</b>	3	
BICILLIN L-A 1,200,000 UNIT/2 ML, 2,400,000 UNIT/4 ML, 600,000 UNIT/ML INTRAMUSCULAR SYRINGE <b>MO</b>	3	
cefaclor 125 mg/5 ml, 250 mg/5 ml, 375 mg/5 ml susp; cefaclor 125 mg/5 ml, 250 mg/5 ml, 375 mg/5 ml suspen <b>MO</b>	1	
cefaclor 250 mg, 500 mg capsule <b>MO</b>	1	
cefaclor er 500 mg tablet <b>MO</b>	1	
cefadroxil 1 gm tablet <b>MO</b>	1	
cefadroxil 250 mg/5 ml, 500 mg/5 ml susp <b>MO</b>	1	
cefadroxil 500 mg capsule <b>MO</b>	1	
cefazolin 1 gm add-van vial; cefazolin 1 gm vial; cefazolin 1 gram, 10 gram, 500 mg vial; cefazolin 10 gm vial <b>MO</b>	1	
cefazolin 1 g/50 ml-dextrose; cefazolin 2 g/100 ml-dextrose; cefazolin 2 g/50 ml-dextrose <b>MO</b>	1	
cefdinir 125 mg/5 ml, 250 mg/5 ml susp <b>MO</b>	1	
cefdinir 300 mg capsule <b>MO</b>	1	
cefepime hcl 1 gm vial; cefepime hcl 1 gram, 2 gram vial <b>MO</b>	1	
cefepime-dextrose 1 gm/50 ml; cefepime-dextrose 2 gm/50 ml <b>MO</b>	1	
cefepime 1 gm injection; cefepime 2 gm injection <b>MO</b>	3	
cefixime 100 mg/5 ml, 200 mg/5 ml susp <b>MO</b>	1	
cefixime 400 mg capsule <b>MO</b>	1	
CEFOTAN 1 GRAM, 2 GRAM SOLUTION FOR INJECTION <b>MO</b>	3	
cefotaxime sodium 1 gm vial <b>MO</b>	1	
cefotetan 1 gm vial; cefotetan 10 gm vial; cefotetan 2 gm vial <b>MO</b>	1	
cefotetan-dextr 1 g duplex bag; cefotetan-dextr 2 g duplex bag <b>MO</b>	1	
cefoxitin 1 gm vial; cefoxitin 10 gm vial; cefoxitin 2 gm vial <b>MO</b>	1	
cefoxitin 1 gm piggyback bag; cefoxitin 2 gm piggyback bag <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
cefpodoxime 100 mg, 200 mg tablet <sup>MO</sup>	1	
cefpodoxime 100 mg/5 ml, 50 mg/5 ml susp <sup>MO</sup>	1	
cefprozil 125 mg/5 ml, 250 mg/5 ml susp <sup>MO</sup>	1	
cefprozil 250 mg, 500 mg tablet <sup>MO</sup>	1	
ceftazidime 1 gm vial; ceftazidime 2 gm vial; ceftazidime 6 gm vial <sup>MO</sup>	1	
ceftazidime 1 gm piggyback; ceftazidime 2 gm piggyback <sup>MO</sup>	1	
ceftriaxone 1 gm add-vant vial; ceftriaxone 1 gm vial; ceftriaxone 1 gram, 10 gram, 100 gram, 2 gram, 250 mg, 500 mg bulk bag; ceftriaxone 1 gram, 10 gram, 100 gram, 2 gram, 250 mg, 500 mg vial; ceftriaxone 10 gm vial; ceftriaxone 2 gm add vial; ceftriaxone 2 gm vial <sup>MO</sup>	1	
ceftriaxone 1 gm-d5w bag; ceftriaxone 2 gm-d5w bag <sup>MO</sup>	1	
cefuroxime axetil 250 mg, 500 mg tab <sup>MO</sup>	1	
cefuroxime sod 1.5 gm vial; cefuroxime sod 1.5 gram, 7.5 gram, 750 mg vial; cefuroxime sod 7.5 gm vial <sup>MO</sup>	1	
cephalexin 125 mg/5 ml, 250 mg/5 ml susp <sup>MO</sup>	1	
cephalexin 250 mg, 500 mg tablet <sup>MO</sup>	1	
cephalexin 250 mg, 500 mg, 750 mg capsule <sup>MO</sup>	1	
chloramphen na succ 1 gm vl <sup>MO</sup>	1	
CIPRO 250 MG, 500 MG TABLET <sup>MO</sup>	3	
CIPRO 250 MG/5 ML, 500 MG/5 ML ORAL SUSPENSION <sup>MO</sup>	3	
ciprofloxacin 250 mg/5 ml, 500 mg/5 ml susp <sup>MO</sup>	1	
ciprofloxacin er 1,000 mg, 500 mg tab; ciprofloxacin er 1,000 mg, 500 mg tablet <sup>MO</sup>	1	
ciprofloxacin hcl 100 mg, 250 mg, 500 mg, 750 mg tab <sup>MO</sup>	1	
ciprofloxacin 200 mg/100ml-d5w; ciprofloxacin 400 mg/200ml-d5w <sup>MO</sup>	1	
CLAFORAN 1 GRAM, 10 GRAM, 2 GRAM INTRAVENOUS SOLUTION; CLAFORAN 1 GRAM, 10 GRAM, 2 GRAM SOLUTION FOR INJECTION <sup>MO</sup>	3	
clarithromycin 125 mg/5 ml, 250 mg/5 ml sus <sup>MO</sup>	1	
clarithromycin 250 mg, 500 mg tablet <sup>MO</sup>	1	
clarithromycin er 500 mg tab <sup>MO</sup>	1	
CLEOCIN 100 MG VAGINAL SUPPOSITORY <sup>MO</sup>	3	
CLEOCIN 150 MG/ML, 600 MG/4 ML, 900 MG/6 ML INJECTION SOLUTION; CLEOCIN PHOS 600 MG/4ML ADDVAN; CLEOCIN PHOS 900 MG/6ML ADDVAN <sup>MO</sup>	1	
CLEOCIN 2 % VAGINAL CREAM <sup>MO</sup>	3	PA
cleocin phos 300 mg/2ml addvan <sup>MO</sup>	1	
CLEOCIN HCL 150 MG, 300 MG, 75 MG CAPSULE <sup>MO</sup>	3	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
CLEOCIN 300 MG-D5W-GALAXY; CLEOCIN 600 MG-D5W-GALAXY; CLEOCIN 900 MG-D5W-GALAXY <sup>MO</sup>	3	
CLEOCIN PEDIATRIC 75 MG/5 ML ORAL SOLUTION <sup>MO</sup>	1	
<i>clindamycin hcl 150 mg, 300 mg, 75 mg capsule</i> <sup>MO</sup>	1	
<i>clindamycin 300 mg/50 ml, 600 mg/50 ml, 900 mg/50 ml-ns</i> <sup>MO</sup>	1	B vs D
<i>clindamycin-d5w 300 mg/50 ml, 600 mg/50 ml, 900 mg/50 ml</i> <sup>MO</sup>	1	
<i>clindamycin 75 mg/5 ml soln</i> <sup>MO</sup>	1	
<i>clindamycin pediatric 75 mg/5 ml oral solution</i> <sup>MO</sup>	1	
<i>clindamycin 150 mg/ml, 300 mg/2 ml, 600 mg/4 ml, 900 mg/6 ml addvan;</i> <i>clindamycin ph 600 mg/4 ml vl</i> <sup>MO</sup>	1	
<i>clindamycin 2% vaginal cream</i> <sup>MO</sup>	1	
CLINDESSE 2 % VAGINAL CREAM,EXTENDED RELEASE <sup>MO</sup>	3	
<i>colistimethate 150 mg vial</i> <sup>MO</sup>	1	
COLY-MYCIN M PARENTERAL 150 MG SOLUTION FOR INJECTION <sup>DL</sup>	4	
<i>coremino 135 mg, 45 mg, 90 mg tablet,extended release</i> <sup>MO</sup>	1	ST,QL (30 per 30 days)
CUBICIN 500 MG INTRAVENOUS SOLUTION <sup>DL</sup>	4	
CUBICIN RF 500 MG INTRAVENOUS SOLUTION <sup>DL</sup>	4	
DALVANCE 500 MG INTRAVENOUS SOLUTION <sup>DL</sup>	4	QL (4 per 28 days)
<i>daptomycin 350 mg, 500 mg vial</i> <sup>DL</sup>	4	
<i>demeclocycline 150 mg tablet</i> <sup>MO</sup>	1	QL (240 per 30 days)
<i>demeclocycline 300 mg tablet</i> <sup>MO</sup>	1	QL (120 per 30 days)
<i>dicloxacillin 250 mg, 500 mg capsule</i> <sup>MO</sup>	1	
DIFICID 200 MG TABLET <sup>DL</sup>	4	
<i>doripenem 250 mg, 500 mg vial</i> <sup>MO</sup>	1	
DORYX 200 MG TABLET,DELAYED RELEASE <sup>MO</sup>	3	ST,QL (30 per 30 days)
DORYX 50 MG TABLET,DELAYED RELEASE <sup>MO</sup>	3	ST,QL (60 per 30 days)
DORYX 80 MG TABLET,DELAYED RELEASE <sup>DL</sup>	4	ST,QL (60 per 30 days)
DORYX MPC 120 MG TABLET, DELAYED RELEASE <sup>MO</sup>	3	ST,QL (60 per 30 days)
<i>doxy-100 100 mg intravenous solution</i> <sup>MO</sup>	1	
<i>doxycycline 50 mg tablet</i> <sup>MO</sup>	1	ST,QL (180 per 30 days)
<i>doxycycline hyc dr 100 mg tab</i> <sup>MO</sup>	1	ST,QL (90 per 30 days)
<i>doxycycline hyc dr 150 mg, 200 mg tab; doxycycline hyclate 150 mg, 200 mg tab</i> <sup>MO</sup>	1	ST,QL (30 per 30 days)
<i>doxycycline hyc dr 150 mg, 50 mg, 75 mg tab; doxycycline hyclate 150 mg, 50 mg, 75 mg tab</i> <sup>MO</sup>	1	ST,QL (60 per 30 days)
<i>doxycycline hyc dr 80 mg tab</i> <sup>DL</sup>	4	ST,QL (60 per 30 days)
<i>doxycycline hyclate 100 mg vl</i> <sup>MO</sup>	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
doxycycline hyclate 100 mg, 20 mg tab <sup>MO</sup>	1	
doxycycline hyclate 100 mg, 50 mg cap <sup>MO</sup>	1	
doxycycline 25 mg/5 ml susp <sup>MO</sup>	1	
doxycycline ir-dr 40 mg cap <sup>MO</sup>	1	ST,QL (30 per 30 days)
doxycycline mono 100 mg, 150 mg, 50 mg, 75 mg tablet <sup>MO</sup>	1	
doxycycline mono 100 mg, 50 mg cap <sup>MO</sup>	1	
doxycycline mono 150 mg cap <sup>MO</sup>	1	QL (30 per 30 days)
doxycycline mono 75 mg capsule <sup>MO</sup>	1	QL (60 per 30 days)
E.E.S. 400 MG TABLET <sup>MO</sup>	1	
E.E.S. GRANULES 200 MG/5 ML ORAL SUSPENSION <sup>MO</sup>	3	
ertapenem 1 gram vial <sup>DL</sup>	4	
ERY-TAB 250 MG, 333 MG, 500 MG TABLET,DELAYED RELEASE <sup>MO</sup>	1	
ERYPED 200 200 MG/5 ML ORAL SUSPENSION <sup>MO</sup>	3	
ERYPED 400 MG/5 ML ORAL SUSPENSION <sup>DL</sup>	4	
ERYTHROCIN 500 MG INTRAVENOUS SOLUTION <sup>MO</sup>	1	
ERYTHROCIN (AS STEARATE) 250 MG TABLET <sup>MO</sup>	1	
erythromycin 250 mg, 333 mg, 500 mg filmtab; erythromycin dr 250 mg, 333 mg, 500 mg tablet <sup>MO</sup>	1	
erythromycin dr 250 mg cap <sup>MO</sup>	1	
erythromycin 200 mg/5 ml, 400 mg/5 ml susp <sup>MO</sup>	1	
erythromycin es 400 mg tab <sup>MO</sup>	1	
FETROJA 1 GRAM INTRAVENOUS SOLUTION <sup>DL</sup>	4	B vs D,QL (84 per 14 days)
FIRVANQ 25 MG/ML, 50 MG/ML ORAL SOLUTION <sup>MO</sup>	3	
FLAGYL 250 MG, 500 MG TABLET <sup>MO</sup>	3	
FLAGYL 375 MG CAPSULE <sup>MO</sup>	3	QL (320 per 30 days)
FORTAZ 1 GRAM, 2 GRAM, 500 MG SOLUTION FOR INJECTION <sup>MO</sup>	3	
FURADANTIN 25 MG/5 ML ORAL SUSPENSION <sup>MO</sup>	3	
gentamicin 0.1% cream <sup>MO</sup>	1	
gentamicin 0.1% ointment <sup>MO</sup>	1	
gentamicin 20 mg/2 ml, 40 mg/ml vial; gentamicin 80 mg/2 ml vial <sup>MO</sup>	1	
gentamicin 70 mg/ns 50 ml pb; gentamicin 90 mg/ns 100 ml pb; iso gentamicin 100 mg/100 ml, 100 mg/50 ml, 120 mg/100 ml, 60 mg/50 ml, 70 mg/50 ml, 80 mg/100 ml, 80 mg/50 ml, 90 mg/100 ml; isoton gentamicin 100 mg/100 ml, 100 mg/50 ml, 120 mg/100 ml, 60 mg/50 ml, 70 mg/50 ml, 80 mg/100 ml, 80 mg/50 ml, 90 mg/100 ml <sup>MO</sup>	1	
gentamicin ped 20 mg/2 ml vial <sup>MO</sup>	1	
gentamicin 10 mg/ml vial <sup>MO</sup>	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
HIPREX 1 GRAM TABLET <b>MO</b>	3	PA
<i>imipenem-cilastatin 250 mg, 500 mg vial</i> <b>MO</b>	1	
INVANZ 1 GRAM SOLUTION FOR INJECTION <b>DL</b>	4	
KEFLEX 250 MG, 500 MG, 750 MG CAPSULE <b>MO</b>	3	
KITABIS PAK 300 MG/5 ML SOLUTION FOR NEBULIZATION <b>DL</b>	4	PA
KLARON 10 % LOTION (SUSPENSION) <b>MO</b>	3	QL (118 per 30 days)
LEVAQUIN 500 MG, 750 MG TABLET <b>MO</b>	3	
<i>levofloxacin 25 mg/ml solution; levofloxacin 500 mg/20 ml vial</i> <b>MO</b>	1	
<i>levofloxacin 250 mg, 500 mg, 750 mg tablet</i> <b>MO</b>	1	
<i>levofloxacin 250 mg/50 ml, 500 mg/100 ml, 750 mg/150 ml-d5w</i> <b>MO</b>	1	
LINCOCIN 300 MG/ML INJECTION SOLUTION <b>MO</b>	3	
<i>lincomycin hcl 600 mg/2 ml vial</i> <b>MO</b>	1	
<i>linezolid 100 mg/5 ml susp</i> <b>DL</b>	4	QL (1800 per 30 days)
<i>linezolid 600 mg tablet</i> <b>MO</b>	1	QL (60 per 30 days)
<i>linezolid 600 mg/300 ml-d5w</i> <b>MO</b>	1	
<i>linezolid 600mg/300ml-0.9%nacl</i> <b>MO</b>	1	
MACROBID 100 MG CAPSULE <b>MO</b>	3	
MACRODANTIN 100 MG, 25 MG, 50 MG CAPSULE <b>MO</b>	3	
MAXIPIME 1 GM ADD-VANTAGE VL; MAXIPIME 2 GM ADD-VANTAGE VL <b>MO</b>	3	
MAXIPIME 1 GRAM, 2 GRAM VIAL <b>MO</b>	3	PA
<i>meropenem iv 1 gm vial; meropenem iv 1 gram, 500 mg vial</i> <b>MO</b>	1	
<i>meropenem-0.9% nacl 1 gram/50; meropenem-0.9% nacl 500 mg/50</i> <b>MO</b>	1	
MERREM 1 GRAM, 500 MG INTRAVENOUS SOLUTION <b>MO</b>	3	
<i>methenamine hipp 1 gm tablet</i> <b>MO</b>	1	
METRO I.V. 500 MG/100 ML INTRAVENOUS PIGGYBACK <b>MO</b>	3	
METROCREAM 0.75 % TOPICAL <b>MO</b>	3	PA
METROGEL 1 % TOPICAL; METROGEL TOPICAL 1% PUMP <b>MO</b>	3	ST
METROGEL VAGINAL 0.75 % <b>MO</b>	3	
METROLOTION 0.75 % TOPICAL <b>MO</b>	3	PA
<i>metronidazole 0.75% cream</i> <b>MO</b>	1	
<i>metronidazole 0.75% lotion</i> <b>MO</b>	1	
<i>metronidazole 250 mg, 500 mg tablet</i> <b>MO</b>	1	
<i>metronidazole 375 mg capsule</i> <b>MO</b>	1	QL (320 per 30 days)
<i>metronidazole top 1% gel pump; metronidazole topical 0.75% gl;</i> <i>metronidazole topical 1% gel; metronidazole vaginal 0.75% gl</i> <b>MO</b>	1	
<i>metronidazole 500 mg/100 ml</i> <b>MO</b>	1	
MINOCIN 100 MG INTRAVENOUS SOLUTION <b>MO</b>	3	PA

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
MINOCIN 50 MG PELLETTIZED CAP <b>MO</b>	3	PA
<i>minocycline 100 mg, 50 mg, 75 mg capsule</i> <b>MO</b>	1	
<i>minocycline er 105 mg, 115 mg, 135 mg, 45 mg, 55 mg, 65 mg, 80 mg, 90 mg tablet</i> <b>MO</b>	1	ST,QL (30 per 30 days)
<i>minocycline hcl 100 mg, 50 mg, 75 mg tablet</i> <b>MO</b>	1	
MINOLIRA ER 105 MG, 135 MG TABLET, EXTENDED RELEASE <b>MO</b>	3	ST,QL (30 per 30 days)
<i>mondoxynel 100 mg, 50 mg capsule</i> <b>MO</b>	1	ST
<i>mondoxynel 75 mg capsule</i> <b>MO</b>	1	ST,QL (60 per 30 days)
MONODOX 100 MG, 50 MG CAPSULE <b>MO</b>	3	ST
MONODOX 75 MG CAPSULE <b>MO</b>	3	ST,QL (60 per 30 days)
MONUROL 3 GRAM ORAL PACKET <b>MO</b>	3	
<i>morgidox 100 mg, 50 mg capsule</i> <b>MO</b>	1	ST
<i>moxifloxacin hcl 400 mg tablet</i> <b>MO</b>	1	
<i>moxifloxacin 400 mg/250 ml bag</i> <b>MO</b>	1	
<i>moxifloxacin 400 mg/250 ml bag</i> <b>MO</b>	1	
<i>nafcillin 1 gm add-van vial; nafcillin 1 gm vial; nafcillin 10 gm bulk vial; nafcillin 2 gm add-vant vial; nafcillin 2 gm vial</i> <b>MO</b>	1	
<i>nafcillin 1 gm/ 50 ml inj; nafcillin 2 gm/ 100 ml inj</i> <b>DL</b>	4	
<i>neomycin 500 mg tablet</i> <b>MO</b>	1	
<i>nitrofurantoin 25 mg/5 ml susp</i> <b>DL</b>	4	
<i>nitrofurantoin mcr 100 mg, 25 mg, 50 mg cap</i> <b>MO</b>	1	
<i>nitrofurantoin mono-mcr 100 mg</i> <b>MO</b>	1	
NORITATE 1 % TOPICAL CREAM <b>DL</b>	4	ST,QL (60 per 30 days)
NUVESSA 1.3 % VAGINAL GEL <b>MO</b>	3	
NUZYRA 100 MG INTRAVENOUS SOLUTION <b>DL</b>	4	B vs D
NUZYRA 150 MG TABLET <b>DL</b>	4	QL (30 per 14 days)
NUZYRA 150 MG-7 DAY WITH LOAD <b>DL</b>	4	QL (30 per 14 days)
NUZYRA 150 MG TABLET-7 DAY <b>DL</b>	4	QL (30 per 14 days)
<i>ofloxacin 300 mg, 400 mg tablet</i> <b>MO</b>	1	
<i>okebo 75 mg capsule</i> <b>MO</b>	1	ST,QL (60 per 30 days)
ORACEA 40 MG CAPSULE, IMMEDIATE - DELAY RELEASE <b>DL</b>	4	ST,QL (30 per 30 days)
ORBACTIV 400 MG INTRAVENOUS SOLUTION <b>DL</b>	4	QL (3 per 28 days)
<i>oxacillin 1 gm add-vantage vl; oxacillin 1 gm vial; oxacillin 2 gm add-vantage vl; oxacillin 2 gm vial</i> <b>MO</b>	1	
<i>oxacillin 10 gm vial</i> <b>DL</b>	4	
<i>oxacillin 1 gm/ 50 ml inj; oxacillin 2 gm/ 50 ml inj</i> <b>MO</b>	3	
<i>paromomycin 250 mg capsule</i> <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
pen g k 1 million unit/50 ml, 2 million unit/50 ml, 3 million unit/50 ml <b>MO</b>	3	
penicillin gk 20 million unit, 5 million unit <b>MO</b>	1	
pen g 1.2 million unit/2 ml <b>MO</b>	1	
penicillin g 600,000 unit/1 ml <b>DL</b>	4	
penicillin g na 5 million unit <b>DL</b>	4	
penicillin vk 125 mg/5 ml, 250 mg/5 ml soln <b>MO</b>	1	
penicillin vk 250 mg, 500 mg tablet <b>MO</b>	1	
pfizerpen-g 20 million unit, 5 million unit solution for injection <b>DL</b>	4	
piperacil-tazobact 13.5 gm vl; piperacil-tazobact 13.5 gram, 2.25 gram, 3.375 gram, 4.5 gram, 40.5 gram; piperacil-tazobact 2.25 gm vl; piperacil-tazobact 3.375 gm vl; piperacil-tazobact 4.5 gm vial <b>MO</b>	1	
polymyxin b sulfatate vial <b>MO</b>	1	
PRIMAXIN 500 MG INTRAVENOUS SOLUTION <b>MO</b>	3	
PRIMSOL 50 MG/5 ML ORAL SOLUTION <b>MO</b>	3	
RECARBRIO 1.25 GRAM INTRAVENOUS SOLUTION <b>DL</b>	4	
rosadan 0.75 % topical cream <b>MO</b>	1	ST
rosadan 0.75 % topical gel <b>MO</b>	1	ST
SEYSARA 100 MG, 150 MG, 60 MG TABLET <b>DL</b>	4	ST,QL (30 per 30 days)
SIVEXTRO 200 MG INTRAVENOUS SOLUTION <b>DL</b>	4	QL (6 per 28 days)
SIVEXTRO 200 MG TABLET <b>DL</b>	4	QL (6 per 28 days)
SOLODYN 105 MG, 115 MG, 55 MG, 65 MG, 80 MG TABLET,EXTENDED RELEASE <b>DL</b>	4	ST,QL (30 per 30 days)
SOLOSEC 2 GRAM ORAL DR GRANULES IN PACKET <b>MO</b>	3	PA
soloxide dr 150 mg tablet <b>MO</b>	1	ST,QL (60 per 30 days)
streptomycin sulf 1 gm vial <b>DL</b>	4	
sulfacetamide 10% eye ointment <b>MO</b>	1	
sulfacetamide sod 10% top susp <b>MO</b>	1	QL (118 per 30 days)
sulfadiazine 500 mg tablet <b>MO</b>	1	
sulfamethoxazole-tmp ds tablet; sulfamethoxazole-tmp ss tablet <b>MO</b>	1	
sulfamethoxazole-tmp iv vial <b>MO</b>	1	
sulfamethoxazole-tmp susp <b>MO</b>	1	
SULFATRIM 200 MG-40 MG/5 ML ORAL SUSPENSION <b>MO</b>	3	
SUPRAX 100 MG, 200 MG CHEWABLE TABLET <b>MO</b>	1	
SUPRAX 100 MG/5 ML, 200 MG/5 ML ORAL SUSPENSION <b>MO</b>	1	
SUPRAX 400 MG CAPSULE <b>MO</b>	3	
SUPRAX 500 MG/5 ML ORAL SUSPENSION <b>MO</b>	3	
SYNERCID 500 MG INTRAVENOUS SOLUTION <b>DL</b>	4	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
TARGADOX 50 MG TABLET <b>MO</b>	1	ST,QL (180 per 30 days)
tazicef 1 gram, 2 gram, 6 gram intravenous solution; tazicef 1 gram, 2 gram, 6 gram solution for injection <b>MO</b>	1	
TEFLARO 400 MG, 600 MG INTRAVENOUS SOLUTION <b>DL</b>	4	
tetracycline 250 mg, 500 mg capsule <b>MO</b>	1	
tigecycline 50 mg vial <b>DL</b>	4	
TINDAMAX 500 MG TABLET <b>MO</b>	3	
tinidazole 250 mg, 500 mg tablet <b>MO</b>	1	
TOBI 300 MG/5 ML SOLUTION FOR NEBULIZATION <b>DL</b>	4	PA
tobramycin 300 mg/5 ml ampule <b>DL</b>	4	PA
tobramycin 1.2 gm vial <b>DL</b>	4	
tobramycin 10 mg/ml, 40 mg/ml vial <b>MO</b>	1	
tobramycin pak 300 mg/5 ml <b>DL</b>	4	PA
trimethoprim 100 mg tablet <b>MO</b>	1	
TYGACIL 50 MG INTRAVENOUS SOLUTION <b>DL</b>	4	
UNASYN 1.5 GRAM, 15 GRAM, 3 GRAM SOLUTION FOR INJECTION <b>MO</b>	3	
VABOMERE 2 GRAM INTRAVENOUS SOLUTION <b>DL</b>	4	QL (84 per 14 days)
VANCOGIN 125 MG CAPSULE <b>DL</b>	4	PA,QL (120 per 30 days)
VANCOGIN 250 MG CAPSULE <b>DL</b>	4	PA,QL (240 per 30 days)
vancomycin 1 gm vial; vancomycin 1,000 mg, 1.25 gram, 1.5 gram, 10 gram, 250 mg, 5 gram, 50 mg/ml, 500 mg, 750 mg vial; vancomycin 250 mg/5 ml soln; vancomycin hcl 1,000 mg, 1.25 gram, 1.5 gram, 10 gram, 250 mg, 5 gram, 50 mg/ml, 500 mg, 750 mg vial; vancomycin hcl 10 gm vial; vancomycin hcl 5 gm vial <b>MO</b>	1	
vancomycin hcl 125 mg capsule <b>MO</b>	1	PA,QL (120 per 30 days)
vancomycin hcl 250 mg capsule <b>DL</b>	4	PA,QL (240 per 30 days)
vanco 1 gram/200 ml, 500 mg/100 ml, 750 mg/150 ml-0.9% nacl; vancomycin 1 g/200ml-0.9% nacl <b>MO</b>	3	
vancomycin 1 gram/200 ml, 750 mg/150 ml bag; vancomycin hcl 1g/200 ml bag <b>MO</b>	3	
vancomycin 1 gram/200 ml, 1.25 gram/250 ml, 1.5 gram/300 ml, 1.75 gram/350 ml, 2 gram/400 ml, 500 mg/100 ml, 750 mg/150 ml bag; vancomycin 1.25 gm/250 ml bag; vancomycin 1.75 gm/350 ml bag <b>MO</b>	3	
VANDAZOLE 0.75 % VAGINAL GEL <b>MO</b>	3	
VIBATIV 750 MG INTRAVENOUS SOLUTION <b>DL</b>	4	
VIBRAMYCIN 100 MG CAPSULE <b>MO</b>	3	
VIBRAMYCIN 25 MG/5 ML ORAL SUSPENSION <b>MO</b>	3	ST
VIBRAMYCIN 50 MG/5 ML ORAL SYRUP <b>MO</b>	3	ST

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
XENLETA 150 MG/15 ML INTRAVENOUS SOLUTION <b>DL</b>	4	B vs D, QL (210 per 7 days)
XENLETA 600 MG TABLET <b>DL</b>	4	QL (10 per 5 days)
XERAVA 50 MG INTRAVENOUS SOLUTION <b>DL</b>	4	B vs D
XIMINO 135 MG, 45 MG, 90 MG CAPSULE, EXTENDED RELEASE <b>MO</b>	3	ST, QL (30 per 30 days)
ZEMDRI 50 MG/ML INTRAVENOUS SOLUTION <b>DL</b>	4	
ZERBAXA 1.5 GRAM INTRAVENOUS SOLUTION <b>DL</b>	4	
ZITHROMAX 1 GRAM ORAL PACKET <b>MO</b>	3	
ZITHROMAX 100 MG/5 ML, 200 MG/5 ML ORAL SUSPENSION <b>MO</b>	3	
ZITHROMAX 250 MG, 500 MG, 600 MG TABLET <b>MO</b>	3	
ZITHROMAX 500 MG INTRAVENOUS SOLUTION <b>MO</b>	3	
ZITHROMAX TRI-PAK 500 MG TABLET <b>MO</b>	3	
ZITHROMAX Z-PAK 250 MG TABLET <b>MO</b>	3	
ZOSYN 2.25 GRAM, 3.375 GRAM, 4.5 GRAM, 40.5 GRAM BULK VIAL; ZOSYN 2.25 GRAM, 3.375 GRAM, 4.5 GRAM, 40.5 GRAM VIAL <b>MO</b>	3	
ZOSYN 2.25 GRAM/50 ML, 3.375 GRAM/50 ML, 4.5 GRAM/100 ML IN DEXTROSE (ISO-OSMOTIC) INTRAVENOUS PIGGYBACK <b>MO</b>	3	
ZYVOX 100 MG/5 ML ORAL SUSPENSION <b>DL</b>	4	PA, QL (1800 per 30 days)
ZYVOX 200 MG/100 ML, 600 MG/300 ML INTRAVENOUS PIGGYBACK <b>MO</b>	3	
ZYVOX 600 MG TABLET <b>DL</b>	4	PA, QL (60 per 30 days)
<b>ANTICONVULSANTS</b>		
APTIOM 200 MG, 400 MG TABLET <b>DL</b>	4	PA, QL (30 per 30 days)
APTIOM 600 MG, 800 MG TABLET <b>DL</b>	4	PA, QL (60 per 30 days)
BANZEL 200 MG TABLET <b>DL</b>	4	PA, QL (480 per 30 days)
BANZEL 40 MG/ML ORAL SUSPENSION <b>DL</b>	4	PA, QL (2760 per 30 days)
BANZEL 400 MG TABLET <b>DL</b>	4	PA, QL (240 per 30 days)
BRIVIACT 10 MG, 100 MG, 25 MG, 50 MG, 75 MG TABLET <b>DL</b>	4	PA, QL (60 per 30 days)
BRIVIACT 10 MG/ML ORAL SOLUTION <b>DL</b>	4	PA, QL (600 per 30 days)
BRIVIACT 50 MG/5 ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA
carbamazepine 100 mg tab chew <b>MO</b>	1	
carbamazepine 100 mg/5 ml susp <b>MO</b>	1	
carbamazepine 200 mg tablet <b>MO</b>	1	
carbamazepine er 100 mg, 200 mg tablet <b>MO</b>	1	QL (120 per 30 days)
carbamazepine er 100 mg, 200 mg, 300 mg cap <b>MO</b>	1	
carbamazepine er 400 mg tablet <b>MO</b>	1	QL (225 per 30 days)
CARBATROL 100 MG, 200 MG, 300 MG CAPSULE, EXTENDED RELEASE <b>MO</b>	3	
CELONTIN 300 MG CAPSULE <b>MO</b>	3	
CEREBYX 100 MG PE/2 ML, 500 MG PE/10 ML INJECTION SOLUTION <b>MO</b>	3	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>clobazam 10 mg, 20 mg tablet</i> <b>DL</b>	1	PA
<i>clobazam 2.5 mg/ml suspension</i> <b>DL</b>	1	PA
DEPAACON 500 MG VIAL <b>MO</b>	3	
DEPAKENE 250 MG CAPSULE <b>MO</b>	3	
DEPAKENE 250 MG/5 ML SOLUTION <b>MO</b>	3	
DEPAKOTE 125 MG, 250 MG, 500 MG TABLET, DELAYED RELEASE <b>MO</b>	3	
DEPAKOTE ER 250 MG, 500 MG TABLET, EXTENDED RELEASE <b>MO</b>	3	
DEPAKOTE SPRINKLES 125 MG CAPSULE, DELAYED RELEASE <b>MO</b>	3	
DIASTAT 2.5 MG RECTAL KIT <b>DL</b>	3	PA
DIASTAT ACUDIAL 12.5 MG-15 MG-17.5 MG-20 MG RECTAL KIT <b>DL</b>	3	
DIASTAT ACUDIAL 5 MG-7.5 MG-10 MG RECTAL KIT <b>DL</b>	3	PA
<i>diazepam 10 mg rectal gel syst; diazepam 12.5-15-17.5-20 mg, 2.5 mg, 5-7.5-10 mg rectal gel sys; diazepam 20 mg rectal gel syst</i> <b>DL</b>	1	
DILANTIN 30 MG CAPSULE <b>MO</b>	1	
DILANTIN EXTENDED 100 MG CAPSULE <b>MO</b>	1	
DILANTIN INFATABS 50 MG CHEWABLE TABLET <b>MO</b>	1	
DILANTIN-125 125 MG/5 ML ORAL SUSPENSION <b>MO</b>	3	
<i>divalproex dr 125 mg cap sprnk</i> <b>MO</b>	1	
<i>divalproex sod dr 125 mg, 250 mg, 500 mg tab</i> <b>MO</b>	1	
<i>divalproex sod er 250 mg, 500 mg tab</i> <b>MO</b>	1	
EPIDIOLEX 100 MG/ML ORAL SOLUTION <b>DL</b>	4	PA
<i>epitol 200 mg tablet</i> <b>MO</b>	1	
EQUETRO 100 MG, 200 MG, 300 MG CAPSULE, EXTENDED RELEASE <b>MO</b>	3	PA
<i>ethosuximide 250 mg capsule</i> <b>MO</b>	1	
<i>ethosuximide 250 mg/5 ml soln</i> <b>MO</b>	1	
<i>felbamate 400 mg, 600 mg tablet</i> <b>MO</b>	1	
<i>felbamate 600 mg/5 ml susp</i> <b>DL</b>	4	
FELBATOL 400 MG, 600 MG TABLET <b>DL</b>	4	
FELBATOL 600 MG/5 ML ORAL SUSPENSION <b>DL</b>	4	
FINTEPLA 2.2 MG/ML ORAL SOLUTION <b>DL</b>	4	PA, QL (360 per 30 days)
<i>fosphenytoin 100 mg pe/2 ml, 500 mg pe/10 ml; fosphenytoin 100 mg pe/2 ml, 500 mg pe/10 ml v1</i> <b>MO</b>	1	
FYCOMPA 0.5 MG/ML ORAL SUSPENSION <b>DL</b>	4	PA, QL (680 per 28 days)
FYCOMPA 10 MG, 12 MG, 2 MG, 4 MG, 6 MG, 8 MG TABLET <b>DL</b>	4	PA, QL (30 per 30 days)
<i>gabapentin 100 mg, 300 mg, 400 mg capsule</i> <b>MO</b>	1	QL (270 per 30 days)
<i>gabapentin 250 mg/5 ml soln; gabapentin 250 mg/5 ml, 250 mg/5 ml (5 ml), 300 mg/6 ml (6 ml) soln; gabapentin 300 mg/6 ml soln</i> <b>MO</b>	1	QL (2250 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>gabapentin 600 mg, 800 mg tablet</i> <b>MO</b>	1	QL (180 per 30 days)
GABITRIL 12 MG, 16 MG, 2 MG, 4 MG TABLET <b>DL</b>	4	
KEPPRA 1,000 MG, 500 MG, 750 MG TABLET <b>DL</b>	4	
KEPPRA 100 MG/ML, 500 MG/5 ML INTRAVENOUS SOLUTION; KEPPRA 100 MG/ML, 500 MG/5 ML ORAL SOLUTION <b>DL</b>	4	
KEPPRA 250 MG TABLET <b>DL</b>	4	QL (60 per 30 days)
KEPPRA XR 500 MG TABLET,EXTENDED RELEASE <b>DL</b>	4	PA,QL (180 per 30 days)
KEPPRA XR 750 MG TABLET,EXTENDED RELEASE <b>DL</b>	4	PA,QL (120 per 30 days)
LAMICTAL 100 MG, 150 MG, 200 MG, 25 MG TABLET <b>DL</b>	4	
LAMICTAL 25 MG, 5 MG CHEWABLE DISPERSIBLE TABLET <b>DL</b>	4	
LAMICTAL ODT 100 MG, 200 MG, 25 MG, 50 MG DISINTEGRATING TABLET <b>DL</b>	4	
LAMICTAL ODT STARTER (BLUE) 25 MG (21)-50 MG (7) TABLET,DISINTEGRATING <b>DL</b>	4	
LAMICTAL ODT STARTER (GREEN) 50 MG (42)-100 MG (14) TABLET,DISINTEGRAT <b>DL</b>	4	
LAMICTAL ODT STARTER(ORANGE) 25 MG(14)-50 MG(14)-100 MG(7) TAB,DISINT <b>DL</b>	4	
LAMICTAL STARTER (BLUE) KIT 25 MG (35) TABLETS IN A DOSE PACK <b>DL</b>	4	
LAMICTAL STARTER (GREEN) KIT 25 MG (84)-100 MG (14) TABLETS, DOSE PACK <b>DL</b>	4	
LAMICTAL STARTER (ORANGE) KIT 25 MG (42)-100 MG (7) TABLETS, DOSE PACK <b>DL</b>	4	
LAMICTAL XR 100 MG, 200 MG, 25 MG, 250 MG, 300 MG, 50 MG TABLET,EXTENDED RELEASE <b>DL</b>	4	
LAMICTAL XR STARTER (BLUE) 25 MG (21)-50 MG (7) TABLET,EXTEND RELEASE <b>MO</b>	3	
LAMICTAL XR STARTER (GREEN) 50 MG(14)-100 MG(14)-200 MG(7) TAB,EXT.REL <b>MO</b>	3	
LAMICTAL XR STARTER (ORANGE) 25 MG(14)-50 MG(14)-100 MG(7) TAB,EXT.REL <b>MO</b>	3	
<i>lamotrigine 100 mg, 150 mg, 200 mg, 25 mg, 25 mg (21) -50 mg (7), 25 mg (35), 25 mg (42) -100 mg (7), 25 mg (84) -100 mg (14), 25 mg(14)-50 mg (14)-100 mg (7), 50 mg, 50 mg (42) -100 mg (14) tablet; lamotrigine odt 100 mg, 150 mg, 200 mg, 25 mg, 25 mg (21) -50 mg (7), 25 mg (35), 25 mg (42) -100 mg (7), 25 mg (84) -100 mg (14), 25 mg(14)-50 mg (14)-100 mg (7), 50 mg, 50 mg (42) -100 mg (14) tablet; lamotrigine odt kit (blue); lamotrigine odt kit (green); lamotrigine odt kit (orange); lamotrigine tab start kit-blue; lamotrigine tab start kt-green; lamotrigine tab start kt-orang</i> <b>MO</b>	1	
<i>lamotrigine 25 mg, 5 mg disper tab; lamotrigine 25 mg, 5 mg disper tablet</i> <b>MO</b>	1	
<i>lamotrigine er 100 mg, 200 mg, 25 mg, 250 mg, 300 mg, 50 mg tablet</i> <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
levetiracetam 1,000 mg, 500 mg, 750 mg tablet <b>MO</b>	1	
levetiracetam 100 mg/ml, 500 mg/5 ml soln; levetiracetam 100 mg/ml, 500 mg/5 ml vial <b>MO</b>	1	
levetiracetam 250 mg tablet <b>MO</b>	1	QL (60 per 30 days)
levetiracetam 500 mg/5 ml soln <b>MO</b>	1	QL (900 per 30 days)
levetiracetam er 500 mg tablet <b>MO</b>	1	QL (180 per 30 days)
levetiracetam er 750 mg tablet <b>MO</b>	1	QL (120 per 30 days)
levetiracetam-nacl 1,000mg/100; levetiracetam-nacl 1,500mg/100; levetiracetam-nacl 500 mg/100 <b>MO</b>	1	
MYSOLINE 250 MG, 50 MG TABLET <b>DL</b>	4	PA
NAYZILAM 5 MG/SPRAY (0.1 ML) NASAL SPRAY <b>DL</b>	3	QL (10 per 30 days)
NEMBUTAL SODIUM 50 MG/ML INJECTION SOLUTION <b>MO</b>	1	
NEURONTIN 100 MG, 300 MG, 400 MG CAPSULE <b>DL</b>	4	PA,QL (270 per 30 days)
NEURONTIN 250 MG/5 ML ORAL SOLUTION <b>MO</b>	3	PA,QL (2250 per 30 days)
NEURONTIN 600 MG, 800 MG TABLET <b>DL</b>	4	PA,QL (180 per 30 days)
ONFI 10 MG, 20 MG TABLET <b>DL</b>	4	PA
ONFI 2.5 MG/ML ORAL SUSPENSION <b>DL</b>	4	PA
oxcarbazepine 150 mg, 300 mg tablet <b>MO</b>	1	QL (60 per 30 days)
oxcarbazepine 300 mg/5 ml susp <b>MO</b>	1	
oxcarbazepine 600 mg tablet <b>MO</b>	1	
OXTELLAR XR 150 MG, 300 MG, 600 MG TABLET,EXTENDED RELEASE <b>DL</b>	4	ST
PEGANONE 250 MG TABLET <b>MO</b>	3	
pentobarbital 2,500 mg/50 ml <b>MO</b>	1	
phenobarbital 100 mg, 16.2 mg, 32.4 mg, 64.8 mg, 97.2 mg tablet <b>MO</b>	1	QL (90 per 30 days)
phenobarbital 15 mg, 60 mg tablet <b>MO</b>	1	QL (120 per 30 days)
phenobarbital 20 mg/5 ml elix <b>MO</b>	1	QL (1500 per 30 days)
phenobarbital 30 mg tablet <b>MO</b>	1	QL (300 per 30 days)
phenobarbital 130 mg/ml, 65 mg/ml vial <b>DL</b>	4	
PHENYTEK 200 MG, 300 MG CAPSULE <b>MO</b>	1	
phenytoin 100 mg/4 ml, 125 mg/5 ml susp <b>MO</b>	1	
phenytoin 50 mg tablet chew <b>MO</b>	1	
phenytoin 50 mg/ml syringe <b>MO</b>	1	
phenytoin 50 mg/ml vial <b>MO</b>	1	
phenytoin sod ext 100 mg, 200 mg, 300 mg cap <b>MO</b>	1	
primidone 250 mg, 50 mg tablet <b>MO</b>	1	
QUDEXY XR 100 MG, 50 MG CAPSULE SPRINKLE,EXTENDED RELEASE <b>DL</b>	4	PA,QL (30 per 30 days)
QUDEXY XR 150 MG, 200 MG CAPSULE SPRINKLE,EXTENDED RELEASE <b>DL</b>	4	PA,QL (60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
QUDEXY XR 25 MG CAPSULE SPRINKLE,EXTENDED RELEASE <b>DL</b>	4	PA,QL (90 per 30 days)
<i>roweepra 1,000 mg, 500 mg, 750 mg tablet</i> <b>MO</b>	1	
<i>roweepra xr 500 mg tablet,extended release</i> <b>MO</b>	1	QL (180 per 30 days)
<i>roweepra xr 750 mg tablet,extended release</i> <b>MO</b>	1	QL (120 per 30 days)
SABRIL 500 MG ORAL POWDER PACKET <b>DL</b>	4	PA,QL (180 per 30 days)
SABRIL 500 MG TABLET <b>DL</b>	4	PA,QL (180 per 30 days)
SECONAL SODIUM 100 MG CAPSULE <b>DL</b>	4	QL (90 per 30 days)
SPRITAM 1,000 MG TABLET FOR ORAL SUSPENSION <b>MO</b>	3	ST,QL (90 per 30 days)
SPRITAM 250 MG TABLET FOR ORAL SUSPENSION <b>MO</b>	3	ST,QL (360 per 30 days)
SPRITAM 500 MG TABLET FOR ORAL SUSPENSION <b>MO</b>	3	ST,QL (180 per 30 days)
SPRITAM 750 MG TABLET FOR ORAL SUSPENSION <b>MO</b>	3	ST,QL (120 per 30 days)
<i>subvenite 100 mg, 150 mg, 200 mg, 25 mg tablet</i> <b>MO</b>	1	
<i>subvenite starter (blue) kit 25 mg (35) tablets in a dose pack</i> <b>MO</b>	1	
<i>subvenite starter (green) kit 25 mg (84)-100 mg (14) tablet, dose pack</i> <b>MO</b>	1	
<i>subvenite starter (orange) kit 25 mg (42)-100 mg (7) tablet, dose pack</i> <b>MO</b>	1	
SYMPAZAN 10 MG, 20 MG, 5 MG ORAL FILM <b>DL</b>	4	PA,QL (60 per 30 days)
TEGRETOL 100 MG/5 ML ORAL SUSPENSION <b>MO</b>	3	
TEGRETOL 200 MG TABLET <b>MO</b>	3	
TEGRETOL XR 100 MG, 200 MG TABLET,EXTENDED RELEASE <b>MO</b>	3	QL (120 per 30 days)
TEGRETOL XR 400 MG TABLET,EXTENDED RELEASE <b>MO</b>	3	QL (225 per 30 days)
<i>tiagabine hcl 12 mg, 16 mg, 2 mg, 4 mg tablet</i> <b>MO</b>	1	
TOPAMAX 100 MG, 200 MG, 50 MG TABLET <b>DL</b>	4	QL (120 per 30 days)
TOPAMAX 15 MG, 25 MG SPRINKLE CAPSULE <b>DL</b>	4	
TOPAMAX 25 MG TABLET <b>DL</b>	4	QL (90 per 30 days)
<i>topiramate 100 mg, 200 mg, 50 mg tablet</i> <b>MO</b>	1	QL (120 per 30 days)
<i>topiramate 15 mg, 25 mg sprinkle cap</i> <b>MO</b>	1	
<i>topiramate 25 mg tablet</i> <b>MO</b>	1	QL (90 per 30 days)
<i>topiramate er 100 mg, 50 mg capsule</i> <b>MO</b>	3	PA,QL (30 per 30 days)
<i>topiramate er 150 mg, 200 mg capsule</i> <b>MO</b>	3	PA,QL (60 per 30 days)
<i>topiramate er 25 mg capsule</i> <b>MO</b>	3	PA,QL (90 per 30 days)
TRILEPTAL 150 MG, 300 MG TABLET <b>DL</b>	4	PA,QL (60 per 30 days)
TRILEPTAL 300 MG/5 ML (60 MG/ML) ORAL SUSPENSION <b>DL</b>	4	PA
TRILEPTAL 600 MG TABLET <b>DL</b>	4	PA
TROKENDI XR 100 MG, 50 MG CAPSULE, EXTENDED RELEASE <b>DL</b>	4	PA,QL (30 per 30 days)
TROKENDI XR 200 MG CAPSULE, EXTENDED RELEASE <b>DL</b>	4	PA,QL (60 per 30 days)
TROKENDI XR 25 MG CAPSULE,EXTENDED RELEASE <b>DL</b>	4	PA,QL (90 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
valproate sod 500 mg/5 ml vl <b>MO</b>	1	
valproic acid 250 mg capsule <b>MO</b>	1	
valproic acid 250 mg/5 ml soln; valproic acid 250 mg/5 ml, 250 mg/5 ml (5 ml), 500 mg/10 ml (10 ml) soln; valproic acid 500 mg/10 ml sol <b>MO</b>	1	
VALTOCO 10 MG/SPRAY (0.1 ML), 15 MG/2 SPRAY (7.5/0.1ML X 2), 20 MG/2 SPRAY (10MG/0.1ML X2), 5 MG/SPRAY (0.1 ML) NASAL SPRAY; VALTOCO 15 MG/2 SPRAY(7.5MG/0.1ML X2) NASAL SPRAY <b>DL</b>	4	QL (10 per 30 days)
vigabatrin 500 mg powder packt <b>DL</b>	4	PA,QL (180 per 30 days)
vigabatrin 500 mg tablet <b>DL</b>	4	PA,QL (180 per 30 days)
vigadrone 500 mg oral powder packet <b>DL</b>	4	PA,QL (180 per 30 days)
VIMPAT 10 MG/ML ORAL SOLUTION <b>MO</b>	3	QL (1395 per 30 days)
VIMPAT 100 MG, 150 MG, 200 MG, 50 MG TABLET <b>MO</b>	3	QL (60 per 30 days)
VIMPAT 200 MG/20 ML INTRAVENOUS SOLUTION <b>MO</b>	3	
XCOPRI 100 MG, 50 MG TABLET <b>DL</b>	4	PA,QL (30 per 30 days)
XCOPRI 150 MG, 200 MG TABLET <b>DL</b>	4	PA,QL (60 per 30 days)
XCOPRI MAINTENANCE PACK 250 MG/DAY (200 MG X 1 AND 50 MG X 1) TABLETS; XCOPRI MAINTENANCE PACK 350 MG/DAY (200 MG X 1 AND 150 MG X 1) TABLETS <b>DL</b>	4	PA,QL (56 per 28 days)
XCOPRI TITRATION PACK 12.5 MG (14)-25 MG (14) TABLETS IN A DOSE PACK <b>MO</b>	3	PA,QL (28 per 28 days)
XCOPRI TITRATION PACK 150 MG (14)-200 MG (14) TABLETS IN A DOSE PACK; XCOPRI TITRATION PACK 50 MG (14)-100 MG (14) TABLETS IN A DOSE PACK <b>DL</b>	4	PA,QL (28 per 28 days)
ZARONTIN 250 MG CAPSULE <b>MO</b>	3	
ZARONTIN 250 MG/5 ML ORAL SOLUTION <b>MO</b>	1	
ZONEGRAN 100 MG, 25 MG CAPSULE <b>DL</b>	4	PA
zonisamide 100 mg, 25 mg, 50 mg capsule <b>MO</b>	1	
<b>Antidementia Agents</b>		
ARICEPT 10 MG TABLET <b>MO</b>	3	PA,QL (60 per 30 days)
ARICEPT 23 MG, 5 MG TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
donepezil hcl 10 mg tablet <b>MO</b>	1	QL (60 per 30 days)
donepezil hcl 10 mg, 23 mg, 5 mg tablet; donepezil hcl odt 10 mg, 23 mg, 5 mg tablet <b>MO</b>	1	QL (30 per 30 days)
ergoloid mesylates 1 mg tab <b>DL</b>	4	
EXELON PATCH 13.3 MG/24 HOUR, 4.6 MG/24 HR, 9.5 MG/24 HR TRANSDERMAL <b>MO</b>	3	PA,QL (30 per 30 days)
galantamine 4 mg/ml oral soln <b>MO</b>	1	QL (200 per 30 days)
galantamine er 16 mg, 24 mg, 8 mg capsule <b>MO</b>	1	QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
galantamine hbr 12 mg, 4 mg, 8 mg tablet <b>MO</b>	1	QL (60 per 30 days)
memantine 5-10 mg titration pk <b>MO</b>	1	PA,QL (98 per 30 days)
memantine hcl 10 mg, 5 mg tablet <b>MO</b>	1	PA,QL (60 per 30 days)
memantine hcl 2 mg/ml solution <b>MO</b>	1	PA,QL (360 per 30 days)
memantine hcl er 14 mg, 21 mg, 28 mg, 7 mg capsule <b>MO</b>	1	PA,QL (30 per 30 days)
NAMENDA 10 MG, 5 MG TABLET <b>MO</b>	3	PA,QL (60 per 30 days)
NAMENDA TITRATION PAK 5 MG-10 MG TABLETS IN A DOSE PACK <b>MO</b>	3	PA,QL (98 per 30 days)
NAMENDA XR 14 MG, 21 MG, 28 MG, 7 MG CAPSULE SPRINKLE,EXTENDED RELEASE <b>MO</b>	3	PA,QL (30 per 30 days)
NAMENDA XR 7 MG-14 MG-21 MG-28 MG CAPSULE,SPRINKLE,EXT REL, DOSE PACK <b>MO</b>	3	PA,QL (28 per 28 days)
NAMZARIC 14 MG-10 MG CAPSULE SPRINKLE,EXTENDED RELEASE; NAMZARIC 21 MG-10 MG CAPSULE SPRINKLE,EXTENDED RELEASE; NAMZARIC 28 MG-10 MG CAPSULE SPRINKLE,EXTENDED RELEASE; NAMZARIC 7 MG-10 MG CAPSULE SPRINKLE,EXTENDED RELEASE <b>MO</b>	2	QL (30 per 30 days)
NAMZARIC 7/14/21/28 MG-10 MG CAPSULE,SPRINKLE,EXTEND RELEASE,DOSE PACK <b>MO</b>	2	QL (28 per 28 days)
RAZADYNE 12 MG, 4 MG, 8 MG TABLET <b>MO</b>	3	PA,QL (60 per 30 days)
RAZADYNE ER 16 MG, 24 MG, 8 MG CAPSULE,EXTENDED RELEASE <b>MO</b>	3	PA,QL (30 per 30 days)
rivastigmine 13.3 mg/24hr ptch; rivastigmine 4.6 mg/24hr patch; rivastigmine 9.5 mg/24hr patch <b>MO</b>	1	QL (30 per 30 days)
rivastigmine 1.5 mg, 3 mg capsule <b>MO</b>	1	QL (90 per 30 days)
rivastigmine 4.5 mg, 6 mg capsule <b>MO</b>	1	QL (60 per 30 days)
<b>Antidepressants</b>		
amitriptyline hcl 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg tab <b>MO</b>	1	
chlordiazepo-amitriptyl 5-12.5; chlordiazepox-amitriptyl 10-25 <b>DL</b>	1	
amoxapine 100 mg, 150 mg, 25 mg, 50 mg tablet <b>MO</b>	1	
ANAFRANIL 25 MG, 50 MG, 75 MG CAPSULE <b>DL</b>	4	
APLENZIN 174 MG, 348 MG, 522 MG TABLET,EXTENDED RELEASE <b>DL</b>	4	ST,QL (30 per 30 days)
BRISDELLE 7.5 MG CAPSULE <b>MO</b>	3	QL (30 per 30 days)
bupropion hcl 100 mg, 75 mg tablet <b>MO</b>	1	QL (180 per 30 days)
bupropion hcl sr 100 mg tablet <b>MO</b>	1	QL (120 per 30 days)
bupropion hcl sr 150 mg tablet <b>MO</b>	1	QL (90 per 30 days)
bupropion hcl sr 200 mg tablet <b>MO</b>	1	QL (60 per 30 days)
bupropion hcl xl 150 mg tablet <b>MO</b>	1	QL (90 per 30 days)
bupropion hcl xl 300 mg tablet <b>MO</b>	1	QL (60 per 30 days)
bupropion hcl xl 450 mg tablet <b>MO</b>	1	ST,QL (30 per 30 days)
CELEXA 10 MG, 40 MG TABLET <b>MO</b>	3	PA,QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
CELEXA 20 MG TABLET <b>MO</b>	3	PA,QL (60 per 30 days)
citalopram hbr 10 mg, 40 mg tablet <b>MO</b>	1	QL (30 per 30 days)
citalopram hbr 10 mg/5 ml soln <b>MO</b>	1	
citalopram hbr 20 mg tablet <b>MO</b>	1	QL (60 per 30 days)
clomipramine 25 mg, 50 mg, 75 mg capsule <b>MO</b>	1	
CYMBALTA 20 MG, 30 MG, 60 MG CAPSULE,DELAYED RELEASE <b>MO</b>	3	QL (60 per 30 days)
desipramine 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg tablet <b>MO</b>	1	
desvenlafaxine er 100 mg, 50 mg tab; desvenlafaxine er 100 mg, 50 mg tablet <b>MO</b>	3	ST,QL (30 per 30 days)
desvenlafaxine succnt er 100 mg, 25 mg, 50 mg; desvenlafaxine succnt er 100mg <b>MO</b>	1	QL (30 per 30 days)
DRIZALMA SPRINKLE 20 MG, 30 MG, 40 MG, 60 MG CAPSULE,DELAYED RELEASE <b>MO</b>	3	PA,QL (60 per 30 days)
duloxetine hcl dr 20 mg, 30 mg, 40 mg, 60 mg cap <b>MO</b>	1	QL (60 per 30 days)
EFFEXOR XR 150 MG CAPSULE,EXTENDED RELEASE <b>DL</b>	4	PA,QL (60 per 30 days)
EFFEXOR XR 37.5 MG CAPSULE,EXTENDED RELEASE <b>DL</b>	4	PA,QL (30 per 30 days)
EFFEXOR XR 75 MG CAPSULE,EXTENDED RELEASE <b>DL</b>	4	PA,QL (90 per 30 days)
EMSAM 12 MG/24 HR, 6 MG/24 HR, 9 MG/24 HR TRANSDERMAL 24 HOUR PATCH <b>DL</b>	4	QL (30 per 30 days)
escitalopram 10 mg tablet <b>MO</b>	1	QL (45 per 30 days)
escitalopram 20 mg, 5 mg tablet <b>MO</b>	1	QL (30 per 30 days)
escitalopram oxalate 5 mg/5 ml <b>MO</b>	1	QL (600 per 30 days)
FETZIMA 120 MG, 20 MG, 40 MG, 80 MG CAPSULE,EXTENDED RELEASE <b>MO</b>	3	PA,QL (30 per 30 days)
FETZIMA 20 MG (2)-40 MG (26) CAPSULE,EXTENDED RELEASE,24 HR,DOSE PACK <b>MO</b>	3	PA,QL (28 per 28 days)
fluoxetine 20 mg/5 ml solution <b>MO</b>	1	
fluoxetine dr 90 mg capsule <b>MO</b>	1	QL (4 per 28 days)
fluoxetine hcl 10 mg tablet <b>MO</b>	1	QL (240 per 30 days)
fluoxetine hcl 10 mg, 40 mg capsule <b>MO</b>	1	QL (60 per 30 days)
fluoxetine hcl 20 mg capsule <b>MO</b>	1	QL (120 per 30 days)
fluoxetine hcl 20 mg tablet <b>MO</b>	1	QL (120 per 30 days)
fluoxetine hcl 60 mg tablet <b>MO</b>	1	QL (30 per 30 days)
fluvoxamine er 100 mg, 150 mg capsule <b>MO</b>	1	QL (60 per 30 days)
fluvoxamine maleate 100 mg, 25 mg, 50 mg tab <b>MO</b>	1	QL (90 per 30 days)
FORFIVO XL 450 MG TABLET,EXTENDED RELEASE <b>MO</b>	3	ST,QL (30 per 30 days)
imipramine hcl 10 mg, 25 mg, 50 mg tablet <b>MO</b>	1	
imipramine pamoate 100 mg, 125 mg, 150 mg, 75 mg cap <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
KHEDEZLA ER 100 MG, 50 MG TABLET <b>MO</b>	3	ST,QL (30 per 30 days)
LEXAPRO 10 MG TABLET <b>MO</b>	3	PA,QL (45 per 30 days)
LEXAPRO 20 MG, 5 MG TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
<i>maprotiline 25 mg, 50 mg, 75 mg tablet</i> <b>MO</b>	1	
MARPLAN 10 MG TABLET <b>MO</b>	3	
<i>mirtazapine 15 mg, 30 mg, 45 mg odt</i> <b>MO</b>	1	QL (30 per 30 days)
<i>mirtazapine 15 mg, 30 mg, 45 mg, 7.5 mg tablet</i> <b>MO</b>	1	
NARDIL 15 MG TABLET <b>MO</b>	3	
<i>nefazodone hcl 100 mg, 150 mg, 200 mg, 250 mg, 50 mg tablet</i> <b>MO</b>	1	
NORPRAMIN 10 MG, 25 MG TABLET <b>MO</b>	3	
<i>nortriptyline 10 mg/5 ml soln</i> <b>MO</b>	1	
<i>nortriptyline hcl 10 mg, 25 mg, 50 mg, 75 mg cap</i> <b>MO</b>	1	
<i>olanzapine-fluoxetine 12-25 mg, 12-50 mg, 3-25 mg, 6-25 mg, 6-50 mg</i> <b>MO</b>	1	QL (30 per 30 days)
PAMELOR 10 MG, 25 MG, 50 MG, 75 MG CAPSULE <b>DL</b>	4	
PARNATE 10 MG TABLET <b>DL</b>	4	
<i>paroxetine er 12.5 mg, 37.5 mg tablet</i> <b>MO</b>	1	QL (60 per 30 days)
<i>paroxetine er 25 mg tablet</i> <b>MO</b>	1	QL (90 per 30 days)
<i>paroxetine hcl 10 mg, 20 mg tablet</i> <b>MO</b>	1	QL (30 per 30 days)
<i>paroxetine hcl 30 mg, 40 mg tablet</i> <b>MO</b>	1	QL (60 per 30 days)
<i>paroxetine mesylate 7.5 mg cap</i> <b>MO</b>	1	QL (30 per 30 days)
PAXIL 10 MG, 20 MG TABLET <b>MO</b>	3	QL (30 per 30 days)
PAXIL 10 MG/5 ML ORAL SUSPENSION <b>MO</b>	3	
PAXIL 30 MG, 40 MG TABLET <b>MO</b>	3	QL (60 per 30 days)
PAXIL CR 12.5 MG, 37.5 MG TABLET,EXTENDED RELEASE <b>MO</b>	3	QL (60 per 30 days)
PAXIL CR 25 MG TABLET,EXTENDED RELEASE <b>MO</b>	3	QL (90 per 30 days)
<i>perphen-amitrip 2 mg-10 mg tab; perphen-amitrip 2 mg-25 mg tab; perphen-amitrip 4 mg-10 mg tab; perphen-amitrip 4 mg-25 mg tab; perphen-amitrip 4 mg-50 mg tab</i> <b>MO</b>	1	
PEXEVA 10 MG, 20 MG TABLET <b>MO</b>	3	QL (30 per 30 days)
PEXEVA 30 MG, 40 MG TABLET <b>MO</b>	3	QL (60 per 30 days)
<i>phenelzine sulfate 15 mg tab</i> <b>MO</b>	1	
PRISTIQ 100 MG, 25 MG, 50 MG TABLET,EXTENDED RELEASE <b>MO</b>	3	PA,QL (30 per 30 days)
<i>protriptyline hcl 10 mg, 5 mg tablet</i> <b>MO</b>	1	
PROZAC 10 MG, 40 MG CAPSULE <b>DL</b>	4	PA,QL (60 per 30 days)
PROZAC 20 MG CAPSULE <b>DL</b>	4	PA,QL (120 per 30 days)
REMERON 15 MG, 30 MG TABLET <b>MO</b>	3	
REMERON SOLTAB 15 MG, 30 MG, 45 MG DISINTEGRATING TABLET <b>MO</b>	3	QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
SARAFEM 10 MG TABLET <b>MO</b>	3	QL (240 per 30 days)
SARAFEM 20 MG TABLET <b>MO</b>	3	QL (120 per 30 days)
sertraline 20 mg/ml oral conc <b>MO</b>	1	
sertraline hcl 100 mg tablet <b>MO</b>	1	QL (60 per 30 days)
sertraline hcl 25 mg, 50 mg tablet <b>MO</b>	1	QL (90 per 30 days)
SURMONTIL 100 MG, 25 MG, 50 MG CAPSULE <b>MO</b>	3	
SYMBYAX 12 MG-50 MG CAPSULE; SYMBYAX 12-25 MG, 12-50 MG, 3-25 MG, 6-25 MG, 6-50 MG CAPSULE; SYMBYAX 3 MG-25 MG CAPSULE; SYMBYAX 6 MG-25 MG CAPSULE; SYMBYAX 6 MG-50 MG CAPSULE <b>MO</b>	3	PA,QL (30 per 30 days)
TOFRANIL 10 MG, 25 MG, 50 MG TABLET <b>DL</b>	4	
tranylcypromine sulf 10 mg tab <b>MO</b>	1	
trazodone 100 mg, 150 mg, 300 mg, 50 mg tablet <b>MO</b>	1	
trimipramine maleate 100 mg, 25 mg, 50 mg cap; trimipramine maleate 100 mg, 25 mg, 50 mg cp <b>MO</b>	1	
TRINTELLIX 10 MG, 20 MG, 5 MG TABLET <b>MO</b>	3	ST,QL (30 per 30 days)
venlafaxine hcl 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg tablet <b>MO</b>	1	
venlafaxine hcl er 150 mg cap <b>MO</b>	1	QL (60 per 30 days)
venlafaxine hcl er 150 mg, 225 mg, 37.5 mg tab <b>MO</b>	1	QL (30 per 30 days)
venlafaxine hcl er 37.5 mg cap <b>MO</b>	1	QL (30 per 30 days)
venlafaxine hcl er 75 mg cap <b>MO</b>	1	QL (90 per 30 days)
venlafaxine hcl er 75 mg tab <b>MO</b>	1	QL (60 per 30 days)
VIIBRYD 10 MG (7)-20 MG (23) TABLETS IN A DOSE PACK; VIIBRYD 10 MG, 10 MG (7)- 20 MG (23), 20 MG, 40 MG TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
WELLBUTRIN SR 100 MG TABLET, 12 HR SUSTAINED-RELEASE <b>MO</b>	3	PA,QL (120 per 30 days)
WELLBUTRIN SR 150 MG TABLET, 12 HR SUSTAINED-RELEASE <b>MO</b>	3	PA,QL (90 per 30 days)
WELLBUTRIN SR 200 MG TABLET, 12 HR SUSTAINED-RELEASE <b>MO</b>	3	PA,QL (60 per 30 days)
WELLBUTRIN XL 150 MG 24 HR TABLET, EXTENDED RELEASE <b>DL</b>	4	PA,QL (90 per 30 days)
WELLBUTRIN XL 300 MG 24 HR TABLET, EXTENDED RELEASE <b>DL</b>	4	PA,QL (60 per 30 days)
ZOLOFT 100 MG TABLET <b>MO</b>	3	PA,QL (60 per 30 days)
ZOLOFT 20 MG/ML ORAL CONCENTRATE <b>MO</b>	3	PA
ZOLOFT 25 MG, 50 MG TABLET <b>MO</b>	3	PA,QL (90 per 30 days)
ZULRESSO 5 MG/ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA,QL (100 per 365 days)
<b>Antiemetics</b>		
AKYNZEO (FOSNETUPITANT) 235 MG-0.25 MG INTRAVENOUS POWDER FOR SOLUTION <b>DL</b>	4	PA,QL (4 per 28 days)
AKYNZEO (FOSNETUPITANT) 235 MG-0.25 MG/20 ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA,QL (80 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
AKYNZEO (NETUPITANT) 300 MG-0.5 MG CAPSULE <b>DL</b>	4	PA,QL (4 per 28 days)
ANZEMET 100 MG, 50 MG TABLET <b>MO</b>	3	B vs D,QL (4 per 28 days)
<i>aprepitant 125 mg, 40 mg capsule</i> <b>MO</b>	1	B vs D,QL (2 per 28 days)
<i>aprepitant 125-80-80 mg pack</i> <b>MO</b>	1	B vs D,QL (6 per 28 days)
<i>aprepitant 80 mg capsule</i> <b>MO</b>	1	B vs D,QL (4 per 28 days)
BONJESTA 20 MG-20 MG TABLET,IMMEDIATE AND DELAY RELEASE <b>MO</b>	3	QL (60 per 30 days)
CESAMET 1 MG CAPSULE <b>DL</b>	4	PA,QL (180 per 30 days)
COMPAZINE 10 MG, 5 MG TABLET <b>MO</b>	3	B vs D
COMPAZINE 25 MG RECTAL SUPPOSITORY <b>MO</b>	1	
<i>compro 25 mg rectal suppository</i> <b>MO</b>	1	
DICLEGIS 10 MG-10 MG TABLET,DELAYED RELEASE <b>MO</b>	3	QL (120 per 30 days)
<i>dimenhydrinate 50 mg/ml vial</i> <b>MO</b>	1	
<i>doxylamine-pyridoxine 10-10 mg</i> <b>MO</b>	1	QL (120 per 30 days)
<i>dronabinol 10 mg, 2.5 mg, 5 mg capsule</i> <b>MO</b>	1	B vs D,QL (120 per 30 days)
EMEND 125 MG (1)-80 MG (2) CAPSULES IN A DOSE PACK <b>MO</b>	3	PA,QL (6 per 28 days)
EMEND 125 MG (25 MG/ML FINAL CONC.) ORAL SUSPENSION <b>MO</b>	3	B vs D,QL (3 per 28 days)
EMEND 125 MG, 40 MG CAPSULE <b>MO</b>	3	PA,QL (2 per 28 days)
EMEND 80 MG CAPSULE <b>MO</b>	3	PA,QL (4 per 28 days)
EMEND (FOSAPREPITANT) 150 MG INTRAVENOUS SOLUTION <b>MO</b>	3	PA
<i>fosaprepitant 150 mg vial</i> <b>MO</b>	1	PA
<i>granisetron hcl 0.1 mg/ml vial; granisetron hcl 1 mg/ml vial</i> <b>MO</b>	1	
<i>granisetron hcl 1 mg tablet</i> <b>MO</b>	1	B vs D,QL (28 per 28 days)
<i>granisetron hcl 1 mg/ml vial; granisetron hcl 4 mg/4 ml vial</i> <b>MO</b>	1	
MARINOL 10 MG, 2.5 MG, 5 MG CAPSULE <b>DL</b>	4	PA,QL (120 per 30 days)
<i>meclizine 12.5 mg, 25 mg tablet</i> <b>MO</b>	1	
<i>metoclopramide 10 mg, 5 mg tablet</i> <b>MO</b>	1	
<i>metoclopramide 10 mg/2 ml syr</i> <b>MO</b>	1	
<i>metoclopramide 10 mg/2 ml vial; metoclopramide 5 mg/5 ml, 5 mg/ml soln</i> <b>MO</b>	1	
<i>metoclopramide hcl 10 mg odt</i> <b>MO</b>	1	QL (180 per 30 days)
<i>metoclopramide hcl 5 mg odt</i> <b>MO</b>	1	QL (360 per 30 days)
<i>ondansetron odt 4 mg, 8 mg tablet</i> <b>MO</b>	1	B vs D,QL (90 per 30 days)
<i>ondansetron 4 mg/5 ml solution</i> <b>MO</b>	1	B vs D,QL (450 per 30 days)
<i>ondansetron 40 mg/20 ml vial</i> <b>MO</b>	1	
<i>ondansetron hcl 24 mg tablet</i> <b>MO</b>	1	B vs D,QL (30 per 30 days)
<i>ondansetron hcl 4 mg, 8 mg tablet</i> <b>MO</b>	1	B vs D,QL (90 per 30 days)
<i>ondansetron hcl 4 mg/2 ml syr</i> <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ondansetron hcl 4 mg/2 ml vial <b>MO</b>	1	
phenadoz 12.5 mg, 25 mg suppository <b>MO</b>	1	
PHENERGAN 25 MG/ML, 50 MG/ML INJECTION SOLUTION <b>MO</b>	1	
prochlorperazine 25 mg supp <b>MO</b>	1	
prochlorperazine 10 mg/2 ml vl <b>MO</b>	1	
prochlorperazine 10 mg, 5 mg tab; prochlorperazine 10 mg, 5 mg tablet <b>MO</b>	1	B vs D
promethazine 12.5 mg, 25 mg, 50 mg suppos; promethazine 12.5 mg, 25 mg, 50 mg suppository <b>MO</b>	1	
promethazine 12.5 mg, 25 mg, 50 mg tablet <b>MO</b>	1	
promethazine 25 mg/ml, 50 mg/ml vial <b>MO</b>	1	
promethazine 6.25 mg/5 ml syrj <b>MO</b>	1	
promethegan 12.5 mg, 25 mg, 50 mg rectal suppository <b>MO</b>	1	
REGLAN 10 MG, 5 MG TABLET <b>MO</b>	3	
SANCUSO 3.1 MG/24 HOUR TRANSDERMAL PATCH <b>MO</b>	3	QL (4 per 30 days)
scopolamine 1 mg/3 day patch <b>MO</b>	1	QL (10 per 30 days)
SYNDROS 5 MG/ML ORAL SOLUTION <b>DL</b>	4	PA
TIGAN 100 MG/ML INTRAMUSCULAR SOLUTION <b>MO</b>	3	
TIGAN 300 MG CAPSULE <b>MO</b>	3	B vs D
TRANSDERM-SCOP 1.5 MG TRANSDERMAL PATCH (1 MG OVER 3 DAYS) <b>MO</b>	3	QL (10 per 30 days)
trimethobenzamide 300 mg cap <b>MO</b>	1	B vs D
VARUBI 166.5 MG/92.5 ML INTRAVENOUS EMULSION <b>MO</b>	3	PA,QL (185 per 28 days)
ZOFRAN 4 MG, 8 MG TABLET <b>DL</b>	4	PA,QL (90 per 30 days)
ZOFRAN 4 MG/5 ML ORAL SOLN <b>MO</b>	3	PA,QL (450 per 30 days)
ZOFRAN ODT 4 MG, 8 MG TABLET <b>MO</b>	3	PA,QL (90 per 30 days)
ZUPLENZ 4 MG, 8 MG ORAL SOLUBLE FILM <b>DL</b>	4	B vs D,QL (90 per 30 days)
<b>Antifungals</b>		
ABELCET 5 MG/ML INTRAVENOUS SUSPENSION <b>DL</b>	4	B vs D
AMBISOME 50 MG INTRAVENOUS SUSPENSION <b>DL</b>	4	B vs D
amphotericin b 50 mg vial <b>MO</b>	1	B vs D
ANCOBON 250 MG, 500 MG CAPSULE <b>DL</b>	4	
CANCIDAS 50 MG, 70 MG INTRAVENOUS SOLUTION <b>DL</b>	4	PA
caspofungin acetate 50 mg, 70 mg vial <b>DL</b>	4	
ciclodan 8 % topical solution <b>MO</b>	1	QL (13.2 per 30 days)
ciclopirox 0.77% cream <b>MO</b>	1	QL (90 per 30 days)
ciclopirox 0.77% gel <b>MO</b>	1	QL (100 per 30 days)
ciclopirox 0.77% topical susp <b>MO</b>	1	QL (60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>ciclopirox 1% shampoo</i> <sup>MO</sup>	1	QL (120 per 30 days)
<i>ciclopirox 8% solution</i> <sup>MO</sup>	1	QL (13.2 per 30 days)
<i>clotrimazole 1% solution</i> <sup>MO</sup>	1	
<i>clotrimazole 1% topical cream</i> <sup>MO</sup>	1	
<i>clotrimazole 10 mg troche</i> <sup>MO</sup>	1	
<i>clotrimazole-betamethasone crm</i> <sup>MO</sup>	1	QL (180 per 30 days)
<i>clotrimazole-betamethasone lot</i> <sup>MO</sup>	1	QL (90 per 28 days)
CRESEMBA 186 MG CAPSULE <sup>DL</sup>	4	PA,QL (180 per 30 days)
CRESEMBA 372 MG INTRAVENOUS SOLUTION <sup>DL</sup>	4	PA
DIFLUCAN 10 MG/ML, 40 MG/ML ORAL SUSPENSION <sup>DL</sup>	4	PA
DIFLUCAN 100 MG, 150 MG, 200 MG, 50 MG TABLET <sup>MO</sup>	3	PA
<i>econazole nitrate 1% cream</i> <sup>MO</sup>	1	PA,QL (85 per 30 days)
ERAXIS(WATER DILUENT) 100 MG INTRAVENOUS SOLUTION <sup>DL</sup>	4	
ERAXIS(WATER DILUENT) 50 MG INTRAVENOUS SOLUTION <sup>MO</sup>	3	
ERTACZO 2 % TOPICAL CREAM <sup>DL</sup>	4	QL (60 per 30 days)
EXELDERM 1 % TOPICAL CREAM <sup>MO</sup>	3	
EXELDERM 1 % TOPICAL SOLUTION <sup>MO</sup>	3	QL (60 per 30 days)
EXTINA 2 % TOPICAL FOAM <sup>MO</sup>	3	QL (100 per 30 days)
<i>fluconazole 10 mg/ml, 40 mg/ml susp</i> <sup>MO</sup>	1	
<i>fluconazole 100 mg, 150 mg, 200 mg, 50 mg tablet</i> <sup>MO</sup>	1	
<i>fluconazole-dext 200 mg/100 ml</i> <sup>MO</sup>	1	
<i>fluconazole-nacl 100 mg/50 ml, 200 mg/100 ml, 400 mg/200 ml</i> <sup>MO</sup>	1	
<i>flucytosine 250 mg, 500 mg capsule</i> <sup>DL</sup>	4	
<i>griseofulvin 125 mg/5 ml susp</i> <sup>MO</sup>	1	
<i>griseofulvin micro 500 mg tab</i> <sup>MO</sup>	1	
<i>griseofulvin ultra 125 mg, 250 mg tab</i> <sup>MO</sup>	1	
<i>gynazole-1 2 % vaginal cream</i> <sup>MO</sup>	1	
<i>itraconazole 10 mg/ml solution</i> <sup>MO</sup>	1	QL (150 per 30 days)
<i>itraconazole 100 mg capsule</i> <sup>MO</sup>	1	QL (120 per 30 days)
JUBLIA 10 % TOPICAL SOLUTION WITH APPLICATOR <sup>DL</sup>	4	PA,QL (4 per 28 days)
KERYDIN 5 % TOPICAL SOLUTION WITH APPLICATOR <sup>DL</sup>	4	QL (10 per 30 days)
<i>ketoconazole 2% cream</i> <sup>MO</sup>	1	QL (60 per 30 days)
<i>ketoconazole 2% foam</i> <sup>MO</sup>	1	QL (100 per 30 days)
<i>ketoconazole 2% shampoo</i> <sup>MO</sup>	1	QL (120 per 30 days)
<i>ketoconazole 200 mg tablet</i> <sup>MO</sup>	1	PA
<i>ketodan 2 % topical foam</i> <sup>MO</sup>	1	QL (100 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
LOPROX 1 % SHAMPOO <b>MO</b>	3	PA,QL (120 per 30 days)
LOPROX (AS OLAMINE) 0.77 % TOPICAL CREAM <b>MO</b>	3	PA,QL (90 per 30 days)
LOPROX (AS OLAMINE) 0.77 % TOPICAL SUSPENSION <b>MO</b>	3	PA,QL (60 per 30 days)
LOTRISONE CREAM <b>MO</b>	3	PA,QL (180 per 30 days)
<i>luliconazole 1% cream</i> <b>MO</b>	1	ST,QL (60 per 28 days)
LUZU 1 % TOPICAL CREAM <b>MO</b>	3	ST,QL (60 per 28 days)
MENTAX 1 % TOPICAL CREAM <b>MO</b>	3	QL (30 per 30 days)
<i>micafungin 100 mg, 50 mg vial</i> <b>DL</b>	4	
<i>miconazole-zinc-petro 0.25-15%</i> <b>MO</b>	1	
<i>miconazole-3 200 mg vaginal suppository</i> <b>MO</b>	1	
MYCAMINE 100 MG, 50 MG INTRAVENOUS SOLUTION <b>DL</b>	4	
<i>naftifine hcl 1% cream</i> <b>MO</b>	1	ST,QL (90 per 30 days)
<i>naftifine hcl 1% gel</i> <b>MO</b>	1	ST,QL (90 per 30 days)
<i>naftifine hcl 2% cream</i> <b>MO</b>	1	ST,QL (120 per 30 days)
NAFTIN 1 % TOPICAL GEL <b>MO</b>	3	ST,QL (90 per 30 days)
NAFTIN 2 % TOPICAL CREAM <b>MO</b>	3	ST,QL (120 per 30 days)
NAFTIN 2 % TOPICAL GEL <b>MO</b>	3	ST,QL (120 per 30 days)
NIZORAL 2 % SHAMPOO <b>MO</b>	3	QL (120 per 30 days)
NOXAFIL 100 MG TABLET,DELAYED RELEASE <b>DL</b>	4	PA
NOXAFIL 200 MG/5 ML (40 MG/ML) ORAL SUSPENSION <b>DL</b>	4	PA,QL (840 per 28 days)
NOXAFIL 300 MG/16.7 ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA
<i>nyamyc 100,000 unit/gram topical powder</i> <b>MO</b>	1	PA
<i>nystatin 100,000 unit/gm cream</i> <b>MO</b>	1	
<i>nystatin 100,000 unit/gm oint</i> <b>MO</b>	1	
<i>nystatin 100,000 unit/gm powd</i> <b>MO</b>	1	PA
<i>nystatin 100,000 unit/ml susp</i> <b>MO</b>	1	
<i>nystatin 500,000 unit oral tab</i> <b>MO</b>	1	
<i>nystatin-triamcinolone cream</i> <b>MO</b>	1	
<i>nystatin-triamcinolone ointm</i> <b>MO</b>	1	
<i>nystop 100,000 unit/gram topical powder</i> <b>MO</b>	1	PA
ONMEL 200 MG TABLET <b>DL</b>	4	QL (28 per 28 days)
ORAVIG 50 MG BUCCAL TABLET <b>DL</b>	4	QL (14 per 30 days)
<i>oxiconazole nitrate 1% cream</i> <b>DL</b>	4	PA
OXISTAT 1 % LOTION <b>DL</b>	4	PA
OXISTAT 1 % TOPICAL CREAM <b>DL</b>	4	
PENLAC 8% SOLUTION <b>MO</b>	3	QL (13.2 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
posaconazole 200 mg/5 ml susp <sup>DL</sup>	4	PA,QL (840 per 28 days)
posaconazole dr 100 mg tablet <sup>DL</sup>	4	PA
SPORANOX 10 MG/ML ORAL SOLUTION <sup>DL</sup>	4	QL (150 per 30 days)
SPORANOX 100 MG CAPSULE <sup>DL</sup>	4	PA,QL (120 per 30 days)
SPORANOX PULSEPAK 100 MG CAPSULE <sup>MO</sup>	3	PA,QL (120 per 30 days)
terbinafine hcl 250 mg tablet <sup>MO</sup>	1	
terconazole 0.4% cream; terconazole 0.8% cream <sup>MO</sup>	1	
terconazole 80 mg suppository <sup>MO</sup>	1	
TOLSURA 65 MG ORAL SOLID DISPERSION CAPSULE <sup>DL</sup>	4	PA,QL (120 per 30 days)
VFEND 200 MG, 50 MG TABLET <sup>DL</sup>	4	PA,QL (120 per 30 days)
VFEND 200 MG/5 ML (40 MG/ML) ORAL SUSPENSION <sup>DL</sup>	4	PA,QL (400 per 30 days)
VFEND IV 200 MG INTRAVENOUS SOLUTION <sup>DL</sup>	4	B vs D
voriconazole 200 mg vial <sup>DL</sup>	4	PA
voriconazole 200 mg, 50 mg tablet <sup>MO</sup>	1	PA,QL (120 per 30 days)
voriconazole 40 mg/ml susp <sup>DL</sup>	4	PA,QL (400 per 30 days)
VUSION 0.25 %-15 %-81.35 % TOPICAL OINTMENT <sup>MO</sup>	3	
XOLEGEL 2 % TOPICAL <sup>DL</sup>	4	
<b>Antigout Agents</b>		
allopurinol 100 mg, 300 mg tablet <sup>MO</sup>	1	
allopurinol sodium 500 mg vial <sup>MO</sup>	1	
ALOPRIM 500 MG INTRAVENOUS SOLUTION <sup>MO</sup>	3	
DUZALLO 200 MG-200 MG TABLET; DUZALLO 200 MG-300 MG TABLET <sup>MO</sup>	3	PA,QL (30 per 30 days)
febuxostat 40 mg, 80 mg tablet <sup>MO</sup>	1	ST,QL (30 per 30 days)
GLOPERBA 0.6 MG/5 ML ORAL SOLUTION <sup>MO</sup>	3	PA,QL (300 per 30 days)
MITIGARE 0.6 MG CAPSULE <sup>MO</sup>	2	
probenecid 500 mg tablet <sup>MO</sup>	1	
probenecid-colchicine tablet <sup>MO</sup>	1	
ULORIC 40 MG, 80 MG TABLET <sup>MO</sup>	3	ST,QL (30 per 30 days)
ZURAMPIC 200 MG TABLET <sup>MO</sup>	3	PA,QL (30 per 30 days)
ZYLOPRIM 100 MG, 300 MG TABLET <sup>MO</sup>	3	
<b>ANTIMIGRAINE AGENTS</b>		
AIMOVIG AUTOINJECTOR 140 MG/ML SUBCUTANEOUS AUTO-INJECTOR <sup>MO</sup>	3	PA,QL (1 per 30 days)
AIMOVIG AUTOINJECTOR 70 MG/ML SUBCUTANEOUS AUTO-INJECTOR <sup>MO</sup>	3	PA,QL (2 per 30 days)
AIMOVIG 140 MG DOSE-2 AUTOINJ <sup>MO</sup>	3	PA,QL (2 per 30 days)
AJOVY 225 MG/1.5 ML SUBCUTANEOUS AUTO-INJECTOR <sup>MO</sup>	3	PA,QL (1.5 per 30 days)
AJOVY SYRINGE 225 MG/1.5 ML SUBCUTANEOUS <sup>MO</sup>	3	PA,QL (1.5 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>almotriptan malate 12.5 mg, 6.25 mg tab</i> <b>MO</b>	1	ST,QL (9 per 30 days)
AMERGE 1 MG, 2.5 MG TABLET <b>MO</b>	3	PA,QL (9 per 30 days)
CAFERGOT 1 MG-100 MG TABLET <b>MO</b>	1	QL (40 per 30 days)
D.H.E.45 1 MG/ML INJECTION SOLUTION <b>DL</b>	4	
<i>dihydroergotamine 1 mg/ml amp</i> <b>DL</b>	4	
<i>dihydroergotamine 4 mg/ml spry</i> <b>DL</b>	4	QL (8 per 30 days)
<i>eletriptan hbr 20 mg, 40 mg tablet</i> <b>MO</b>	1	ST,QL (9 per 30 days)
EMGALITY PEN 120 MG/ML SUBCUTANEOUS PEN INJECTOR <b>MO</b>	3	PA,QL (2 per 30 days)
EMGALITY 120 MG/ML SUBCUTANEOUS SYRINGE <b>MO</b>	3	PA,QL (2 per 30 days)
EMGALITY 300 MG/3 ML (100 MG/ML X 3) SUBCUTANEOUS SYRINGE <b>MO</b>	3	PA,QL (3 per 30 days)
ERGOMAR 2 MG SUBLINGUAL TABLET <b>DL</b>	4	QL (20 per 28 days)
<i>ergotamine-caffeine 1-100mg tb</i> <b>MO</b>	1	QL (40 per 30 days)
FROVA 2.5 MG TABLET <b>DL</b>	4	ST,QL (12 per 30 days)
<i>frovatriptan succ 2.5 mg tab</i> <b>MO</b>	1	ST,QL (12 per 30 days)
IMITREX 100 MG, 25 MG, 50 MG TABLET <b>DL</b>	4	PA,QL (9 per 30 days)
IMITREX 20 MG/ACTUATION, 5 MG/ACTUATION NASAL SPRAY <b>DL</b>	4	PA,QL (12 per 30 days)
IMITREX 6 MG/0.5 ML SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA,QL (6 per 30 days)
IMITREX STATDOSE PEN 4 MG/0.5 ML, 6 MG/0.5 ML SUBCUTANEOUS PEN INJECTOR <b>MO</b>	3	PA,QL (6 per 30 days)
IMITREX STATDOSE REFILL 4 MG/0.5 ML, 6 MG/0.5 ML SUBCUTANEOUS CARTRIDGE <b>DL</b>	4	PA,QL (6 per 30 days)
MAXALT 10 MG TABLET <b>MO</b>	3	PA,QL (12 per 30 days)
MAXALT MLT 10 MG, 5 MG TABLET; MAXALT-MLT 10 MG, 5 MG DISINTEGRATING TABLET <b>MO</b>	3	PA,QL (12 per 30 days)
<i>migergot 2 mg-100 mg rectal suppository</i> <b>DL</b>	4	QL (20 per 28 days)
MIGRANAL 0.5 MG/PUMP ACT. (4 MG/ML) NASAL SPRAY <b>DL</b>	4	QL (8 per 30 days)
<i>naratriptan hcl 1 mg, 2.5 mg tablet</i> <b>MO</b>	1	QL (9 per 30 days)
ONZETRA XSAIL 11 MG POWDER FOR NASAL INHALATION <b>DL</b>	4	ST,QL (16 per 30 days)
RELPAZ 20 MG, 40 MG TABLET <b>MO</b>	3	ST,QL (9 per 30 days)
REYVOW 100 MG TABLET <b>MO</b>	3	PA,QL (8 per 30 days)
REYVOW 50 MG TABLET <b>MO</b>	3	PA,QL (4 per 30 days)
<i>rizatriptan 10 mg, 5 mg odt; rizatriptan 10 mg, 5 mg tablet</i> <b>MO</b>	1	QL (12 per 30 days)
<i>sumatriptan 20 mg nasal spray; sumatriptan 5 mg nasal spray</i> <b>MO</b>	1	QL (12 per 30 days)
<i>sumatriptan 4 mg/0.5 ml, 6 mg/0.5 ml cart</i> <b>MO</b>	3	QL (6 per 30 days)
<i>sumatriptan 4 mg/0.5 ml, 6 mg/0.5 ml inject</i> <b>MO</b>	1	QL (6 per 30 days)
<i>sumatriptan 6 mg/0.5 ml syrng</i> <b>MO</b>	1	QL (6 per 30 days)
<i>sumatriptan 6 mg/0.5 ml vial</i> <b>MO</b>	1	QL (6 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
sumatriptan succ 100 mg, 25 mg, 50 mg tablet <b>MO</b>	1	QL (9 per 30 days)
sumatriptan-naproxen 85-500 mg <b>MO</b>	1	ST,QL (18 per 30 days)
SUMAVEL DOSEPRO 6 MG/0.5 ML <b>MO</b>	3	ST,QL (6 per 30 days)
TOSYMRA 10 MG/ACTUATION NASAL SPRAY <b>MO</b>	3	ST,QL (12 per 30 days)
TREXIMET 10-60 MG, 85-500 MG TABLET; TREXIMET 85 MG-500 MG TABLET <b>DL</b>	4	ST,QL (18 per 30 days)
VYEPTI 100 MG/ML INTRAVENOUS SOLUTION <b>MO</b>	3	PA,QL (1 per 90 days)
ZEMBRACE SYMTOUCH 3 MG/0.5 ML SUBCUTANEOUS PEN INJECTOR <b>DL</b>	4	ST,QL (6 per 30 days)
zolmitriptan 2.5 mg, 5 mg odt; zolmitriptan 2.5 mg, 5 mg tablet <b>MO</b>	1	ST,QL (9 per 30 days)
ZOMIG 2.5 MG, 5 MG NASAL SPRAY <b>DL</b>	4	ST,QL (12 per 30 days)
ZOMIG 2.5 MG, 5 MG TABLET <b>DL</b>	4	ST,QL (9 per 30 days)
ZOMIG ZMT 2.5 MG, 5 MG DISINTEGRATING TABLET <b>DL</b>	4	ST,QL (9 per 30 days)
<b>Antimyasthenic Agents</b>		
guanidine hcl 125 mg tablet <b>MO</b>	1	
MESTINON 60 MG TABLET <b>DL</b>	4	PA
MESTINON 60 MG/5 ML ORAL SYRUP <b>DL</b>	4	
MESTINON TIMESPAN 180 MG TABLET,EXTENDED RELEASE <b>DL</b>	4	PA
pyridostigmine 60 mg/5 ml soln <b>DL</b>	4	
pyridostigmine br 30 mg, 60 mg tablet <b>MO</b>	1	
pyridostigmine er 180 mg tab <b>MO</b>	1	
REGONOL 5 MG/ML INJECTION SOLUTION <b>MO</b>	3	
<b>Antimycobacterials</b>		
CAPASTAT 1 GRAM SOLUTION FOR INJECTION <b>MO</b>	3	
cycloserine 250 mg capsule <b>DL</b>	4	
dapsone 100 mg, 25 mg tablet <b>MO</b>	1	
ethambutol hcl 100 mg, 400 mg tablet <b>MO</b>	1	
isoniazid 100 mg, 300 mg tablet <b>MO</b>	1	
isoniazid 100 mg/ml, 50 mg/5 ml solution; isoniazid 100 mg/ml, 50 mg/5 ml vial <b>MO</b>	1	
MYAMBUTOL 400 MG TABLET <b>MO</b>	3	
MYCOBUTIN 150 MG CAPSULE <b>MO</b>	3	
PASER 4 GRAM GRANULES DELAYED-RELEASE PACKET <b>MO</b>	1	
PRETOMANID 200 MG TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
PRIFTIN 150 MG TABLET <b>MO</b>	3	
pyrazinamide 500 mg tablet <b>MO</b>	1	
rifabutin 150 mg capsule <b>MO</b>	1	
RIFADIN 150 MG, 300 MG CAPSULE <b>MO</b>	3	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
RIFADIN 600 MG INTRAVENOUS SOLUTION <b>MO</b>	3	
RIFAMATE 300 MG-150 MG CAPSULE <b>MO</b>	1	
<i>rifampin 150 mg, 300 mg capsule</i> <b>MO</b>	1	
<i>rifampin iv 600 mg vial</i> <b>DL</b>	4	
RIFATER 50 MG-120 MG-300 MG TABLET <b>MO</b>	3	
SIRTURO 100 MG TABLET <b>DL</b>	4	PA,QL (68 per 28 days)
SIRTURO 20 MG TABLET <b>DL</b>	4	PA,QL (340 per 28 days)
TRECTOR 250 MG TABLET <b>MO</b>	3	
<b>Antineoplastics</b>		
<i>abiraterone acetate 250 mg tab</i> <b>DL</b>	4	PA,QL (120 per 30 days)
ABRAXANE 100 MG INTRAVENOUS SUSPENSION <b>DL</b>	4	PA
ADCETRIS 50 MG INTRAVENOUS SOLUTION <b>DL</b>	4	PA
<i>adriamycin 10 mg, 10 mg/5 ml, 2 mg/ml, 20 mg/10 ml, 50 mg/25 ml intravenous solution</i> <b>MO</b>	1	B vs D
ADRIAMYCIN 50 MG INTRAVENOUS SOLUTION <b>MO</b>	1	B vs D
<i>adrucil 2.5 gram/50 ml, 5 gram/100 ml, 500 mg/10 ml intravenous solution; adrucil 2.5 gram/50 ml, 5 gram/100 ml, 500 mg/10 ml vial</i> <b>MO</b>	1	B vs D
AFINITOR 10 MG, 2.5 MG, 5 MG, 7.5 MG TABLET <b>DL</b>	4	PA,QL (30 per 30 days)
AFINITOR DISPERZ 2 MG, 3 MG, 5 MG TABLET FOR ORAL SUSPENSION <b>DL</b>	4	PA
ALECENSA 150 MG CAPSULE <b>DL</b>	4	PA,QL (240 per 30 days)
ALIMTA 100 MG, 500 MG INTRAVENOUS SOLUTION <b>DL</b>	4	PA
ALIQOPA 60 MG INTRAVENOUS SOLUTION <b>DL</b>	4	PA,QL (3 per 28 days)
ALKERAN 2 MG TABLET <b>MO</b>	3	B vs D
ALKERAN (AS HCL) 50 MG INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D
ALUNBRIG 180 MG, 90 MG, 90 MG (7)- 180 MG (23) TABLET; ALUNBRIG 90 MG (7)-180 MG (23) TABLETS IN A DOSE PACK <b>DL</b>	4	PA,QL (30 per 30 days)
ALUNBRIG 30 MG TABLET <b>DL</b>	4	PA,QL (180 per 30 days)
<i>amifostine 500 mg vial</i> <b>DL</b>	4	B vs D
<i>anastrozole 1 mg tablet</i> <b>MO</b>	1	QL (30 per 30 days)
ARIMIDEX 1 MG TABLET <b>DL</b>	4	PA,QL (30 per 30 days)
AROMASIN 25 MG TABLET <b>DL</b>	4	PA,QL (60 per 30 days)
ARRANON 250 MG/50 ML INTRAVENOUS SOLUTION <b>DL</b>	4	
<i>arsenic trioxide 10 mg/10ml vl; arsenic trioxide 12 mg/6 ml vl</i> <b>DL</b>	4	PA
ARZERRA 1,000 MG/50 ML, 100 MG/5 ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA,QL (400 per 28 days)
ASPARLAS 750 UNIT/ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA
AVASTIN 25 MG/ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA
AYVAKIT 100 MG, 200 MG, 300 MG TABLET <b>DL</b>	4	PA,QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
azacitidine 100 mg vial <b>DL</b>	4	PA
BALVERSA 3 MG TABLET <b>DL</b>	4	PA,QL (90 per 30 days)
BALVERSA 4 MG TABLET <b>DL</b>	4	PA,QL (60 per 30 days)
BALVERSA 5 MG TABLET <b>DL</b>	4	PA,QL (30 per 30 days)
BAVENCIO 20 MG/ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA
BELEODAQ 500 MG INTRAVENOUS SOLUTION <b>DL</b>	4	PA
BENDEKA 25 MG/ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA
BESPONSIA 0.9 MG(0.25 MG/ML INITIAL CONCENTRATION) INTRAVENOUS SOLUTION <b>DL</b>	4	PA
bexarotene 75 mg capsule <b>DL</b>	4	PA,QL (300 per 30 days)
bicalutamide 50 mg tablet <b>MO</b>	1	QL (30 per 30 days)
BICNU 100 MG INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D
BLENREP 100 MG INTRAVENOUS SOLUTION <b>DL</b>	4	PA
bleomycin sulfate 15 unit, 30 unit vial <b>MO</b>	1	B vs D
bortezomib 3.5 mg vial <b>DL</b>	4	PA
BOSULIF 100 MG TABLET <b>DL</b>	4	PA,QL (120 per 30 days)
BOSULIF 400 MG, 500 MG TABLET <b>DL</b>	4	PA,QL (30 per 30 days)
BRAFTOVI 50 MG CAPSULE <b>DL</b>	4	PA,QL (120 per 30 days)
BRAFTOVI 75 MG CAPSULE <b>DL</b>	4	PA,QL (180 per 30 days)
BRUKINSA 80 MG CAPSULE <b>DL</b>	4	PA,QL (120 per 30 days)
busulfan 60 mg/10 ml vial <b>MO</b>	1	B vs D
BUSULFEX 60 MG/10 ML INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D
CABOMETYX 20 MG, 40 MG, 60 MG TABLET <b>DL</b>	4	PA,QL (30 per 30 days)
CALQUENCE 100 MG CAPSULE <b>DL</b>	4	PA,QL (60 per 30 days)
CAMPTOSAR 100 MG/5 ML, 300 MG/15 ML, 40 MG/2 ML INTRAVENOUS SOLUTION <b>DL</b>	4	B vs D
CAPRELSA 100 MG TABLET <b>DL</b>	4	PA,QL (60 per 30 days)
CAPRELSA 300 MG TABLET <b>DL</b>	4	PA,QL (30 per 30 days)
carboplatin 50 mg/5 ml vial <b>MO</b>	1	B vs D
carmustine 100 mg vial <b>MO</b>	1	B vs D
CASODEX 50 MG TABLET <b>DL</b>	4	QL (30 per 30 days)
cisplatin 100 mg/100 ml vial <b>MO</b>	1	B vs D
cladribine 10 mg/10 ml vial <b>DL</b>	4	B vs D
clofarabine 20 mg/20 ml vial <b>DL</b>	4	B vs D
CLOLAR 20 MG/20 ML INTRAVENOUS SOLUTION <b>DL</b>	4	B vs D
COMETRIQ 100 MG/DAY (80 MG X 1-20 MG X 1) CAPSULES <b>DL</b>	4	PA,QL (56 per 28 days)
COMETRIQ 140 MG/DAY (80 MG X 1-20 MG X 3) CAPSULES <b>DL</b>	4	PA,QL (112 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
COMETRIQ 60 MG/DAY (20 MG X 3/DAY) CAPSULES <b>DL</b>	4	PA,QL (84 per 28 days)
COPIKTRA 15 MG, 25 MG CAPSULE <b>DL</b>	4	PA,QL (56 per 28 days)
COSMEGEN 0.5 MG INTRAVENOUS SOLUTION <b>DL</b>	4	B vs D
COTELLIC 20 MG TABLET <b>DL</b>	4	PA,QL (63 per 28 days)
cyclophosphamide 1 gm vial; cyclophosphamide 1 gram, 2 gram, 500 mg vial; cyclophosphamide 2 gm vial <b>MO</b>	1	B vs D
CYCLOPHOSPHAMIDE 1 GM/5 ML VL <b>MO</b>	1	B vs D
cyclophosphamide 25 mg, 50 mg capsule <b>MO</b>	1	B vs D
CYRAMZA 10 MG/ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA
cytarabine 20 mg/ml vial <b>MO</b>	1	B vs D
cytarabine 100 mg/5 ml (20 mg/ml), 2 gram/20 ml (100 mg/ml), 20 mg/ml vial; cytarabine 100 mg/5 ml vial; cytarabine 2 g/20 ml vial <b>MO</b>	1	B vs D
dacarbazine 100 mg, 200 mg vial <b>MO</b>	1	B vs D
DACOGEN 50 MG INTRAVENOUS SOLUTION <b>DL</b>	4	PA
dactinomycin 0.5 mg vial <b>DL</b>	4	B vs D
DARZALEX 20 MG/ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA
DARZALEX FASPRO 1,800 MG-30,000 UNIT/15 ML SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA
daunorubicin 20 mg/4 ml vial <b>MO</b>	1	B vs D
DAURISMO 100 MG TABLET <b>DL</b>	4	PA,QL (30 per 30 days)
DAURISMO 25 MG TABLET <b>DL</b>	4	PA,QL (60 per 30 days)
decitabine 50 mg vial <b>DL</b>	4	PA
dexrazoxane 250 mg, 500 mg vial <b>MO</b>	1	B vs D
DOCEFREZ 20 MG INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D
DOCEFREZ 80 MG INTRAVENOUS SOLUTION <b>DL</b>	4	B vs D
docetaxel 160 mg/16 ml vial; docetaxel 160 mg/8 ml vial; docetaxel 20 mg/2 ml vial; docetaxel 20 mg/ml vial; docetaxel 200 mg/10 ml vial; docetaxel 80 mg/4 ml vial; docetaxel 80 mg/8 ml vial <b>MO</b>	1	B vs D
DOXIL 2 MG/ML INTRAVENOUS SUSPENSION <b>DL</b>	4	B vs D
doxorubicin 10 mg, 10 mg/5 ml, 2 mg/ml, 20 mg/10 ml, 50 mg, 50 mg/25 ml vial; doxorubicin 150 mg/75 ml vial <b>MO</b>	1	B vs D
doxorubicin liposome 20mg/10ml <b>DL</b>	4	PA
ELITEK 1.5 MG, 7.5 MG INTRAVENOUS SOLUTION <b>DL</b>	4	PA
ELLENC 200 MG/100 ML, 50 MG/25 ML INTRAVENOUS SOLUTION <b>DL</b>	4	B vs D
ELZONRIS 1,000 MCG/ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA,QL (10 per 21 days)
EMCYT 140 MG CAPSULE <b>DL</b>	4	
EMPLICITI 300 MG, 400 MG INTRAVENOUS SOLUTION <b>DL</b>	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ENHERTU 100 MG INTRAVENOUS SOLUTION <b>DL</b>	4	PA
epirubicin 200 mg/100 ml, 50 mg/25 ml vial <b>MO</b>	1	B vs D
epirubicin hcl 50 mg vial <b>MO</b>	3	B vs D
ERBITUX 100 MG/50 ML, 200 MG/100 ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA
ERIVEDGE 150 MG CAPSULE <b>DL</b>	4	PA,QL (28 per 28 days)
ERLEADA 60 MG TABLET <b>DL</b>	4	PA,QL (120 per 30 days)
erlotinib hcl 100 mg, 150 mg tablet <b>DL</b>	4	PA,QL (30 per 30 days)
erlotinib hcl 25 mg tablet <b>DL</b>	4	PA,QL (90 per 30 days)
ERWINAZE 10,000 UNIT SOLUTION FOR INJECTION <b>DL</b>	4	PA
ETHYOL 500 MG INTRAVENOUS SOLUTION <b>DL</b>	4	B vs D
ETOPOPHOS 100 MG INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D
etoposide 100 mg/5 ml vial <b>MO</b>	1	B vs D
EVOMELA 50 MG INTRAVENOUS SOLUTION <b>DL</b>	4	PA
exemestane 25 mg tablet <b>MO</b>	1	QL (60 per 30 days)
FARESTON 60 MG TABLET <b>DL</b>	4	QL (30 per 30 days)
FARYDAK 10 MG, 15 MG, 20 MG CAPSULE <b>DL</b>	4	PA,QL (6 per 21 days)
FASLODEX 250 MG/5 ML INTRAMUSCULAR SYRINGE <b>DL</b>	4	PA,QL (30 per 30 days)
FEMARA 2.5 MG TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
floxuridine 500 mg vial <b>MO</b>	1	B vs D
fludarabine 50 mg, 50 mg/2 ml vial <b>MO</b>	1	B vs D
fluorouracil 1 gram/20 ml, 2.5 gram/50 ml, 5 gram/100 ml, 500 mg/10 ml vial; fluorouracil 1,000 mg/20 ml vial; fluorouracil 2,500 mg/50 ml vial; fluorouracil 5,000 mg/100 ml <b>MO</b>	1	B vs D
flutamide 125 mg capsule <b>MO</b>	1	
FOLOTYN 20 MG/ML (1 ML), 40 MG/2 ML (20 MG/ML) INTRAVENOUS SOLUTION <b>DL</b>	4	PA
fulvestrant 250 mg/5 ml syring <b>DL</b>	4	PA,QL (30 per 30 days)
FUSILEV 50 MG INTRAVENOUS SOLUTION <b>DL</b>	4	PA
GAZYVA 1,000 MG/40 ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA,QL (120 per 28 days)
gemcitabine 1 gram/26.3 ml vial; gemcitabine 2 gram/52.6 ml vial; gemcitabine 200 mg/5.26 ml vial; gemcitabine hcl 1 gram, 1 gram/26.3 ml (38 mg/ml), 2 gram, 2 gram/52.6 ml (38 mg/ml), 200 mg, 200 mg/5.26 ml (38 mg/ml) vial <b>MO</b>	1	B vs D
GEMZAR 1 GRAM, 200 MG VIAL <b>DL</b>	4	PA
GILOTRIF 20 MG, 30 MG, 40 MG TABLET <b>DL</b>	4	PA,QL (30 per 30 days)
GLEEVEC 100 MG TABLET <b>DL</b>	4	PA,QL (90 per 30 days)
GLEEVEC 400 MG TABLET <b>DL</b>	4	PA,QL (60 per 30 days)
HALAVEN 1 MG/2 ML (0.5 MG/ML) INTRAVENOUS SOLUTION <b>DL</b>	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
HERCEPTIN 150 MG, 440 MG INTRAVENOUS SOLUTION; HERCEPTIN 150 MG, 440 MG VIAL <b>DL</b>	4	PA
HERCEPTIN HYLECTA 600 MG-10,000 UNIT/5 ML SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA,QL (5 per 21 days)
HERZUMA 150 MG, 420 MG INTRAVENOUS SOLUTION <b>DL</b>	4	PA
HEXALEN 50 MG CAPSULE <b>DL</b>	4	
HYCAMTIN 4 MG INTRAVENOUS SOLUTION <b>DL</b>	4	B vs D
HYDREA 500 MG CAPSULE <b>MO</b>	3	
<i>hydroxyurea 500 mg capsule</i> <b>MO</b>	1	
IBRANCE 100 MG, 125 MG, 75 MG CAPSULE <b>DL</b>	4	PA,QL (21 per 28 days)
IBRANCE 100 MG, 125 MG, 75 MG TABLET <b>DL</b>	4	PA,QL (21 per 28 days)
ICLUSIG 15 MG TABLET <b>DL</b>	4	PA,QL (60 per 30 days)
ICLUSIG 45 MG TABLET <b>DL</b>	4	PA,QL (30 per 30 days)
IDAMYCIN PFS 1 MG/ML INTRAVENOUS SOLUTION <b>DL</b>	4	B vs D
<i>idarubicin hcl 20 mg/20 ml vial</i> <b>DL</b>	4	B vs D
IDHIFA 100 MG, 50 MG TABLET <b>DL</b>	4	PA,QL (30 per 30 days)
IFEX 1 GRAM, 3 GRAM INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D
<i>ifosfamide 1 gm vial; ifosfamide 1 gm/20 ml vial; ifosfamide 3 gm vial; ifosfamide 3 gm/60 ml vial</i> <b>MO</b>	1	B vs D
<i>imatinib mesylate 100 mg tab</i> <b>DL</b>	4	PA,QL (90 per 30 days)
<i>imatinib mesylate 400 mg tab</i> <b>DL</b>	4	PA,QL (60 per 30 days)
IMBRUVICA 140 MG CAPSULE <b>DL</b>	4	PA,QL (90 per 30 days)
IMBRUVICA 420 MG, 560 MG TABLET <b>DL</b>	4	PA,QL (28 per 28 days)
IMBRUVICA 70 MG CAPSULE <b>DL</b>	4	PA,QL (28 per 28 days)
IMFINZI 50 MG/ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA
IMLYGIC 10EXP6 (1 MILLION) PFU/ML SUSPENSION FOR INJECTION <b>DL</b>	4	PA,QL (4 per 365 days)
IMLYGIC 10EXP8 (100 MILLION) PFU/ML SUSPENSION FOR INJECTION <b>DL</b>	4	PA,QL (8 per 28 days)
INFUGEM 1,200 MG/120 ML (10 MG/ML), 1,300 MG/130 ML (10 MG/ML), 1,400 MG/140 ML (10 MG/ML), 1,500 MG/150 ML (10 MG/ML), 1,600 MG/160 ML (10 MG/ML), 1,700 MG/170 ML (10 MG/ML), 1,800 MG/180 ML (10 MG/ML), 1,900 MG/190 ML (10 MG/ML), 2,000 MG/200 ML (10 MG/ML), 2,200 MG/220 ML (10 MG/ML) INTRAVENOUS PIGGYBACK <b>DL</b>	4	B vs D
INLYTA 1 MG TABLET <b>DL</b>	4	PA,QL (180 per 30 days)
INLYTA 5 MG TABLET <b>DL</b>	4	PA,QL (60 per 30 days)
INQOVI 35 MG-100 MG TABLET <b>DL</b>	4	PA,QL (5 per 28 days)
INREBIC 100 MG CAPSULE <b>DL</b>	4	PA,QL (120 per 30 days)
IRESSA 250 MG TABLET <b>DL</b>	4	PA,QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>irinotecan hcl 100 mg/5 ml, 300 mg/15 ml, 40 mg/2 ml, 500 mg/25 ml vial; irinotecan hcl 100 mg/5 ml, 300 mg/15 ml, 40 mg/2 ml, 500 mg/25 ml vial</i> <sup>MO</sup>	1	B vs D
ISTODAX 10 MG/2 ML INTRAVENOUS SOLUTION <sup>DL</sup>	4	PA
IXEMPRA 15 MG, 45 MG INTRAVENOUS SOLUTION <sup>DL</sup>	4	PA
JAKAFI 10 MG, 15 MG, 20 MG, 25 MG, 5 MG TABLET <sup>DL</sup>	4	PA,QL (60 per 30 days)
JEVTANA 10 MG/ML (FIRST DILUTION) INTRAVENOUS SOLUTION <sup>DL</sup>	4	PA
KADCYLA 100 MG, 160 MG INTRAVENOUS SOLUTION <sup>DL</sup>	4	PA
KANJINTI 150 MG, 420 MG INTRAVENOUS SOLUTION <sup>DL</sup>	4	PA
KEYTRUDA 25 MG/ML INTRAVENOUS SOLUTION <sup>DL</sup>	4	PA
KHAPZORY 175 MG, 300 MG INTRAVENOUS SOLUTION <sup>DL</sup>	4	PA
KISQALI 200 MG/DAY (200 MG X 1) TABLET <sup>DL</sup>	4	PA,QL (21 per 28 days)
KISQALI 400 MG/DAY (200 MG X 2) TABLET <sup>DL</sup>	4	PA,QL (42 per 28 days)
KISQALI 600 MG/DAY (200 MG X 3) TABLET <sup>DL</sup>	4	PA,QL (63 per 28 days)
KISQALI FEMARA CO-PACK 200 MG/DAY(200 MG X 1)-2.5 MG TABLET <sup>DL</sup>	4	PA,QL (49 per 28 days)
KISQALI FEMARA CO-PACK 400 MG/DAY(200 MG X 2)-2.5 MG TABLET <sup>DL</sup>	4	PA,QL (70 per 28 days)
KISQALI FEMARA CO-PACK 600 MG/DAY(200 MG X 3)-2.5 MG TABLET <sup>DL</sup>	4	PA,QL (91 per 28 days)
KOSELUGO 10 MG CAPSULE <sup>DL</sup>	4	PA,QL (240 per 30 days)
KOSELUGO 25 MG CAPSULE <sup>DL</sup>	4	PA,QL (120 per 30 days)
KYPROLIS 10 MG INTRAVENOUS SOLUTION <sup>DL</sup>	4	PA,QL (6 per 28 days)
KYPROLIS 30 MG INTRAVENOUS SOLUTION <sup>DL</sup>	4	PA,QL (3 per 28 days)
KYPROLIS 60 MG INTRAVENOUS SOLUTION <sup>DL</sup>	4	PA,QL (12 per 28 days)
LARTRUVO 500 MG/50 ML VIAL <sup>DL</sup>	4	PA
LENVIMA 10 MG/DAY (10 MG X 1), 4 MG CAPSULE <sup>DL</sup>	4	PA,QL (30 per 30 days)
LENVIMA 12 MG/DAY (4 MG X 3), 18 MG/DAY (10 MG X 1-4 MG X2), 24 MG/DAY(10 MG X 2-4 MG X 1) CAPSULE; LENVIMA 18 MG/DAY (10 MG X 1 AND 4 MG X 2) CAPSULE; LENVIMA 24 MG PER DAY (10 MG X 2 AND 4 MG X 1) CAPSULE <sup>DL</sup>	4	PA,QL (90 per 30 days)
LENVIMA 14 MG/DAY(10 MG X 1-4 MG X 1), 20 MG/DAY (10 MG X 2), 8 MG/DAY (4 MG X 2) CAPSULE <sup>DL</sup>	4	PA,QL (60 per 30 days)
<i>letrozole 2.5 mg tablet</i> <sup>MO</sup>	1	QL (30 per 30 days)
<i>leucovorin cal 500 mg/50 ml vial; leucovorin calcium 10 mg/ml, 100 mg, 200 mg, 350 mg, 50 mg, 500 mg vial; leucovorin calcium 10 mg/ml, 100 mg, 200 mg, 350 mg, 50 mg, 500 mg vial</i> <sup>MO</sup>	1	B vs D
<i>leucovorin calcium 10 mg, 15 mg, 25 mg, 5 mg tab</i> <sup>MO</sup>	1	
LEUKERAN 2 MG TABLET <sup>MO</sup>	3	
<i>levoleucovorin 10 mg/ml, 175 mg, 50 mg vial; levoleucovorin 175 mg/17.5 ml</i> <sup>DL</sup>	4	PA
LEVULAN 20 % TOPICAL SOLUTION <sup>MO</sup>	3	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
LIBTAYO 50 MG/ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA,QL (7 per 21 days)
<i>lipodox 2 mg/ml vial</i> <b>DL</b>	4	PA
<i>lipodox 50 2 mg/ml vial</i> <b>DL</b>	4	PA
LONSURF 15 MG-6.14 MG TABLET <b>DL</b>	4	PA,QL (100 per 30 days)
LONSURF 20 MG-8.19 MG TABLET <b>DL</b>	4	PA,QL (80 per 30 days)
LORBRENA 100 MG TABLET <b>DL</b>	4	PA,QL (30 per 30 days)
LORBRENA 25 MG TABLET <b>DL</b>	4	PA,QL (90 per 30 days)
LUMOXITI 1 MG INTRAVENOUS SOLUTION <b>DL</b>	4	PA
LYNPARZA 100 MG, 150 MG TABLET <b>DL</b>	4	PA,QL (120 per 30 days)
MARQIBO 5 MG/31 ML (0.16 MG/ML) (FINAL CONC.) INTRAVENOUS KIT <b>DL</b>	4	PA
MATULANE 50 MG CAPSULE <b>DL</b>	4	
MEKINIST 0.5 MG TABLET <b>DL</b>	4	PA,QL (120 per 30 days)
MEKINIST 2 MG TABLET <b>DL</b>	4	PA,QL (30 per 30 days)
MEKTOVI 15 MG TABLET <b>DL</b>	4	PA,QL (180 per 30 days)
<i>melphalan 2 mg tablet</i> <b>MO</b>	1	B vs D
<i>melphalan hcl 50 mg vial</i> <b>MO</b>	1	B vs D
<i>mercaptopurine 50 mg tablet</i> <b>MO</b>	1	
<i>mesna 1 gram/10 ml vial</i> <b>MO</b>	1	B vs D
MESNEX 100 MG/ML INTRAVENOUS SOLUTION <b>DL</b>	4	B vs D
MESNEX 400 MG TABLET <b>DL</b>	4	
<i>mitomycin 20 mg, 40 mg, 5 mg vial</i> <b>DL</b>	4	B vs D
<i>mitoxantrone 30 mg/15 ml vial</i> <b>MO</b>	1	B vs D
MUSTARGEN 10 MG VIAL <b>MO</b>	3	B vs D
MUTAMYCIN 20 MG, 40 MG, 5 MG INTRAVENOUS SOLUTION <b>DL</b>	4	B vs D
MVASI 25 MG/ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA
MYLOTARG 4.5 MG (1 MG/ML INITIAL CONCENTRATION) INTRAVENOUS SOLUTION <b>DL</b>	4	PA
NAVELBINE 10 MG/ML, 50 MG/5 ML INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D
NERLYNX 40 MG TABLET <b>DL</b>	4	PA,QL (180 per 30 days)
NEXAVAR 200 MG TABLET <b>DL</b>	4	PA,QL (120 per 30 days)
NILANDRON 150 MG TABLET <b>DL</b>	4	PA,QL (60 per 30 days)
<i>nilutamide 150 mg tablet</i> <b>DL</b>	4	QL (60 per 30 days)
NINLARO 2.3 MG, 3 MG, 4 MG CAPSULE <b>DL</b>	4	PA,QL (3 per 28 days)
NIPENT 10 MG INTRAVENOUS SOLUTION <b>DL</b>	4	B vs D
NUBEQA 300 MG TABLET <b>DL</b>	4	PA,QL (120 per 30 days)
ODOMZO 200 MG CAPSULE <b>DL</b>	4	PA,QL (30 per 30 days)
OGIVRI 150 MG, 420 MG INTRAVENOUS SOLUTION <b>DL</b>	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ONCASPAR 750 UNIT/ML INJECTION SOLUTION <b>DL</b>	4	PA
ONIVYDE 4.3 MG/ML INTRAVENOUS DISPERSION <b>DL</b>	4	PA
ONTRUZANT 150 MG, 420 MG INTRAVENOUS SOLUTION <b>DL</b>	4	PA
ONUREG 200 MG, 300 MG TABLET <b>DL</b>	4	PA,QL (14 per 28 days)
OPDIVO 100 MG/10 ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA,QL (40 per 28 days)
OPDIVO 240 MG/24 ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA,QL (48 per 28 days)
OPDIVO 40 MG/4 ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA,QL (16 per 28 days)
oxaliplatin 100 mg, 100 mg/20 ml, 50 mg, 50 mg/10 ml (5 mg/ml) vial; oxaliplatin 50 mg/10 ml vial <b>MO</b>	1	B vs D
paclitaxel 100 mg/16.7 ml vial <b>MO</b>	1	B vs D
PADCEV 20 MG INTRAVENOUS SOLUTION <b>DL</b>	4	PA,QL (21 per 28 days)
PADCEV 30 MG INTRAVENOUS SOLUTION <b>DL</b>	4	PA,QL (15 per 28 days)
PANRETIN 0.1 % TOPICAL GEL <b>DL</b>	4	
paraplatin 10 mg/ml intravenous solution <b>MO</b>	1	B vs D
PEMAZYRE 13.5 MG, 4.5 MG, 9 MG TABLET <b>DL</b>	4	PA,QL (14 per 21 days)
PERJETA 420 MG/14 ML (30 MG/ML) INTRAVENOUS SOLUTION <b>DL</b>	4	PA
PHESGO 1,200 MG-600 MG-30,000 UNIT/15 ML SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA,QL (15 per 21 days)
PHESGO 600 MG-600 MG-20,000 UNIT/10 ML SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA,QL (10 per 21 days)
PIQRAY 200 MG/DAY (200 MG X 1) TABLET <b>DL</b>	4	PA,QL (28 per 28 days)
PIQRAY 250 MG/DAY (200 MG X 1-50 MG X 1) TABLET; PIQRAY 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2) TABLET <b>DL</b>	4	PA,QL (56 per 28 days)
POLIVY 140 MG INTRAVENOUS SOLUTION <b>DL</b>	4	PA,QL (2 per 21 days)
POMALYST 1 MG, 2 MG, 3 MG, 4 MG CAPSULE <b>DL</b>	4	PA,QL (21 per 28 days)
PORTRAZZA 800 MG/50 ML (16 MG/ML) INTRAVENOUS SOLUTION <b>DL</b>	4	PA,QL (100 per 21 days)
POTELIGEO 4 MG/ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA
PROLEUKIN 22 MILLION UNIT INTRAVENOUS SOLUTION <b>DL</b>	4	
PURIXAN 20 MG/ML ORAL SUSPENSION <b>DL</b>	4	QL (300 per 30 days)
QINLOCK 50 MG TABLET <b>DL</b>	4	PA,QL (90 per 30 days)
RETEVMO 40 MG CAPSULE <b>DL</b>	4	PA,QL (180 per 30 days)
RETEVMO 80 MG CAPSULE <b>DL</b>	4	PA,QL (120 per 30 days)
REVLIMID 10 MG, 15 MG, 2.5 MG, 20 MG, 25 MG, 5 MG CAPSULE <b>DL</b>	4	PA,QL (28 per 28 days)
RITUXAN 10 MG/ML CONCENTRATE, INTRAVENOUS <b>DL</b>	4	PA
RITUXAN HYCELA 1,400 MG/11.7 ML (120 MG/ML) SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA,QL (46.8 per 28 days)
RITUXAN HYCELA 1,600 MG/13.4 ML (120 MG/ML) SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA,QL (13.4 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>romidepsin 10 mg kit</i> <b>DL</b>	4	PA
ROMIDEPSIN 27.5 MG/5.5 ML VIAL <b>DL</b>	4	PA
ROZLYTREK 100 MG, 200 MG CAPSULE <b>DL</b>	4	PA,QL (90 per 30 days)
RUBRACA 200 MG, 250 MG, 300 MG TABLET <b>DL</b>	4	PA,QL (120 per 30 days)
RUXIENCE 10 MG/ML CONCENTRATE, INTRAVENOUS <b>DL</b>	4	PA
RYDAPT 25 MG CAPSULE <b>DL</b>	4	PA,QL (224 per 28 days)
SARCLISA 20 MG/ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA,QL (16 per 28 days)
SOLTAMOX 20 MG/10 ML ORAL SOLUTION <b>DL</b>	4	
SPRYCEL 100 MG, 50 MG, 70 MG, 80 MG TABLET <b>DL</b>	4	PA,QL (60 per 30 days)
SPRYCEL 140 MG TABLET <b>DL</b>	4	PA,QL (30 per 30 days)
SPRYCEL 20 MG TABLET <b>DL</b>	4	PA,QL (90 per 30 days)
STIVARGA 40 MG TABLET <b>DL</b>	4	PA,QL (84 per 28 days)
SUTENT 12.5 MG, 25 MG, 37.5 MG, 50 MG CAPSULE <b>DL</b>	4	PA,QL (28 per 28 days)
SYNRIBO 3.5 MG SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA,QL (28 per 28 days)
TABLOID 40 MG TABLET <b>MO</b>	3	
TABRECTA 150 MG, 200 MG TABLET <b>DL</b>	4	PA,QL (112 per 28 days)
TAFINLAR 50 MG CAPSULE <b>DL</b>	4	PA,QL (180 per 30 days)
TAFINLAR 75 MG CAPSULE <b>DL</b>	4	PA,QL (120 per 30 days)
TAGRISSE 40 MG, 80 MG TABLET <b>DL</b>	4	PA,QL (30 per 30 days)
TALZENNA 0.25 MG CAPSULE <b>DL</b>	4	PA,QL (90 per 30 days)
TALZENNA 1 MG CAPSULE <b>DL</b>	4	PA,QL (30 per 30 days)
<i>tamoxifen 10 mg, 20 mg tablet</i> <b>MO</b>	1	
TARCEVA 100 MG, 150 MG TABLET <b>DL</b>	4	PA,QL (30 per 30 days)
TARCEVA 25 MG TABLET <b>DL</b>	4	PA,QL (90 per 30 days)
TARGRETIN 1 % TOPICAL GEL <b>DL</b>	4	PA
TARGRETIN 75 MG CAPSULE <b>DL</b>	4	PA,QL (300 per 30 days)
TASIGNA 150 MG, 200 MG, 50 MG CAPSULE <b>DL</b>	4	PA,QL (120 per 30 days)
TAXOTERE 20 MG/ML (1 ML), 80 MG/4 ML (20 MG/ML) INTRAVENOUS SOLUTION <b>DL</b>	4	B vs D
TAZVERIK 200 MG TABLET <b>DL</b>	4	PA,QL (240 per 30 days)
TECENTRIQ 1,200 MG/20 ML (60 MG/ML) INTRAVENOUS SOLUTION <b>DL</b>	4	PA,QL (20 per 21 days)
TECENTRIQ 840 MG/14 ML (60 MG/ML) INTRAVENOUS SOLUTION <b>DL</b>	4	PA,QL (28 per 28 days)
TEMODAR 100 MG INTRAVENOUS SOLUTION <b>DL</b>	4	PA,QL (27 per 30 days)
<i>temsirolimus 25 mg vial</i> <b>DL</b>	4	PA,QL (8 per 28 days)
<i>teniposide 50 mg/5 ml ampule</i> <b>MO</b>	1	B vs D
THALOMID 100 MG, 200 MG, 50 MG CAPSULE <b>DL</b>	4	PA,QL (30 per 30 days)
THALOMID 150 MG CAPSULE <b>DL</b>	4	PA,QL (60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
thiotepa 100 mg vial <b>DL</b>	4	B vs D
thiotepa 15 mg vial <b>MO</b>	1	B vs D
TIBSOVO 250 MG TABLET <b>DL</b>	4	PA,QL (60 per 30 days)
toposar 20 mg/ml intravenous solution <b>MO</b>	1	B vs D
topotecan hcl 1 mg/ml (1 ml), 4 mg, 4 mg/4 ml (1 mg/ml) vial; topotecan hcl 1 mg/ml vial; topotecan hcl 4 mg/4 ml vial <b>DL</b>	4	B vs D
toremifene citrate 60 mg tab <b>DL</b>	4	QL (30 per 30 days)
TORISEL 30 MG/3 ML (10 MG/ML) (FIRST DILUTION) INTRAVENOUS SOLUTION <b>DL</b>	4	PA,QL (8 per 28 days)
TOTECT 500 MG INTRAVENOUS SOLUTION <b>DL</b>	4	B vs D
TRAZIMERA 420 MG INTRAVENOUS SOLUTION <b>DL</b>	4	PA
TREANDA 100 MG, 25 MG INTRAVENOUS POWDER FOR SOLUTION <b>DL</b>	4	PA
tretinoin 10 mg capsule <b>DL</b>	4	
TRISENOX 2 MG/ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA
TRUXIMA 10 MG/ML CONCENTRATE,INTRAVENOUS <b>DL</b>	4	PA
TUKYSA 150 MG TABLET <b>DL</b>	4	PA,QL (120 per 30 days)
TUKYSA 50 MG TABLET <b>DL</b>	4	PA,QL (300 per 30 days)
TURALIO 200 MG CAPSULE <b>DL</b>	4	PA,QL (120 per 30 days)
TYKERB 250 MG TABLET <b>DL</b>	4	PA,QL (150 per 30 days)
UNITUXIN 3.5 MG/ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA
VALCHLOR 0.016 % TOPICAL GEL <b>DL</b>	4	PA,QL (60 per 28 days)
valrubicin 200 mg/5 ml vial <b>DL</b>	4	PA,QL (80 per 28 days)
VALSTAR 40 MG/ML INTRAVESICAL SOLUTION <b>DL</b>	4	PA,QL (80 per 28 days)
VECTIBIX 100 MG/5 ML (20 MG/ML), 400 MG/20 ML (20 MG/ML) INTRAVENOUS SOLUTION <b>DL</b>	4	PA
VELCADE 3.5 MG SOLUTION FOR INJECTION <b>DL</b>	4	PA
VENCLEXTA 10 MG TABLET <b>MO</b>	2	PA,QL (56 per 28 days)
VENCLEXTA 100 MG TABLET <b>DL</b>	4	PA,QL (180 per 30 days)
VENCLEXTA 50 MG TABLET <b>MO</b>	2	PA,QL (28 per 28 days)
VENCLEXTA STARTING PACK 10 MG-50 MG-100 MG TABLETS IN A DOSE PACK <b>DL</b>	4	PA,QL (42 per 28 days)
VERZENIO 100 MG, 150 MG, 200 MG, 50 MG TABLET <b>DL</b>	4	PA,QL (60 per 30 days)
VIDAZA 100 MG SOLUTION FOR INJECTION <b>DL</b>	4	PA
vinblastine 1 mg/ml vial <b>MO</b>	1	B vs D
vincasar pfs 1 mg/ml, 2 mg/2 ml intravenous solution <b>MO</b>	1	B vs D
vincristine 1 mg/ml, 2 mg/2 ml vial <b>MO</b>	1	B vs D
vinorelbine 10 mg/ml, 50 mg/5 ml vial <b>MO</b>	1	B vs D

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
VISTOGARD 10 GRAM ORAL GRANULES IN PACKET <b>DL</b>	4	QL (20 per 365 days)
VITRAKVI 100 MG CAPSULE <b>DL</b>	4	PA,QL (60 per 30 days)
VITRAKVI 20 MG/ML ORAL SOLUTION <b>DL</b>	4	PA,QL (300 per 30 days)
VITRAKVI 25 MG CAPSULE <b>DL</b>	4	PA,QL (180 per 30 days)
VIZIMPRO 15 MG, 30 MG, 45 MG TABLET <b>DL</b>	4	PA,QL (30 per 30 days)
VOTRIENT 200 MG TABLET <b>DL</b>	4	PA,QL (120 per 30 days)
VYXEOS 44 MG-100 MG INTRAVENOUS SOLUTION <b>DL</b>	4	PA
XALKORI 200 MG, 250 MG CAPSULE <b>DL</b>	4	PA,QL (60 per 30 days)
XOSPATA 40 MG TABLET <b>DL</b>	4	PA,QL (90 per 30 days)
XPOVIO 100 MG/WEEK (20 MG X 5) TABLET <b>DL</b>	4	PA,QL (20 per 28 days)
XPOVIO 40 MG TWICE WEEKLY (80 MG/WEEK) (20 MG X 4) TABLET; XPOVIO 40MG TWICE WEEK (80 MG/WEEK), 80 MG/WEEK (20 MG X 4) TABLET <b>DL</b>	4	PA,QL (16 per 28 days)
XPOVIO 40 MG/WEEK (20 MG X 2) TABLET <b>DL</b>	4	PA,QL (8 per 28 days)
XPOVIO 60 MG TWICE WEEKLY (120 MG/WEEK) (20 MG X 6) TABLET <b>DL</b>	4	PA,QL (24 per 28 days)
XPOVIO 60 MG/WEEK (20 MG X 3) TABLET <b>DL</b>	4	PA,QL (12 per 28 days)
XPOVIO 80 MG TWICE WEEKLY (160 MG/WEEK) (20 MG X 8) TABLET <b>DL</b>	4	PA,QL (32 per 28 days)
XTANDI 40 MG CAPSULE <b>DL, LA</b>	4	PA,QL (120 per 30 days)
YERVOY 200 MG/40 ML (5 MG/ML), 50 MG/10 ML (5 MG/ML) INTRAVENOUS SOLUTION <b>DL</b>	4	PA
YONDELIS 1 MG INTRAVENOUS SOLUTION <b>DL</b>	4	PA
YONSA 125 MG TABLET <b>DL</b>	4	PA,QL (120 per 30 days)
ZALTRAP 100 MG/4 ML (25 MG/ML), 200 MG/8 ML (25 MG/ML) INTRAVENOUS SOLUTION <b>DL</b>	4	PA
ZANOSAR 1 GRAM INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D
ZEJULA 100 MG CAPSULE <b>DL</b>	4	PA,QL (90 per 30 days)
ZELBORAF 240 MG TABLET <b>DL</b>	4	PA,QL (240 per 30 days)
ZEPZELCA 4 MG INTRAVENOUS SOLUTION <b>DL</b>	4	PA
ZINECARD 250 MG, 500 MG VIAL <b>DL</b>	4	B vs D
ZIRABEV 25 MG/ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA
ZOLINZA 100 MG CAPSULE <b>DL</b>	4	PA,QL (120 per 30 days)
ZYDELIG 100 MG, 150 MG TABLET <b>DL</b>	4	PA,QL (60 per 30 days)
ZYKADIA 150 MG CAPSULE <b>DL</b>	4	PA,QL (150 per 30 days)
ZYKADIA 150 MG TABLET <b>DL</b>	4	PA,QL (150 per 30 days)
ZYTIGA 250 MG TABLET <b>DL</b>	4	PA,QL (120 per 30 days)
ZYTIGA 500 MG TABLET <b>DL</b>	4	PA,QL (60 per 30 days)
<b>Antiparasitics</b>		
albendazole 200 mg tablet <b>DL</b>	4	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ALBENZA 200 MG TABLET <b>DL</b>	4	
ALINIA 100 MG/5 ML ORAL SUSPENSION <b>DL</b>	4	QL (150 per 30 days)
ALINIA 500 MG TABLET <b>DL</b>	4	QL (40 per 30 days)
<i>atovaquone 750 mg/5 ml susp</i> <b>DL</b>	4	
<i>atovaquone-proguanil 250-100; atovaquone-proguanil 62.5-25</i> <b>MO</b>	1	
<i>benznidazole 100 mg tablet</i> <b>MO</b>	3	QL (240 per 365 days)
<i>benznidazole 12.5 mg tablet</i> <b>MO</b>	3	QL (720 per 365 days)
BILTRICIDE 600 MG TABLET <b>DL</b>	4	PA
<i>chloroquine ph 250 mg, 500 mg tablet</i> <b>MO</b>	1	
COARTEM 20 MG-120 MG TABLET <b>MO</b>	3	QL (24 per 30 days)
DARAPRIM 25 MG TABLET <b>DL</b>	4	PA,QL (90 per 30 days)
EGATEN 250 MG TABLET <b>MO</b>	3	
<i>emverm 100 mg chewable tablet</i> <b>DL</b>	4	
<i>hydroxychloroquine 200 mg tab</i> <b>MO</b>	1	
IMPAVIDO 50 MG CAPSULE <b>DL</b>	4	QL (84 per 28 days)
<i>ivermectin 3 mg tablet</i> <b>MO</b>	1	
KRINTAFEL 150 MG TABLET <b>MO</b>	2	QL (4 per 180 days)
MALARONE 250 MG-100 MG TABLET <b>MO</b>	3	PA
MALARONE PEDIATRIC 62.5 MG-25 MG TABLET <b>MO</b>	3	PA
<i>mefloquine hcl 250 mg tablet</i> <b>MO</b>	1	
MEPRON 750 MG/5 ML ORAL SUSPENSION <b>DL</b>	4	
NEBUPENT 300 MG SOLUTION FOR INHALATION <b>MO</b>	3	B vs D
PENTAM 300 MG SOLUTION FOR INJECTION <b>MO</b>	3	
<i>pentamidine 300 mg inhal powdr</i> <b>MO</b>	1	B vs D
<i>pentamidine 300 mg vial</i> <b>MO</b>	1	
PLAQUENIL 200 MG TABLET <b>MO</b>	3	PA
<i>praziquantel 600 mg tablet</i> <b>MO</b>	1	
<i>primaquine 26.3 mg tablet</i> <b>MO</b>	1	
<i>pyrimethamine 25 mg tablet</i> <b>DL</b>	4	QL (90 per 30 days)
QUALAQUIN 324 MG CAPSULE <b>MO</b>	3	PA,QL (42 per 7 days)
<i>quinine sulfate 324 mg capsule</i> <b>MO</b>	1	PA,QL (42 per 7 days)
SKLICE 0.5 % LOTION <b>MO</b>	3	QL (117 per 30 days)
STROMEKTOL 3 MG TABLET <b>MO</b>	3	
<b>Antiparkinson Agents</b>		
<i>amantadine 100 mg capsule</i> <b>MO</b>	1	
<i>amantadine 100 mg tablet</i> <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>amantadine 50 mg/5 ml solution</i> <b>MO</b>	1	
APOKYN 10 MG/ML SUBCUTANEOUS CARTRIDGE <b>DL</b>	4	PA,QL (84 per 28 days)
AZILECT 0.5 MG, 1 MG TABLET <b>DL</b>	4	PA,QL (30 per 30 days)
<i>benztropine 2 mg/2 ml ampule</i> <b>MO</b>	1	
<i>benztropine mes 0.5 mg, 1 mg, 2 mg tab; benztropine mes 0.5 mg, 1 mg, 2 mg tablet</i> <b>MO</b>	1	
<i>bromocriptine 2.5 mg tablet</i> <b>MO</b>	1	
<i>bromocriptine 5 mg capsule</i> <b>MO</b>	1	QL (600 per 30 days)
<i>carbidopa 25 mg tablet</i> <b>MO</b>	1	
<i>carbidopa-levo 10-100 mg, 25-100 mg, 25-250 mg odt; carbidopa-levodopa 10-100 tab; carbidopa-levodopa 25-100 tab; carbidopa-levodopa 25-250 tab</i> <b>MO</b>	1	
<i>carbidopa-levo er 25-100 tab; carbidopa-levo er 50-200 tab</i> <b>MO</b>	1	
<i>carbidopa-levodopa 100 mg-enta; carbidopa-levodopa 125 mg-enta; carbidopa-levodopa 150 mg-enta; carbidopa-levodopa 50 mg-enta; carbidopa-levodopa 75 mg-enta</i> <b>MO</b>	1	QL (240 per 30 days)
<i>carbidopa-levodopa 200 mg-enta</i> <b>MO</b>	1	
COGENTIN 1 MG/ML INJECTION SOLUTION <b>MO</b>	3	
COMTAN 200 MG TABLET <b>DL</b>	4	PA,QL (300 per 30 days)
DUOPA 4.63 MG-20 MG/ML SUSPENSION IN J-TUBE PUMP <b>DL</b>	4	PA,QL (2800 per 28 days)
<i>entacapone 200 mg tablet</i> <b>MO</b>	1	QL (300 per 30 days)
GOCOVRI 137 MG CAPSULE,EXTENDED RELEASE <b>DL</b>	4	PA,QL (60 per 30 days)
GOCOVRI 68.5 MG CAPSULE,EXTENDED RELEASE <b>DL</b>	4	PA,QL (30 per 30 days)
INBRIJA 42 MG CAPSULE WITH INHALATION DEVICE; INBRIJA 42 MG CAPSULES FOR INHALATION <b>DL</b>	4	PA,QL (300 per 30 days)
KYNMOBI 10 MG, 10-15-20-25-30 MG, 15 MG, 20 MG, 25 MG, 30 MG SUBLINGUAL FILM; KYNMOBI 10 MG-15 MG-20 MG-25 MG-30 MG SUBLINGUAL FILM <b>DL</b>	4	PA,QL (150 per 30 days)
LODOSYN 25 MG TABLET <b>DL</b>	4	PA
MIRAPEX 0.125 MG, 0.25 MG, 0.5 MG, 0.75 MG, 1 MG, 1.5 MG TABLET <b>MO</b>	3	ST
MIRAPEX ER 0.375 MG, 0.75 MG, 1.5 MG, 2.25 MG, 3 MG, 3.75 MG, 4.5 MG TABLET,EXTENDED RELEASE <b>DL</b>	4	ST,QL (30 per 30 days)
NEUPRO 1 MG/24 HOUR, 2 MG/24 HOUR, 3 MG/24 HOUR, 4 MG/24 HOUR, 6 MG/24 HOUR, 8 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH <b>MO</b>	3	QL (30 per 30 days)
NOURIANZ 20 MG, 40 MG TABLET <b>DL</b>	4	PA,QL (30 per 30 days)
ONGENTYS 50 MG CAPSULE <b>MO</b>	3	PA,QL (30 per 30 days)
OSMOLEX ER 129 MG, 193 MG, 258 MG TABLET, EXTENDED RELEASE <b>MO</b>	3	PA,QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
OSMOLEX ER 322 MG/DAY (129 MG AND 193 MG) TABLET, EXTENDED RELEASE <b>MO</b>	3	PA,QL (60 per 30 days)
PARLODEL 2.5 MG TABLET <b>MO</b>	3	PA
PARLODEL 5 MG CAPSULE <b>MO</b>	3	PA,QL (600 per 30 days)
pramipexole 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.5 mg tablet <b>MO</b>	1	
pramipexole er 0.375 mg, 0.75 mg, 1.5 mg, 2.25 mg, 3 mg, 3.75 mg, 4.5 mg tablet <b>MO</b>	1	ST,QL (30 per 30 days)
rasagiline mesylate 0.5 mg, 1 mg tab <b>MO</b>	1	QL (30 per 30 days)
REQUIP 0.25 MG, 0.5 MG, 1 MG, 2 MG, 3 MG, 4 MG, 5 MG TABLET <b>MO</b>	3	ST
REQUIP XL 12 MG, 2 MG, 4 MG, 6 MG, 8 MG TABLET; REQUIP XL 12 MG, 2 MG, 4 MG, 6 MG, 8 MG TABLET,EXTENDED RELEASE <b>MO</b>	3	ST,QL (90 per 30 days)
ropinirole hcl 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg tablet <b>MO</b>	1	
ropinirole hcl er 12 mg, 2 mg, 4 mg, 6 mg, 8 mg tablet <b>MO</b>	1	ST,QL (90 per 30 days)
RYTARY 23.75 MG-95 MG CAPSULE,EXTENDED RELEASE; RYTARY 48.75 MG-195 MG CAPSULE,EXTENDED RELEASE <b>MO</b>	3	ST,QL (360 per 30 days)
RYTARY 36.25 MG-145 MG CAPSULE,EXTENDED RELEASE <b>MO</b>	3	ST,QL (270 per 30 days)
RYTARY 61.25 MG-245 MG CAPSULE,EXTENDED RELEASE <b>MO</b>	3	ST,QL (300 per 30 days)
selegiline hcl 5 mg capsule <b>MO</b>	1	
selegiline hcl 5 mg tablet <b>MO</b>	1	
SINEMET 10 MG-100 MG TABLET; SINEMET 25 MG-100 MG TABLET; SINEMET 25 MG-250 MG TABLET <b>MO</b>	3	PA
SINEMET CR 25-100 TABLET; SINEMET CR 50-200 TABLET <b>MO</b>	3	PA
STALEVO 100 25 MG-100 MG-200 MG TABLET <b>DL</b>	4	PA,QL (240 per 30 days)
STALEVO 125 31.25 MG-125 MG-200 MG TABLET <b>DL</b>	4	PA,QL (240 per 30 days)
STALEVO 150 37.5 MG-150 MG-200 MG TABLET <b>DL</b>	4	PA,QL (240 per 30 days)
STALEVO 200 50 MG-200 MG-200 MG TABLET <b>DL</b>	4	PA
STALEVO 50 12.5 MG-50 MG-200 MG TABLET <b>DL</b>	4	PA,QL (240 per 30 days)
STALEVO 75 18.75 MG-75 MG-200 MG TABLET <b>DL</b>	4	PA,QL (240 per 30 days)
TASMAR 100 MG TABLET <b>DL</b>	4	PA
tolcapone 100 mg tablet <b>DL</b>	4	PA
trihexyphenidyl 2 mg, 5 mg tablet <b>MO</b>	1	
trihexyphenidyl 2 mg/5 ml elx <b>MO</b>	1	
XADAGO 100 MG, 50 MG TABLET <b>DL</b>	4	PA,QL (30 per 30 days)
ZELAPAR 1.25 MG DISINTEGRATING TABLET <b>DL</b>	4	
<b>Antipsychotics</b>		
ABILIFY 10 MG, 15 MG, 2 MG, 20 MG, 30 MG, 5 MG TABLET <b>DL</b>	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ABILIFY MAINTENA 300 MG, 400 MG INTRAMUSCULAR SUSPENSION,EXTENDED RELEASE <b>DL</b>	4	QL (1 per 28 days)
ABILIFY MAINTENA 300 MG, 400 MG SUSPENSION,EXTENDED REL. INTRAMUSCULAR SYRINGE <b>DL</b>	4	QL (1 per 28 days)
ABILIFY MYCITE 10 MG, 15 MG, 2 MG, 20 MG, 30 MG, 5 MG TABLET WITH SENSOR AND PATCH <b>DL</b>	4	PA,QL (30 per 30 days)
<i>aripiprazole 1 mg/ml solution</i> <b>DL</b>	4	QL (750 per 30 days)
<i>aripiprazole 10 mg, 15 mg, 2 mg, 20 mg, 30 mg, 5 mg tablet</i> <b>MO</b>	1	
<i>aripiprazole odt 10 mg, 15 mg tablet</i> <b>DL</b>	4	QL (60 per 30 days)
ARISTADA 1,064 MG/3.9 ML SUSPENSION, EXTEND.REL. IM SYRINGE <b>MO</b>	4	QL (3.9 per 56 days)
ARISTADA 441 MG/1.6 ML SUSPENSION, EXTEND.REL. IM SYRINGE <b>DL</b>	4	QL (1.6 per 28 days)
ARISTADA 662 MG/2.4 ML SUSPENSION, EXTEND.REL. IM SYRINGE <b>DL</b>	4	QL (2.4 per 28 days)
ARISTADA 882 MG/3.2 ML SUSPENSION, EXTEND.REL. IM SYRINGE <b>DL</b>	4	QL (3.2 per 28 days)
ARISTADA INITIO 675 MG/2.4 ML SUSPENSION, EXTEND.REL. IM SYRINGE <b>DL</b>	4	QL (2.4 per 42 days)
CAPLYTA 42 MG CAPSULE <b>DL</b>	4	PA,QL (30 per 30 days)
<i>chlorpromazine 10 mg, 25 mg tablet</i> <b>MO</b>	1	B vs D
<i>chlorpromazine 100 mg, 200 mg, 50 mg tablet</i> <b>MO</b>	1	
<i>chlorpromazine 25 mg/ml amp</i> <b>MO</b>	1	
<i>clozapine 100 mg tablet</i> <b>MO</b>	1	QL (270 per 30 days)
<i>clozapine 200 mg tablet</i> <b>MO</b>	1	QL (135 per 30 days)
<i>clozapine 25 mg tablet</i> <b>MO</b>	1	QL (1080 per 30 days)
<i>clozapine 50 mg tablet</i> <b>MO</b>	1	
<i>clozapine odt 100 mg tablet</i> <b>MO</b>	1	PA,QL (270 per 30 days)
<i>clozapine odt 12.5 mg tablet</i> <b>MO</b>	1	PA
<i>clozapine odt 150 mg tablet</i> <b>MO</b>	1	PA,QL (180 per 30 days)
<i>clozapine odt 200 mg tablet</i> <b>MO</b>	1	PA,QL (135 per 30 days)
<i>clozapine odt 25 mg tablet</i> <b>MO</b>	1	PA,QL (1080 per 30 days)
CLOZARIL 100 MG TABLET <b>DL</b>	4	QL (270 per 30 days)
CLOZARIL 200 MG TABLET <b>DL</b>	4	QL (135 per 30 days)
CLOZARIL 25 MG TABLET <b>DL</b>	4	QL (1080 per 30 days)
CLOZARIL 50 MG TABLET <b>DL</b>	4	
<i>droperidol 5 mg/2 ml vial</i> <b>MO</b>	1	
FANAPT 1 MG, 10 MG, 12 MG, 2 MG, 4 MG, 6 MG, 8 MG TABLET <b>DL</b>	4	PA,QL (60 per 30 days)
FANAPT 1MG(2)-2 MG(2)-4MG(2)-6 MG(2) TABLETS IN A DOSE PACK <b>DL</b>	3	PA,QL (60 per 30 days)
FAZACLO 100 MG ODT <b>DL</b>	4	PA,QL (270 per 30 days)
FAZACLO 12.5 MG ODT <b>DL</b>	4	PA
FAZACLO 150 MG ODT <b>DL</b>	4	PA,QL (180 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
FAZACLO 200 MG ODT <b>DL</b>	4	PA,QL (135 per 30 days)
FAZACLO 25 MG ODT <b>DL</b>	4	PA,QL (1080 per 30 days)
fluphenazine dec 125 mg/5 ml <b>MO</b>	1	
fluphenazine 1 mg, 10 mg, 2.5 mg, 5 mg tablet <b>MO</b>	1	
fluphenazine 2.5 mg/5 ml elix <b>MO</b>	1	
fluphenazine 2.5 mg/ml vial <b>MO</b>	1	
fluphenazine 5 mg/ml conc <b>MO</b>	1	
GEODON 20 MG, 40 MG, 60 MG, 80 MG CAPSULE <b>DL</b>	4	PA
GEODON 20 MG/ML (FINAL CONCENTRATION) INTRAMUSCULAR SOLUTION <b>MO</b>	3	PA
HALDOL 5 MG/ML INJECTION SOLUTION <b>MO</b>	3	
HALDOL DECANOATE 100 MG/ML, 50 MG/ML INTRAMUSCULAR SOLUTION <b>MO</b>	3	PA
haloperidol 0.5 mg, 1 mg, 10 mg, 2 mg, 20 mg, 5 mg tablet <b>MO</b>	1	
haloperidol dec 100 mg/ml, 50 mg/ml amp; haloperidol decan 100 mg/ml, 50 mg/ml amp <b>MO</b>	1	
haloperidol lac 2 mg/ml conc <b>MO</b>	1	
haloperidol lac 5 mg/ml syring <b>MO</b>	1	
haloperidol lac 5 mg/ml vial <b>MO</b>	1	
INVEGA 1.5 MG, 3 MG, 9 MG TABLET,EXTENDED RELEASE <b>DL</b>	4	PA,QL (30 per 30 days)
INVEGA 6 MG TABLET,EXTENDED RELEASE <b>DL</b>	4	PA,QL (60 per 30 days)
INVEGA SUSTENNA 117 MG/0.75 ML, 234 MG/1.5 ML, 78 MG/0.5 ML INTRAMUSCULAR SYRINGE <b>DL</b>	4	QL (1.5 per 28 days)
INVEGA SUSTENNA 156 MG/ML INTRAMUSCULAR SYRINGE <b>DL</b>	4	QL (1 per 28 days)
INVEGA SUSTENNA 39 MG/0.25 ML INTRAMUSCULAR SYRINGE <b>MO</b>	3	QL (1.5 per 28 days)
INVEGA TRINZA 273 MG/0.875 ML INTRAMUSCULAR SYRINGE <b>MO</b>	4	QL (0.87 per 90 days)
INVEGA TRINZA 410 MG/1.315 ML INTRAMUSCULAR SYRINGE <b>MO</b>	4	QL (1.31 per 90 days)
INVEGA TRINZA 546 MG/1.75 ML INTRAMUSCULAR SYRINGE <b>MO</b>	4	QL (1.75 per 90 days)
INVEGA TRINZA 819 MG/2.625 ML INTRAMUSCULAR SYRINGE <b>MO</b>	4	QL (2.62 per 90 days)
LATUDA 120 MG, 20 MG, 40 MG, 60 MG TABLET <b>DL</b>	4	PA,QL (30 per 30 days)
LATUDA 80 MG TABLET <b>DL</b>	4	PA,QL (60 per 30 days)
loxapine 10 mg, 25 mg, 5 mg, 50 mg capsule <b>MO</b>	1	
molindone hcl 10 mg tablet <b>MO</b>	1	PA,QL (240 per 30 days)
molindone hcl 25 mg tablet <b>MO</b>	1	PA,QL (270 per 30 days)
molindone hcl 5 mg tablet <b>MO</b>	1	PA,QL (360 per 30 days)
NUPLAZID 10 MG TABLET <b>DL</b>	4	PA,QL (30 per 30 days)
NUPLAZID 17 MG TABLET <b>DL</b>	4	PA,QL (60 per 30 days)
NUPLAZID 34 MG CAPSULE <b>DL</b>	4	PA,QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
olanzapine 10 mg vial <b>MO</b>	1	
olanzapine 10 mg, 15 mg, 2.5 mg, 20 mg, 5 mg, 7.5 mg tablet <b>MO</b>	1	
olanzapine odt 10 mg, 5 mg tablet <b>MO</b>	1	QL (30 per 30 days)
olanzapine odt 15 mg, 20 mg tablet <b>MO</b>	1	QL (60 per 30 days)
ORAP 2 MG TABLET <b>MO</b>	3	
paliperidone er 1.5 mg, 3 mg, 9 mg tablet <b>MO</b>	1	QL (30 per 30 days)
paliperidone er 6 mg tablet <b>MO</b>	1	QL (60 per 30 days)
perphenazine 16 mg, 2 mg, 4 mg, 8 mg tablet <b>MO</b>	1	
PERSERIS 120 MG, 90 MG ABDOMINAL SUBCUTANEOUS EXTEND RELEASE SUSP SYRINGE KIT <b>DL</b>	4	QL (1 per 28 days)
pimozide 1 mg, 2 mg tablet <b>MO</b>	1	
quetiapine er 150 mg tablet <b>MO</b>	1	QL (90 per 30 days)
quetiapine er 200 mg tablet <b>MO</b>	1	QL (30 per 30 days)
quetiapine er 300 mg, 400 mg tablet <b>MO</b>	1	QL (60 per 30 days)
quetiapine er 50 mg tablet <b>MO</b>	1	QL (120 per 30 days)
quetiapine fumarate 100 mg tab <b>MO</b>	1	QL (90 per 30 days)
quetiapine fumarate 200 mg, 25 mg, 50 mg tab <b>MO</b>	1	QL (120 per 30 days)
quetiapine fumarate 300 mg, 400 mg tab <b>MO</b>	1	QL (60 per 30 days)
REXULTI 0.25 MG, 0.5 MG, 1 MG, 2 MG, 3 MG, 4 MG TABLET <b>DL</b>	4	PA,QL (30 per 30 days)
RISPERDAL 0.25 MG, 1 MG, 2 MG, 3 MG, 4 MG TABLET <b>DL</b>	4	QL (60 per 30 days)
RISPERDAL 0.5 MG TABLET <b>DL</b>	4	QL (120 per 30 days)
RISPERDAL 1 MG/ML ORAL SOLUTION <b>DL</b>	4	
RISPERDAL CONSTA 12.5 MG/2 ML, 25 MG/2 ML INTRAMUSCULAR SUSP,EXTENDED RELEASE <b>MO</b>	3	QL (2 per 28 days)
RISPERDAL CONSTA 37.5 MG/2 ML, 50 MG/2 ML INTRAMUSCULAR SUSP,EXTENDED RELEASE <b>DL</b>	4	QL (2 per 28 days)
risperidone 0.25 mg, 1 mg, 2 mg, 3 mg, 4 mg odt; risperidone 0.25 mg, 1 mg, 2 mg, 3 mg, 4 mg tablet <b>MO</b>	1	QL (60 per 30 days)
risperidone 0.5 mg odt; risperidone 0.5 mg tablet <b>MO</b>	1	QL (120 per 30 days)
risperidone 1 mg/ml solution <b>MO</b>	1	
SAPHRIS 10 MG, 2.5 MG, 5 MG SUBLINGUAL TABLET <b>DL</b>	4	PA,QL (60 per 30 days)
SECUADO 3.8 MG/24 HOUR, 5.7 MG/24 HOUR, 7.6 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH <b>DL</b>	4	PA,QL (30 per 30 days)
SEROQUEL 100 MG TABLET <b>MO</b>	3	QL (90 per 30 days)
SEROQUEL 200 MG, 25 MG, 50 MG TABLET <b>MO</b>	3	QL (120 per 30 days)
SEROQUEL 300 MG, 400 MG TABLET <b>MO</b>	3	QL (60 per 30 days)
SEROQUEL XR 150 MG TABLET,EXTENDED RELEASE <b>MO</b>	3	PA,QL (90 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
SEROQUEL XR 200 MG TABLET,EXTENDED RELEASE <b>MO</b>	3	PA,QL (30 per 30 days)
SEROQUEL XR 300 MG, 400 MG TABLET,EXTENDED RELEASE <b>MO</b>	3	PA,QL (60 per 30 days)
SEROQUEL XR 50 MG TABLET,EXTENDED RELEASE <b>MO</b>	3	PA,QL (120 per 30 days)
SEROQUEL XR 50 MG(3)-200 MG(1)-300 MG(11) TABLET, ER 24 HR DOSE PACK <b>MO</b>	3	PA,QL (15 per 30 days)
<i>thioridazine 10 mg, 100 mg, 25 mg, 50 mg tablet</i> <b>MO</b>	1	
<i>thiothixene 1 mg, 10 mg, 2 mg, 5 mg capsule</i> <b>MO</b>	1	
<i>trifluoperazine 1 mg, 10 mg, 2 mg, 5 mg tablet</i> <b>MO</b>	1	
VERSACLOZ 50 MG/ML ORAL SUSPENSION <b>DL</b>	4	PA,QL (540 per 30 days)
VRAYLAR 1.5 MG (1)-3 MG (6) CAPSULES IN A DOSE PACK <b>MO</b>	3	PA
VRAYLAR 1.5 MG, 3 MG, 4.5 MG, 6 MG CAPSULE <b>DL</b>	4	PA,QL (30 per 30 days)
<i>ziprasidone hcl 20 mg, 40 mg, 60 mg, 80 mg capsule</i> <b>MO</b>	1	
<i>ziprasidone 20 mg/ml vial</i> <b>MO</b>	1	
ZYPREXA 10 MG INTRAMUSCULAR SOLUTION <b>MO</b>	3	
ZYPREXA 10 MG, 15 MG, 2.5 MG, 20 MG, 5 MG, 7.5 MG TABLET <b>DL</b>	4	
ZYPREXA RELPREVV 210 MG INTRAMUSCULAR SUSPENSION <b>DL</b>	4	QL (4 per 28 days)
ZYPREXA RELPREVV 300 MG INTRAMUSCULAR SUSPENSION <b>DL</b>	4	QL (2 per 28 days)
ZYPREXA RELPREVV 405 MG INTRAMUSCULAR SUSPENSION <b>DL</b>	4	QL (1 per 28 days)
ZYPREXA ZYDIS 10 MG, 5 MG DISINTEGRATING TABLET <b>DL</b>	4	QL (30 per 30 days)
ZYPREXA ZYDIS 15 MG, 20 MG DISINTEGRATING TABLET <b>DL</b>	4	QL (60 per 30 days)
<b>Antispasticity Agents</b>		
<i>baclofen 10 mg, 20 mg tablet</i> <b>MO</b>	1	
<i>baclofen 5 mg tablet</i> <b>MO</b>	1	QL (90 per 30 days)
DANTRIUM 20 MG INTRAVENOUS SOLUTION <b>MO</b>	3	
DANTRIUM 25 MG, 50 MG CAPSULE <b>MO</b>	3	
<i>dantrolene sodium 100 mg, 25 mg, 50 mg cap</i> <b>MO</b>	1	
<i>dantrolene sodium 20 mg vial</i> <b>MO</b>	1	
<i>revonto 20 mg intravenous solution</i> <b>MO</b>	1	
<i>tizanidine hcl 2 mg, 4 mg tablet</i> <b>MO</b>	1	
<i>tizanidine hcl 2 mg, 4 mg, 6 mg capsule</i> <b>MO</b>	1	ST
ZANAFLEX 2 MG, 4 MG, 6 MG CAPSULE <b>MO</b>	3	ST
ZANAFLEX 4 MG TABLET <b>MO</b>	3	ST
<b>Antivirals</b>		
<i>abacavir 20 mg/ml solution</i> <b>MO</b>	1	QL (960 per 30 days)
<i>abacavir 300 mg tablet</i> <b>MO</b>	1	QL (60 per 30 days)
<i>abacavir-lamivudine 600-300 mg</i> <b>MO</b>	1	QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
abacavir-lamivudine-zidov tab <b>DL</b>	4	QL (60 per 30 days)
acyclovir 200 mg capsule <b>MO</b>	1	
acyclovir 200 mg/5 ml susp <b>MO</b>	1	
acyclovir 400 mg, 800 mg tablet <b>MO</b>	1	
acyclovir 5% cream <b>DL</b>	4	PA,QL (5 per 30 days)
acyclovir 5% ointment <b>MO</b>	1	PA,QL (30 per 30 days)
acyclovir 1,000 mg/20 ml vial; acyclovir sodium 1 gm vial; acyclovir sodium 1,000 mg, 50 mg/ml, 500 mg vial <b>MO</b>	1	B vs D
adefovir dipivoxil 10 mg tab <b>DL</b>	4	
APTIVUS 250 MG CAPSULE <b>DL</b>	4	QL (120 per 30 days)
APTIVUS (WITH VITAMIN E) 100 MG/ML ORAL SOLUTION <b>DL</b>	4	QL (285 per 28 days)
atazanavir sulfate 150 mg, 200 mg cap <b>MO</b>	1	QL (60 per 30 days)
atazanavir sulfate 300 mg cap <b>MO</b>	1	QL (30 per 30 days)
ATRIPLA 600 MG-200 MG-300 MG TABLET <b>DL</b>	4	QL (30 per 30 days)
BARACLUDE 0.05 MG/ML ORAL SOLUTION <b>MO</b>	3	QL (630 per 30 days)
BARACLUDE 0.5 MG, 1 MG TABLET <b>DL</b>	4	PA,QL (30 per 30 days)
BIKTARVY 50 MG-200 MG-25 MG TABLET <b>DL</b>	4	QL (30 per 30 days)
cidofovir 375 mg/5 ml vial <b>MO</b>	1	
CIMDUO 300 MG-300 MG TABLET <b>DL</b>	4	QL (30 per 30 days)
COMBIVIR 150 MG-300 MG TABLET <b>DL</b>	4	QL (60 per 30 days)
COMPLERA 200 MG-25 MG-300 MG TABLET <b>DL</b>	4	QL (30 per 30 days)
CRIXIVAN 200 MG CAPSULE <b>MO</b>	2	QL (450 per 30 days)
CRIXIVAN 400 MG CAPSULE <b>MO</b>	3	QL (270 per 30 days)
CYTOVENE 500 MG INTRAVENOUS SOLUTION <b>DL</b>	4	B vs D
DAKLINZA 30 MG, 60 MG, 90 MG TABLET <b>DL</b>	4	PA,QL (28 per 28 days)
DELSTRIGO 100 MG-300 MG-300 MG TABLET <b>DL</b>	4	QL (30 per 30 days)
DENAVIR 1 % TOPICAL CREAM <b>DL</b>	4	PA
DESCOVY 200 MG-25 MG TABLET <b>DL</b>	4	QL (30 per 30 days)
didanosine dr 125 mg capsule <b>MO</b>	1	QL (90 per 30 days)
didanosine dr 200 mg capsule <b>MO</b>	1	QL (60 per 30 days)
didanosine dr 250 mg, 400 mg capsule <b>MO</b>	1	QL (30 per 30 days)
DOVATO 50 MG-300 MG TABLET <b>DL</b>	4	QL (30 per 30 days)
EDURANT 25 MG TABLET <b>DL</b>	4	QL (30 per 30 days)
efavirenz 200 mg capsule <b>MO</b>	1	QL (120 per 30 days)
efavirenz 50 mg capsule <b>MO</b>	1	QL (480 per 30 days)
efavirenz 600 mg tablet <b>MO</b>	1	QL (30 per 30 days)
EMTRIVA 10 MG/ML ORAL SOLUTION <b>MO</b>	3	QL (680 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
EMTRIVA 200 MG CAPSULE <b>MO</b>	3	QL (30 per 30 days)
<i>entecavir 0.5 mg, 1 mg tablet</i> <b>MO</b>	1	QL (30 per 30 days)
EPCLUSA 400 MG-100 MG TABLET <b>DL</b>	4	PA,QL (28 per 28 days)
EPIVIR 10 MG/ML ORAL SOLUTION <b>MO</b>	3	QL (900 per 30 days)
EPIVIR 150 MG TABLET <b>MO</b>	3	QL (60 per 30 days)
EPIVIR 300 MG TABLET <b>MO</b>	3	QL (30 per 30 days)
EPIVIR HBV 100 MG TABLET <b>MO</b>	3	QL (90 per 30 days)
EPIVIR HBV 25 MG/5 ML (5 MG/ML) ORAL SOLUTION <b>MO</b>	3	
EPZICOM 600 MG-300 MG TABLET <b>DL</b>	4	QL (30 per 30 days)
EVOTAZ 300 MG-150 MG TABLET <b>DL</b>	4	QL (30 per 30 days)
<i>famciclovir 125 mg, 250 mg, 500 mg tablet</i> <b>MO</b>	1	QL (90 per 30 days)
FLUMADINE 100 MG TABLET <b>MO</b>	3	
<i>fosamprenavir 700 mg tablet</i> <b>DL</b>	4	QL (120 per 30 days)
FOSCAVIR 24 MG/ML INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D
FUZEON 90 MG SUBCUTANEOUS SOLUTION <b>DL</b>	4	QL (60 per 30 days)
<i>ganciclovir 50 mg/ml, 500 mg vial; ganciclovir 500 mg/10 ml vial</i> <b>DL</b>	4	B vs D
GENVOYA 150 MG-150 MG-200 MG-10 MG TABLET <b>DL</b>	4	QL (30 per 30 days)
HARVONI 33.75 MG-150 MG ORAL PELLETS IN PACKET <b>DL</b>	4	PA,QL (28 per 28 days)
HARVONI 45 MG-200 MG ORAL PELLETS IN PACKET <b>DL</b>	4	PA,QL (56 per 28 days)
HARVONI 45 MG-200 MG TABLET; HARVONI 90 MG-400 MG TABLET <b>DL</b>	4	PA,QL (28 per 28 days)
HEPSERA 10 MG TABLET <b>DL</b>	4	
INTELENCE 100 MG, 25 MG TABLET <b>DL</b>	4	QL (120 per 30 days)
INTELENCE 200 MG TABLET <b>DL</b>	4	QL (60 per 30 days)
INVIRASE 200 MG CAPSULE <b>DL</b>	4	QL (300 per 30 days)
INVIRASE 500 MG TABLET <b>DL</b>	4	QL (120 per 30 days)
ISENTRESS 100 MG CHEWABLE TABLET <b>DL</b>	4	QL (180 per 30 days)
ISENTRESS 100 MG ORAL POWDER PACKET <b>MO</b>	2	QL (300 per 30 days)
ISENTRESS 25 MG CHEWABLE TABLET <b>MO</b>	3	QL (180 per 30 days)
ISENTRESS 400 MG TABLET <b>DL</b>	4	QL (120 per 30 days)
ISENTRESS HD 600 MG TABLET <b>DL</b>	4	QL (60 per 30 days)
JULUCA 50 MG-25 MG TABLET <b>DL</b>	4	QL (30 per 30 days)
KALETRA 100 MG-25 MG TABLET <b>DL</b>	3	QL (300 per 30 days)
KALETRA 200 MG-50 MG TABLET <b>DL</b>	4	QL (150 per 30 days)
KALETRA 400 MG-100 MG/5 ML ORAL SOLUTION <b>DL</b>	4	
<i>lamivudine 10 mg/ml oral soln</i> <b>MO</b>	1	QL (900 per 30 days)
<i>lamivudine 150 mg tablet</i> <b>MO</b>	1	QL (60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
lamivudine 300 mg tablet <b>MO</b>	1	QL (30 per 30 days)
lamivudine hbv 100 mg tablet <b>MO</b>	1	QL (90 per 30 days)
lamivudine-zidovudine tablet <b>MO</b>	1	QL (60 per 30 days)
ledipasvir-sofosbuvir 90-400mg <b>DL</b>	4	PA,QL (28 per 28 days)
LEXIVA 50 MG/ML ORAL SUSPENSION <b>MO</b>	3	QL (1575 per 28 days)
LEXIVA 700 MG TABLET <b>DL</b>	4	QL (120 per 30 days)
lopinavir-ritonavir 80-20mg/ml <b>MO</b>	1	
MAVYRET 100 MG-40 MG TABLET <b>DL</b>	4	PA,QL (84 per 28 days)
moderiba 200 mg tablet <b>DL</b>	4	QL (168 per 28 days)
nevirapine 200 mg tablet <b>MO</b>	1	QL (60 per 30 days)
nevirapine 50 mg/5 ml susp <b>MO</b>	1	QL (1200 per 30 days)
nevirapine er 100 mg tablet <b>MO</b>	1	QL (120 per 30 days)
nevirapine er 400 mg tablet <b>MO</b>	1	QL (30 per 30 days)
NORVIR 100 MG ORAL POWDER PACKET <b>MO</b>	3	QL (360 per 30 days)
NORVIR 100 MG TABLET <b>MO</b>	3	QL (360 per 30 days)
NORVIR 80 MG/ML ORAL SOLUTION <b>MO</b>	3	QL (480 per 30 days)
ODEFSEY 200 MG-25 MG-25 MG TABLET <b>DL</b>	4	QL (30 per 30 days)
oseltamivir 6 mg/ml suspension <b>MO</b>	1	QL (1440 per 365 days)
oseltamivir phos 30 mg capsule <b>MO</b>	1	QL (224 per 365 days)
oseltamivir phos 45 mg, 75 mg capsule <b>MO</b>	1	QL (112 per 365 days)
PIFELTRO 100 MG TABLET <b>DL</b>	4	QL (60 per 30 days)
PREVYMIS 240 MG, 480 MG TABLET <b>DL</b>	4	PA,QL (28 per 28 days)
PREVYMIS 240 MG/12 ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA,QL (336 per 28 days)
PREVYMIS 480 MG/24 ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA,QL (672 per 28 days)
PREZCOBIX 800 MG-150 MG TABLET <b>DL</b>	4	QL (30 per 30 days)
PREZISTA 100 MG/ML ORAL SUSPENSION <b>DL</b>	4	QL (360 per 30 days)
PREZISTA 150 MG TABLET <b>DL</b>	4	QL (240 per 30 days)
PREZISTA 600 MG TABLET <b>DL</b>	4	QL (60 per 30 days)
PREZISTA 75 MG TABLET <b>MO</b>	3	QL (480 per 30 days)
PREZISTA 800 MG TABLET <b>DL</b>	4	QL (30 per 30 days)
REBETOL 40 MG/ML SOLUTION <b>MO</b>	3	QL (1000 per 30 days)
RELENZA DISKHALER 5 MG/ACTUATION POWDER FOR INHALATION <b>MO</b>	3	QL (60 per 180 days)
RESCRIPTOR 100 MG TABLET <b>MO</b>	3	QL (360 per 30 days)
RESCRIPTOR 200 MG TABLET <b>MO</b>	3	QL (180 per 30 days)
RETROVIR 10 MG/ML INTRAVENOUS SOLUTION <b>MO</b>	3	
RETROVIR 10 MG/ML ORAL SYRUP <b>MO</b>	3	QL (1680 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
RETROVIR 100 MG CAPSULE <b>MO</b>	3	QL (180 per 30 days)
REYATAZ 150 MG, 200 MG CAPSULE <b>DL</b>	4	QL (60 per 30 days)
REYATAZ 300 MG CAPSULE <b>DL</b>	4	QL (30 per 30 days)
REYATAZ 50 MG ORAL POWDER PACKET <b>MO</b>	3	
<i>ribasphere 200 mg capsule</i> <b>DL</b>	4	QL (168 per 28 days)
<i>ribasphere 200 mg tablet</i> <b>MO</b>	1	QL (168 per 28 days)
<i>ribasphere 400 mg tablet</i> <b>MO</b>	1	QL (112 per 30 days)
<i>ribasphere 600 mg tablet</i> <b>MO</b>	1	
RIBASPHERE RIBAPAK 600-400 MG; RIBASPHERE RIBAPAK 600-600 MG <b>DL</b>	4	
<i>ribavirin 200 mg capsule</i> <b>MO</b>	1	QL (168 per 28 days)
<i>ribavirin 200 mg tablet</i> <b>MO</b>	1	QL (168 per 28 days)
<i>rimantadine hcl 100 mg tablet</i> <b>MO</b>	1	
<i>ritonavir 100 mg tablet</i> <b>MO</b>	1	QL (360 per 30 days)
RUKOBIA 600 MG TABLET,EXTENDED RELEASE <b>DL</b>	4	QL (60 per 30 days)
SELZENTRY 150 MG, 25 MG TABLET <b>DL</b>	4	QL (240 per 30 days)
SELZENTRY 20 MG/ML ORAL SOLUTION <b>DL</b>	4	QL (1800 per 30 days)
SELZENTRY 300 MG, 75 MG TABLET <b>DL</b>	4	QL (120 per 30 days)
SITAVIG 50 MG BUCCAL TABLET <b>MO</b>	3	PA,QL (1 per 28 days)
SOVALDI 150 MG ORAL PELLETS IN PACKET <b>DL</b>	4	PA,QL (28 per 28 days)
SOVALDI 200 MG ORAL PELLETS IN PACKET <b>DL</b>	4	PA,QL (56 per 28 days)
SOVALDI 200 MG, 400 MG TABLET <b>DL</b>	4	PA,QL (28 per 28 days)
<i>stavudine 15 mg, 20 mg capsule</i> <b>MO</b>	1	QL (120 per 30 days)
<i>stavudine 30 mg, 40 mg capsule</i> <b>MO</b>	1	QL (60 per 30 days)
STRIBILD 150 MG-150 MG-200 MG-300 MG TABLET <b>DL</b>	4	QL (30 per 30 days)
SUSTIVA 200 MG CAPSULE <b>DL</b>	4	QL (120 per 30 days)
SUSTIVA 50 MG CAPSULE <b>DL</b>	4	QL (480 per 30 days)
SUSTIVA 600 MG TABLET <b>DL</b>	4	QL (30 per 30 days)
SYMFI 600 MG-300 MG-300 MG TABLET <b>DL</b>	4	QL (30 per 30 days)
SYMFI LO 400 MG-300 MG-300 MG TABLET <b>DL</b>	4	QL (30 per 30 days)
SYMTUZA 800 MG-150 MG-200 MG-10 MG TABLET <b>DL</b>	4	QL (30 per 30 days)
TAMIFLU 30 MG CAPSULE <b>MO</b>	3	PA,QL (224 per 365 days)
TAMIFLU 45 MG, 75 MG CAPSULE <b>MO</b>	3	PA,QL (112 per 365 days)
TAMIFLU 6 MG/ML ORAL SUSPENSION <b>MO</b>	3	PA,QL (1440 per 365 days)
TEMIXYS 300 MG-300 MG TABLET <b>DL</b>	4	QL (30 per 30 days)
<i>tenofovir disop fum 300 mg tb</i> <b>MO</b>	1	QL (30 per 30 days)
TIVICAY 10 MG TABLET <b>DL</b>	3	QL (60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
TIVICAY 25 MG, 50 MG TABLET <b>DL</b>	4	QL (60 per 30 days)
TIVICAY PD 5 MG TABLET FOR ORAL SUSPENSION <b>DL</b>	4	QL (180 per 30 days)
TRIUMEQ 600 MG-50 MG-300 MG TABLET <b>DL</b>	4	QL (30 per 30 days)
TRIZIVIR 300 MG-150 MG-300 MG TABLET <b>DL</b>	4	QL (60 per 30 days)
TROGARZO 200 MG/1.33 ML (150 MG/ML) INTRAVENOUS SOLUTION <b>DL</b>	4	
TRUVADA 100 MG-150 MG TABLET; TRUVADA 133 MG-200 MG TABLET; TRUVADA 167 MG-250 MG TABLET; TRUVADA 200 MG-300 MG TABLET <b>DL</b>	4	QL (30 per 30 days)
TYBOST 150 MG TABLET <b>MO</b>	3	QL (30 per 30 days)
<i>valacyclovir hcl 1 gram, 500 mg tablet</i> <b>MO</b>	1	
VALCYTE 450 MG TABLET <b>DL</b>	4	PA,QL (120 per 30 days)
VALCYTE 50 MG/ML ORAL SOLUTION <b>DL</b>	4	PA,QL (1056 per 30 days)
<i>valganciclovir 450 mg tablet</i> <b>DL</b>	4	QL (120 per 30 days)
<i>valganciclovir hcl 50 mg/ml</i> <b>DL</b>	4	QL (1056 per 30 days)
VALTREX 1 GRAM, 500 MG TABLET <b>MO</b>	3	PA
VEMLIDY 25 MG TABLET <b>DL, LA</b>	4	QL (30 per 30 days)
VIDEX 2 GM PEDIATRIC SOLN <b>MO</b>	3	QL (1200 per 30 days)
VIDEX 4 GM PEDIATRIC SOLN <b>MO</b>	3	QL (1200 per 30 days)
VIDEX EC 125 MG CAPSULE <b>MO</b>	3	QL (90 per 30 days)
VIDEX EC 200 MG CAPSULE <b>MO</b>	3	QL (60 per 30 days)
VIDEX EC 250 MG, 400 MG CAPSULE <b>MO</b>	3	QL (30 per 30 days)
VIEKIRA PAK 12.5 MG-75 MG-50 MG/250 MG TABLETS IN A DOSE PACK <b>DL</b>	4	PA,QL (112 per 28 days)
VIRACEPT 250 MG TABLET <b>DL</b>	4	QL (300 per 30 days)
VIRACEPT 625 MG TABLET <b>DL</b>	4	QL (120 per 30 days)
VIRAMUNE 200 MG TABLET <b>DL</b>	4	QL (60 per 30 days)
VIRAMUNE 50 MG/5 ML ORAL SUSPENSION <b>DL</b>	4	QL (1200 per 30 days)
VIRAMUNE XR 100 MG TABLET <b>DL</b>	4	QL (120 per 30 days)
VIRAMUNE XR 400 MG TABLET,EXTENDED RELEASE <b>DL</b>	4	QL (30 per 30 days)
VIREAD 150 MG, 200 MG, 250 MG, 300 MG TABLET <b>DL</b>	4	QL (30 per 30 days)
VIREAD 40 MG/SCOOP (40 MG/GRAM) ORAL POWDER <b>DL</b>	4	QL (240 per 30 days)
VOSEVI 400 MG-100 MG-100 MG TABLET <b>DL</b>	4	PA,QL (28 per 28 days)
XERESE 5 %-1 % TOPICAL CREAM <b>DL</b>	4	QL (5 per 30 days)
XOFLUZA 20 MG, 40 MG TABLET <b>MO</b>	3	QL (10 per 365 days)
ZEPATIER 50 MG-100 MG TABLET <b>DL</b>	4	PA,QL (28 per 28 days)
ZERIT 1 MG/ML SOLUTION <b>MO</b>	3	QL (2400 per 30 days)
ZERIT 15 MG, 20 MG CAPSULE <b>MO</b>	3	QL (120 per 30 days)
ZERIT 30 MG, 40 MG CAPSULE <b>MO</b>	3	QL (60 per 30 days)
ZIAGEN 20 MG/ML ORAL SOLUTION <b>MO</b>	3	QL (960 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ZIAGEN 300 MG TABLET <b>MO</b>	3	QL (60 per 30 days)
zidovudine 100 mg capsule <b>MO</b>	1	QL (180 per 30 days)
zidovudine 300 mg tablet <b>MO</b>	1	QL (60 per 30 days)
zidovudine 50 mg/5 ml syrup <b>MO</b>	1	QL (1680 per 28 days)
ZIRGAN 0.15 % EYE GEL <b>MO</b>	3	QL (5 per 30 days)
ZOVIRAX 200 MG CAPSULE <b>MO</b>	3	PA
ZOVIRAX 200 MG/5 ML ORAL SUSPENSION <b>MO</b>	3	PA
ZOVIRAX 400 MG, 800 MG TABLET <b>MO</b>	3	PA
ZOVIRAX 5 % TOPICAL CREAM <b>DL</b>	4	PA,QL (5 per 30 days)
ZOVIRAX 5 % TOPICAL OINTMENT <b>DL</b>	4	PA,QL (30 per 30 days)
<b>Anxiolytics</b>		
alprazolam 0.25 mg, 0.5 mg, 1 mg tablet <b>DL</b>	1	QL (120 per 30 days)
alprazolam 2 mg tablet <b>DL</b>	1	QL (150 per 30 days)
alprazolam er 0.5 mg, 1 mg, 2 mg, 3 mg tablet <b>DL</b>	1	QL (60 per 30 days)
alprazolam odt 0.25 mg, 0.5 mg, 1 mg, 2 mg tab <b>DL</b>	1	
alprazolam intensol 1 mg/ml oral concentrate <b>DL</b>	1	
ATIVAN 0.5 MG, 1 MG TABLET <b>DL</b>	4	PA,QL (90 per 30 days)
ATIVAN 2 MG TABLET <b>DL</b>	4	PA,QL (150 per 30 days)
ATIVAN 2 MG/ML, 4 MG/ML INJECTION SOLUTION <b>DL</b>	3	PA
bupirone hcl 10 mg, 15 mg, 30 mg, 5 mg, 7.5 mg tablet <b>MO</b>	1	
chlordiazepoxide 10 mg, 25 mg, 5 mg capsule <b>DL</b>	1	QL (120 per 30 days)
clonazepam 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg dis tab; clonazepam 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg dis tablet; clonazepam 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg odt; clonazepam 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg tablet <b>DL</b>	1	
clorazepate 15 mg, 3.75 mg, 7.5 mg tablet <b>DL</b>	1	
diazepam 10 mg tablet <b>DL</b>	1	QL (120 per 30 days)
diazepam 10 mg/2 ml carpject <b>DL</b>	1	
diazepam 2 mg, 5 mg tablet <b>DL</b>	1	QL (90 per 30 days)
diazepam 5 mg/5 ml solution <b>DL</b>	1	QL (1200 per 30 days)
diazepam 5 mg/ml oral conc <b>DL</b>	1	QL (240 per 30 days)
diazepam 50 mg/10 ml vial <b>DL</b>	1	
diazepam intensol 5 mg/ml oral concentrate <b>DL</b>	1	QL (240 per 30 days)
doxepin 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg capsule <b>MO</b>	1	
doxepin 10 mg/ml oral conc <b>MO</b>	1	
hydroxyzine 10 mg/5 ml, 25 mg/ml, 50 mg/ml soln; hydroxyzine 10 mg/5 ml, 25 mg/ml, 50 mg/ml vial <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
hydroxyzine hcl 10 mg, 25 mg, 50 mg tablet <sup>MO</sup>	1	
KLONOPIN 0.5 MG, 1 MG, 2 MG TABLET <sup>DL</sup>	3	PA
lorazepam 0.5 mg, 1 mg tablet <sup>DL</sup>	1	QL (90 per 30 days)
lorazepam 2 mg tablet <sup>DL</sup>	1	QL (150 per 30 days)
lorazepam 2 mg/ml oral concent <sup>DL</sup>	1	QL (150 per 30 days)
lorazepam 2 mg/ml, 4 mg/ml carpujet <sup>DL</sup>	1	
lorazepam 2 mg/ml, 4 mg/ml vial <sup>DL</sup>	1	
lorazepam intensol 2 mg/ml oral concentrate <sup>DL</sup>	1	QL (150 per 30 days)
meprobamate 200 mg, 400 mg tablet <sup>MO</sup>	1	
oxazepam 10 mg, 15 mg, 30 mg capsule <sup>DL</sup>	1	
TRANXENE T-TAB 7.5 MG TABLET <sup>DL</sup>	4	PA
VALIUM 10 MG TABLET <sup>DL</sup>	3	PA,QL (120 per 30 days)
VALIUM 2 MG, 5 MG TABLET <sup>DL</sup>	3	PA,QL (90 per 30 days)
XANAX 0.25 MG, 0.5 MG, 1 MG TABLET <sup>DL</sup>	4	PA,QL (120 per 30 days)
XANAX 2 MG TABLET <sup>DL</sup>	4	PA,QL (150 per 30 days)
XANAX XR 0.5 MG, 1 MG, 2 MG, 3 MG TABLET,EXTENDED RELEASE <sup>DL</sup>	3	PA,QL (60 per 30 days)
<b>Bipolar Agents</b>		
lithium carbonate 150 mg, 300 mg, 600 mg cap <sup>MO</sup>	1	
lithium carbonate 300 mg tab <sup>MO</sup>	1	
lithium carbonate er 300 mg, 450 mg tb <sup>MO</sup>	1	
lithium 8 meq/5 ml solution <sup>MO</sup>	1	
LITHOBID 300 MG TABLET,EXTENDED RELEASE <sup>DL</sup>	4	
<b>Blood Glucose Regulators</b>		
acarbose 100 mg, 25 mg, 50 mg tablet <sup>MO</sup>	1	
ACTOPLUS MET 15 MG-500 MG TABLET; ACTOPLUS MET 15 MG-850 MG TABLET <sup>MO</sup>	3	PA,QL (90 per 30 days)
ACTOPLUS MET XR 15 MG-1,000 MG TABLET,EXTENDED RELEASE <sup>MO</sup>	3	QL (60 per 30 days)
ACTOPLUS MET XR 30-1,000 MG TB <sup>MO</sup>	3	QL (30 per 30 days)
ACTOS 15 MG, 30 MG, 45 MG TABLET <sup>MO</sup>	3	PA,QL (30 per 30 days)
ADLYXIN 10 MCG/0.2 ML- 20 MCG/0.2 ML, 20 MCG/0.2 ML SUBCUTANEOUS PEN INJECTOR; ADLYXIN 10 MCG/0.2 ML-20 MCG/0.2 ML SUBCUTANEOUS PEN INJECTOR <sup>MO</sup>	3	ST,QL (6 per 28 days)
ADMELOG SOLOSTAR U-100 INSULIN LISPRO 100 UNIT/ML SUBCUTANEOUS PEN <sup>MO</sup>	3	ST
ADMELOG U-100 INSULIN LISPRO 100 UNIT/ML SUBCUTANEOUS SOLUTION <sup>MO</sup>	3	ST

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
AFREZZA (REGULAR INSULIN) 8 UNIT (90)/12 UNIT (90) CARTRIDGE,INHALER; AFREZZA 4 UNIT (60)/8 UNIT (60)/12 UNIT (60) CARTRIDGE WITH INHALER; AFREZZA 4 UNIT (90)/8 UNIT (90) CARTRIDGE WITH INHALER <b>DL</b>	4	PA,QL (180 per 30 days)
AFREZZA 12 UNIT, 4 UNIT, 8 UNIT CARTRIDGE WITH INHALER <b>DL</b>	4	PA,QL (90 per 30 days)
AMARYL 1 MG, 2 MG, 4 MG TABLET <b>MO</b>	3	PA
APIDRA SOLOSTAR U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS PEN <b>MO</b>	3	ST
APIDRA U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS SOLUTION <b>MO</b>	3	ST
AVANDIA 2 MG, 4 MG TABLET <b>MO</b>	3	QL (60 per 30 days)
BAQSIMI 3 MG/ACTUATION NASAL SPRAY <b>MO</b>	2	
BASAGLAR KWIKPEN U-100 INSULIN 100 UNIT/ML (3 ML) SUBCUTANEOUS <b>MO</b>	3	PA
BYDUREON 2 MG VIAL <b>MO</b>	3	QL (4 per 28 days)
BYDUREON 2 MG/0.65 ML SUBCUTANEOUS PEN INJECTOR <b>MO</b>	3	QL (4 per 28 days)
BYDUREON BCISE 2 MG/0.85 ML SUBCUTANEOUS AUTO-INJECTOR <b>MO</b>	3	QL (3.4 per 28 days)
BYETTA 10 MCG/DOSE(250 MCG/ML)2.4 ML SUBCUTANEOUS PEN INJECTOR; BYETTA 5 MCG/DOSE (250 MCG/ML)1.2 ML SUBCUTANEOUS PEN INJECTOR <b>DL</b>	4	ST,QL (2.4 per 30 days)
<i>chlorpropamide 100 mg, 250 mg tablet</i> <b>MO</b>	1	
CYCLOSET 0.8 MG TABLET <b>MO</b>	3	ST,QL (180 per 30 days)
<i>diazoxide 50 mg/ml oral susp</i> <b>DL</b>	4	
DUETACT 30 MG-2 MG TABLET; DUETACT 30 MG-4 MG TABLET <b>MO</b>	3	QL (30 per 30 days)
FARXIGA 10 MG, 5 MG TABLET <b>MO</b>	3	QL (30 per 30 days)
FIASP FLEXTOUCH U-100 INSULIN 100 UNIT/ML (3 ML) SUBCUTANEOUS PEN <b>MO</b>	2	
FIASP PENFILL U-100 INSULIN 100 UNIT/ML (3 ML) SUBCUTANEOUS CARTRIDGE <b>MO</b>	2	
FIASP U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS SOLUTION <b>MO</b>	2	
FORTAMET 1,000 MG TABLET,EXTENDED RELEASE <b>DL</b>	4	ST,QL (60 per 30 days)
FORTAMET 500 MG TABLET,EXTENDED RELEASE <b>DL</b>	4	ST,QL (150 per 30 days)
<i>glimepiride 1 mg, 2 mg, 4 mg tablet</i> <b>MO</b>	1	
<i>glipizide 10 mg, 5 mg tablet</i> <b>MO</b>	1	
<i>glipizide er 10 mg, 2.5 mg, 5 mg tablet; glipizide xl 10 mg, 2.5 mg, 5 mg tablet</i> <b>MO</b>	1	
<i>glipizide-metformin 2.5-250 mg, 2.5-500 mg, 5-500 mg</i> <b>MO</b>	1	
GLUCAGEN HYPOKIT 1 MG INJECTION <b>MO</b>	2	
GLUCAGON (HCL) EMERGENCY KIT 1 MG SOLUTION FOR INJECTION <b>MO</b>	3	ST
GLUCAGON EMERGENCY KIT (HUMAN-RECOMB) 1 MG SOLUTION FOR INJECTION <b>MO</b>	3	ST

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
GLUCOPHAGE 1,000 MG, 500 MG, 850 MG TABLET <b>MO</b>	3	PA
GLUCOPHAGE XR 500 MG TABLET,EXTENDED RELEASE <b>MO</b>	3	PA,QL (120 per 30 days)
GLUCOPHAGE XR 750 MG TABLET,EXTENDED RELEASE <b>MO</b>	3	PA,QL (60 per 30 days)
GLUCOTROL 10 MG, 5 MG TABLET <b>MO</b>	3	
GLUCOTROL XL 10 MG, 2.5 MG, 5 MG TABLET,EXTENDED RELEASE <b>MO</b>	3	
GLUMETZA 1,000 MG TABLET,EXTENDED RELEASE <b>DL</b>	4	ST,QL (60 per 30 days)
GLUMETZA 500 MG TABLET,EXTENDED RELEASE <b>DL</b>	4	ST,QL (120 per 30 days)
glyburide 1.25 mg, 2.5 mg, 5 mg tablet <b>MO</b>	1	
glyburide micro 1.5 mg, 3 mg, 6 mg tab; glyburide micro 1.5 mg, 3 mg, 6 mg tablet <b>MO</b>	1	
glyburid-metformin 1.25-250 mg, 2.5-500 mg, 5-500 mg; glyburide-metformin 1.25-250 mg, 2.5-500 mg, 5-500 mg <b>MO</b>	1	
GLYNASE 1.5 MG, 3 MG, 6 MG TABLET <b>MO</b>	3	
GLYSET 100 MG, 25 MG, 50 MG TABLET <b>MO</b>	3	
GLYXAMBI 10 MG-5 MG TABLET; GLYXAMBI 25 MG-5 MG TABLET <b>MO</b>	2	QL (30 per 30 days)
GVOKE HYPOPEN 1-PACK 0.5 MG/0.1 ML, 1 MG/0.2 ML SUBCUTANEOUS AUTO-INJECTOR <b>MO</b>	2	
GVOKE HYPOPEN 2-PACK 0.5 MG/0.1 ML, 1 MG/0.2 ML SUBCUTANEOUS AUTO-INJECTOR <b>MO</b>	2	
GVOKE PFS 1-PACK 0.5 MG/0.1 ML, 1 MG/0.2 ML SUBCUTANEOUS SYRINGE <b>MO</b>	2	
GVOKE PFS 2-PACK 0.5 MG/0.1 ML, 1 MG/0.2 ML SUBCUTANEOUS SYRINGE <b>MO</b>	2	
HUMALOG JUNIOR KWIKPEN (U-100) 100 UNIT/ML SUBCUTANEOUS HALF-UNIT PEN <b>MO</b>	3	ST
HUMALOG KWIKPEN (U-100) INSULIN 100 UNIT/ML, 200 UNIT/ML (3 ML) SUBCUTANEOUS; HUMALOG KWIKPEN U-200 INSULIN 100 UNIT/ML, 200 UNIT/ML (3 ML) SUBCUTANEOUS <b>MO</b>	3	ST
HUMALOG MIX 50-50 (U-100) INSULIN 100 UNIT/ML SUBCUTANEOUS SUSPENSION <b>MO</b>	3	ST
HUMALOG MIX 50-50 KWIKPEN U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS PEN <b>MO</b>	3	ST
HUMALOG MIX 75-25 KWIKPEN U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS PEN <b>MO</b>	3	ST
HUMALOG MIX 75-25 (U-100) INSULIN 100 UNIT/ML SUBCUTANEOUS SUSPENSION <b>MO</b>	3	ST
HUMALOG U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS CARTRIDGE <b>MO</b>	3	ST
HUMALOG U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS SOLUTION <b>MO</b>	3	ST
HUMULIN 70/30 U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS SUSPENSION <b>MO</b>	3	ST

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
HUMULIN 70/30 U-100 INSULIN KWIKPEN 100 UNIT/ML SUBCUTANEOUS <b>MO</b>	3	ST
HUMULIN N NPH U-100 INSULIN KWIKPEN 100 UNIT/ML (3 ML) SUBCUTANEOUS <b>MO</b>	3	ST
HUMULIN N NPH U-100 INSULIN (ISOPHANE SUSP) 100 UNIT/ML SUBCUTANEOUS <b>MO</b>	3	ST
HUMULIN R REGULAR U-100 INSULIN 100 UNIT/ML INJECTION SOLUTION <b>MO</b>	3	ST
HUMULIN R U-500 (CONCENTRATED) INSULIN 500 UNIT/ML SUBCUTANEOUS SOLN <b>DL</b>	4	
HUMULIN R U-500 (CONC) INSULIN KWIKPEN 500 UNIT/ML (3 ML) SUBCUTANEOUS <b>DL</b>	4	
INSULIN ASPART PROT-INSULN ASP <b>MO</b>	2	
INSULIN ASPART 100 UNIT/ML CRT <b>MO</b>	2	
INSULIN ASPART 100 UNIT/ML PEN <b>MO</b>	2	
INSULIN ASPART 100 UNIT/ML VL <b>MO</b>	2	
INSULIN LISPRO 100 UNIT/ML PEN; INSULIN LISPRO JR 100 UNIT/ML <b>MO</b>	3	ST
INSULIN LISPRO 100 UNIT/ML VL <b>MO</b>	3	ST
INSULIN LISPRO MIX 75-25 KWKPN <b>MO</b>	3	ST
INVOKAMET 150 MG-1,000 MG TABLET; INVOKAMET 150 MG-500 MG TABLET; INVOKAMET 50 MG-1,000 MG TABLET; INVOKAMET 50 MG-500 MG TABLET <b>MO</b>	2	QL (60 per 30 days)
INVOKAMET XR 150 MG-1,000 MG TABLET, EXTENDED RELEASE; INVOKAMET XR 150 MG-500 MG TABLET, EXTENDED RELEASE; INVOKAMET XR 50 MG-1,000 MG TABLET, EXTENDED RELEASE; INVOKAMET XR 50 MG-500 MG TABLET, EXTENDED RELEASE <b>MO</b>	2	QL (60 per 30 days)
INVOKANA 100 MG, 300 MG TABLET <b>MO</b>	2	QL (30 per 30 days)
JANUMET 50 MG-1,000 MG TABLET; JANUMET 50 MG-500 MG TABLET <b>MO</b>	2	QL (60 per 30 days)
JANUMET XR 100 MG-1,000 MG TABLET,EXTENDED RELEASE <b>MO</b>	2	QL (30 per 30 days)
JANUMET XR 50 MG-1,000 MG TABLET,EXTENDED RELEASE; JANUMET XR 50 MG-500 MG TABLET,EXTENDED RELEASE <b>MO</b>	2	QL (60 per 30 days)
JANUVIA 100 MG, 25 MG, 50 MG TABLET <b>MO</b>	2	QL (30 per 30 days)
JARDIANCE 10 MG, 25 MG TABLET <b>MO</b>	2	QL (30 per 30 days)
JENTADUETO 2.5 MG-1,000 MG TABLET; JENTADUETO 2.5 MG-500 MG TABLET; JENTADUETO 2.5 MG-850 MG TABLET <b>MO</b>	2	QL (60 per 30 days)
JENTADUETO XR 2.5 MG-1,000 MG TABLET, EXTENDED RELEASE <b>MO</b>	2	QL (60 per 30 days)
JENTADUETO XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE <b>MO</b>	2	QL (30 per 30 days)
KAZANO 12.5 MG-1,000 MG TABLET; KAZANO 12.5 MG-500 MG TABLET <b>MO</b>	3	PA,QL (60 per 30 days)
KOMBIGLYZE XR 2.5 MG-1,000 MG TABLET,EXTENDED RELEASE <b>MO</b>	3	QL (60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
KOMBIGLYZE XR 5 MG-1,000 MG TABLET,EXTENDED RELEASE; KOMBIGLYZE XR 5 MG-500 MG TABLET,EXTENDED RELEASE <b>MO</b>	3	QL (30 per 30 days)
LANTUS SOLOSTAR U-100 INSULIN 100 UNIT/ML (3 ML) SUBCUTANEOUS PEN <b>MO</b>	2	
LANTUS U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS SOLUTION <b>MO</b>	2	
LEVEMIR FLEXTOUCH U-100 INSULIN 100 UNIT/ML (3 ML) SUBCUTANEOUS PEN <b>MO</b>	2	
LEVEMIR U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS SOLUTION <b>MO</b>	2	
LYUMJEV KWIKPEN U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS <b>MO</b>	3	ST
LYUMJEV KWIKPEN U-200 INSULIN 200 UNIT/ML (3 ML) SUBCUTANEOUS <b>MO</b>	3	ST
LYUMJEV U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS SOLUTION <b>MO</b>	3	ST
<i>metformin er 1,000 mg gastr-tb; metformin er 1,000 mg osm-tab</i> <b>DL</b>	4	ST,QL (60 per 30 days)
<i>metformin er 500 mg gastrc-tb</i> <b>DL</b>	4	ST,QL (120 per 30 days)
<i>metformin er 500 mg osmotic tb</i> <b>DL</b>	4	ST,QL (150 per 30 days)
<i>metformin hcl 1,000 mg, 500 mg, 850 mg tablet</i> <b>MO</b>	1	
<i>metformin hcl er 500 mg tablet</i> <b>MO</b>	1	QL (120 per 30 days)
<i>metformin hcl er 750 mg tablet</i> <b>MO</b>	1	QL (60 per 30 days)
<i>miglitol 100 mg, 25 mg, 50 mg tablet</i> <b>MO</b>	1	
<i>nateglinide 120 mg, 60 mg tablet</i> <b>MO</b>	1	
NESINA 12.5 MG, 25 MG, 6.25 MG TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
NOVOLIN 70-30 FLEXPEN U-100 INSULIN 100 UNIT/ML (70-30) SUBCUTANEOUS <b>MO</b>	2	
NOVOLIN 70/30 U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS SUSPENSION <b>MO</b>	2	
NOVOLIN N FLEXPEN 100 UNIT/ML (3 ML) SUBCUTANEOUS INSULIN PEN <b>MO</b>	2	
NOVOLIN N NPH U-100 INSULIN ISOPHANE 100 UNIT/ML SUBCUTANEOUS SUSP <b>MO</b>	2	
NOVOLIN R FLEXPEN 100 UNIT/ML (3 ML) SUBCUTANEOUS INSULIN PEN <b>MO</b>	2	
NOVOLIN R REGULAR U-100 INSULIN 100 UNIT/ML INJECTION SOLUTION <b>MO</b>	2	
NOVOLOG FLEXPEN U-100 INSULIN ASPART 100 UNIT/ML (3 ML) SUBCUTANEOUS <b>MO</b>	2	
NOVOLOG MIX 70-30 U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS SOLUTION <b>MO</b>	2	
NOVOLOG MIX 70-30 FLEXPEN U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS PEN <b>MO</b>	2	
NOVOLOG PENFILL U-100 INSULIN ASPART 100 UNIT/ML SUBCUTANEOUS CARTRIDG <b>MO</b>	2	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
NOVOLOG U-100 INSULIN ASPART 100 UNIT/ML SUBCUTANEOUS SOLUTION <b>MO</b>	2	
ONGLYZA 2.5 MG, 5 MG TABLET <b>MO</b>	3	QL (30 per 30 days)
OSENI 12.5 MG-15 MG TABLET; OSENI 12.5 MG-30 MG TABLET; OSENI 12.5 MG-45 MG TABLET; OSENI 25 MG-15 MG TABLET; OSENI 25 MG-30 MG TABLET; OSENI 25 MG-45 MG TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
OZEMPIC 0.25 MG OR 0.5 MG (2 MG/1.5 ML) SUBCUTANEOUS PEN INJECTOR <b>MO</b>	2	QL (1.5 per 28 days)
OZEMPIC 1 MG/DOSE (2 MG/1.5 ML) SUBCUTANEOUS PEN INJECTOR <b>MO</b>	2	QL (3 per 28 days)
<i>pioglitazone hcl 15 mg, 30 mg, 45 mg tablet</i> <b>MO</b>	1	QL (30 per 30 days)
<i>pioglitazone-glimepiride 30-2; pioglitazone-glimepiride 30-4</i> <b>MO</b>	1	QL (30 per 30 days)
<i>pioglitazone-metformin 15-500; pioglitazone-metformin 15-850</i> <b>MO</b>	1	QL (90 per 30 days)
PRANDIN 1 MG, 2 MG TABLET <b>MO</b>	3	
PRECOSE 100 MG, 25 MG, 50 MG TABLET <b>MO</b>	3	
PROGLYCEM 50 MG/ML ORAL SUSPENSION <b>DL</b>	4	
QTERN 10 MG-5 MG TABLET; QTERN 5 MG-5 MG TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
<i>repaglinide 0.5 mg, 1 mg, 2 mg tablet</i> <b>MO</b>	1	
<i>repaglinide-metformin 1-500 mg, 2-500 mg</i> <b>MO</b>	1	
RIOMET 500 MG/5 ML ORAL SOLUTION <b>MO</b>	3	QL (750 per 30 days)
RIOMET ER 500 MG/5 ML ORAL SUSPENSION, EXTENDED RELEASE <b>MO</b>	3	QL (750 per 30 days)
RYBELSUS 14 MG, 3 MG, 7 MG TABLET <b>MO</b>	2	QL (30 per 30 days)
SEGLUROMET 2.5 MG-1,000 MG TABLET; SEGLUROMET 2.5 MG-500 MG TABLET; SEGLUROMET 7.5 MG-1,000 MG TABLET; SEGLUROMET 7.5 MG-500 MG TABLET <b>MO</b>	3	PA,QL (60 per 30 days)
SEMGLEE PEN U-100 INSULIN 100 UNIT/ML (3 ML) SUBCUTANEOUS <b>MO</b>	3	PA
SEMGLEE U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS SOLUTION <b>MO</b>	3	PA
SOLIQUA 100/33 100 UNIT-33 MCG/ML SUBCUTANEOUS INSULIN PEN <b>MO</b>	2	QL (15 per 24 days)
STARLIX 120 MG, 60 MG TABLET <b>MO</b>	3	PA
STEGLATRO 15 MG, 5 MG TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
STEGLUJAN 15 MG-100 MG TABLET; STEGLUJAN 5 MG-100 MG TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
SYMLINPEN 120 2,700 MCG/2.7 ML SUBCUTANEOUS PEN INJECTOR <b>DL</b>	4	QL (10.8 per 30 days)
SYMLINPEN 60 1,500 MCG/1.5 ML SUBCUTANEOUS PEN INJECTOR <b>DL</b>	4	QL (10.5 per 28 days)
SYNJARDY 12.5 MG-1,000 MG TABLET; SYNJARDY 12.5 MG-500 MG TABLET; SYNJARDY 5 MG-1,000 MG TABLET; SYNJARDY 5 MG-500 MG TABLET <b>MO</b>	2	QL (60 per 30 days)
SYNJARDY XR 10 MG-1,000 MG TABLET, EXTENDED RELEASE; SYNJARDY XR 25 MG-1,000 MG TABLET, EXTENDED RELEASE <b>MO</b>	2	QL (30 per 30 days)
SYNJARDY XR 12.5 MG-1,000 MG TABLET, EXTENDED RELEASE; SYNJARDY XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE <b>MO</b>	2	QL (60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
tolazamide 250 mg, 500 mg tablet <b>MO</b>	1	
tolbutamide 500 mg tablet <b>MO</b>	1	
TOUJEO MAX U-300 SOLOSTAR 300 UNIT/ML (3 ML) SUBCUTANEOUS INSULIN PEN <b>MO</b>	2	
TOUJEO SOLOSTAR U-300 INSULIN 300 UNIT/ML (1.5 ML) SUBCUTANEOUS PEN <b>MO</b>	2	
TRADJENTA 5 MG TABLET <b>MO</b>	2	QL (30 per 30 days)
TRESIBA FLEXTOUCH U-100 INSULIN 100 UNIT/ML (3 ML) SUBCUTANEOUS PEN <b>MO</b>	2	
TRESIBA FLEXTOUCH U-200 INSULIN 200 UNIT/ML (3 ML) SUBCUTANEOUS PEN <b>MO</b>	2	
TRESIBA U-100 INSULIN 100 UNIT/ML SUBCUTANEOUS SOLUTION <b>MO</b>	2	
TRIJARDY XR 10 MG-5 MG-1,000 MG TABLET, EXTENDED RELEASE; TRIJARDY XR 25 MG-5 MG-1,000 MG TABLET, EXTENDED RELEASE <b>MO</b>	2	QL (30 per 30 days)
TRIJARDY XR 12.5 MG-2.5 MG-1,000 MG TABLET, EXTENDED RELEASE; TRIJARDY XR 5 MG-2.5 MG-1,000 MG TABLET, EXTENDED RELEASE <b>MO</b>	2	QL (60 per 30 days)
TRULICITY 0.75 MG/0.5 ML, 1.5 MG/0.5 ML SUBCUTANEOUS PEN INJECTOR <b>MO</b>	2	QL (2 per 28 days)
VICTOZA 2-PAK 0.6 MG/0.1 ML (18 MG/3 ML) SUBCUTANEOUS PEN INJECTOR <b>MO</b>	2	QL (9 per 30 days)
VICTOZA 3-PAK 0.6 MG/0.1 ML (18 MG/3 ML) SUBCUTANEOUS PEN INJECTOR <b>MO</b>	2	QL (9 per 30 days)
XIGDUO XR 10 MG-1,000 MG TABLET,EXTENDED RELEASE; XIGDUO XR 10 MG-500 MG TABLET,EXTENDED RELEASE; XIGDUO XR 5 MG-500 MG TABLET,EXTENDED RELEASE <b>MO</b>	3	QL (30 per 30 days)
XIGDUO XR 2.5 MG-1,000 MG TABLET,EXTENDED RELEASE; XIGDUO XR 5 MG-1,000 MG TABLET,EXTENDED RELEASE <b>MO</b>	3	QL (60 per 30 days)
XULTOPHY 100/3.6 100 UNIT-3.6 MG/ML (3 ML) SUBCUTANEOUS INSULIN PEN <b>MO</b>	2	QL (15 per 30 days)
<b>BLOOD PRODUCTS AND MODIFIERS</b>		
AGGRASTAT CONCENTRATE 250 MCG/ML INTRAVENOUS <b>MO</b>	3	
AGGRASTAT 12.5 MG/250 ML (50 MCG/ML), 5 MG/100 ML (50 MCG/ML) IN 0.9 % SODIUM CHLORIDE IV; AGGRASTAT 12.5 MG/250 ML (50 MCG/ML), 5 MG/100 ML (50 MCG/ML) IN ISO-OSMOTIC SODIUM CHLORIDE IV <b>MO</b>	3	
AGGRENOX 25 MG-200 MG CAPSULE, EXTENDED RELEASE <b>MO</b>	3	ST,QL (60 per 30 days)
AGRYLIN 0.5 MG CAPSULE <b>MO</b>	3	PA
AMICAR 1,000 MG, 500 MG TABLET <b>DL</b>	4	PA
AMICAR 250 MG/ML (25 %) ORAL SOLUTION <b>DL</b>	4	
aminocaproic acid 0.25 gram/ml <b>DL</b>	4	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>aminocaproic acid 1,000 mg, 500 mg tab</i> <b>DL</b>	4	
<i>aminocaproic acid 5 g/20 ml vl</i> <b>MO</b>	1	
<i>anagrelide hcl 0.5 mg, 1 mg capsule</i> <b>MO</b>	1	
ARANESP 10 MCG/0.4 ML, 40 MCG/0.4 ML (IN POLYSORBATE) INJECTION SYRINGE <b>MO</b>	3	PA,QL (1.6 per 30 days)
ARANESP 100 MCG/0.5 ML (IN POLYSORBATE) INJECTION SYRINGE <b>DL</b>	4	PA,QL (2 per 30 days)
ARANESP 100 MCG/ML, 200 MCG/ML, 300 MCG/ML (IN POLYSORBATE) INJECTION <b>DL</b>	4	PA,QL (4 per 30 days)
ARANESP 150 MCG/0.3 ML (IN POLYSORBATE) INJECTION SYRINGE <b>DL</b>	4	PA,QL (1.2 per 30 days)
ARANESP 150 MCG/0.75 ML (IN POLYSORBATE) INJECTION <b>DL</b>	4	PA,QL (3 per 30 days)
ARANESP 200 MCG/0.4 ML (IN POLYSORBATE) INJECTION SYRINGE <b>DL</b>	4	PA,QL (1.6 per 30 days)
ARANESP 25 MCG/0.42 ML (IN POLYSORBATE) INJECTION SYRINGE <b>MO</b>	3	PA,QL (1.68 per 30 days)
ARANESP 25 MCG/ML, 40 MCG/ML, 60 MCG/ML (IN POLYSORBATE) INJECTION <b>MO</b>	3	PA,QL (4 per 30 days)
ARANESP 300 MCG/0.6 ML (IN POLYSORBATE) INJECTION SYRINGE <b>DL</b>	4	PA,QL (2.4 per 30 days)
ARANESP 500 MCG/ML (IN POLYSORBATE) INJECTION SYRINGE <b>DL</b>	4	PA,QL (4 per 30 days)
ARANESP 60 MCG/0.3 ML (IN POLYSORBATE) INJECTION SYRINGE <b>MO</b>	3	PA,QL (1.2 per 30 days)
ARIXTRA 10 MG/0.8 ML SUBCUTANEOUS SOLUTION SYRINGE <b>DL</b>	4	PA,QL (24 per 30 days)
ARIXTRA 2.5 MG/0.5 ML SUBCUTANEOUS SOLUTION SYRINGE <b>DL</b>	4	PA,QL (15 per 30 days)
ARIXTRA 5 MG/0.4 ML SUBCUTANEOUS SOLUTION SYRINGE <b>DL</b>	4	PA,QL (12 per 30 days)
ARIXTRA 7.5 MG/0.6 ML SUBCUTANEOUS SOLUTION SYRINGE <b>DL</b>	4	PA,QL (18 per 30 days)
<i>aspirin-dipyridam er 25-200 mg</i> <b>MO</b>	1	ST,QL (60 per 30 days)
BEVYXXA 40 MG, 80 MG CAPSULE <b>MO</b>	3	PA,QL (41 per 41 days)
BRILINTA 60 MG, 90 MG TABLET <b>MO</b>	2	QL (60 per 30 days)
CABLIVI 11 MG INJECTION KIT <b>DL</b>	4	PA,QL (30 per 30 days)
<i>cilostazol 100 mg, 50 mg tablet</i> <b>MO</b>	1	
<i>clopidogrel 300 mg tablet</i> <b>MO</b>	1	
<i>clopidogrel 75 mg tablet</i> <b>MO</b>	1	QL (30 per 30 days)
COUMADIN 1 MG, 10 MG, 2 MG, 2.5 MG, 3 MG, 4 MG, 5 MG, 6 MG, 7.5 MG TABLET <b>MO</b>	3	
CYKLOKAPRON 1,000 MG/10 ML (100 MG/ML) INTRAVENOUS SOLUTION <b>DL</b>	4	PA
<i>dipyridamole 25 mg, 50 mg, 75 mg tablet</i> <b>MO</b>	1	
DOPTELET (10 TAB PACK) 20 MG TABLET <b>DL</b>	4	PA,QL (60 per 30 days)
DOPTELET (15 TAB PACK) 20 MG TABLET <b>DL</b>	4	PA,QL (60 per 30 days)
DOPTELET (30 TAB PACK) 20 MG TABLET <b>DL</b>	4	PA,QL (60 per 30 days)
EFFIENT 10 MG, 5 MG TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
ELIQUIS 2.5 MG TABLET <b>MO</b>	2	QL (60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ELIQUIS 5 MG TABLET <b>MO</b>	2	QL (74 per 30 days)
ELIQUIS DVT-PE TREATMENT 30-DAY STARTER 5 MG (74 TABLETS) IN DOSE PACK <b>MO</b>	2	QL (74 per 30 days)
enoxaparin 100 mg/ml, 150 mg/ml syringe <b>MO</b>	1	QL (28 per 28 days)
enoxaparin 120 mg/0.8 ml, 80 mg/0.8 ml syr <b>MO</b>	1	QL (22.4 per 28 days)
enoxaparin 30 mg/0.3 ml, 60 mg/0.6 ml syr <b>MO</b>	1	QL (16.8 per 28 days)
enoxaparin 300 mg/3 ml vial <b>MO</b>	1	QL (84 per 28 days)
enoxaparin 40 mg/0.4 ml syr <b>MO</b>	1	QL (11.2 per 28 days)
EPOGEN 10,000 UNIT/ML, 20,000 UNIT/ML INJECTION SOLUTION <b>DL</b>	4	PA,QL (14 per 30 days)
EPOGEN 2,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML INJECTION SOLUTION <b>MO</b>	3	PA,QL (14 per 30 days)
EPOGEN 20,000 UNIT/2 ML INJECTION SOLUTION <b>MO</b>	3	PA,QL (28 per 30 days)
eptifibatide 200 mg/100 ml vl; eptifibatide 75 mg/100 ml vial <b>MO</b>	1	
fondaparinux 10 mg/0.8 ml syr <b>DL</b>	4	QL (24 per 30 days)
fondaparinux 2.5 mg/0.5 ml syr <b>DL</b>	4	QL (15 per 30 days)
fondaparinux 5 mg/0.4 ml syr <b>DL</b>	4	QL (12 per 30 days)
fondaparinux 7.5 mg/0.6 ml syr <b>DL</b>	4	QL (18 per 30 days)
FRAGMIN 10,000 ANTI-XA UNIT/ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	QL (30 per 30 days)
FRAGMIN 12,500 ANTI-XA UNIT/0.5 ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	QL (15 per 30 days)
FRAGMIN 15,000 ANTI-XA UNIT/0.6 ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	QL (18 per 30 days)
FRAGMIN 18,000 ANTI-XA UNIT/0.72 ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	QL (21.6 per 30 days)
FRAGMIN 2,500 ANTI-XA UNIT/0.2 ML, 5,000 ANTI-XA UNIT/0.2 ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	QL (6 per 30 days)
FRAGMIN 25,000 ANTI-XA UNIT/ML SUBCUTANEOUS SOLUTION <b>DL</b>	4	QL (22.8 per 30 days)
FRAGMIN 7,500 ANTI-XA UNIT/0.3 ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	QL (9 per 30 days)
FULPHILA 6 MG/0.6 ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA,QL (1.2 per 28 days)
GRANIX 300 MCG/0.5 ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA,QL (7 per 28 days)
GRANIX 300 MCG/ML SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA,QL (14 per 28 days)
GRANIX 480 MCG/0.8 ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA,QL (11.2 per 28 days)
GRANIX 480 MCG/1.6 ML SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA,QL (22.4 per 28 days)
heparin 5,000 unit/ml carpuct <b>MO</b>	1	
heparin sod 1,000 unit/ml, 10,000 unit/ml, 20,000 unit/ml, 5,000 unit/ml vial; heparin sod 1,000 unit/ml, 10,000 unit/ml, 20,000 unit/ml, 5,000 unit/ml vl <b>MO</b>	1	
heparin sod 5,000 unit/ml syrg <b>MO</b>	1	
heparin 2,000 unit/2 ml vial; heparin sod 1,000 unit/ml, 5,000 unit/0.5 ml <b>MO</b>	1	
heparin sod 5,000 unit/0.5 ml, 5,000 unit/ml; heparin sod 5,000 unit/0.5 ml, 5,000 unit/ml syrg <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
INTEGRILIN 0.75 MG/ML, 2 MG/ML INTRAVENOUS SOLUTION <b>MO</b>	3	
<i>jantoven</i> 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg tablet <b>MO</b>	1	
KENGREAL 50 MG INTRAVENOUS SOLUTION <b>DL</b>	4	
LEUKINE 250 MCG SOLUTION FOR INJECTION <b>DL</b>	4	PA
LOVENOX 100 MG/ML, 150 MG/ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA,QL (28 per 28 days)
LOVENOX 120 MG/0.8 ML, 80 MG/0.8 ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA,QL (22.4 per 28 days)
LOVENOX 30 MG/0.3 ML, 60 MG/0.6 ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA,QL (16.8 per 28 days)
LOVENOX 300 MG/3 ML SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA,QL (84 per 28 days)
LOVENOX 40 MG/0.4 ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA,QL (11.2 per 28 days)
LYSTEDA 650 MG TABLET <b>MO</b>	3	QL (30 per 5 days)
MIRCERA 100 MCG/0.3 ML INJECTION SYRINGE <b>DL</b>	4	PA,QL (1.2 per 28 days)
MIRCERA 150 MCG/0.3 ML, 200 MCG/0.3 ML, 30 MCG/0.3 ML INJECTION SYRINGE <b>DL</b>	4	PA,QL (0.6 per 28 days)
MIRCERA 50 MCG/0.3 ML, 75 MCG/0.3 ML INJECTION SYRINGE <b>DL</b>	4	PA,QL (0.9 per 28 days)
MOZOBIL 24 MG/1.2 ML (20 MG/ML) SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA,QL (9.6 per 30 days)
MULPLETA 3 MG TABLET <b>DL</b>	4	PA,QL (7 per 30 days)
NEULASTA 6 MG/0.6 ML SUBCUTANEOUS SYRINGE; NEULASTA 6 MG/0.6 ML WITH WEARABLE SUBCUTANEOUS INJECTOR <b>DL</b>	4	PA,QL (1.2 per 28 days)
NEUPOGEN 300 MCG/0.5 ML INJECTION SYRINGE <b>DL</b>	4	PA,QL (7 per 30 days)
NEUPOGEN 300 MCG/ML INJECTION SOLUTION <b>DL</b>	4	PA,QL (14 per 30 days)
NEUPOGEN 480 MCG/0.8 ML INJECTION SYRINGE <b>DL</b>	4	PA,QL (11.2 per 30 days)
NEUPOGEN 480 MCG/1.6 ML INJECTION SOLUTION <b>DL</b>	4	PA,QL (22.4 per 30 days)
NIVESTYM 300 MCG/0.5 ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA,QL (7 per 30 days)
NIVESTYM 300 MCG/ML INJECTION SOLUTION <b>DL</b>	4	PA,QL (14 per 30 days)
NIVESTYM 480 MCG/0.8 ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA,QL (11.2 per 30 days)
NIVESTYM 480 MCG/1.6 ML INJECTION SOLUTION <b>DL</b>	4	PA,QL (22.4 per 30 days)
PLAVIX 300 MG TABLET <b>MO</b>	3	PA
PLAVIX 75 MG TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
PRADAXA 110 MG, 150 MG, 75 MG CAPSULE <b>MO</b>	3	QL (60 per 30 days)
<i>prasugrel</i> 10 mg, 5 mg tablet <b>MO</b>	1	QL (30 per 30 days)
PROCRIT 10,000 UNIT/ML, 2,000 UNIT/ML, 20,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML, 40,000 UNIT/ML INJECTION SOLUTION <b>MO</b>	3	PA,QL (14 per 30 days)
PROCRIT 20,000 UNIT/2 ML INJECTION SOLUTION <b>MO</b>	3	PA,QL (28 per 30 days)
PROMACTA 12.5 MG ORAL POWDER PACKET <b>DL, LA</b>	4	PA,QL (360 per 30 days)
PROMACTA 12.5 MG, 75 MG TABLET <b>DL, LA</b>	4	PA,QL (60 per 30 days)
PROMACTA 25 MG ORAL POWDER PACKET <b>DL, LA</b>	4	PA,QL (180 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
PROMACTA 25 MG TABLET <b>DL, LA</b>	4	PA,QL (30 per 30 days)
PROMACTA 50 MG TABLET <b>DL, LA</b>	4	PA,QL (90 per 30 days)
REBLOZYL 25 MG, 75 MG SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA
REOPRO 10 MG/5 ML VIAL <b>DL</b>	4	
RETACRIT 10,000 UNIT/ML, 2,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML, 40,000 UNIT/ML INJECTION SOLUTION <b>MO</b>	3	PA,QL (14 per 30 days)
RIASTAP 1 GRAM (900 MG-1,300 MG) INTRAVENOUS SOLUTION <b>MO</b>	3	
SAVAYSA 15 MG, 30 MG, 60 MG TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
TAVALISSE 100 MG, 150 MG TABLET <b>DL</b>	4	PA,QL (60 per 30 days)
tranexamic acid 1,000 mg/10 ml <b>MO</b>	1	PA
tranexamic acid 650 mg tablet <b>MO</b>	1	QL (30 per 5 days)
UDENYCA 6 MG/0.6 ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA,QL (1.2 per 28 days)
warfarin sodium 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg tablet <b>MO</b>	1	
XARELTO 10 MG, 20 MG TABLET <b>MO</b>	2	QL (30 per 30 days)
XARELTO 15 MG, 2.5 MG TABLET <b>MO</b>	2	QL (60 per 30 days)
XARELTO DVT-PE TREATMENT 30-DAY STARTER 15 MG(42)-20 MG(9) TABLET PACK <b>MO</b>	2	QL (51 per 30 days)
YOSPRALA 325 MG-40 MG TABLET,IMMEDIATE AND DELAY RELEASE; YOSPRALA 81 MG-40 MG TABLET,IMMEDIATE AND DELAY RELEASE <b>MO</b>	3	PA,QL (30 per 30 days)
ZARXIO 300 MCG/0.5 ML INJECTION SYRINGE <b>DL</b>	4	PA,QL (7 per 30 days)
ZARXIO 480 MCG/0.8 ML INJECTION SYRINGE <b>DL</b>	4	PA,QL (11.2 per 30 days)
ZIEXTENZO 6 MG/0.6 ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA,QL (1.2 per 28 days)
ZONTIVITY 2.08 MG TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
<b>Cardiovascular Agents</b>		
ACCUPRIL 10 MG, 20 MG, 40 MG, 5 MG TABLET <b>MO</b>	3	
ACCURETIC 10 MG-12.5 MG TABLET; ACCURETIC 20 MG-12.5 MG TABLET; ACCURETIC 20 MG-25 MG TABLET <b>MO</b>	3	
acebutolol 200 mg, 400 mg capsule <b>MO</b>	1	
acetazolamide 125 mg, 250 mg tablet <b>MO</b>	1	
acetazolamide er 500 mg cap <b>MO</b>	1	
acetazolamide sod 500 mg vial <b>MO</b>	1	
ADALAT CC 30 MG, 60 MG, 90 MG TABLET,EXTENDED RELEASE <b>MO</b>	3	QL (60 per 30 days)
adenosine 12 mg/4 ml vial <b>MO</b>	1	
adenosine 6 mg/2 ml syringe <b>MO</b>	1	
afeditab cr 30 mg, 60 mg tablet <b>MO</b>	1	QL (60 per 30 days)
ALDACTAZIDE 25 MG-25 MG TABLET; ALDACTAZIDE 50 MG-50 MG TABLET <b>MO</b>	3	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ALDACTONE 100 MG, 25 MG, 50 MG TABLET <b>MO</b>	3	
aliskiren 150 mg, 300 mg tablet <b>MO</b>	1	QL (30 per 30 days)
ALTACE 1.25 MG, 10 MG, 2.5 MG, 5 MG CAPSULE <b>MO</b>	3	PA
ALTOPREV 20 MG, 40 MG, 60 MG TABLET,EXTENDED RELEASE <b>DL</b>	4	ST,QL (30 per 30 days)
amiloride hcl 5 mg tablet <b>MO</b>	1	
amiloride hcl-hctz 5-50 mg tab <b>MO</b>	1	
amiodarone 150 mg/3 ml syringe <b>MO</b>	1	
amiodarone 900 mg/18 ml vial <b>MO</b>	1	
amiodarone hcl 100 mg, 200 mg tablet <b>MO</b>	1	
amiodarone hcl 400 mg tablet <b>MO</b>	1	QL (60 per 30 days)
amlodipine besylate 10 mg tab <b>MO</b>	1	QL (60 per 30 days)
amlodipine besylate 2.5 mg, 5 mg tab <b>MO</b>	1	QL (30 per 30 days)
amlodipine-atorvast 10-10 mg, 10-20 mg, 10-40 mg, 10-80 mg, 2.5-10 mg, 2.5-20 mg, 2.5-40 mg, 5-10 mg, 5-20 mg, 5-40 mg, 5-80 mg <b>MO</b>	1	QL (30 per 30 days)
amlodipine-benazepril 10-20 mg, 2.5-10 mg, 5-10 mg, 5-20 mg; amlodipine-benazepril 2.5-10 <b>MO</b>	1	QL (60 per 30 days)
amlodipine-benazepril 10-40 mg, 5-40 mg <b>MO</b>	1	QL (30 per 30 days)
amlodipine-olmesartan 10-20 mg, 10-40 mg, 5-20 mg, 5-40 mg <b>MO</b>	1	QL (30 per 30 days)
amlodipine-valsartan 10-160 mg, 10-320 mg, 5-160 mg, 5-320 mg <b>MO</b>	1	QL (30 per 30 days)
amlod-vals-hctz 10-160-12.5 mg, 10-160-25 mg, 10-320-25 mg, 5-160-12.5 mg, 5-160-25 mg; amlod-vals-hctz 10-160-12.5mg <b>MO</b>	1	QL (30 per 30 days)
ANTARA 30 MG, 90 MG CAPSULE <b>MO</b>	3	QL (30 per 30 days)
ATACAND 16 MG, 4 MG, 8 MG TABLET <b>MO</b>	3	ST,QL (60 per 30 days)
ATACAND 32 MG TABLET <b>MO</b>	3	ST,QL (30 per 30 days)
ATACAND HCT 16 MG-12.5 MG TABLET; ATACAND HCT 32 MG-12.5 MG TABLET; ATACAND HCT 32 MG-25 MG TABLET <b>MO</b>	3	ST,QL (30 per 30 days)
atenolol 100 mg, 25 mg, 50 mg tablet <b>MO</b>	1	
atenolol-chlorthalidone 100-25; atenolol-chlorthalidone 50-25 <b>MO</b>	1	
atorvastatin 10 mg, 20 mg, 40 mg, 80 mg tablet <b>MO</b>	1	
AVALIDE 150 MG-12.5 MG TABLET <b>MO</b>	3	PA,QL (60 per 30 days)
AVALIDE 300 MG-12.5 MG TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
AVAPRO 150 MG, 300 MG, 75 MG TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
AZOR 10 MG-20 MG TABLET; AZOR 10 MG-40 MG TABLET; AZOR 5 MG-20 MG TABLET; AZOR 5 MG-40 MG TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
benazepril hcl 10 mg, 20 mg, 40 mg, 5 mg tablet <b>MO</b>	1	
benazepril-hctz 10-12.5 mg, 20-12.5 mg, 20-25 mg, 5-6.25 mg tab <b>MO</b>	1	
BENICAR 20 MG, 40 MG, 5 MG TABLET <b>MO</b>	3	PA,QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
BENICAR HCT 20 MG-12.5 MG TABLET; BENICAR HCT 40 MG-12.5 MG TABLET; BENICAR HCT 40 MG-25 MG TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
BETAPACE 120 MG, 160 MG, 240 MG, 80 MG TABLET <b>DL</b>	4	PA
BETAPACE AF 120 MG, 160 MG, 80 MG TABLET <b>DL</b>	4	PA
<i>betaxolol 10 mg, 20 mg tablet</i> <b>MO</b>	1	
BIDIL 20 MG-37.5 MG TABLET <b>MO</b>	3	QL (180 per 30 days)
BIORPHEN 0.1 MG/ML INTRAVENOUS SOLUTION <b>MO</b>	3	
<i>bisoprolol fumarate 10 mg, 5 mg tab</i> <b>MO</b>	1	
<i>bisoprolol-hctz 10-6.25 mg, 2.5-6.25 mg, 5-6.25 mg tab; bisoprolol-hctz 10-6.25 mg, 2.5-6.25 mg, 5-6.25 mg tb</i> <b>MO</b>	1	
<i>bretylum 500 mg/10 ml vial</i> <b>MO</b>	1	
BREVIBLOC 100 MG/10 ML (10 MG/ML) INTRAVENOUS SOLUTION <b>MO</b>	3	
BREVIBLOC 2,000 MG/100 ML, 2,500 MG/250 ML (10 MG/ML) (20 MG/ML) IN SODIUM CHLORIDE (ISO-OSM) IV; BREVIBLOC 2,000 MG/100 ML, 2,500 MG/250 ML (10 MG/ML) IN SODIUM CHLORIDE (ISO-OSM) IV <b>MO</b>	3	
<i>bumetanide 0.5 mg, 1 mg, 2 mg tablet</i> <b>MO</b>	1	
<i>bumetanide 1 mg/4 ml vial</i> <b>MO</b>	1	
BYSTOLIC 10 MG TABLET <b>MO</b>	2	QL (120 per 30 days)
BYSTOLIC 2.5 MG, 5 MG TABLET <b>MO</b>	2	QL (30 per 30 days)
BYSTOLIC 20 MG TABLET <b>MO</b>	2	QL (60 per 30 days)
BYVALSON 5 MG-80 MG TABLET <b>MO</b>	3	ST,QL (30 per 30 days)
CADUET 10 MG-10 MG TABLET; CADUET 10 MG-20 MG TABLET; CADUET 10 MG-40 MG TABLET; CADUET 10 MG-80 MG TABLET; CADUET 5 MG-10 MG TABLET; CADUET 5 MG-20 MG TABLET; CADUET 5 MG-40 MG TABLET; CADUET 5 MG-80 MG TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
CALAN 120 MG TABLET <b>MO</b>	3	QL (120 per 30 days)
CALAN SR 120 MG TABLET,EXTENDED RELEASE <b>MO</b>	3	QL (30 per 30 days)
CALAN SR 180 MG, 240 MG TABLET,EXTENDED RELEASE <b>MO</b>	3	
<i>candesartan cilexetil 16 mg, 4 mg, 8 mg tab; candesartan cilexetil 16 mg, 4 mg, 8 mg tb</i> <b>MO</b>	1	QL (60 per 30 days)
<i>candesartan cilexetil 32 mg tb</i> <b>MO</b>	1	QL (30 per 30 days)
<i>candesartan-hctz 16-12.5 mg, 32-12.5 mg, 32-25 mg tab; candesartan-hctz 16-12.5 mg, 32-12.5 mg, 32-25 mg tb</i> <b>MO</b>	1	QL (30 per 30 days)
<i>captopril 100 mg, 12.5 mg, 25 mg, 50 mg tablet</i> <b>MO</b>	1	
<i>captopril-hctz 25-15 mg, 25-25 mg, 50-15 mg, 50-25 mg tablet</i> <b>MO</b>	1	
CARDIZEM 120 MG, 30 MG, 60 MG TABLET <b>MO</b>	3	
CARDIZEM CD 120 MG, 180 MG, 240 MG CAPSULE,EXTENDED RELEASE <b>DL</b>	4	PA,QL (60 per 30 days)
CARDIZEM CD 300 MG, 360 MG CAPSULE,EXTENDED RELEASE <b>DL</b>	4	PA,QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
CARDIZEM LA 120 MG, 300 MG, 360 MG, 420 MG TABLET,EXTENDED RELEASE <b>MO</b>	3	QL (30 per 30 days)
CARDIZEM LA 180 MG, 240 MG TABLET,EXTENDED RELEASE <b>MO</b>	3	QL (60 per 30 days)
CARDURA 1 MG, 2 MG, 4 MG, 8 MG TABLET <b>MO</b>	3	
CARDURA XL 4 MG, 8 MG TABLET,EXTENDED RELEASE <b>MO</b>	3	QL (30 per 30 days)
CAROSPIR 25 MG/5 ML ORAL SUSPENSION <b>DL</b>	4	PA,QL (450 per 30 days)
<i>cartia xt 120 mg, 180 mg, 240 mg capsule,extended release</i> <b>MO</b>	1	QL (60 per 30 days)
<i>cartia xt 300 mg capsule,extended release</i> <b>MO</b>	1	QL (30 per 30 days)
<i>carvedilol 12.5 mg, 25 mg, 3.125 mg, 6.25 mg tablet</i> <b>MO</b>	1	
<i>carvedilol er 10 mg, 20 mg, 40 mg, 80 mg capsule</i> <b>MO</b>	1	QL (30 per 30 days)
CATAPRES 0.1 MG, 0.2 MG, 0.3 MG TABLET <b>MO</b>	3	
CATAPRES-TTS-1 0.1 MG/24 HR TRANSDERMAL PATCH <b>MO</b>	3	PA,QL (4 per 28 days)
CATAPRES-TTS-2 0.2 MG/24 HR TRANSDERMAL PATCH <b>MO</b>	3	PA,QL (4 per 28 days)
CATAPRES-TTS-3 0.3 MG/24 HR TRANSDERMAL PATCH <b>MO</b>	3	PA,QL (4 per 28 days)
<i>chlorothiazide 250 mg, 500 mg tablet</i> <b>MO</b>	1	
<i>chlorothiazide sod 500 mg vial</i> <b>MO</b>	1	
<i>chlorthalidone 25 mg, 50 mg tablet</i> <b>MO</b>	1	
<i>cholestyramine packet; cholestyramine powder</i> <b>MO</b>	1	
<i>cholestyramine light 4 gram oral powder; cholestyramine light 4 gram powder for susp in a packet</i> <b>MO</b>	1	
CLEVIPREX 25 MG/50 ML, 50 MG/100 ML INTRAVENOUS EMULSION <b>MO</b>	3	
<i>clonidine 0.1 mg/day patch; clonidine 0.2 mg/day patch; clonidine 0.3 mg/day patch</i> <b>MO</b>	1	QL (4 per 28 days)
<i>clonidine hcl 0.1 mg, 0.2 mg, 0.3 mg tablet</i> <b>MO</b>	1	
<i>colesevelam 625 mg tablet</i> <b>MO</b>	1	PA,QL (180 per 30 days)
<i>colesevelam hcl 3.75 g packet</i> <b>MO</b>	1	PA,QL (30 per 30 days)
COLESTID 1 GRAM TABLET <b>MO</b>	3	
COLESTID 5 GRAM ORAL GRANULES <b>MO</b>	3	QL (1000 per 30 days)
COLESTID 5 GRAM ORAL PACKET <b>MO</b>	3	
COLESTID FLAVORED 5 GRAM ORAL GRANULES <b>MO</b>	3	QL (1000 per 30 days)
COLESTID FLAVORED 7.5 GRAM PACKET <b>MO</b>	3	
<i>colestipol hcl granules</i> <b>MO</b>	1	QL (1000 per 30 days)
<i>colestipol hcl granules packet</i> <b>MO</b>	1	
<i>colestipol micronized 1 gm tab</i> <b>MO</b>	1	
COREG 12.5 MG, 25 MG, 3.125 MG, 6.25 MG TABLET <b>MO</b>	3	PA
COREG CR 10 MG, 20 MG, 40 MG, 80 MG CAPSULE, EXTENDED RELEASE <b>MO</b>	3	PA,QL (30 per 30 days)
CORGARD 20 MG, 40 MG, 80 MG TABLET <b>MO</b>	3	PA

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
CORLANOR 5 MG, 7.5 MG TABLET <b>MO</b>	3	PA,QL (60 per 30 days)
CORLANOR 5 MG/5 ML ORAL SOLUTION <b>MO</b>	3	PA,QL (560 per 28 days)
CORLOPAM 10 MG/ML INTRAVENOUS SOLUTION <b>MO</b>	3	
CORVERT 0.1 MG/ML INTRAVENOUS SOLUTION <b>MO</b>	3	
CORZIDE 40-5 TABLET; CORZIDE 80-5 TABLET <b>MO</b>	3	
COZAAR 100 MG, 25 MG, 50 MG TABLET <b>MO</b>	3	PA,QL (60 per 30 days)
CRESTOR 10 MG, 20 MG, 40 MG, 5 MG TABLET <b>MO</b>	3	PA
DEMADEX 10 MG TABLET <b>MO</b>	3	
DEMSEER 250 MG CAPSULE <b>DL</b>	4	
DIBENZYLIN 10 MG CAPSULE <b>DL</b>	4	
<i>digitek 125 mcg (0.125 mg), 250 mcg (0.25 mg) tablet</i> <b>MO</b>	1	QL (30 per 30 days)
<i>digox 125 mcg (0.125 mg), 250 mcg (0.25 mg) tablet</i> <b>MO</b>	1	QL (30 per 30 days)
<i>digoxin 0.05 mg/ml solution; digoxin 500 mcg/2 ml ampule</i> <b>MO</b>	1	
<i>digoxin 125 mcg tablet; digoxin 250 mcg tablet</i> <b>MO</b>	1	QL (30 per 30 days)
DILATRATE-SR 40 MG CAPSULE, EXTENDED RELEASE <b>MO</b>	3	
<i>dilt-xr 120 mg, 180 mg, 240 mg capsule, extended release</i> <b>MO</b>	1	QL (60 per 30 days)
<i>diltiazem 100 mg, 5 mg/ml add-van vial; diltiazem 125 mg/25 ml vial</i> <b>MO</b>	1	
<i>diltiazem 120 mg, 30 mg, 60 mg, 90 mg tablet</i> <b>MO</b>	1	
<i>diltiazem 12hr er 120 mg cap</i> <b>MO</b>	1	QL (90 per 30 days)
<i>diltiazem 12hr er 60 mg, 90 mg cap</i> <b>MO</b>	1	QL (180 per 30 days)
<i>diltiazem 24h er(cd) 120 mg, 180 mg, 240 mg cp; diltiazem 24hr er 120 mg, 180 mg, 240 mg cap</i> <b>MO</b>	1	QL (60 per 30 days)
<i>diltiazem 24h er(cd) 300 mg, 360 mg, 420 mg cp; diltiazem 24hr er 300 mg, 360 mg, 420 mg cap</i> <b>MO</b>	1	QL (30 per 30 days)
<i>diltiazem 24h er(la) 180 mg, 240 mg tb</i> <b>MO</b>	1	QL (60 per 30 days)
<i>diltiazem 24h er(la) 300 mg, 360 mg, 420 mg tb</i> <b>MO</b>	1	QL (30 per 30 days)
<i>diltiazem 24h er(xr) 120 mg, 180 mg, 240 mg cp</i> <b>MO</b>	1	QL (60 per 30 days)
DIOVAN 160 MG, 320 MG, 40 MG, 80 MG TABLET <b>MO</b>	3	PA,QL (60 per 30 days)
DIOVAN HCT 160 MG-12.5 MG TABLET; DIOVAN HCT 160 MG-25 MG TABLET; DIOVAN HCT 320 MG-12.5 MG TABLET; DIOVAN HCT 320 MG-25 MG TABLET; DIOVAN HCT 80 MG-12.5 MG TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
<i>disopyramide 100 mg, 150 mg capsule</i> <b>MO</b>	1	
DIURIL 250 MG/5 ML ORAL SUSPENSION <b>MO</b>	3	
DIURIL 500 MG INTRAVENOUS SOLUTION <b>MO</b>	3	
<i>dobutamine 12.5 mg/ml vial; dobutamine 250 mg/20 ml vial</i> <b>MO</b>	1	B vs D
<i>dobutamine 1,000 mg/250 ml d5w; dobutamine 250 mg/250 ml-d5w; dobutamine 500 mg/250 ml d5w</i> <b>MO</b>	1	B vs D

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
dofetilide 125 mcg, 250 mcg, 500 mcg capsule <b>MO</b>	1	
dopamine 160 mg/ml vial; dopamine 200 mg/5 ml vial; dopamine 400 mg/10 ml vial; dopamine 80 mg/ml vial <b>MO</b>	1	B vs D
dopamine 200 mg-d5w 250 ml; dopamine 400 mg-d5w 500 ml; dopamine 400 mg/250 ml-d5w bag; dopamine 800 mg/250 ml-d5w bag; dopamine 800 mg/500 ml-d5w bag <b>MO</b>	1	B vs D
doxazosin mesylate 1 mg, 2 mg, 4 mg, 8 mg tab <b>MO</b>	1	
DUTOPROL 100 MG-12.5 MG TABLET,EXTENDED RELEASE <b>MO</b>	3	QL (120 per 30 days)
DUTOPROL 25 MG-12.5 MG TABLET,EXTENDED RELEASE; DUTOPROL 50 MG-12.5 MG TABLET,EXTENDED RELEASE <b>MO</b>	3	QL (60 per 30 days)
DYAZIDE 37.5 MG-25 MG CAPSULE <b>MO</b>	3	
DYRENIUM 100 MG, 50 MG CAPSULE <b>MO</b>	3	
EDARBI 40 MG, 80 MG TABLET <b>MO</b>	3	ST,QL (30 per 30 days)
EDARBYCLOR 40 MG-12.5 MG TABLET; EDARBYCLOR 40 MG-25 MG TABLET <b>MO</b>	3	ST,QL (30 per 30 days)
EDECIN 25 MG TABLET <b>DL</b>	4	QL (480 per 30 days)
enalapril maleate 10 mg, 2.5 mg, 20 mg, 5 mg tab; enalapril maleate 10 mg, 2.5 mg, 20 mg, 5 mg tablet <b>MO</b>	1	
enalapril-hctz 10-25 mg, 5-12.5 mg tab; enalapril-hctz 10-25 mg, 5-12.5 mg tablet <b>MO</b>	1	
enalaprilat 1.25 mg/ml vial <b>MO</b>	1	
ENTRESTO 24 MG-26 MG TABLET; ENTRESTO 49 MG-51 MG TABLET; ENTRESTO 97 MG-103 MG TABLET <b>MO</b>	2	QL (60 per 30 days)
EPANED 1 MG/ML ORAL SOLUTION <b>MO</b>	3	
eplerenone 25 mg, 50 mg tablet <b>MO</b>	1	
eprosartan mesylate 600 mg tab <b>MO</b>	1	QL (60 per 30 days)
esmolol hcl 100 mg/10 ml vial <b>MO</b>	1	
esmolol 2,000 mg/100 ml, 2,500 mg/250 ml (10 mg/ml)-nacl; esmolol 2,500 mg/250 ml-nacl <b>MO</b>	1	
ethacrynate sodium 50 mg vial <b>MO</b>	1	
ethacrynic acid 25 mg tablet <b>DL</b>	4	QL (480 per 30 days)
EXFORGE 10 MG-160 MG TABLET; EXFORGE 10 MG-320 MG TABLET; EXFORGE 5 MG-160 MG TABLET; EXFORGE 5 MG-320 MG TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
EXFORGE HCT 10 MG-160 MG-12.5 MG TABLET; EXFORGE HCT 10 MG-160 MG-25 MG TABLET; EXFORGE HCT 10 MG-320 MG-25 MG TABLET; EXFORGE HCT 5 MG-160 MG-12.5 MG TABLET; EXFORGE HCT 5 MG-160 MG-25 MG TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
EZALLOR SPRINKLE 10 MG, 20 MG, 40 MG, 5 MG CAPSULE <b>MO</b>	3	ST,QL (30 per 30 days)
ezetimibe 10 mg tablet <b>MO</b>	1	QL (30 per 30 days)
ezetimibe-simvastatin 10-10 mg, 10-20 mg, 10-40 mg, 10-80 mg <b>MO</b>	1	QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>felodipine er 10 mg, 2.5 mg, 5 mg tablet</i> <sup>MO</sup>	1	QL (30 per 30 days)
<i>fenofibrate 120 mg, 160 mg tablet</i> <sup>MO</sup>	1	QL (30 per 30 days)
<i>fenofibrate 150 mg capsule</i> <sup>MO</sup>	1	QL (30 per 30 days)
<i>fenofibrate 40 mg, 54 mg tablet</i> <sup>MO</sup>	1	QL (60 per 30 days)
<i>fenofibrate 50 mg capsule</i> <sup>MO</sup>	1	QL (60 per 30 days)
<i>fenofibrate 130 mg, 43 mg capsule</i> <sup>MO</sup>	1	ST,QL (30 per 30 days)
<i>fenofibrate 134 mg, 200 mg capsule</i> <sup>MO</sup>	1	QL (30 per 30 days)
<i>fenofibrate 67 mg capsule</i> <sup>MO</sup>	1	QL (60 per 30 days)
<i>fenofibrate 145 mg, 160 mg tablet</i> <sup>MO</sup>	1	QL (30 per 30 days)
<i>fenofibrate 48 mg tablet</i> <sup>MO</sup>	1	QL (60 per 30 days)
<i>fenofibric acid 105 mg, 35 mg tablet</i> <sup>MO</sup>	2	QL (30 per 30 days)
<i>fenofibric acid dr 135 mg, 45 mg cap</i> <sup>MO</sup>	1	QL (30 per 30 days)
FENOGLIDE 120 MG TABLET <sup>DL</sup>	4	QL (30 per 30 days)
FENOGLIDE 40 MG TABLET <sup>DL</sup>	4	QL (60 per 30 days)
FIBRICOR 105 MG, 35 MG TABLET <sup>MO</sup>	3	QL (30 per 30 days)
<i>flecainide acetate 100 mg, 150 mg, 50 mg tab</i> <sup>MO</sup>	1	
FLOLIPID 20 MG/5 ML (4 MG/ML), 40 MG/5 ML (8 MG/ML) ORAL SUSPENSION <sup>MO</sup>	3	ST,QL (150 per 30 days)
<i>fluvastatin er 80 mg tablet</i> <sup>MO</sup>	1	ST,QL (30 per 30 days)
<i>fluvastatin sodium 20 mg, 40 mg cap</i> <sup>MO</sup>	1	ST,QL (60 per 30 days)
<i>fosinopril sodium 10 mg, 20 mg, 40 mg tab</i> <sup>MO</sup>	1	
<i>fosinopril-hctz 10-12.5 mg, 20-12.5 mg tab</i> <sup>MO</sup>	1	
<i>furosemide 10 mg/ml, 40 mg/5 ml (8 mg/ml) solution; furosemide 40 mg/4 ml vial; furosemide 40 mg/5 ml soln</i> <sup>MO</sup>	1	
<i>furosemide 100 mg/10 ml syringe</i> <sup>MO</sup>	1	
<i>furosemide 20 mg, 40 mg, 80 mg tablet</i> <sup>MO</sup>	1	
<i>gemfibrozil 600 mg tablet</i> <sup>MO</sup>	1	QL (60 per 30 days)
GONITRO 400 MCG SUBLINGUAL POWDER IN A PACKET <sup>MO</sup>	3	
<i>guanfacine 1 mg, 2 mg tablet</i> <sup>MO</sup>	1	
HEMANGEOL 4.28 MG/ML ORAL SOLUTION <sup>MO</sup>	3	
<i>hydralazine 10 mg, 100 mg, 25 mg, 50 mg tablet</i> <sup>MO</sup>	1	
<i>hydralazine 20 mg/ml vial</i> <sup>MO</sup>	1	
<i>hydrochlorothiazide 12.5 mg cp</i> <sup>MO</sup>	1	
<i>hydrochlorothiazide 12.5 mg, 25 mg, 50 mg tab; hydrochlorothiazide 12.5 mg, 25 mg, 50 mg tb</i> <sup>MO</sup>	1	
HYZAAR 100 MG-12.5 MG TABLET; HYZAAR 100 MG-25 MG TABLET; HYZAAR 50 MG-12.5 MG TABLET <sup>MO</sup>	3	PA,QL (60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>ibutilide fum 1 mg/10 ml vial</i> <b>MO</b>	1	
<i>indapamide 1.25 mg, 2.5 mg tablet</i> <b>MO</b>	1	
INDERAL LA 120 MG, 160 MG, 60 MG, 80 MG CAPSULE,EXTENDED RELEASE <b>DL</b>	4	PA
INNOPRAN XL 120 MG, 80 MG CAPSULE,EXTENDED RELEASE <b>DL</b>	4	
INSPIRA 25 MG, 50 MG TABLET <b>MO</b>	3	PA
<i>irbesartan 150 mg, 300 mg, 75 mg tablet</i> <b>MO</b>	1	QL (30 per 30 days)
<i>irbesartan-hctz 150-12.5 mg tb</i> <b>MO</b>	1	QL (60 per 30 days)
<i>irbesartan-hctz 300-12.5 mg tb</i> <b>MO</b>	1	QL (30 per 30 days)
<i>isochron 40 mg tablet,extended release</i> <b>MO</b>	1	
ISORDIL 40 MG TABLET <b>DL</b>	4	
ISORDIL TITRADOSE 5 MG TABLET <b>DL</b>	4	PA
<i>isosorbide dinitr er 40 mg tab</i> <b>MO</b>	1	
<i>isosorbide dinitrate 10 mg, 20 mg, 30 mg, 5 mg tab</i> <b>MO</b>	1	
<i>isosorbide dinitrate 40 mg tab</i> <b>DL</b>	4	
<i>isosorbide mononit 10 mg, 20 mg tab</i> <b>MO</b>	1	
<i>isosorbide mononit er 120 mg, 30 mg, 60 mg; isosorbide mononit er 120 mg, 30 mg, 60 mg tb</i> <b>MO</b>	1	
<i>isradipine 2.5 mg, 5 mg capsule</i> <b>MO</b>	1	
ISUPREL 0.2 MG/ML INJECTION SOLUTION <b>MO</b>	3	
JUXTAPID 10 MG, 30 MG, 40 MG, 5 MG, 60 MG CAPSULE <b>DL</b>	4	PA,QL (28 per 28 days)
JUXTAPID 20 MG CAPSULE <b>DL</b>	4	PA,QL (84 per 28 days)
KAPSPARGO SPRINKLE 100 MG, 25 MG, 50 MG CAPSULE,EXTENDED RELEASE <b>MO</b>	3	ST,QL (30 per 30 days)
KAPSPARGO SPRINKLE 200 MG CAPSULE,EXTENDED RELEASE <b>MO</b>	3	ST,QL (60 per 30 days)
KATERZIA 1 MG/ML ORAL SUSPENSION <b>MO</b>	3	QL (300 per 30 days)
<i>labetalol hcl 100 mg, 200 mg, 300 mg tablet</i> <b>MO</b>	1	
<i>labetalol hcl 100 mg/20 ml vl</i> <b>MO</b>	1	
LANOXIN 125 MCG (0.125 MG), 187.5 MCG (0.1875 MG), 250 MCG (0.25 MG), 62.5 MCG (0.0625 MG) TABLET; LANOXIN 187.5 MCG TABLET <b>MO</b>	3	QL (30 per 30 days)
LANOXIN 250 MCG/ML (0.25 MG/ML), 500 MCG/2 ML (0.5 MG/2 ML) INJECTION SOLUTION; LANOXIN 500 MCG/2 ML (250 MCG/ML) (0.5 MG/2 ML) INJECTION SOLUTION <b>MO</b>	3	
LANOXIN PEDIATRIC 100 MCG/ML (0.1 MG/ML) INJECTION SOLUTION <b>MO</b>	3	
LASIX 20 MG, 40 MG, 80 MG TABLET <b>MO</b>	3	
LESCOL 20 MG, 40 MG CAPSULE <b>MO</b>	3	ST,QL (60 per 30 days)
LESCOL XL 80 MG TABLET,EXTENDED RELEASE <b>MO</b>	3	ST,QL (30 per 30 days)
LEVOPHED 1 MG/ML INTRAVENOUS SOLUTION <b>MO</b>	3	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>lidocaine hcl 2% vial</i> <sup>MO</sup>	1	
<i>lidocaine 0.4% in d5w 250 ml; lidocaine 0.8% in d5w soln</i> <sup>MO</sup>	1	
LIPITOR 10 MG, 20 MG, 40 MG, 80 MG TABLET <sup>MO</sup>	3	PA
LIPOFEN 150 MG CAPSULE <sup>MO</sup>	3	QL (30 per 30 days)
LIPOFEN 50 MG CAPSULE <sup>MO</sup>	3	QL (60 per 30 days)
<i>lisinopril 10 mg, 2.5 mg, 20 mg, 30 mg, 40 mg, 5 mg tablet</i> <sup>MO</sup>	1	
<i>lisinopril-hctz 10-12.5 mg, 20-12.5 mg, 20-25 mg tab</i> <sup>MO</sup>	1	
LIVALO 1 MG, 2 MG, 4 MG TABLET <sup>MO</sup>	3	ST,QL (30 per 30 days)
LOPID 600 MG TABLET <sup>MO</sup>	3	PA,QL (60 per 30 days)
LOPRESSOR 100 MG, 50 MG TABLET <sup>MO</sup>	3	
LOPRESSOR 5 MG/5 ML INTRAVENOUS SOLUTION <sup>MO</sup>	3	
LOPRESSOR HCT 50 MG-25 MG TABLET <sup>MO</sup>	3	
<i>losartan potassium 100 mg, 25 mg, 50 mg tab</i> <sup>MO</sup>	1	QL (60 per 30 days)
<i>losartan-hctz 100-12.5 mg, 100-25 mg, 50-12.5 mg tab</i> <sup>MO</sup>	1	QL (60 per 30 days)
LOTENSIN 10 MG, 20 MG, 40 MG TABLET <sup>MO</sup>	3	
LOTENSIN HCT 10 MG-12.5 MG TABLET; LOTENSIN HCT 20 MG-12.5 MG TABLET; LOTENSIN HCT 20 MG-25 MG TABLET <sup>MO</sup>	3	
LOTREL 10 MG-20 MG CAPSULE; LOTREL 5 MG-10 MG CAPSULE; LOTREL 5 MG-20 MG CAPSULE <sup>MO</sup>	3	PA,QL (60 per 30 days)
LOTREL 10 MG-40 MG CAPSULE; LOTREL 5 MG-40 MG CAPSULE <sup>MO</sup>	3	PA,QL (30 per 30 days)
<i>lovastatin 10 mg, 20 mg, 40 mg tablet</i> <sup>MO</sup>	1	
LOVAZA 1 GRAM CAPSULE <sup>MO</sup>	3	PA,QL (120 per 30 days)
<i>mannitol 10% iv solution</i> <sup>MO</sup>	1	
<i>mannitol 20% iv solution</i> <sup>MO</sup>	1	
<i>mannitol 25% vial</i> <sup>MO</sup>	1	
<i>mannitol 5% iv solution</i> <sup>MO</sup>	1	
<i>matzim la 180 mg, 240 mg tablet,extended release</i> <sup>MO</sup>	1	QL (60 per 30 days)
<i>matzim la 300 mg, 360 mg, 420 mg tablet,extended release</i> <sup>MO</sup>	1	QL (30 per 30 days)
MAXZIDE 75 MG-50 MG TABLET <sup>MO</sup>	3	PA
MAXZIDE-25MG 37.5 MG-25 MG TABLET <sup>MO</sup>	3	PA
<i>methazolamide 25 mg, 50 mg tablet</i> <sup>MO</sup>	1	
<i>methyclothiazide 5 mg tablet</i> <sup>MO</sup>	1	
<i>methyl dopa 250 mg, 500 mg tablet</i> <sup>MO</sup>	1	
<i>methyl dopa-hctz 250-15 mg, 250-25 mg tab</i> <sup>MO</sup>	1	
<i>methyl dopate 250 mg/5 ml vial</i> <sup>MO</sup>	1	
<i>metolazone 10 mg, 2.5 mg, 5 mg tablet</i> <sup>MO</sup>	1	
<i>metoprolol succ er 100 mg, 200 mg, 25 mg, 50 mg tab</i> <sup>MO</sup>	1	QL (60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
metoprolol-hctz 100-25 mg, 100-50 mg, 50-25 mg tab <sup>MO</sup>	1	
metoprolol 5 mg/5 ml carpject <sup>MO</sup>	1	
metoprolol tart 5 mg/5 ml vial <sup>MO</sup>	1	
metoprolol tartrate 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg tab; metoprolol tartrate 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg tb <sup>MO</sup>	1	
metirosine 250 mg capsule <sup>DL</sup>	4	
mexiletine 150 mg, 200 mg, 250 mg capsule <sup>MO</sup>	1	
MICARDIS 20 MG, 40 MG TABLET <sup>MO</sup>	3	ST,QL (30 per 30 days)
MICARDIS 80 MG TABLET <sup>MO</sup>	3	ST,QL (60 per 30 days)
MICARDIS HCT 40 MG-12.5 MG TABLET; MICARDIS HCT 80 MG-25 MG TABLET <sup>MO</sup>	3	ST,QL (30 per 30 days)
MICARDIS HCT 80 MG-12.5 MG TABLET <sup>MO</sup>	3	ST,QL (60 per 30 days)
MICROZIDE 12.5 MG CAPSULE <sup>MO</sup>	3	
midodrine hcl 10 mg, 2.5 mg, 5 mg tablet <sup>MO</sup>	1	
milrinone lact 20 mg/20 ml vl <sup>MO</sup>	1	B vs D
milrinone-d5w 20 mg/100 ml; milrinone-d5w 40 mg/200 ml <sup>MO</sup>	1	B vs D
MINIPRESS 1 MG, 2 MG, 5 MG CAPSULE <sup>MO</sup>	3	
minitran 0.1 mg/hr, 0.2 mg/hr, 0.6 mg/hr transdermal 24 hour patch <sup>MO</sup>	1	QL (30 per 30 days)
minitran 0.4 mg/hr transdermal 24 hour patch <sup>MO</sup>	1	QL (60 per 30 days)
minoxidil 10 mg, 2.5 mg tablet <sup>MO</sup>	1	
moexipril hcl 15 mg, 7.5 mg tablet <sup>MO</sup>	1	
moexipril-hctz 15-12.5 mg, 15-25 mg, 7.5-12.5 mg tab; moexipril-hctz 15-12.5 mg, 15-25 mg, 7.5-12.5 mg tablet <sup>MO</sup>	1	
MULTAQ 400 MG TABLET <sup>MO</sup>	2	QL (60 per 30 days)
nadolol 20 mg, 40 mg, 80 mg tablet <sup>MO</sup>	1	
nadolol-bendroflu 40-5 mg, 80-5 mg tab <sup>MO</sup>	1	
NATRECOR 1.5 MG VIAL <sup>MO</sup>	3	
NEXLETOL 180 MG TABLET <sup>MO</sup>	3	PA,QL (30 per 30 days)
NEXLIZET 180 MG-10 MG TABLET <sup>MO</sup>	3	PA,QL (30 per 30 days)
NEXTERONE 150 MG/100 ML (1.5 MG/ML), 360 MG/200 ML (1.8 MG/ML) INTRAVENOUS SOLUTION <sup>MO</sup>	3	
niacin er 1,000 mg, 500 mg, 750 mg tablet <sup>MO</sup>	1	
niacor 500 mg tablet <sup>MO</sup>	1	
NIASPAN 1,000 MG, 500 MG, 750 MG TABLET,EXTENDED RELEASE <sup>MO</sup>	3	PA
nicardipine 20 mg, 30 mg capsule <sup>MO</sup>	1	
nicardipine 25 mg/10 ml ampule <sup>MO</sup>	1	
nifedipine 10 mg, 20 mg capsule <sup>MO</sup>	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>nifedipine er 30 mg, 60 mg, 90 mg tablet</i> <b>MO</b>	1	QL (60 per 30 days)
<i>nimodipine 30 mg capsule</i> <b>MO</b>	1	
<i>nisoldipine er 17 mg, 20 mg, 34 mg, 40 mg, 8.5 mg tablet</i> <b>MO</b>	1	QL (30 per 30 days)
<i>nisoldipine er 25.5 mg, 30 mg tablet</i> <b>MO</b>	1	QL (60 per 30 days)
NITRO-BID 2 % TRANSDERMAL OINTMENT <b>MO</b>	1	
NITRO-DUR 0.1 MG/HR, 0.2 MG/HR, 0.6 MG/HR TRANSDERMAL 24 HOUR PATCH <b>DL</b>	4	QL (30 per 30 days)
NITRO-DUR 0.3 MG/HR, 0.8 MG/HR TRANSDERMAL 24 HOUR PATCH <b>DL</b>	4	
NITRO-DUR 0.4 MG/HR TRANSDERMAL 24 HOUR PATCH <b>DL</b>	4	QL (60 per 30 days)
<i>nitroglycerin 0.1 mg/hr, 0.2 mg/hr, 0.6 mg/hr patch</i> <b>MO</b>	1	QL (30 per 30 days)
<i>nitroglycerin 0.3 mg, 0.4 mg, 0.6 mg tablet sl</i> <b>MO</b>	1	
<i>nitroglycerin 0.4 mg/hr patch</i> <b>MO</b>	1	QL (60 per 30 days)
<i>nitroglycerin 5 mg/ml vial</i> <b>MO</b>	1	
<i>nitroglycerin lingual 400 mcg</i> <b>MO</b>	1	
<i>ntg 0.2 mg/ml in d5w; ntg 100 mg/250 ml in d5w; ntg 200 mg/500 ml in d5w; ntg 25 mg/250 ml in d5w; ntg 50 mg/500 ml in d5w</i> <b>MO</b>	1	
NITROLINGUAL 400 MCG/SPRAY <b>MO</b>	3	
NITROSTAT 0.3 MG, 0.4 MG, 0.6 MG SUBLINGUAL TABLET <b>MO</b>	2	
<i>norepinephrine 4 mg/4 ml vial</i> <b>MO</b>	1	
NORPACE 100 MG, 150 MG CAPSULE <b>MO</b>	3	
NORPACE CR 100 MG, 150 MG CAPSULE, EXTENDED RELEASE <b>MO</b>	3	
NORTHERA 100 MG, 200 MG CAPSULE <b>DL</b>	4	PA, QL (90 per 30 days)
NORTHERA 300 MG CAPSULE <b>DL</b>	4	PA, QL (180 per 30 days)
NORVASC 10 MG TABLET <b>MO</b>	3	PA, QL (60 per 30 days)
NORVASC 2.5 MG, 5 MG TABLET <b>MO</b>	3	PA, QL (30 per 30 days)
NYMALIZE 30 MG/10 ML SOLUTION <b>DL</b>	4	QL (1260 per 28 days)
NYMALIZE 30 MG/5 ML ORAL SYRINGE (FOR ORAL USE ONLY) <b>DL</b>	4	QL (630 per 28 days)
NYMALIZE 60 MG/10 ML ORAL SYRINGE (FOR ORAL USE ONLY) <b>DL</b>	4	QL (1260 per 28 days)
NYMALIZE 60 MG/20 ML SOLUTION <b>DL</b>	4	QL (2838 per 28 days)
<i>olmesartan medoxomil 20 mg, 40 mg, 5 mg tab</i> <b>MO</b>	1	QL (30 per 30 days)
<i>olmsrtn-amldpn-hctz 20-5-12.5; olmsrtn-amldpn-hctz 20-5-12.5 mg, 40-10-12.5 mg, 40-10-25 mg, 40-5-12.5 mg, 40-5-25 mg; olmsrtn-amldpn-hctz 40-10-12.5; olmsrtn-amldpn-hctz 40-10-25mg; olmsrtn-amldpn-hctz 40-5-12.5</i> <b>MO</b>	1	QL (30 per 30 days)
<i>olmesartan-hctz 20-12.5 mg, 40-12.5 mg, 40-25 mg tab</i> <b>MO</b>	1	QL (30 per 30 days)
<i>omega-3 ethyl esters 1 gm cap</i> <b>MO</b>	1	QL (120 per 30 days)
OSMITROL 10 % INTRAVENOUS SOLUTION <b>MO</b>	3	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
OSMITROL 15 % INTRAVENOUS SOLUTION <b>MO</b>	3	
OSMITROL 20 % INTRAVENOUS SOLUTION <b>MO</b>	3	
OSMITROL 5 % INTRAVENOUS SOLUTION <b>MO</b>	3	
PACERONE 100 MG TABLET <b>MO</b>	1	
<i>pacerone 200 mg tablet</i> <b>MO</b>	1	
PACERONE 400 MG TABLET <b>MO</b>	1	QL (60 per 30 days)
<i>pentoxifylline er 400 mg tab</i> <b>MO</b>	1	
<i>perindopril erbumine 2 mg, 4 mg, 8 mg tab</i> <b>MO</b>	1	
<i>phenoxybenzamine hcl 10 mg cap</i> <b>DL</b>	4	
<i>phenylephrine 100 mg/10 ml vl</i> <b>MO</b>	1	
<i>pindolol 10 mg, 5 mg tablet</i> <b>MO</b>	1	
PRALUENT PEN 150 MG/ML, 75 MG/ML SUBCUTANEOUS PEN INJECTOR <b>MO</b>	3	PA,QL (2 per 28 days)
PRAVACHOL 20 MG, 40 MG, 80 MG TABLET <b>MO</b>	3	PA
<i>pravastatin sodium 10 mg, 20 mg, 40 mg, 80 mg tab</i> <b>MO</b>	1	
<i>prazosin 1 mg, 2 mg, 5 mg capsule</i> <b>MO</b>	1	
PRESTALIA 14 MG-10 MG TABLET; PRESTALIA 3.5 MG-2.5 MG TABLET; PRESTALIA 7 MG-5 MG TABLET <b>MO</b>	3	QL (30 per 30 days)
<i>prevalite 4 gram oral powder; prevalite 4 gram powder for susp in a packet</i> <b>MO</b>	1	
PRINIVIL 10 MG, 20 MG, 5 MG TABLET <b>MO</b>	3	
<i>procainamide 1 gram/10 ml vial; procainamide 1,000 mg/2 ml vl</i> <b>MO</b>	1	
PROCARDIA 10 MG CAPSULE <b>MO</b>	3	PA
PROCARDIA XL 30 MG, 60 MG, 90 MG TABLET, EXTENDED RELEASE <b>MO</b>	3	PA,QL (60 per 30 days)
<i>propafenone hcl 150 mg, 225 mg, 300 mg tab; propafenone hcl 150 mg, 225 mg, 300 mg tablet</i> <b>MO</b>	1	
<i>propafenone hcl er 225 mg, 325 mg cap</i> <b>MO</b>	1	QL (60 per 30 days)
<i>propafenone hcl er 425 mg cap</i> <b>MO</b>	1	
<i>propranolol 1 mg/ml, 20 mg/5 ml (4 mg/ml), 40 mg/5 ml (8 mg/ml) vial; propranolol 20 mg/5 ml soln; propranolol 40 mg/5 ml soln</i> <b>MO</b>	1	
<i>propranolol 10 mg, 20 mg, 40 mg, 60 mg, 80 mg tablet</i> <b>MO</b>	1	
<i>propranolol er 120 mg, 160 mg, 60 mg, 80 mg capsule</i> <b>MO</b>	1	
<i>propranolol-hctz 40-25 mg, 80-25 mg tab</i> <b>MO</b>	1	
QBRELIS 1 MG/ML ORAL SOLUTION <b>DL</b>	4	QL (1200 per 30 days)
QUESTRAN 4 GRAM ORAL POWDER; QUESTRAN 4 GRAM POWDER FOR SUSP IN A PACKET <b>MO</b>	1	
QUESTRAN LIGHT 4 GRAM ORAL POWDER <b>MO</b>	1	
<i>quinapril 10 mg, 20 mg, 40 mg, 5 mg tablet</i> <b>MO</b>	1	
<i>quinapril-hctz 10-12.5 mg, 20-12.5 mg, 20-25 mg tab</i> <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
quinidine gluc 80 mg/ml vial <sup>MO</sup>	1	
quinidine gluc er 324 mg tab <sup>MO</sup>	1	
quinidine sulfate 200 mg, 300 mg tab <sup>MO</sup>	1	
ramipril 1.25 mg, 10 mg, 2.5 mg, 5 mg capsule <sup>MO</sup>	1	
RANEXA 1,000 MG, 500 MG TABLET,EXTENDED RELEASE <sup>MO</sup>	3	PA,QL (120 per 30 days)
ranolazine er 1,000 mg, 500 mg tablet <sup>MO</sup>	1	QL (120 per 30 days)
REPATHA PUSHTRONEX 420 MG/3.5 ML SUBCUTANEOUS WEARABLE INJECTOR <sup>MO</sup>	2	PA,QL (3.5 per 28 days)
REPATHA SURECLICK 140 MG/ML SUBCUTANEOUS PEN INJECTOR <sup>MO</sup>	2	PA,QL (3 per 28 days)
REPATHA SYRINGE 140 MG/ML SUBCUTANEOUS SYRINGE <sup>MO</sup>	2	PA,QL (3 per 28 days)
RESECTISOL 5% SOLUTION <sup>MO</sup>	3	
rosuvastatin calcium 10 mg, 20 mg, 40 mg, 5 mg tab <sup>MO</sup>	1	
RYTHMOL SR 225 MG CAPSULE,EXTENDED RELEASE <sup>MO</sup>	3	PA,QL (60 per 30 days)
RYTHMOL SR 325 MG CAPSULE,EXTENDED RELEASE <sup>DL</sup>	4	PA,QL (60 per 30 days)
RYTHMOL SR 425 MG CAPSULE,EXTENDED RELEASE <sup>DL</sup>	4	PA
simvastatin 10 mg, 20 mg, 40 mg, 5 mg, 80 mg tablet <sup>MO</sup>	1	
SODIUM EDECRIN 50 MG INTRAVENOUS SOLUTION <sup>MO</sup>	3	
sorine 120 mg, 160 mg, 240 mg, 80 mg tablet <sup>MO</sup>	1	
sotalol 120 mg, 160 mg, 240 mg, 80 mg tablet <sup>MO</sup>	1	
sotalol hcl 150 mg/10 ml vial <sup>MO</sup>	1	
sotalol of 120 mg, 160 mg, 80 mg tablet <sup>MO</sup>	1	
SOTYLIZE 5 MG/ML ORAL SOLUTION <sup>MO</sup>	3	
spironolactone-hctz 25-25 tab <sup>MO</sup>	1	
spironolactone 100 mg, 25 mg, 50 mg tablet <sup>MO</sup>	1	
SULAR 17 MG, 34 MG, 8.5 MG TABLET,EXTENDED RELEASE <sup>DL</sup>	4	PA,QL (30 per 30 days)
TARKA 2 MG-180 MG TABLET, EXTENDED RELEASE; TARKA 2 MG-240 MG TABLET, EXTENDED RELEASE; TARKA 4 MG-240 MG TABLET, EXTENDED RELEASE <sup>MO</sup>	3	
taztia xt 120 mg, 180 mg, 240 mg capsule,extended release <sup>MO</sup>	1	QL (60 per 30 days)
taztia xt 300 mg, 360 mg capsule,extended release <sup>MO</sup>	1	QL (30 per 30 days)
TEKTURNA 150 MG, 300 MG TABLET <sup>MO</sup>	3	PA,QL (30 per 30 days)
TEKTURNA HCT 150 MG-12.5 MG TABLET; TEKTURNA HCT 150 MG-25 MG TABLET; TEKTURNA HCT 300 MG-12.5 MG TABLET; TEKTURNA HCT 300 MG-25 MG TABLET <sup>MO</sup>	2	QL (30 per 30 days)
telmisartan 20 mg, 40 mg tablet <sup>MO</sup>	1	QL (30 per 30 days)
telmisartan 80 mg tablet <sup>MO</sup>	1	QL (60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
telmisartan-amlodipine 40-10; telmisartan-amlodipine 40-10 mg, 40-5 mg, 80-10 mg, 80-5 mg; telmisartan-amlodipine 80-10 <sup>MO</sup>	1	QL (30 per 30 days)
telmisartan-hctz 40-12.5 mg, 80-25 mg tab; telmisartan-hctz 40-12.5 mg, 80-25 mg tb <sup>MO</sup>	1	ST,QL (30 per 30 days)
telmisartan-hctz 80-12.5 mg tb <sup>MO</sup>	1	ST,QL (60 per 30 days)
TENORETIC 100 100 MG-25 MG TABLET <sup>MO</sup>	3	
TENORETIC 50 50 MG-25 MG TABLET <sup>MO</sup>	3	PA
TENORMIN 100 MG, 25 MG, 50 MG TABLET <sup>MO</sup>	3	
terazosin 1 mg, 10 mg, 2 mg, 5 mg capsule <sup>MO</sup>	1	
tiadylt er 120 mg, 180 mg, 240 mg capsule,extended release <sup>MO</sup>	1	QL (60 per 30 days)
tiadylt er 300 mg, 360 mg, 420 mg capsule,extended release <sup>MO</sup>	1	QL (30 per 30 days)
TIAZAC 120 MG, 180 MG, 240 MG CAPSULE,EXTENDED RELEASE <sup>MO</sup>	3	QL (60 per 30 days)
TIAZAC 300 MG, 360 MG, 420 MG CAPSULE,EXTENDED RELEASE <sup>MO</sup>	3	QL (30 per 30 days)
TIKOSYN 125 MCG, 250 MCG, 500 MCG CAPSULE <sup>DL</sup>	4	PA
timolol maleate 10 mg, 20 mg, 5 mg tablet <sup>MO</sup>	1	
TOPROL XL 100 MG, 200 MG, 25 MG, 50 MG TABLET,EXTENDED RELEASE <sup>MO</sup>	3	QL (60 per 30 days)
torse mide 10 mg, 100 mg, 20 mg, 5 mg tablet <sup>MO</sup>	1	
trandolapril 1 mg, 2 mg, 4 mg tablet <sup>MO</sup>	1	
trandolapr-verapam er 1-240 mg, 2-180 mg, 2-240 mg, 4-240 mg <sup>MO</sup>	1	
triamterene 100 mg, 50 mg capsule <sup>MO</sup>	1	
triamterene-hctz 37.5-25 mg, 50-25 mg cap; triamterene-hctz 37.5-25 mg, 50-25 mg cp <sup>MO</sup>	1	
triamterene-hctz 37.5-25 mg, 75-50 mg tab; triamterene-hctz 37.5-25 mg, 75-50 mg tb <sup>MO</sup>	1	
TRIBENZOR 20 MG-5 MG-12.5 MG TABLET; TRIBENZOR 40 MG-10 MG-12.5 MG TABLET; TRIBENZOR 40 MG-10 MG-25 MG TABLET; TRIBENZOR 40 MG-5 MG-12.5 MG TABLET; TRIBENZOR 40 MG-5 MG-25 MG TABLET <sup>MO</sup>	3	PA,QL (30 per 30 days)
TRICOR 145 MG TABLET <sup>MO</sup>	3	PA,QL (30 per 30 days)
TRICOR 48 MG TABLET <sup>MO</sup>	3	PA,QL (60 per 30 days)
TRIGLIDE 160 MG TABLET <sup>MO</sup>	3	QL (30 per 30 days)
triklo 1 gm capsule <sup>MO</sup>	1	QL (120 per 30 days)
TRILIPIX 135 MG, 45 MG CAPSULE,DELAYED RELEASE <sup>MO</sup>	3	PA,QL (30 per 30 days)
TWYNSTA 40 MG-10 MG TABLET; TWYNSTA 40 MG-5 MG TABLET; TWYNSTA 80 MG-10 MG TABLET; TWYNSTA 80 MG-5 MG TABLET <sup>MO</sup>	3	PA,QL (30 per 30 days)
valsartan 160 mg, 320 mg, 40 mg, 80 mg tablet <sup>MO</sup>	1	QL (60 per 30 days)
valsartan-hctz 160-12.5 mg, 160-25 mg, 320-12.5 mg, 320-25 mg, 80-12.5 mg tab <sup>MO</sup>	1	QL (30 per 30 days)
VASCEPA 0.5 GRAM CAPSULE <sup>MO</sup>	3	PA,QL (240 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
VASCEPA 1 GRAM CAPSULE <b>MO</b>	3	PA,QL (120 per 30 days)
VASERETIC 10 MG-25 MG TABLET <b>MO</b>	3	
VASOTEC 10 MG, 2.5 MG, 20 MG, 5 MG TABLET <b>DL</b>	4	PA
VAZCULEP 10 MG/ML INJECTION SOLUTION <b>MO</b>	3	
vecamyl 2.5 mg tablet <b>DL</b>	4	QL (300 per 30 days)
verapamil 10 mg/4 ml syringe <b>MO</b>	1	
verapamil 120 mg, 180 mg, 240 mg, 360 mg cap pellet; verapamil sr 120 mg, 180 mg, 240 mg, 360 mg capsule <b>MO</b>	1	QL (60 per 30 days)
verapamil 120 mg, 40 mg, 80 mg tablet <b>MO</b>	1	QL (120 per 30 days)
verapamil 5 mg/2 ml ampul <b>MO</b>	1	
verapamil er 120 mg tablet <b>MO</b>	1	QL (30 per 30 days)
verapamil er 180 mg, 240 mg tablet <b>MO</b>	1	
verapamil er pm 100 mg, 300 mg capsule <b>MO</b>	1	QL (30 per 30 days)
verapamil er pm 200 mg capsule <b>MO</b>	1	QL (60 per 30 days)
VERELAN 120 MG, 180 MG, 240 MG, 360 MG CAPSULE, EXTENDED RELEASE <b>MO</b>	3	QL (60 per 30 days)
VERELAN PM 100 MG, 300 MG CAPSULE, EXTENDED RELEASE <b>MO</b>	3	PA,QL (30 per 30 days)
VERELAN PM 200 MG CAPSULE, EXTENDED RELEASE <b>MO</b>	3	PA,QL (60 per 30 days)
VYTORIN 10 MG-10 MG TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
VYTORIN 10 MG-20 MG TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
VYTORIN 10 MG-40 MG TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
VYTORIN 10 MG-80 MG TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
WELCHOL 3.75 GRAM ORAL POWDER PACKET <b>MO</b>	3	PA,QL (30 per 30 days)
WELCHOL 625 MG TABLET <b>MO</b>	3	PA,QL (180 per 30 days)
ZESTORETIC 10 MG-12.5 MG TABLET; ZESTORETIC 20 MG-12.5 MG TABLET; ZESTORETIC 20 MG-25 MG TABLET <b>MO</b>	3	
ZESTRIL 10 MG, 2.5 MG, 20 MG, 30 MG, 40 MG, 5 MG TABLET <b>MO</b>	3	PA
ZETIA 10 MG TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
ZIAC 10 MG-6.25 MG TABLET; ZIAC 2.5 MG-6.25 MG TABLET; ZIAC 5 MG-6.25 MG TABLET <b>MO</b>	3	PA
ZOCOR 10 MG, 20 MG, 40 MG, 80 MG TABLET <b>MO</b>	3	PA
ZYPITAMAG 1 MG, 2 MG, 4 MG TABLET <b>MO</b>	3	ST,QL (30 per 30 days)
<b>Central Nervous System Agents</b>		
ADDERALL 10 MG, 12.5 MG, 15 MG, 20 MG, 5 MG, 7.5 MG TABLET <b>MO</b>	1	PA,QL (90 per 30 days)
ADDERALL 30 MG TABLET <b>MO</b>	1	PA,QL (60 per 30 days)
ADDERALL XR 10 MG, 15 MG, 5 MG CAPSULE, EXTENDED RELEASE <b>MO</b>	3	PA,QL (30 per 30 days)
ADDERALL XR 20 MG, 25 MG, 30 MG CAPSULE, EXTENDED RELEASE <b>MO</b>	3	PA,QL (60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ADZENYS ER 1.25 MG/ML SUSPENSION, EXTENDED RELEASE 24HR <b>MO</b>	3	QL (450 per 30 days)
ADZENYS XR-ODT 12.5 MG, 15.7 MG, 18.8 MG, 3.1 MG, 6.3 MG, 9.4 MG EXTENDED RELEASE DISINTEGRATING TABLET <b>MO</b>	3	QL (30 per 30 days)
<i>amphetamine er 1.25 mg/ml susp</i> <b>MO</b>	3	QL (450 per 30 days)
<i>amphetamine sulfate 10 mg, 5 mg tab</i> <b>MO</b>	1	QL (90 per 30 days)
AMPYRA 10 MG TABLET,EXTENDED RELEASE <b>DL</b>	4	PA,QL (60 per 30 days)
APTENSIO XR 10 MG, 15 MG, 20 MG, 30 MG, 40 MG, 50 MG, 60 MG CAPSULE,EXTENDED RELEASE SPRINKLE <b>MO</b>	3	QL (30 per 30 days)
<i>atomoxetine hcl 10 mg, 18 mg, 25 mg, 40 mg capsule</i> <b>MO</b>	1	QL (60 per 30 days)
<i>atomoxetine hcl 100 mg, 60 mg, 80 mg capsule</i> <b>MO</b>	1	QL (30 per 30 days)
AUBAGIO 14 MG, 7 MG TABLET <b>DL, LA</b>	4	PA,QL (30 per 30 days)
AUSTEDO 12 MG, 9 MG TABLET <b>DL</b>	4	PA,QL (120 per 30 days)
AUSTEDO 6 MG TABLET <b>DL</b>	4	PA,QL (60 per 30 days)
AVONEX 30 MCG/0.5 ML INTRAMUSCULAR PEN KIT <b>DL</b>	4	PA,QL (1 per 28 days)
AVONEX 30 MCG/0.5 ML INTRAMUSCULAR SYRINGE KIT <b>DL</b>	4	PA,QL (1 per 28 days)
AVONEX 30 MCG VIAL KIT <b>DL</b>	4	PA,QL (4 per 28 days)
BAFIERTAM 95 MG CAPSULE,DELAYED RELEASE <b>DL</b>	4	PA,QL (120 per 30 days)
BETASERON 0.3 MG SUBCUTANEOUS KIT <b>DL</b>	4	PA,QL (15 per 30 days)
<i>clonidine hcl er 0.1 mg tablet</i> <b>MO</b>	1	QL (120 per 30 days)
CONCERTA 18 MG, 27 MG, 54 MG TABLET,EXTENDED RELEASE <b>MO</b>	3	PA,QL (30 per 30 days)
CONCERTA 36 MG TABLET,EXTENDED RELEASE <b>MO</b>	3	PA,QL (60 per 30 days)
COPAXONE 20 MG/ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA,QL (30 per 30 days)
COPAXONE 40 MG/ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA,QL (12 per 28 days)
COTEMPLA XR-ODT 17.3 MG, 8.6 MG EXTENDED RELEASE DISINTEGRATING TABLET <b>MO</b>	3	QL (30 per 30 days)
COTEMPLA XR-ODT 25.9 MG EXTENDED RELEASE DISINTEGRATING TABLET <b>MO</b>	3	QL (60 per 30 days)
<i>dalfampridine er 10 mg tablet</i> <b>MO</b>	1	PA,QL (60 per 30 days)
DAYTRANA 10 MG/9 HR, 15 MG/9 HR, 20 MG/9 HR, 30 MG/9 HR DAILY PATCH <b>MO</b>	3	QL (30 per 30 days)
DESOXYN 5 MG TABLET <b>DL</b>	4	PA,QL (150 per 30 days)
DEXEDRINE SPANSULE 10 MG CAPSULE,EXTENDED RELEASE <b>DL</b>	4	PA,QL (180 per 30 days)
DEXEDRINE SPANSULE 15 MG CAPSULE,EXTENDED RELEASE <b>DL</b>	4	PA,QL (120 per 30 days)
DEXEDRINE SPANSULE 5 MG CAPSULE,EXTENDED RELEASE <b>DL</b>	4	PA,QL (60 per 30 days)
<i>dexmethylphenidate 10 mg, 2.5 mg, 5 mg tab</i> <b>MO</b>	1	QL (60 per 30 days)
<i>dexmethylphenidate er 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 5 mg cap; dexmethylphenidate er 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 5 mg cp</i> <b>MO</b>	1	QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
dextroamphetamine 10 mg tab <b>MO</b>	1	QL (180 per 30 days)
dextroamphetamine 5 mg tab <b>MO</b>	1	QL (150 per 30 days)
dextroamphetamine 5 mg/5 ml <b>MO</b>	1	QL (1800 per 30 days)
dextroamphetamine er 10 mg cap <b>MO</b>	1	QL (180 per 30 days)
dextroamphetamine er 15 mg cap <b>MO</b>	1	QL (120 per 30 days)
dextroamphetamine er 5 mg cap <b>MO</b>	1	QL (60 per 30 days)
dextroamp-amphet er 10 mg, 15 mg, 5 mg cap <b>MO</b>	1	QL (30 per 30 days)
dextroamp-amphet er 20 mg, 25 mg, 30 mg cap <b>MO</b>	1	QL (60 per 30 days)
dextroamp-amphetam 10 mg, 12.5 mg, 15 mg, 20 mg, 5 mg, 7.5 mg tab; dextroamp-amphetamin 10 mg, 12.5 mg, 15 mg, 20 mg, 5 mg, 7.5 mg tab; dextroamp-amphetamine 10 mg, 12.5 mg, 15 mg, 20 mg, 5 mg, 7.5 mg tab <b>MO</b>	1	QL (90 per 30 days)
dextroamp-amphetamin 30 mg tab <b>MO</b>	1	QL (60 per 30 days)
DYANAVEL XR 2.5 MG/ML ORAL 24 HR EXTENDED RELEASE SUSPENSION <b>MO</b>	3	QL (240 per 30 days)
EVEKEO 10 MG, 5 MG TABLET <b>MO</b>	1	QL (90 per 30 days)
EVEKEO ODT 10 MG, 5 MG DISINTEGRATING TABLET <b>MO</b>	3	QL (90 per 30 days)
EVEKEO ODT 15 MG, 20 MG DISINTEGRATING TABLET <b>MO</b>	3	QL (60 per 30 days)
EXTAVIA 0.3 MG SUBCUTANEOUS KIT <b>DL</b>	4	PA,QL (15 per 30 days)
EXTAVIA 0.3 MG SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA,QL (15 per 30 days)
FIRDAPSE 10 MG TABLET <b>DL</b>	4	PA,QL (240 per 30 days)
FOCALIN 10 MG, 2.5 MG, 5 MG TABLET <b>MO</b>	3	PA,QL (60 per 30 days)
FOCALIN XR 10 MG, 15 MG, 20 MG, 25 MG, 30 MG, 35 MG, 40 MG, 5 MG CAPSULE,EXTENDED RELEASE <b>MO</b>	3	QL (30 per 30 days)
GILENYA 0.25 MG, 0.5 MG CAPSULE <b>DL</b>	4	PA,QL (30 per 30 days)
glatiramer 20 mg/ml syringe <b>DL</b>	4	PA,QL (30 per 30 days)
glatiramer 40 mg/ml syringe <b>DL</b>	4	PA,QL (12 per 28 days)
glatopa 20 mg/ml subcutaneous syringe <b>DL</b>	4	PA,QL (30 per 30 days)
glatopa 40 mg/ml subcutaneous syringe <b>DL</b>	4	PA,QL (12 per 28 days)
GRALISE 300 MG TABLET,EXTENDED RELEASE <b>DL</b>	4	ST,QL (30 per 30 days)
GRALISE 600 MG TABLET,EXTENDED RELEASE <b>DL</b>	4	ST,QL (90 per 30 days)
GRALISE 30-DAY STARTER PACK <b>DL</b>	4	ST,QL (78 per 30 days)
guanfacine hcl er 1 mg, 2 mg, 3 mg, 4 mg tablet <b>MO</b>	1	QL (30 per 30 days)
HORIZANT ER 300 MG, 600 MG TABLET,EXTENDED RELEASE <b>MO</b>	3	PA,QL (60 per 30 days)
INGREZZA 40 MG, 80 MG CAPSULE <b>DL</b>	4	PA,QL (30 per 30 days)
INGREZZA INITIATION PACK 40 MG (7)-80 MG (21) CAPSULES IN A DOSE PACK <b>DL</b>	4	PA,QL (28 per 28 days)
INTUNIV ER 1 MG, 2 MG, 3 MG, 4 MG TABLET,EXTENDED RELEASE <b>MO</b>	3	QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
JORNAY PM 100 MG, 20 MG, 40 MG, 60 MG, 80 MG CAPSULE, DELAYED RELEASE, EXTENDED RELEASE SPRINKLE <b>MO</b>	3	QL (30 per 30 days)
KAPVAY 0.1 MG TABLET, EXTENDED RELEASE <b>MO</b>	3	QL (120 per 30 days)
LEMTRADA 12 MG/1.2 ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA, QL (6 per 365 days)
LYRICA 100 MG, 150 MG, 200 MG, 25 MG, 50 MG, 75 MG CAPSULE <b>MO</b>	3	QL (90 per 30 days)
LYRICA 20 MG/ML ORAL SOLUTION <b>MO</b>	3	QL (900 per 30 days)
LYRICA 225 MG, 300 MG CAPSULE <b>MO</b>	3	QL (60 per 30 days)
LYRICA CR 165 MG, 82.5 MG TABLET, EXTENDED RELEASE <b>MO</b>	3	PA, QL (30 per 30 days)
LYRICA CR 330 MG TABLET, EXTENDED RELEASE <b>MO</b>	3	PA, QL (60 per 30 days)
MAVENCLAD (10 TABLET PACK) 10 MG TABLET <b>DL</b>	4	PA, QL (40 per 365 days)
MAVENCLAD (4 TABLET PACK) 10 MG TABLET <b>DL</b>	4	PA, QL (40 per 365 days)
MAVENCLAD (5 TABLET PACK) 10 MG TABLET <b>DL</b>	4	PA, QL (40 per 365 days)
MAVENCLAD (6 TABLET PACK) 10 MG TABLET <b>DL</b>	4	PA, QL (40 per 365 days)
MAVENCLAD (7 TABLET PACK) 10 MG TABLET <b>DL</b>	4	PA, QL (40 per 365 days)
MAVENCLAD (8 TABLET PACK) 10 MG TABLET <b>DL</b>	4	PA, QL (40 per 365 days)
MAVENCLAD (9 TABLET PACK) 10 MG TABLET <b>DL</b>	4	PA, QL (40 per 365 days)
MAYZENT 0.25 MG TABLET <b>DL</b>	4	PA, QL (120 per 30 days)
MAYZENT 2 MG TABLET <b>DL</b>	4	PA, QL (30 per 30 days)
MAYZENT STARTER PACK 0.25 MG (12 TABS) TABLETS <b>DL</b>	4	PA, QL (12 per 30 days)
<i>metadate er 20 mg tablet, extended release</i> <b>MO</b>	1	QL (90 per 30 days)
<i>methamphetamine 5 mg tablet</i> <b>DL</b>	4	QL (150 per 30 days)
METHYLIN 10 MG/5 ML ORAL SOLUTION <b>MO</b>	3	PA, QL (900 per 30 days)
METHYLIN 5 MG/5 ML ORAL SOLUTION <b>MO</b>	3	PA, QL (1800 per 30 days)
<i>methylphenidate 10 mg chew tab</i> <b>MO</b>	1	QL (180 per 30 days)
<i>methylphenidate 10 mg, 20 mg, 5 mg tablet</i> <b>MO</b>	1	QL (90 per 30 days)
<i>methylphenidate 10 mg/5 ml sol</i> <b>MO</b>	1	QL (900 per 30 days)
<i>methylphenidate 2.5 mg, 5 mg chew tab; methylphenidate 2.5 mg, 5 mg chew tb</i> <b>MO</b>	1	QL (150 per 30 days)
<i>methylphenidate 5 mg/5 ml soln</i> <b>MO</b>	1	QL (1800 per 30 days)
<i>methylphenidate cd 10 mg, 20 mg, 40 mg, 50 mg, 60 mg cap;</i> <i>methylphenidate la 10 mg, 20 mg, 40 mg, 50 mg, 60 mg cap</i> <b>MO</b>	1	QL (30 per 30 days)
<i>methylphenidate cd 20 mg, 30 mg cap; methylphenidate la 20 mg, 30 mg cap</i> <b>MO</b>	1	QL (60 per 30 days)
<i>methylphenidate er 10 mg tab</i> <b>MO</b>	1	QL (180 per 30 days)
<i>methylphenidate er 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg cap</i> <b>MO</b>	3	QL (30 per 30 days)
<i>methylphenidate er 18 mg, 27 mg, 54 mg, 72 mg tab</i> <b>MO</b>	1	QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>methylphenidate er 20 mg tab</i> <b>MO</b>	1	QL (90 per 30 days)
<i>methylphenidate er 36 mg tab</i> <b>MO</b>	1	QL (60 per 30 days)
MYDAYIS 12.5 MG, 25 MG, 37.5 MG, 50 MG CAPSULE EXTENDED RELEASE 24 HR <b>MO</b>	3	QL (30 per 30 days)
NUEDEXTA 20 MG-10 MG CAPSULE <b>DL</b>	4	PA,QL (60 per 30 days)
OCREVUS 30 MG/ML INTRAVENOUS SOLUTION <b>LA,MO</b>	4	PA,QL (40 per 365 days)
PLEGRIDY 125 MCG/0.5 ML, 63 MCG/0.5 ML- 94 MCG/0.5 ML SUBCUTANEOUS PEN INJECTOR; PLEGRIDY 63 MCG/0.5 ML-94 MCG/0.5 ML SUBCUTANEOUS PEN INJECTOR <b>DL</b>	4	PA,QL (1 per 28 days)
PLEGRIDY 125 MCG/0.5 ML, 63 MCG/0.5 ML- 94 MCG/0.5 ML SUBCUTANEOUS SYRINGE; PLEGRIDY 63 MCG/0.5 ML-94 MCG/0.5 ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA,QL (1 per 28 days)
<i>pregabalin 100 mg, 150 mg, 200 mg, 25 mg, 50 mg, 75 mg capsule</i> <b>MO</b>	1	QL (90 per 30 days)
<i>pregabalin 20 mg/ml solution</i> <b>MO</b>	1	QL (900 per 30 days)
<i>pregabalin 225 mg, 300 mg capsule</i> <b>MO</b>	1	QL (60 per 30 days)
<i>procentra 5 mg/5 ml oral solution</i> <b>DL</b>	4	QL (1800 per 30 days)
QUILLICHEW ER 20 MG, 40 MG CHEWABLE TABLET, EXTENDED RELEASE; QUILLICHEW ER 20 MG, 40 MG CHEWABLE, EXTENDED RELEASE TABLET <b>DL</b>	4	QL (30 per 30 days)
QUILLICHEW ER 30 MG CHEWABLE TABLET, EXTENDED RELEASE <b>DL</b>	4	QL (60 per 30 days)
QUILLIVANT XR 5 MG/ML (25 MG/5 ML) ORAL SUSPENSION,EXTEND RELEASE 24HR <b>MO</b>	3	QL (360 per 30 days)
RADICAVA 30 MG/100 ML INTRAVENOUS PIGGYBACK <b>DL, LA</b>	4	PA
REBIF (WITH ALBUMIN) 22 MCG/0.5 ML, 44 MCG/0.5 ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA,QL (6 per 28 days)
REBIF REBIDOSE 22 MCG/0.5 ML, 44 MCG/0.5 ML SUBCUTANEOUS PEN INJECTOR <b>DL</b>	4	PA,QL (6 per 28 days)
REBIF REBIDOSE 8.8 MCG/0.2 ML-22 MCG/0.5 ML (6) SUBCUTANEOUS PEN INJ. <b>DL</b>	4	PA,QL (4.2 per 28 days)
REBIF TITRATION PACK 8.8 MCG/0.2 ML-22 MCG/0.5 ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA,QL (4.2 per 28 days)
<i>relexii 72 mg tablet,extended release</i> <b>MO</b>	1	QL (30 per 30 days)
RILUTEK 50 MG TABLET <b>DL</b>	4	
<i>riluzole 50 mg tablet</i> <b>MO</b>	1	
RITALIN 10 MG, 20 MG, 5 MG TABLET <b>MO</b>	3	PA,QL (90 per 30 days)
RITALIN LA 10 MG, 20 MG, 40 MG CAPSULE,EXTENDED RELEASE <b>MO</b>	3	PA,QL (30 per 30 days)
RITALIN LA 30 MG CAPSULE,EXTENDED RELEASE <b>MO</b>	3	PA,QL (60 per 30 days)
RUZURGI 10 MG TABLET <b>DL</b>	4	PA,QL (300 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
SAVELLA 100 MG, 12.5 MG, 12.5 MG (5)-25 MG(8)-50 MG(42), 25 MG, 50 MG TABLET; SAVELLA 12.5 MG (5)-25 MG(8)-50MG(42) TABLETS IN A DOSE PACK <b>MO</b>	2	QL (60 per 30 days)
STRATTERA 10 MG, 18 MG, 25 MG, 40 MG CAPSULE <b>MO</b>	3	PA,QL (60 per 30 days)
STRATTERA 100 MG, 60 MG, 80 MG CAPSULE <b>MO</b>	3	PA,QL (30 per 30 days)
TECFIDERA 120 MG (14)- 240 MG (46), 240 MG CAPSULE,DELAYED RELEASE; TECFIDERA 120 MG (14)-240 MG (46) CAPSULE,DELAYED RELEASE <b>DL</b>	4	PA,QL (60 per 30 days)
TECFIDERA 120 MG CAPSULE,DELAYED RELEASE <b>DL</b>	4	PA,QL (14 per 30 days)
tetrabenazine 12.5 mg tablet <b>DL</b>	4	PA,QL (240 per 30 days)
tetrabenazine 25 mg tablet <b>DL</b>	4	PA,QL (120 per 30 days)
TIGLUTIK 50 MG/10 ML ORAL SUSPENSION <b>DL</b>	4	PA,QL (600 per 30 days)
TYSABRI 300 MG/15 ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA,QL (15 per 28 days)
VUMERITY 231 MG CAPSULE,DELAYED RELEASE <b>DL</b>	4	PA,QL (120 per 30 days)
VYVANSE 10 MG, 20 MG, 30 MG, 40 MG, 50 MG, 60 MG CHEWABLE TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
VYVANSE 10 MG, 20 MG, 30 MG, 40 MG, 50 MG, 60 MG, 70 MG CAPSULE <b>MO</b>	3	PA,QL (30 per 30 days)
XENAZINE 12.5 MG TABLET <b>DL</b>	4	PA,QL (240 per 30 days)
XENAZINE 25 MG TABLET <b>DL</b>	4	PA,QL (120 per 30 days)
zenzedi 10 mg tablet <b>MO</b>	1	QL (180 per 30 days)
ZENZEDI 15 MG TABLET <b>MO</b>	1	QL (120 per 30 days)
ZENZEDI 2.5 MG, 20 MG, 7.5 MG TABLET <b>MO</b>	1	QL (90 per 30 days)
ZENZEDI 30 MG TABLET <b>MO</b>	1	QL (60 per 30 days)
zenzedi 5 mg tablet <b>MO</b>	1	QL (150 per 30 days)
<b>Dental &amp; Oral Agents</b>		
cevimeline hcl 30 mg capsule <b>MO</b>	1	
chlorhexidine 0.12% rinse <b>MO</b>	1	
EVOXAC 30 MG CAPSULE <b>MO</b>	3	PA
KEPIVANCE 6.25 MG INTRAVENOUS SOLUTION <b>DL</b>	4	
oralone 0.1 % dental paste <b>MO</b>	1	
paroex oral rinse 0.12 % mouthwash <b>MO</b>	1	
periogard 0.12 % mouthwash <b>MO</b>	1	
pilocarpine hcl 5 mg, 7.5 mg tablet <b>MO</b>	1	
SALAGEN (PILOCARPINE) 5 MG, 7.5 MG TABLET <b>MO</b>	3	
triamcinolone 0.1% paste <b>MO</b>	1	
<b>DERMATOLOGICAL AGENTS</b>		
ABSORICA 10 MG, 20 MG, 25 MG, 30 MG, 35 MG CAPSULE <b>DL</b>	4	ST,QL (60 per 30 days)
ABSORICA 40 MG CAPSULE <b>DL</b>	4	ST,QL (120 per 30 days)
ABSORICA LD 16 MG, 24 MG, 8 MG CAPSULE <b>DL</b>	4	ST,QL (60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ABSORICA LD 32 MG CAPSULE <b>DL</b>	4	ST,QL (120 per 30 days)
ACANYA 1.2 %-2.5 % TOPICAL GEL WITH PUMP <b>MO</b>	3	QL (50 per 30 days)
acitretin 10 mg capsule <b>MO</b>	1	PA,QL (90 per 30 days)
acitretin 17.5 mg capsule <b>MO</b>	1	PA,QL (60 per 30 days)
acitretin 25 mg capsule <b>MO</b>	1	PA
ACZONE 5 %, 7.5 % TOPICAL GEL; ACZONE 5 %, 7.5 % TOPICAL GEL WITH PUMP <b>MO</b>	3	QL (90 per 30 days)
adapalene 0.1% cream <b>MO</b>	1	QL (45 per 30 days)
adapalene 0.1% gel; adapalene 0.3% gel; adapalene 0.3% gel pump <b>MO</b>	1	QL (45 per 30 days)
adapalene 0.1% solution <b>DL</b>	4	QL (60 per 30 days)
adapalene 0.1% swab <b>MO</b>	1	QL (30 per 30 days)
adapalene-bnzyl perox 0.1-2.5% <b>MO</b>	1	QL (45 per 30 days)
AKLIEF 0.005 % TOPICAL CREAM <b>MO</b>	3	PA,QL (90 per 30 days)
AKTIPAK 3%-5% GEL POUCH <b>MO</b>	3	
ALA-CORT 1 % TOPICAL CREAM <b>MO</b>	1	QL (240 per 30 days)
ALA-SCALP 2 % LOTION <b>MO</b>	1	QL (236.8 per 30 days)
alclometasone dipr 0.05% oint <b>MO</b>	1	QL (240 per 30 days)
alclometasone dipro 0.05% crm <b>MO</b>	1	QL (240 per 30 days)
ALDARA 5 % TOPICAL CREAM PACKET <b>MO</b>	3	PA,QL (12 per 30 days)
ALTABAX 1 % TOPICAL OINTMENT <b>MO</b>	3	
ALTRENO 0.05 % LOTION <b>MO</b>	3	PA,QL (90 per 30 days)
amcinonide 0.1% cream <b>MO</b>	1	QL (120 per 30 days)
amcinonide 0.1% lotion <b>MO</b>	1	QL (120 per 30 days)
ammonium lactate 12% cream <b>MO</b>	1	
ammonium lactate 12% lotion <b>MO</b>	1	
amnesteem 10 mg, 20 mg capsule <b>MO</b>	1	QL (60 per 30 days)
amnesteem 40 mg capsule <b>MO</b>	1	QL (120 per 30 days)
AMZEEQ 4 % TOPICAL FOAM <b>MO</b>	3	PA,QL (30 per 30 days)
anusol-hc 2.5 % topical cream with perineal applicator <b>MO</b>	1	QL (60 per 30 days)
apexicon e 0.05 % topical cream <b>MO</b>	1	QL (60 per 30 days)
ARAZLO 0.045 % LOTION <b>MO</b>	3	PA
ATRALIN 0.05 % TOPICAL GEL <b>MO</b>	3	PA,QL (45 per 30 days)
AVITA 0.025 % TOPICAL CREAM <b>MO</b>	3	PA,QL (45 per 30 days)
AVITA 0.025 % TOPICAL GEL <b>MO</b>	3	PA,QL (45 per 30 days)
azelaic acid 15% gel <b>MO</b>	1	ST,QL (50 per 30 days)
AZELEX 20 % TOPICAL CREAM <b>MO</b>	3	QL (50 per 30 days)
BACTROBAN 2% CREAM <b>MO</b>	3	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
BACTROBAN NASAL 2% OINTMENT <b>MO</b>	3	
BENZACLIN 1 %-5 % TOPICAL GEL <b>MO</b>	3	QL (50 per 30 days)
BENZACLIN PUMP 1 %-5 % TOPICAL GEL <b>MO</b>	3	QL (50 per 30 days)
BENZAMYCIN 3 %-5 % TOPICAL GEL <b>MO</b>	3	QL (46.6 per 30 days)
<i>beser 0.05 % lotion</i> <b>MO</b>	1	QL (240 per 30 days)
<i>betamethasone dp 0.05% crm</i> <b>MO</b>	1	QL (90 per 30 days)
<i>betamethasone dp 0.05% lot</i> <b>MO</b>	1	QL (120 per 30 days)
<i>betamethasone dp 0.05% oint</i> <b>MO</b>	1	QL (90 per 30 days)
<i>betamethasone va 0.1% cream</i> <b>MO</b>	1	QL (180 per 30 days)
<i>betamethasone va 0.1% lotion</i> <b>MO</b>	1	QL (120 per 30 days)
<i>betamethasone valer 0.1% ointm</i> <b>MO</b>	1	QL (180 per 30 days)
<i>betamethasone valer 0.12% foam</i> <b>MO</b>	1	QL (200 per 30 days)
<i>betamethasone dp aug 0.05% crm</i> <b>MO</b>	1	QL (100 per 30 days)
<i>betamethasone dp aug 0.05% gel</i> <b>MO</b>	1	QL (100 per 30 days)
<i>betamethasone dp aug 0.05% lot</i> <b>MO</b>	1	QL (120 per 30 days)
<i>betamethasone dp aug 0.05% oin</i> <b>MO</b>	1	QL (100 per 30 days)
BRYHALI 0.01 % LOTION <b>MO</b>	3	ST,QL (200 per 30 days)
<i>calcipotriene 0.005% cream</i> <b>MO</b>	1	PA,QL (120 per 30 days)
<i>calcipotriene 0.005% ointment</i> <b>MO</b>	1	QL (240 per 30 days)
<i>calcipotriene 0.005% solution</i> <b>MO</b>	1	QL (60 per 30 days)
<i>calcipotriene-betameth dp oint</i> <b>DL</b>	4	PA,QL (60 per 30 days)
<i>calcipotriene-betameth dp susp</i> <b>MO</b>	2	QL (420 per 30 days)
<i>calcitrene 0.005% ointment</i> <b>MO</b>	1	QL (240 per 30 days)
<i>calcitriol 3 mcg/g ointment</i> <b>MO</b>	1	ST,QL (800 per 28 days)
CAPEX 0.01 % SHAMPOO <b>MO</b>	3	QL (840 per 30 days)
CARAC 0.5 % TOPICAL CREAM <b>DL</b>	4	PA,QL (60 per 30 days)
CENTANY 2 % TOPICAL OINTMENT <b>MO</b>	3	
<i>claravis 10 mg, 20 mg, 30 mg capsule</i> <b>MO</b>	1	QL (60 per 30 days)
<i>claravis 40 mg capsule</i> <b>MO</b>	1	QL (120 per 30 days)
CLEOCIN T 1 % LOTION <b>MO</b>	3	QL (60 per 30 days)
CLEOCIN T 1 % SOLUTION <b>MO</b>	3	QL (60 per 30 days)
CLEOCIN T 1 % TOPICAL GEL <b>MO</b>	3	QL (60 per 30 days)
CLEOCIN T 1% PLEDGETS <b>MO</b>	3	
<i>clindacin etz 1 % topical swab</i> <b>MO</b>	1	
<i>clindacin p 1 % topical swab</i> <b>MO</b>	1	
CLINDAGEL 1 % TOPICAL GEL, ONCE DAILY <b>DL</b>	4	PA,QL (75 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
clindamycin ph 1% gel <b>MO</b>	1	QL (60 per 30 days)
clindamycin ph 1% solution <b>MO</b>	1	QL (60 per 30 days)
clindamycin phos 1% pledget <b>MO</b>	1	
clindamycin phosp 1% lotion <b>MO</b>	1	QL (60 per 30 days)
clindamycin phosphate 1% foam <b>MO</b>	1	QL (100 per 30 days)
clindamycin phosphate 1% gel <b>MO</b>	1	PA,QL (75 per 30 days)
clind ph-benzoyl pero 1.2-2.5%; clinda-benzoyl perox 1-5% pump;	1	QL (50 per 30 days)
clindamycin-benzoyl perox 1-5% <b>MO</b>		
clind ph-benzoyl perox 1.2-5% <b>MO</b>	1	QL (45 per 30 days)
clinda-tretinoin 1.2%-0.025% <b>MO</b>	1	QL (60 per 30 days)
clobetasol 0.05% cream <b>MO</b>	1	QL (120 per 30 days)
clobetasol 0.05% gel <b>MO</b>	1	QL (120 per 28 days)
clobetasol 0.05% ointment <b>MO</b>	1	QL (120 per 28 days)
clobetasol 0.05% shampoo <b>MO</b>	1	QL (240 per 30 days)
clobetasol 0.05% solution <b>MO</b>	1	QL (100 per 30 days)
clobetasol 0.05% topical lotn <b>MO</b>	1	QL (240 per 28 days)
clobetasol prop 0.05% foam <b>MO</b>	1	QL (100 per 28 days)
clobetasol prop 0.05% spray <b>MO</b>	1	QL (240 per 30 days)
clobetasol emollient 0.05% crm <b>MO</b>	1	QL (120 per 30 days)
clobetasol emulsion 0.05% foam <b>MO</b>	1	QL (100 per 30 days)
CLOBEX 0.05 % LOTION <b>MO</b>	3	ST,QL (240 per 28 days)
CLOBEX 0.05 % SHAMPOO <b>MO</b>	3	ST,QL (240 per 30 days)
CLOBEX 0.05 % TOPICAL SPRAY <b>MO</b>	3	ST,QL (240 per 30 days)
clocortolone pivalate 0.1% crm <b>MO</b>	1	QL (180 per 30 days)
clodan 0.05 % shampoo <b>MO</b>	1	QL (240 per 30 days)
CLODERM 0.1 % TOPICAL CREAM <b>MO</b>	3	PA,QL (180 per 30 days)
CONDYLOX 0.5 % TOPICAL GEL <b>DL</b>	4	
CORDRAN 0.025 % TOPICAL CREAM <b>MO</b>	3	ST,QL (240 per 30 days)
CORDRAN 0.05 % LOTION <b>DL</b>	4	ST,QL (240 per 30 days)
CORDRAN 0.05 % TOPICAL CREAM <b>DL</b>	4	ST,QL (240 per 30 days)
CORDRAN 0.05 % TOPICAL OINTMENT <b>DL</b>	4	ST,QL (240 per 30 days)
CORDRAN TAPE LARGE ROLL 4 MCG/CM2 <b>DL</b>	4	QL (2 per 30 days)
cormax 0.05% solution <b>MO</b>	1	QL (100 per 30 days)
CORTEF 10 MG, 20 MG, 5 MG TABLET <b>MO</b>	3	
CORTISPORIN 1 % TOPICAL OINTMENT <b>MO</b>	3	
CORTISPORIN 3.5 MG/G-10,000 UNIT/G-0.5 % TOPICAL CREAM <b>MO</b>	3	
crotan 10 % lotion <b>DL</b>	4	PA,QL (454 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
CUTIVATE 0.05 % LOTION <b>DL</b>	4	PA,QL (240 per 30 days)
CUTIVATE 0.05 % TOPICAL CREAM <b>DL</b>	4	PA,QL (240 per 30 days)
<i>dapsone 5% gel; dapsone 7.5% gel pump</i> <b>MO</b>	1	QL (90 per 30 days)
DERMA-SMOOTHIE/FS BODY OIL 0.01 % <b>MO</b>	3	QL (118.28 per 30 days)
DERMA-SMOOTHIE/FS SCALP OIL 0.01 % <b>MO</b>	3	QL (118.28 per 30 days)
DERMATOP 0.1% OINTMENT <b>MO</b>	3	QL (240 per 30 days)
DESONATE 0.05 % TOPICAL GEL <b>MO</b>	3	QL (240 per 30 days)
<i>desonide 0.05% cream</i> <b>MO</b>	1	QL (240 per 30 days)
<i>desonide 0.05% gel</i> <b>MO</b>	1	QL (240 per 30 days)
<i>desonide 0.05% lotion</i> <b>MO</b>	1	QL (240 per 30 days)
<i>desonide 0.05% ointment</i> <b>MO</b>	1	QL (240 per 30 days)
DESOWEN 0.05 % LOTION <b>MO</b>	1	PA,QL (240 per 30 days)
DESOWEN 0.05 % TOPICAL CREAM <b>MO</b>	3	QL (240 per 30 days)
<i>desoximetasone 0.05% cream</i> <b>MO</b>	1	QL (240 per 30 days)
<i>desoximetasone 0.05% gel</i> <b>MO</b>	1	QL (240 per 30 days)
<i>desoximetasone 0.05% ointment</i> <b>MO</b>	1	QL (240 per 30 days)
<i>desoximetasone 0.25% cream</i> <b>MO</b>	1	QL (120 per 30 days)
<i>desoximetasone 0.25% ointment</i> <b>MO</b>	1	QL (120 per 30 days)
<i>desoximetasone 0.25% spray</i> <b>MO</b>	1	QL (100 per 30 days)
<i>diclofenac sodium 3% gel</i> <b>MO</b>	1	PA
DIFFERIN 0.1 % LOTION <b>MO</b>	3	QL (59 per 30 days)
DIFFERIN 0.1 % TOPICAL CREAM <b>MO</b>	3	PA,QL (45 per 30 days)
DIFFERIN 0.3 % TOPICAL GEL <b>MO</b>	3	PA,QL (45 per 30 days)
DIFFERIN 0.3 % TOPICAL GEL WITH PUMP <b>MO</b>	3	QL (45 per 30 days)
<i>diflorasone 0.05% cream</i> <b>DL</b>	4	QL (120 per 30 days)
<i>diflorasone 0.05% ointment</i> <b>DL</b>	4	QL (120 per 30 days)
DIPROLENE 0.05 % TOPICAL OINTMENT <b>MO</b>	3	QL (100 per 30 days)
DOVONEX 0.005 % TOPICAL CREAM <b>DL</b>	4	PA,QL (120 per 30 days)
<i>doxepin 5% cream</i> <b>DL</b>	4	PA,QL (45 per 30 days)
DUOBRII 0.01 %-0.045 % LOTION <b>DL</b>	4	PA,QL (200 per 28 days)
EFUDEX 5 % TOPICAL CREAM <b>MO</b>	3	PA
ELIDEL 1 % TOPICAL CREAM <b>MO</b>	3	PA,QL (100 per 30 days)
ELIMITE 5 % TOPICAL CREAM <b>MO</b>	3	
ELOCON 0.1% CREAM <b>MO</b>	3	QL (180 per 30 days)
ELOCON 0.1% OINTMENT <b>MO</b>	3	QL (180 per 30 days)
ENSTILAR 0.005 %-0.064 % TOPICAL FOAM <b>MO</b>	3	QL (120 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
EPIDUO 0.1 %-2.5 % TOPICAL GEL WITH PUMP <b>MO</b>	3	QL (45 per 30 days)
EPIDUO FORTE 0.3 %-2.5 % TOPICAL GEL WITH PUMP <b>MO</b>	3	QL (60 per 30 days)
EPIFOAM 1 %-1 % TOPICAL <b>MO</b>	1	
<i>ery pads</i> 2 % topical swab <b>MO</b>	1	QL (60 per 30 days)
ERYGEL 2 % TOPICAL <b>MO</b>	1	QL (60 per 30 days)
<i>erythromycin</i> 2% gel <b>MO</b>	1	QL (60 per 30 days)
<i>erythromycin</i> 2% pledgets <b>MO</b>	1	QL (60 per 30 days)
<i>erythromycin</i> 2% solution <b>MO</b>	1	QL (120 per 30 days)
<i>erythromycin-benzoyl</i> gel <b>MO</b>	1	QL (46.6 per 30 days)
EUCRISA 2 % TOPICAL OINTMENT <b>MO</b>	3	PA,QL (100 per 30 days)
EURAX 10 % LOTION <b>MO</b>	3	PA,QL (454 per 30 days)
EURAX 10 % TOPICAL CREAM <b>MO</b>	3	PA
EVOCLIN 1 % TOPICAL FOAM <b>MO</b>	3	PA,QL (100 per 30 days)
FABIOR 0.1 % TOPICAL FOAM <b>DL</b>	4	PA,QL (100 per 30 days)
FINACEA 15 % TOPICAL FOAM <b>MO</b>	3	ST,QL (50 per 30 days)
FINACEA 15 % TOPICAL GEL <b>MO</b>	3	ST,QL (50 per 30 days)
<i>fluocinolone</i> 0.01% body oil <b>MO</b>	1	QL (118.28 per 30 days)
<i>fluocinolone</i> 0.01% cream; <i>fluocinolone</i> 0.025% cream <b>MO</b>	1	QL (120 per 30 days)
<i>fluocinolone</i> 0.01% solution <b>MO</b>	1	QL (180 per 30 days)
<i>fluocinolone</i> 0.025% ointment <b>MO</b>	1	QL (120 per 30 days)
<i>fluocinolone</i> 0.01% scalp oil <b>MO</b>	1	QL (118.28 per 30 days)
<i>fluocinonide</i> 0.05% cream <b>MO</b>	1	QL (120 per 30 days)
<i>fluocinonide</i> 0.05% gel <b>MO</b>	1	QL (120 per 30 days)
<i>fluocinonide</i> 0.05% ointment <b>MO</b>	1	QL (120 per 30 days)
<i>fluocinonide</i> 0.05% solution <b>MO</b>	1	QL (120 per 30 days)
<i>fluocinonide</i> 0.1% cream <b>MO</b>	1	QL (120 per 28 days)
<i>fluocinonide-e</i> 0.05 % topical cream <b>MO</b>	1	QL (120 per 30 days)
<i>fluocinonide-e</i> 0.05% cream <b>MO</b>	1	QL (120 per 30 days)
FLUOROPLEX 1 % TOPICAL CREAM <b>DL</b>	4	
<i>fluorouracil</i> 0.5% cream <b>DL</b>	4	QL (60 per 30 days)
<i>fluorouracil</i> 2% topical soln; <i>fluorouracil</i> 5% topical soln <b>MO</b>	1	
<i>fluorouracil</i> 5% cream <b>MO</b>	1	
<i>flurandrenolide</i> 0.05% cream <b>MO</b>	1	QL (240 per 30 days)
<i>flurandrenolide</i> 0.05% lotion <b>MO</b>	1	QL (240 per 30 days)
<i>flurandrenolide</i> 0.05% ointment <b>MO</b>	1	QL (240 per 30 days)
<i>fluticasone prop</i> 0.005% oint <b>MO</b>	1	QL (240 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>fluticasone prop 0.05% cream</i> <sup>MO</sup>	1	QL (240 per 30 days)
<i>fluticasone prop 0.05% lotion</i> <sup>MO</sup>	1	QL (240 per 30 days)
<i>halcinonide 0.1% cream</i> <sup>MO</sup>	1	QL (120 per 30 days)
<i>halobetasol prop 0.05% cream</i> <sup>MO</sup>	1	QL (100 per 30 days)
<i>halobetasol prop 0.05% foam</i> <sup>DL</sup>	4	PA,QL (100 per 30 days)
<i>halobetasol prop 0.05% ointmnt</i> <sup>MO</sup>	1	QL (100 per 30 days)
HALOG 0.1 % TOPICAL CREAM <sup>DL</sup>	4	QL (120 per 30 days)
HALOG 0.1 % TOPICAL OINTMENT <sup>DL</sup>	4	QL (120 per 30 days)
HALOG 0.1 % TOPICAL SOLUTION <sup>DL</sup>	4	QL (120 per 30 days)
<i>hydrocortisone 1% cream</i> <sup>MO</sup>	1	QL (28.4 per 30 days)
<i>hydrocortisone 1% cream; hydrocortisone 2.5% cream</i> <sup>MO</sup>	1	QL (240 per 30 days)
<i>hydrocortisone 1% ointment; hydrocortisone 2.5% ointment</i> <sup>MO</sup>	1	QL (240 per 30 days)
<i>hydrocortisone 10 mg, 20 mg, 5 mg tablet</i> <sup>MO</sup>	1	
<i>hydrocortisone 2.5% cream</i> <sup>MO</sup>	1	QL (60 per 30 days)
<i>hydrocortisone 2.5% lotion</i> <sup>MO</sup>	1	QL (236 per 30 days)
<i>hydrocort buty 0.1% lipid crm</i> <sup>MO</sup>	1	QL (240 per 30 days)
<i>hydrocortisone buty 0.1% cream</i> <sup>MO</sup>	1	QL (240 per 30 days)
<i>hydrocortisone butyr 0.1% lotn</i> <sup>MO</sup>	1	QL (236 per 30 days)
<i>hydrocortisone butyr 0.1% oint</i> <sup>MO</sup>	1	QL (180 per 30 days)
<i>hydrocortisone butyr 0.1% soln</i> <sup>MO</sup>	1	QL (240 per 30 days)
<i>hydrocortisone val 0.2% cream</i> <sup>MO</sup>	1	QL (240 per 30 days)
<i>hydrocortisone val 0.2% ointmt</i> <sup>MO</sup>	1	QL (240 per 30 days)
<i>hydrocortisone 1% absorbase</i> <sup>MO</sup>	1	QL (220 per 30 days)
<i>imiquimod 3.75% cream pump</i> <sup>DL</sup>	4	ST,QL (15 per 30 days)
<i>imiquimod 5% cream packet</i> <sup>MO</sup>	1	QL (12 per 30 days)
IMPOYZ 0.025 % TOPICAL CREAM <sup>MO</sup>	3	ST,QL (120 per 30 days)
<i>isotretinoin 10 mg, 20 mg, 30 mg capsule</i> <sup>MO</sup>	1	QL (60 per 30 days)
<i>isotretinoin 40 mg capsule</i> <sup>MO</sup>	1	QL (120 per 30 days)
<i>ivermectin 1% cream</i> <sup>MO</sup>	1	ST,QL (45 per 30 days)
LEXETTE 0.05 % TOPICAL FOAM <sup>DL</sup>	4	PA,QL (100 per 30 days)
<i>lindane 1% shampoo</i> <sup>MO</sup>	1	QL (60 per 30 days)
LOCOID 0.1 % LOTION <sup>MO</sup>	3	QL (236 per 30 days)
LOCOID 0.1% CREAM <sup>MO</sup>	3	QL (240 per 30 days)
LOCOID 0.1% SOLUTION <sup>MO</sup>	3	QL (240 per 30 days)
LOCOID LIPOCREAM 0.1 % TOPICAL <sup>MO</sup>	3	QL (240 per 30 days)
LUXIQ 0.12 % TOPICAL FOAM <sup>MO</sup>	3	ST,QL (200 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>mafenide acetate 50 gm powd pk</i> <b>DL</b>	4	
<i>malathion 0.5% lotion</i> <b>MO</b>	1	
<i>methoxsalen 10 mg softgel</i> <b>DL</b>	4	
MIRVASO 0.33 % TOPICAL GEL WITH PUMP; MIRVASO 0.33% GEL <b>MO</b>	3	ST,QL (30 per 30 days)
<i>mometasone furoate 0.1% cream</i> <b>MO</b>	1	QL (180 per 30 days)
<i>mometasone furoate 0.1% oint</i> <b>MO</b>	1	QL (180 per 30 days)
<i>mometasone furoate 0.1% soln</i> <b>MO</b>	1	QL (180 per 30 days)
<i>mupirocin 2% ointment</i> <b>MO</b>	1	
<i>mupirocin 2% cream</i> <b>MO</b>	1	
<i>myorisan 10 mg, 20 mg, 30 mg capsule</i> <b>MO</b>	1	QL (60 per 30 days)
<i>myorisan 40 mg capsule</i> <b>MO</b>	1	QL (120 per 30 days)
NATROBA 0.9 % TOPICAL SUSPENSION <b>MO</b>	3	QL (240 per 30 days)
NEO-SYNALAR 0.5 % (0.35 % BASE)-0.025 % TOPICAL CREAM <b>MO</b>	1	
<i>neuac 1.2 % (1 % base)-5 % topical gel</i> <b>MO</b>	1	QL (45 per 30 days)
<i>nolix 0.05 % lotion</i> <b>MO</b>	1	QL (240 per 30 days)
<i>nolix 0.05 % topical cream</i> <b>MO</b>	1	QL (240 per 30 days)
OLUX 0.05 % TOPICAL FOAM <b>MO</b>	3	PA,QL (100 per 28 days)
OLUX-E 0.05 % TOPICAL FOAM <b>MO</b>	3	PA,QL (100 per 30 days)
ONEXTON 1.2 % (1 % BASE)-3.75 % TOPICAL GEL <b>MO</b>	3	
ONEXTON 1.2 % (1 % BASE)-3.75 % TOPICAL GEL WITH PUMP <b>MO</b>	3	QL (50 per 30 days)
OTEZLA 30 MG TABLET <b>DL</b>	4	PA,QL (60 per 30 days)
OTEZLA STARTER 10 MG (4)-20 MG (4)-30 MG(19) TABLETS IN A DOSE PACK <b>DL</b>	4	PA,QL (27 per 30 days)
OTEZLA STARTER 10 MG (4)-20 MG (4)-30 MG(47) TABLETS IN A DOSE PACK <b>DL</b>	4	PA,QL (55 per 28 days)
OVIDE 0.5 % LOTION <b>MO</b>	3	PA
OXSORALEN ULTRA 10 MG LIQUID-FILLED,RAPID RELEASE CAPSULE <b>DL</b>	4	
PANDEL 0.1 % TOPICAL CREAM <b>DL</b>	4	QL (160 per 30 days)
<i>permethrin 5% cream</i> <b>MO</b>	1	
PICATO 0.015 % TOPICAL GEL <b>MO</b>	3	QL (3 per 30 days)
PICATO 0.05 % TOPICAL GEL <b>MO</b>	3	QL (2 per 30 days)
<i>pimecrolimus 1% cream</i> <b>MO</b>	1	QL (100 per 30 days)
<i>plixda 0.1% swab</i> <b>MO</b>	1	QL (30 per 30 days)
<i>podofilox 0.5% topical soln</i> <b>MO</b>	1	QL (7 per 30 days)
<i>prednicarbate 0.1% cream</i> <b>MO</b>	1	QL (240 per 30 days)
<i>prednicarbate 0.1% ointment</i> <b>MO</b>	1	QL (240 per 30 days)
<i>procto-med hc 2.5 % topical cream perineal applicator</i> <b>MO</b>	1	QL (60 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>procto-pak 1 % topical cream perineal applicator</i> <sup>MO</sup>	1	QL (28.4 per 30 days)
<i>proctosol hc 2.5 % topical cream perineal applicator</i> <sup>MO</sup>	1	QL (60 per 30 days)
<i>proctozone-hc 2.5 % topical cream perineal applicator</i> <sup>MO</sup>	1	QL (60 per 30 days)
PROTOPIC 0.03 %, 0.1 % TOPICAL OINTMENT <sup>DL</sup>	4	QL (200 per 30 days)
PRUDOXIN 5 % TOPICAL CREAM <sup>DL</sup>	4	PA,QL (45 per 30 days)
<i>psorcon 0.05 % topical cream</i> <sup>MO</sup>	1	QL (120 per 30 days)
QBREXZA 2.4 % TOWELETTE <sup>MO</sup>	3	PA,QL (30 per 30 days)
REGRANEX 0.01 % TOPICAL GEL <sup>DL</sup>	4	PA
RETIN-A 0.01 %, 0.025 % TOPICAL GEL <sup>MO</sup>	3	PA,QL (45 per 30 days)
RETIN-A 0.025 %, 0.05 %, 0.1 % TOPICAL CREAM <sup>MO</sup>	3	PA,QL (45 per 30 days)
RETIN-A MICRO 0.04 %, 0.1 % TOPICAL GEL <sup>DL</sup>	4	PA,QL (45 per 30 days)
RETIN-A MICRO PUMP 0.04 %, 0.06 %, 0.08 %, 0.1 % TOPICAL GEL <sup>DL</sup>	4	PA,QL (50 per 30 days)
RHOFADE 1 % TOPICAL CREAM <sup>MO</sup>	3	ST,QL (30 per 30 days)
SANTYL 250 UNIT/GRAM TOPICAL OINTMENT <sup>MO</sup>	2	QL (180 per 30 days)
<i>selenium sulfide 2.5% lotion</i> <sup>MO</sup>	1	QL (120 per 30 days)
SERNIVO 0.05 % TOPICAL SPRAY WITH PUMP <sup>DL</sup>	4	PA,QL (120 per 28 days)
SILVADENE 1 % TOPICAL CREAM <sup>MO</sup>	2	
<i>silver sulfadiazine 1% cream</i> <sup>MO</sup>	1	
SOLARAZE 3 % TOPICAL GEL <sup>MO</sup>	3	PA
SOOLANTRA 1 % TOPICAL CREAM <sup>MO</sup>	3	ST,QL (45 per 30 days)
SORIATANE 10 MG CAPSULE <sup>DL</sup>	4	PA,QL (90 per 30 days)
SORIATANE 25 MG CAPSULE <sup>DL</sup>	4	PA
SORILUX 0.005 % TOPICAL FOAM <sup>DL</sup>	4	ST,QL (120 per 28 days)
SSD 1 % TOPICAL CREAM <sup>MO</sup>	1	
SULFAMYLLON 50 GRAM TOPICAL PACKET <sup>MO</sup>	3	
SULFAMYLLON 85 MG/G TOPICAL CREAM <sup>MO</sup>	3	
SYNALAR 0.01 % TOPICAL SOLUTION <sup>MO</sup>	3	QL (180 per 30 days)
TACLONEX 0.005 %-0.064 % TOPICAL OINTMENT <sup>DL</sup>	4	PA,QL (60 per 30 days)
TACLONEX 0.005 %-0.064 % TOPICAL SUSPENSION <sup>MO</sup>	2	QL (420 per 30 days)
<i>tacrolimus 0.03% ointment; tacrolimus 0.1% ointment</i> <sup>MO</sup>	1	QL (200 per 30 days)
<i>tazarotene 0.1% cream</i> <sup>MO</sup>	1	PA,QL (120 per 30 days)
TAZORAC 0.05 %, 0.1 % TOPICAL CREAM <sup>DL</sup>	4	PA,QL (120 per 30 days)
TAZORAC 0.05 %, 0.1 % TOPICAL GEL <sup>MO</sup>	3	PA,QL (200 per 30 days)
TEMOVATE 0.05 % TOPICAL CREAM <sup>MO</sup>	3	PA,QL (120 per 30 days)
TEMOVATE 0.05 % TOPICAL OINTMENT <sup>MO</sup>	3	PA,QL (120 per 28 days)
TEXACORT 2.5 % TOPICAL SOLUTION <sup>MO</sup>	1	QL (240 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
TOLAK 4 % TOPICAL CREAM <b>MO</b>	3	PA
TOPICORT 0.05 % TOPICAL CREAM <b>MO</b>	1	QL (240 per 30 days)
TOPICORT 0.05 % TOPICAL GEL <b>MO</b>	1	QL (240 per 30 days)
TOPICORT 0.05 % TOPICAL OINTMENT <b>MO</b>	3	QL (240 per 30 days)
TOPICORT 0.25 % TOPICAL CREAM <b>MO</b>	1	QL (120 per 30 days)
TOPICORT 0.25 % TOPICAL OINTMENT <b>MO</b>	1	QL (120 per 30 days)
TOPICORT 0.25 % TOPICAL SPRAY <b>MO</b>	3	QL (100 per 30 days)
<i>tovet emollient 0.05 % topical foam</i> <b>MO</b>	1	QL (100 per 30 days)
TRETIN-X 0.075 % TOPICAL CREAM <b>MO</b>	1	PA
<i>tretinoin 0.01% gel; tretinoin 0.025% gel; tretinoin 0.05% gel</i> <b>MO</b>	1	PA,QL (45 per 30 days)
<i>tretinoin 0.025% cream; tretinoin 0.05% cream; tretinoin 0.1% cream</i> <b>MO</b>	1	PA,QL (45 per 30 days)
<i>tretinoin gel micro 0.04% pump; tretinoin gel micro 0.1% pump</i> <b>MO</b>	1	PA,QL (50 per 30 days)
<i>tretinoin gel micro 0.04% tube; tretinoin gel micro 0.1% tube</i> <b>MO</b>	1	PA,QL (45 per 30 days)
TRIDESILON 0.05 % TOPICAL CREAM <b>MO</b>	3	QL (240 per 30 days)
ULTRAVATE 0.05 % LOTION <b>DL</b>	4	QL (120 per 30 days)
ULTRAVATE 0.05% CREAM <b>DL</b>	4	QL (100 per 30 days)
ULTRAVATE 0.05% OINTMENT <b>DL</b>	4	QL (100 per 30 days)
UVADEX 20 MCG/ML INJECTION SOLUTION <b>MO</b>	3	B vs D
VANOS 0.1 % TOPICAL CREAM <b>MO</b>	3	QL (120 per 28 days)
VECTICAL 3 MCG/GRAM TOPICAL OINTMENT <b>DL</b>	4	ST,QL (800 per 28 days)
VELTIN 1.2 %-0.025 % TOPICAL GEL <b>MO</b>	3	PA,QL (60 per 30 days)
VERDESO 0.05 % TOPICAL FOAM <b>DL</b>	4	QL (200 per 30 days)
VEREGEN 15 % TOPICAL OINTMENT <b>DL</b>	4	QL (30 per 30 days)
XEPI 1 % TOPICAL CREAM <b>MO</b>	3	PA
<i>zenatane 10 mg, 20 mg, 30 mg capsule</i> <b>MO</b>	1	QL (60 per 30 days)
<i>zenatane 40 mg capsule</i> <b>MO</b>	1	QL (120 per 30 days)
ZIANA 1.2 %-0.025 % TOPICAL GEL <b>MO</b>	3	PA,QL (60 per 30 days)
ZILXI 1.5 % TOPICAL FOAM <b>MO</b>	3	PA,QL (30 per 30 days)
ZONALON 5 % TOPICAL CREAM <b>DL</b>	4	PA,QL (45 per 30 days)
ZYCLARA 2.5 %, 3.75 % TOPICAL CREAM IN A PUMP <b>DL</b>	4	ST,QL (15 per 30 days)
ZYCLARA 3.75 % TOPICAL CREAM PACKET <b>MO</b>	3	ST,QL (28 per 28 days)
<b>Electrolytes/Minerals/Metals/Vitamins</b>		
AMINOSYN 10 % INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D
AMINOSYN 7 % WITH ELECTROLYTES INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D
AMINOSYN 8.5 % INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D
AMINOSYN 8.5 % WITH ELECTROLYTES INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
AMINOSYN II 10 % INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D
AMINOSYN II 15 % INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D
AMINOSYN II 7 % INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D
AMINOSYN II 8.5 % INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D
AMINOSYN II 8.5 % WITH ELECTROLYTES INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D
AMINOSYN M 3.5 % INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D
AMINOSYN-HBC 7% INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D
AMINOSYN-PF 10 % INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D
AMINOSYN-PF 7 % (SULFITE-FREE) INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D
AMINOSYN-RF 5.2 % INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D
AURYXIA 210 MG IRON TABLET <b>MO</b>	3	PA,QL (360 per 30 days)
<i>bal-care dha 27 mg-1 mg-430 mg tablet-capsule, delayed release</i> <b>MO</b>	3	
<i>c-nate dha 28 mg iron-1 mg-200 mg capsule</i> <b>MO</b>	1	
<i>calcium acetate 667 mg gelcap</i> <b>MO</b>	1	
<i>calcium acetate 667 mg tablet</i> <b>MO</b>	1	
<i>calcium chloride 10% syringe</i> <b>MO</b>	1	
<i>calcium chloride 10% vial</i> <b>MO</b>	1	
<i>calcium gluc 1,000mg/50ml-nacl</i> <b>MO</b>	1	
<i>calcium gluc 1,000 mg/10 ml vl</i> <b>MO</b>	1	
CARBAGLU 200 MG DISPERSIBLE TABLET <b>DL</b>	4	PA
CARNITOR 100 MG/ML, 200 MG/ML INTRAVENOUS SOLUTION; CARNITOR 100 MG/ML, 200 MG/ML ORAL SOLUTION <b>MO</b>	3	
CARNITOR 330 MG TABLET <b>MO</b>	3	
CARNITOR (SUGAR-FREE) 100 MG/ML ORAL SOLUTION <b>MO</b>	3	
CHEMET 100 MG CAPSULE <b>DL</b>	4	
CITRANATAL B-CALM (FE GLUC) 20 MG IRON-1 MG-25 MG/25 MG TABLETS <b>MO</b>	3	
CLINIMIX 5 % IN 15 % DEXTROSE SULFITE FREE INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D
CLINIMIX 5 % IN 25 % DEXTROSE SULFITE-FREE INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D
CLINIMIX 2.75%-5% SOLUTION <b>MO</b>	3	B vs D
CLINIMIX 4.25%-20% SOLUTION <b>MO</b>	3	B vs D
CLINIMIX 4.25 % IN 25 % DEXTROSE (SULFITE-FREE) INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D
CLINIMIX 4.25 % IN 10 % DEXTROSE SULFITE FREE INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
CLINIMIX 4.25 % IN 5 % DEXTROSE SULFITE FREE INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D
CLINIMIX 5 % IN 20 % DEXTROSE (SULFITE-FREE) INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D
CLINIMIX E 2.75%-10% SOLUTION <b>MO</b>	3	B vs D
CLINIMIX E 2.75 % IN 5 % DEXTROSE SULFITE FREE INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D
CLINIMIX E 4.25 % IN 10 % DEXTROSE SULFITE FREE INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D
CLINIMIX E 4.25%-25% SOLUTION <b>MO</b>	3	B vs D
CLINIMIX E 4.25 % IN 5 % DEXTROSE SULFITE FREE INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D
CLINIMIX E 5 % IN 15 % DEXTROSE SULFITE FREE INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D
CLINIMIX E 5 % IN 20 % DEXTROSE SULFITE FREE INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D
CLINIMIX E 5%-25% SOLUTION <b>MO</b>	3	B vs D
CLINISOL SF 15 % INTRAVENOUS SOLUTION <b>MO</b>	1	B vs D
CLINOLIPID 20 % INTRAVENOUS EMULSION <b>MO</b>	3	B vs D
clovique 250 mg capsule <b>DL</b>	4	QL (240 per 30 days)
complete natal dha 29 mg-1 mg-250 mg-200 mg oral pack <b>MO</b>	1	
CUPRIMINE 250 MG CAPSULE <b>DL</b>	4	QL (600 per 30 days)
dextrose 10%-0.45% nacl iv sol <b>MO</b>	1	
dextrose 2.5%-0.45% nacl iv <b>MO</b>	1	
dextrose 5%-0.9% nacl iv soln <b>MO</b>	1	
dextrose 5%-0.45% nacl iv soln <b>MO</b>	1	
deferasirox 125 mg, 180 mg, 250 mg, 360 mg, 500 mg, 90 mg tablet; deferasirox 125 mg, 180 mg, 250 mg, 360 mg, 500 mg, 90 mg tb for susp <b>DL</b>	4	PA
deferasirox 180 mg, 360 mg, 90 mg granule <b>DL</b>	4	PA
deferoxamine 2 gram, 500 mg vial <b>MO</b>	1	B vs D
DEPEN TITRATABS 250 MG TABLET <b>DL</b>	4	
DESFERAL 2 GRAM, 500 MG SOLUTION FOR INJECTION <b>MO</b>	3	B vs D
dextrose 10%-0.2% nacl iv soln <b>MO</b>	1	
dextrose 10%-water iv solution <b>MO</b>	1	
dextrose 20%-water iv soln <b>MO</b>	1	
dextrose 25%-water syringe <b>MO</b>	1	
dextrose 30%-water iv soln <b>MO</b>	1	
dextrose 40%-water iv soln <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
dextrose 5%-water iv soln <b>MO</b>	1	
dextrose 5%-lr iv solution <b>MO</b>	1	
dextrose 5%-0.2% nacl iv soln <b>MO</b>	1	
dextrose 5%-0.3% nacl iv soln <b>MO</b>	1	
dextrose 50%-water syringe <b>MO</b>	1	
dextrose 50%-water vial <b>MO</b>	1	
dextrose 70%-water iv soln <b>MO</b>	1	
dothelle dha softgel <b>MO</b>	1	
DUET DHA WITH OMEGA-3 25 MG IRON-1 MG-400 MG ORAL PACK <b>MO</b>	3	
dextrose 5%-electrolyte 48 <b>MO</b>	1	
EXJADE 125 MG, 250 MG, 500 MG DISPERSIBLE TABLET <b>DL, LA</b>	4	PA
FERRIPROX 1,000 MG TABLET <b>DL</b>	4	PA,QL (300 per 30 days)
FERRIPROX 100 MG/ML ORAL SOLUTION <b>DL</b>	4	PA,QL (3600 per 30 days)
FERRIPROX 500 MG TABLET <b>DL</b>	4	PA,QL (720 per 30 days)
FERRIPROX (2 TIMES A DAY) 1,000 MG TABLET <b>DL</b>	4	PA,QL (300 per 30 days)
FOSRENOL 1,000 MG, 500 MG, 750 MG CHEWABLE TABLET <b>DL</b>	4	ST
FOSRENOL 1,000 MG, 750 MG ORAL POWDER PACKET <b>DL</b>	4	ST
FREAMINE HBC 6.9% IV SOLN <b>MO</b>	3	B vs D
FREAMINE III 10 % INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D
GLYCOFOS 1 MMOL/ML INTRAVENOUS SOLUTION <b>MO</b>	1	
hemenatal ob + dha combo pack <b>MO</b>	1	
HEPATAMINE 8% INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D
INTRALIPID 20 %, 30 % INTRAVENOUS EMULSION <b>MO</b>	3	B vs D
IONOSOL-B IN D5W INTRAVENOUS SOLUTION <b>MO</b>	3	
IONOSOL-MB IN D5W INTRAVENOUS SOLUTION <b>MO</b>	3	
ISOLYTE S PH 7.4 INTRAVENOUS SOLUTION <b>MO</b>	3	
ISOLYTE-P IN 5 % DEXTROSE INTRAVENOUS SOLUTION <b>MO</b>	3	
ISOLYTE-S INTRAVENOUS SOLUTION <b>MO</b>	3	
JADENU 180 MG, 360 MG, 90 MG TABLET <b>DL</b>	4	PA
JADENU SPRINKLE 180 MG, 360 MG, 90 MG ORAL GRANULES IN PACKET <b>DL</b>	4	PA
JYNARQUE 15 MG (AM)/15 MG (PM) TABLETS; JYNARQUE 30 MG (AM)/15 MG (PM) TABLETS; JYNARQUE 45 MG (AM)/15 MG (PM) TABLETS; JYNARQUE 60 MG (AM)/30 MG (PM) TABLETS; JYNARQUE 90 MG (AM)/30 MG (PM) TABLETS <b>DL</b>	4	PA,QL (56 per 28 days)
JYNARQUE 15 MG, 30 MG TABLET <b>DL</b>	4	PA,QL (60 per 30 days)
K-TAB 10 MEQ, 20 MEQ, 8 MEQ TABLET,EXTENDED RELEASE <b>MO</b>	3	
KABIVEN 3.31 %-9.8 %-3.9 % INTRAVENOUS EMULSION <b>MO</b>	3	B vs D

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>kionex (with sorbitol) 15 gram-19.3 gram/60 ml oral suspension</i> <sup>MO</sup>	1	
<i>klor-con 20 meq oral packet</i> <sup>MO</sup>	1	QL (240 per 30 days)
KLOR-CON 10 MEQ TABLET,EXTENDED RELEASE <sup>MO</sup>	1	
KLOR-CON 8 MEQ TABLET,EXTENDED RELEASE <sup>MO</sup>	1	
<i>klor-con m10 meq tablet,extended release</i> <sup>MO</sup>	1	
KLOR-CON M15 MEQ TABLET,EXTENDED RELEASE <sup>MO</sup>	1	
<i>klor-con m20 meq tablet,extended release</i> <sup>MO</sup>	1	
<i>klor-con sprinkle er 8 meq cap</i> <sup>MO</sup>	1	
KOSHER PRENATAL PLUS IRON 30 MG IRON-1 MG TABLET <sup>MO</sup>	3	
<i>lactated ringers injection</i> <sup>MO</sup>	1	
<i>lanthanum carb 1,000 mg, 500 mg, 750 mg tab chew; lanthanum carb 1,000 mg, 500 mg, 750 mg tb chw</i> <sup>DL</sup>	4	ST
<i>levocarnitine 330 mg tablet</i> <sup>MO</sup>	1	
<i>levocarnitine sf 1 g/10 ml sol</i> <sup>MO</sup>	1	
<i>levocarnitine 1 g/10 ml soln</i> <sup>MO</sup>	1	
LOKELMA 10 GRAM, 5 GRAM ORAL POWDER PACKET <sup>MO</sup>	2	QL (30 per 30 days)
<i>m-natal plus 27 mg iron-1 mg tablet</i> <sup>MO</sup>	1	
<i>magnesium sulfatate 50% syringe</i> <sup>MO</sup>	1	
<i>magnesium sulfatate 50% vial</i> <sup>MO</sup>	1	
<i>magnesium sulf 1 g/100 ml-d5w</i> <sup>MO</sup>	1	
<i>magnesium sulf 2 g/50 ml bag; magnesium sulf 4 g/100 ml bag; magnesium sulf 4 g/50 ml bag</i> <sup>MO</sup>	1	
<i>magnesium sulf 20 g/500 ml bag; magnesium sulf 40 g/1,000 ml</i> <sup>MO</sup>	1	
NATACHEW (FE BIS-GLYCINATE) 28 MG IRON-1 MG TABLET <sup>MO</sup>	3	
NEPHRAMINE 5.4 % INTRAVENOUS SOLUTION <sup>MO</sup>	3	B vs D
NORMOSOL-M IN 5 % DEXTROSE INTRAVENOUS SOLUTION <sup>MO</sup>	3	
NORMOSOL-R INTRAVENOUS SOLUTION <sup>MO</sup>	3	
NORMOSOL-R IN 5 % DEXTROSE INTRAVENOUS SOLUTION <sup>MO</sup>	3	
NORMOSOL-R PH 7.4 INTRAVENOUS SOLUTION <sup>MO</sup>	3	
NUTRILIPID 20 % INTRAVENOUS EMULSION <sup>MO</sup>	3	B vs D
O-CAL PRENATAL 15 MG IRON-1,000 MCG TABLET <sup>MO</sup>	3	
OB COMPLETE ONE 40 MG-10 MG-1 MG-300 MG CAPSULE <sup>MO</sup>	3	
OB COMPLETE PETITE 35 MG IRON-5 MG IRON-1 MG CAPSULE <sup>MO</sup>	3	
OB COMPLETE PREMIER 30 MG-20 MG-1 MG TABLET <sup>MO</sup>	3	
OMEGAVEN 10 % INTRAVENOUS EMULSION <sup>DL</sup>	4	B vs D
<i>penicillamine 250 mg capsule</i> <sup>DL</sup>	4	QL (600 per 30 days)
<i>penicillamine 250 mg tablet</i> <sup>DL</sup>	4	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
PERIKABIVEN 2.36 %-6.8 %-3.5 % INTRAVENOUS EMULSION <b>MO</b>	3	B vs D
PHOSLYRA 667 MG (169 MG CALCIUM)/5 ML ORAL SOLUTION <b>MO</b>	3	ST
PLASMA-LYTE 148 INTRAVENOUS SOLUTION <b>MO</b>	3	
PLASMA-LYTE A INTRAVENOUS SOLUTION <b>MO</b>	3	
plenamine 15 % intravenous solution <b>MO</b>	1	B vs D
prn ob+dha combo pack <b>MO</b>	1	
potassium acet 100 meq/50 ml <b>MO</b>	1	
d5w-1/2ns-kcl 10 meq/l, 20 meq/l, 30 meq/l, 40 meq/l iv sol; kcl 20 meq in d5w-0.45% nacl <b>MO</b>	1	
potassium cl 10% (20 meq/15ml) <b>MO</b>	1	QL (1125 per 30 days)
potassium cl 20 meq packet <b>MO</b>	1	QL (240 per 30 days)
potassium cl 20% (40 meq/15ml) <b>MO</b>	1	
potassium cl 40 meq/20 ml conc <b>MO</b>	1	
potassium cl er 10 meq, 20 meq tablet <b>MO</b>	1	
potassium cl er 10 meq, 20 meq, 8 meq tablet <b>MO</b>	1	
potassium cl er 10 meq, 8 meq capsule <b>MO</b>	1	
kcl 20 meq-ns 1,000 ml iv soln; kcl 40 meq-ns 1,000 ml iv soln <b>MO</b>	1	
d5w-kcl 20 meq/l, 30 meq/l, 40 meq/l iv solution; kcl 20 meq in d5w solution; kcl 40 meq in d5w solution <b>MO</b>	1	
kcl 20 meq in d5w-lact ringer; kcl 40 meq in d5w-lact ringer <b>MO</b>	1	
potassium cl 10 meq/100 ml, 10 meq/50 ml, 20 meq/100 ml, 20 meq/50 ml, 30 meq/100 ml, 40 meq/100 ml sol <b>MO</b>	1	
potassium cl 20 meq-0.45% nacl <b>MO</b>	1	
d5w-1/4ns-kcl 20 meq/l, 30 meq/l, 40 meq/l iv sol; kcl 20 meq in d5w-0.225% nacl <b>MO</b>	1	
kcl 20 meq in d5w-0.3% nacl <b>MO</b>	1	
kcl 20 meq in d5w-ns; kcl 40 meq in d5w-nacl 0.9% <b>MO</b>	1	
potassium citrate er 10 meq (1,080 mg), 15 meq, 5 meq (540 mg) tb; potassium citrate er 10 meq tb; potassium citrate er 5 meq tab <b>MO</b>	1	
pr natal 400 29 mg-1 mg-400 mg oral pack <b>MO</b>	1	
pr natal 400 ec 29 mg-1 mg-400 mg tablet-capsule, delayed release <b>MO</b>	1	
pr natal 430 29 mg iron-1 mg-430 mg oral pack <b>MO</b>	1	
pr natal 430 ec 29 mg-1 mg-430 mg tablet-capsule, delayed release <b>MO</b>	1	
PREMASOL 10 % INTRAVENOUS SOLUTION <b>MO</b>	1	B vs D
PREMASOL 6% IV SOLUTION <b>MO</b>	1	B vs D
PRENATA 29 MG IRON-1 MG CHEWABLE TABLET <b>MO</b>	3	
PRENATABS FA 29 MG-1 MG TABLET <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>prenatal plus (calcium carbonate) 27 mg iron-1 mg tablet</i> <sup>MO</sup>	1	
<i>prenatal plus dha 27 mg iron-1 mg-312 mg-250 mg oral pack</i> <sup>MO</sup>	3	
<i>prenatal vitamins plus low iron 27 mg iron-1 mg tablet</i> <sup>MO</sup>	1	
PRENATE ELITE 26 MG IRON-1 MG TABLET <sup>MO</sup>	3	
<i>preplus 27 mg iron-1 mg tablet</i> <sup>MO</sup>	1	
PROCALAMINE 3% INTRAVENOUS SOLUTION <sup>MO</sup>	3	B vs D
PROSOL 20 % INTRAVENOUS SOLUTION <sup>MO</sup>	3	B vs D
RENAGEL 800 MG TABLET <sup>DL</sup>	4	ST
REVELA 0.8 GRAM ORAL POWDER PACKET <sup>DL</sup>	4	PA,QL (540 per 30 days)
REVELA 2.4 GRAM ORAL POWDER PACKET <sup>DL</sup>	4	PA,QL (180 per 30 days)
REVELA 800 MG TABLET <sup>DL</sup>	4	PA,QL (540 per 30 days)
<i>ringer's iv solution</i> <sup>MO</sup>	1	
SAMSCA 15 MG, 30 MG TABLET <sup>DL</sup>	4	PA,QL (60 per 30 days)
<i>se-natal 19 chewable 29 mg iron-1 mg tablet</i> <sup>MO</sup>	1	
SELECT-OB 29 MG IRON-1 MG CHEWABLE TABLET <sup>MO</sup>	3	
SELECT-OB (FOLIC ACID) 29 MG IRON-1 MG CHEWABLE TABLET <sup>MO</sup>	3	
SELECT-OB + DHA 29 MG IRON-1 MG-250 MG ORAL PACK <sup>MO</sup>	3	
<i>sevelamer 0.8 gm powder packet</i> <sup>DL</sup>	4	QL (540 per 30 days)
<i>sevelamer 2.4 gm powder packet</i> <sup>DL</sup>	4	QL (180 per 30 days)
<i>sevelamer carbonate 800 mg tab</i> <sup>MO</sup>	1	QL (540 per 30 days)
<i>sevelamer hcl 400 mg, 800 mg tablet</i> <sup>MO</sup>	1	ST
SMOFLIPID 20 % INTRAVENOUS EMULSION <sup>MO</sup>	3	B vs D
<i>sodium acetate 40 meq/20 ml vl</i> <sup>MO</sup>	1	
<i>sodium bicarb 8.4% abboject</i> <sup>MO</sup>	1	
<i>sodium chloride 100 meq/40 ml</i> <sup>MO</sup>	1	
<i>saline 0.45% soln-excel con</i> <sup>MO</sup>	1	
<i>sodium chloride 0.45% soln</i> <sup>MO</sup>	1	
<i>sodium chloride 0.9% solution</i> <sup>MO</sup>	1	
<i>sodium chloride 0.9% vial</i> <sup>MO</sup>	1	
<i>sodium chloride 3% iv soln</i> <sup>MO</sup>	1	
<i>sodium chloride 5% iv soln</i> <sup>MO</sup>	1	
<i>sodium lactate 50 meq/10 ml vl</i> <sup>MO</sup>	1	
<i>sodium phosphate 3mm/ml vial</i> <sup>MO</sup>	1	
<i>sodium polystyrene sulfonate (sorbitol free) 15 gram/60 ml oral susp</i> <sup>MO</sup>	1	
<i>sodium polystyrene sulf powder</i> <sup>MO</sup>	1	
<i>sps 15 gm/60 ml suspension</i> <sup>MO</sup>	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>sps 30 gm/120 ml enema; sps 50 gm/200 ml enema</i> <b>MO</b>	1	
SPS (WITH SORBITOL) 15 GRAM-20 GRAM/60 ML ORAL SUSPENSION <b>MO</b>	1	
SPS (WITH SORBITOL) 30 GRAM-40 GRAM/120 ML ENEMA <b>MO</b>	1	
SYPRINE 250 MG CAPSULE <b>DL</b>	4	PA,QL (240 per 30 days)
THAM 36 MG/ML (0.3 M) INTRAVENOUS SOLUTION <b>MO</b>	3	
<i>tolvaptan 30 mg tablet</i> <b>DL</b>	4	PA,QL (60 per 30 days)
TPN ELECTROLYTES 35 MEQ-20 MEQ-5 MEQ/20 ML INTRAVENOUS SOLUTION <b>MO</b>	3	
TRAVASOL 10 % INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D
TRICARE 27 MG IRON-1 MG TABLET <b>MO</b>	1	
<i>trientine hcl 250 mg capsule</i> <b>DL</b>	4	QL (240 per 30 days)
<i>trinatal rx 1 60 mg iron-1 mg tablet</i> <b>MO</b>	1	
TRISTART DHA 31 MG IRON-1 MG-200 MG CAPSULE <b>MO</b>	3	
<i>triveen-duo dha 29 mg-1 mg-400 mg oral pack</i> <b>MO</b>	1	
TROPHAMINE 10 % INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D
TROPHAMINE 6% IV SOLUTION <b>MO</b>	3	B vs D
UROCIT-K 10 10 MEQ (1,080 MG) TABLET,EXTENDED RELEASE <b>MO</b>	3	
UROCIT-K 15 15 MEQ (1,620 MG) TABLET,EXTENDED RELEASE <b>MO</b>	3	
UROCIT-K 5 5 MEQ (540 MG) TABLET,EXTENDED RELEASE <b>MO</b>	3	
VAPRISOL IN 5 % DEXTROSE 20 MG/100 ML INTRAVENOUS SOLUTION <b>MO</b>	3	
VELPHORO 500 MG CHEWABLE TABLET <b>DL</b>	4	ST
VELTASSA 16.8 GRAM, 25.2 GRAM, 8.4 GRAM ORAL POWDER PACKET <b>DL</b>	4	PA,QL (30 per 30 days)
<i>virt-c dha 35 mg-1 mg-200 mg capsule</i> <b>MO</b>	1	
<i>virt-nate dha 28 mg iron-1 mg-200 mg capsule</i> <b>MO</b>	1	
VITAFOL FE PLUS 90 MG IRON-1 MG-200 MG CAPSULE <b>MO</b>	3	
VITAFOL GUMMIES 3.33 MG IRON-0.33 MG CHEWABLE TABLET <b>MO</b>	3	
VITAFOL NANO 18 MG IRON-1 MG TABLET <b>MO</b>	3	
VITAFOL ULTRA 29 MG IRON-1 MG-200 MG CAPSULE <b>MO</b>	3	
VITAFOL-OB 65 MG-1 MG TABLET <b>MO</b>	3	
VITAFOL-OB+DHA 65 MG-1 MG-250 MG ORAL PACK <b>MO</b>	3	
VITAFOL-ONE 29 MG IRON-1 MG-200 MG CAPSULE <b>MO</b>	3	
VITAMED MD ONE RX 30 MG IRON-1 MG-200 MG CAPSULE <b>MO</b>	3	
VP-PNV-DHA 28 MG IRON-1 MG-200 MG CAPSULE <b>MO</b>	3	
<b>GASTROINTESTINAL AGENTS</b>		
ACIPHEX 20 MG TABLET,DELAYED RELEASE <b>MO</b>	3	PA,QL (30 per 30 days)
ACIPHEX SPRINKLE 10 MG, 5 MG CAPSULE,DELAYED RELEASE <b>DL</b>	4	QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ACTIGALL 300 MG CAPSULE <b>MO</b>	3	PA
AEMCOLO 194 MG TABLET, DELAYED RELEASE <b>MO</b>	3	PA, QL (12 per 30 days)
alosetron hcl 0.5 mg, 1 mg tablet <b>DL</b>	4	PA, QL (60 per 30 days)
AMITIZA 24 MCG, 8 MCG CAPSULE <b>MO</b>	3	PA, QL (60 per 30 days)
lansoprazol-amoxicil-clarithro <b>MO</b>	1	ST
atropine 0.05 mg/ml, 0.1 mg/ml syringe; atropine 1 mg/10 ml syringe <b>MO</b>	1	
BENTYL 10 MG/ML INTRAMUSCULAR SOLUTION <b>MO</b>	3	
CARAFATE 1 GRAM TABLET <b>MO</b>	3	
CARAFATE 100 MG/ML ORAL SUSPENSION <b>MO</b>	3	
CHENODAL 250 MG TABLET <b>DL</b>	4	PA
cimetidine 200 mg, 300 mg, 400 mg, 800 mg tablet <b>MO</b>	1	
cimetidine 300 mg/5 ml soln <b>MO</b>	1	
CLENPIQ 10 MG-3.5 GRAM-12 GRAM/160 ML ORAL SOLUTION <b>MO</b>	3	ST
COLYTE WITH FLAVOR PACKETS <b>MO</b>	3	ST
constulose 10 gram/15 ml oral solution <b>MO</b>	1	
CUVPOSA 1 MG/5 ML (0.2 MG/ML) ORAL SOLUTION <b>MO</b>	3	
CYTOTEC 100 MCG, 200 MCG TABLET <b>DL</b>	4	
DEXILANT 30 MG, 60 MG CAPSULE, DELAYED RELEASE <b>MO</b>	3	QL (30 per 30 days)
dicyclomine 10 mg capsule <b>MO</b>	1	
dicyclomine 10 mg/5 ml, 10 mg/ml soln; dicyclomine 20 mg/2 ml vial <b>MO</b>	1	
dicyclomine 20 mg tablet <b>MO</b>	1	
diphenoxylat-atrop 2.5-0.025/5 <b>MO</b>	1	
diphenoxylate-atrop 2.5-0.025 <b>MO</b>	1	
ENDARI 5 GRAM ORAL POWDER PACKET <b>DL</b>	4	PA, QL (180 per 30 days)
enulose 10 gram/15 ml oral solution <b>MO</b>	1	
esomeprazole dr 10 mg, 20 mg, 40 mg packet <b>MO</b>	1	QL (30 per 30 days)
esomeprazole mag dr 20 mg, 40 mg cap <b>MO</b>	1	QL (30 per 30 days)
esomeprazole sodium 20 mg, 40 mg vial <b>MO</b>	1	
esomeprazole dr 49.3 mg cap <b>MO</b>	3	QL (30 per 30 days)
famotidine 20 mg, 40 mg tablet <b>MO</b>	1	
famotidine 40 mg/4 ml vial <b>MO</b>	1	
famotidine 40 mg/5 ml susp <b>MO</b>	1	
famotidine 20 mg/2 ml vial <b>MO</b>	1	
famotidine 20 mg piggyback <b>MO</b>	1	
GATTEX 30-VIAL 5 MG SUBCUTANEOUS KIT <b>DL, LA</b>	4	PA
GATTEX ONE-VIAL 5 MG SUBCUTANEOUS KIT <b>DL, LA</b>	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>gavilyte-c</i> 240 gram-22.72 gram-6.72 gram-5.84 gram oral solution <b>MO</b>	1	
<i>gavilyte-g</i> 236 gram-22.74 gram-6.74 gram-5.86 gram oral solution <b>MO</b>	1	
<i>gavilyte-n</i> 420 gram oral solution <b>MO</b>	1	
<i>generlac</i> 10 gram/15 ml oral solution <b>MO</b>	1	
GLYCATE 1.5 MG TABLET <b>MO</b>	1	
<i>glycopyrrolate</i> 1 mg, 1.5 mg, 2 mg tablet <b>MO</b>	1	
<i>glycopyrrolate</i> 4 mg/20 ml vial <b>MO</b>	1	
<i>glycopyrrolate</i> 0.2 mg/ml syring <b>MO</b>	1	
GOLYTELY 227.1 GRAM-21.5 GRAM-6.36 GRAM ORAL POWDER PACKET <b>MO</b>	3	ST
GOLYTELY 236 GRAM-22.74 GRAM-6.74 GRAM-5.86 GRAM ORAL SOLUTION <b>MO</b>	3	ST
<i>helidac</i> 250 mg-500 mg-262.4 mg oral pack <b>DL</b>	4	PA,QL (224 per 30 days)
KRISTALOSE 10 GRAM, 20 GRAM ORAL PACKET <b>MO</b>	1	
<i>lactulose</i> 10 gm packet <b>MO</b>	1	
<i>lactulose</i> 10 gm/15 ml solution; <i>lactulose</i> 20 gm/30 ml solution <b>MO</b>	1	
<i>lansoprazole dr</i> 15 mg capsule <b>MO</b>	1	QL (60 per 30 days)
<i>lansoprazole dr</i> 30 mg capsule <b>MO</b>	1	QL (30 per 30 days)
<i>lansoprazole odt</i> 15 mg, 30 mg tablet <b>MO</b>	1	QL (30 per 30 days)
LINZESS 145 MCG, 290 MCG, 72 MCG CAPSULE <b>MO</b>	2	QL (30 per 30 days)
LOMOTIL 2.5 MG-0.025 MG TABLET <b>MO</b>	3	
<i>loperamide</i> 2 mg capsule <b>MO</b>	1	
LOTRONEX 0.5 MG, 1 MG TABLET <b>DL</b>	4	PA,QL (60 per 30 days)
<i>methscopolamine brom</i> 2.5 mg, 5 mg tab; <i>methscopolamine brom</i> 2.5 mg, 5 mg tb <b>MO</b>	1	
<i>misoprostol</i> 100 mcg, 200 mcg tablet <b>MO</b>	1	
MOTEGRITY 1 MG, 2 MG TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
MOTOFEN 1 MG-0.025 MG TABLET <b>MO</b>	3	
MOVANTIK 12.5 MG, 25 MG TABLET <b>MO</b>	2	QL (30 per 30 days)
MOVIPREP 100 GRAM-7.5 GRAM-2.691 GRAM ORAL POWDER PACKET <b>MO</b>	3	ST
MYALEPT 5 MG/ML (FINAL CONCENTRATION) SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA,QL (30 per 30 days)
MYTESI 125 MG TABLET,DELAYED RELEASE <b>DL</b>	4	PA,QL (60 per 30 days)
NEXIUM 20 MG, 40 MG CAPSULE,DELAYED RELEASE <b>MO</b>	3	PA,QL (30 per 30 days)
NEXIUM 40 MG INTRAVENOUS SOLUTION <b>MO</b>	3	PA
NEXIUM PACKET 10 MG, 2.5 MG, 20 MG, 40 MG, 5 MG GRANULES DELAYED RELEASE FOR SUSP <b>MO</b>	3	QL (30 per 30 days)
<i>nizatidine</i> 15 mg/ml solution <b>MO</b>	1	
<i>nizatidine</i> 150 mg, 300 mg capsule <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
NULYTELY LEMON-LIME 420 GRAM ORAL SOLUTION <b>MO</b>	3	ST
NULYTELY WITH FLAVOR PACKS 420 GRAM ORAL SOLUTION <b>MO</b>	3	ST
NUTRESTORE POWDER PACKET <b>DL</b>	4	PA
OCALIVA 10 MG, 5 MG TABLET <b>DL</b>	4	PA,QL (30 per 30 days)
OMECLAMOX-PAK 20 MG-500 MG-500 MG (40) ORAL PACK <b>MO</b>	3	ST
omeppi 20 mg-1,100 mg capsule; omeppi 40 mg-1,100 mg capsule <b>MO</b>	1	ST,QL (30 per 30 days)
omeprazole dr 10 mg, 20 mg, 40 mg capsule <b>MO</b>	1	QL (60 per 30 days)
omeprazole-bicarb 20-1,100 cap; omeprazole-bicarb 40-1,100 cap <b>MO</b>	1	ST,QL (30 per 30 days)
omeprazole-bicarb 20-1,680 pkt; omeprazole-bicarb 40-1,680 pkt <b>DL</b>	4	ST,QL (30 per 30 days)
opium tincture 10 mg/ml <b>MO</b>	3	QL (180 per 30 days)
OSMOPREP 1.5 GRAM (1.102-0.398) TABLET <b>MO</b>	3	ST
pantoprazole 40 mg suspension <b>MO</b>	1	QL (30 per 30 days)
pantoprazole sod dr 20 mg, 40 mg tab <b>MO</b>	1	QL (60 per 30 days)
pantoprazole sodium 40 mg vial <b>MO</b>	1	
peg 3350 electrolyte soln; peg-3350 and electrolytes soln <b>MO</b>	1	
peg 3350-electrolyte solution <b>MO</b>	1	
peg-prep 5 mg-210 gram oral kit <b>MO</b>	1	
pepcid 20 mg, 40 mg tablet <b>MO</b>	3	PA
PEPCID 40 MG/5 ML ORAL SUSP <b>MO</b>	3	PA
PLENVU 140 GRAM-9 GRAM-5.2 GRAM POWDER PACK <b>MO</b>	3	ST
PREPOPIK 10 MG-3.5 GRAM-12 GRAM ORAL POWDER PACKET <b>MO</b>	3	ST
PREVACID 15 MG CAPSULE,DELAYED RELEASE <b>MO</b>	3	PA,QL (60 per 30 days)
PREVACID 30 MG CAPSULE,DELAYED RELEASE <b>MO</b>	3	PA,QL (30 per 30 days)
PREVACID SOLUTAB 15 MG, 30 MG DELAYED RELEASE,DISINTEGRATING TABLET <b>MO</b>	3	QL (30 per 30 days)
PRILOSEC 10 MG, 2.5 MG ORAL SUSPENSION,DELAYED RELEASE <b>MO</b>	3	
propantheline 15 mg tablet <b>MO</b>	1	
PROTONIX 20 MG, 40 MG TABLET,DELAYED RELEASE <b>MO</b>	3	PA,QL (60 per 30 days)
PROTONIX 40 MG GRANULES DELAYED-RELEASE PACKET <b>MO</b>	3	QL (30 per 30 days)
PROTONIX 40 MG INTRAVENOUS SOLUTION <b>MO</b>	3	PA
PYLERA 140 MG-125 MG-125 MG CAPSULE <b>MO</b>	3	QL (120 per 30 days)
rabeprazole sod dr 20 mg tab <b>MO</b>	1	QL (30 per 30 days)
RELISTOR 12 MG/0.6 ML SUBCUTANEOUS SOLUTION <b>MO</b>	3	QL (36 per 30 days)
RELISTOR 12 MG/0.6 ML SUBCUTANEOUS SYRINGE <b>MO</b>	3	QL (36 per 28 days)
RELISTOR 150 MG TABLET <b>MO</b>	3	QL (90 per 30 days)
RELISTOR 8 MG/0.4 ML SUBCUTANEOUS SYRINGE <b>MO</b>	3	QL (12 per 30 days)
ROBINUL 1 MG TABLET <b>MO</b>	3	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ROBINUL FORTE 2 MG TABLET <b>MO</b>	3	PA
<i>sucralfate 1 gm tablet</i> <b>MO</b>	1	
<i>sucralfate 1 gm/10 ml susp</i> <b>MO</b>	1	
SUPREP BOWEL PREP KIT 17.5 GRAM-3.13 GRAM-1.6 GRAM ORAL SOLUTION <b>MO</b>	2	
SYMPROIC 0.2 MG TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
TALICIA 10 MG-250 MG-12.5 MG CAPSULE,IMMEDIATE - DELAY RELEASE <b>MO</b>	3	ST,QL (168 per 30 days)
<i>trilyte with flavor packets 420 gram oral solution</i> <b>MO</b>	1	
TRULANCE 3 MG TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
URSO 250 250 MG TABLET <b>MO</b>	3	PA
URSO FORTE 500 MG TABLET <b>DL</b>	4	PA
<i>ursodiol 250 mg, 500 mg tablet</i> <b>MO</b>	1	
<i>ursodiol 300 mg capsule</i> <b>MO</b>	1	
VIBERZI 100 MG, 75 MG TABLET <b>DL</b>	4	PA,QL (60 per 30 days)
XERMELO 250 MG TABLET <b>DL</b>	4	PA,QL (84 per 28 days)
XIFAXAN 200 MG TABLET <b>DL</b>	4	PA,QL (9 per 30 days)
XIFAXAN 550 MG TABLET <b>DL</b>	4	PA,QL (84 per 28 days)
ZEGERID 20 MG-1,680 MG ORAL PACKET; ZEGERID 40 MG-1,680 MG ORAL PACKET <b>DL</b>	4	ST,QL (30 per 30 days)
ZEGERID 20 MG-1.1 GRAM CAPSULE; ZEGERID 40 MG-1.1 GRAM CAPSULE <b>DL</b>	4	ST,QL (30 per 30 days)
ZELNORM 6 MG TABLET <b>MO</b>	3	PA,QL (60 per 30 days)
ZINPLAVA 25 MG/ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA
<b>GENETIC/ENZYME/PROTEIN DISORDER: REPLACEMENT, MODIFIERS, TREATMENT</b>		
ADAGEN 250 UNIT/ML VIAL <b>DL</b>	4	
ALDURAZYME 2.9 MG/5 ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA
ARALAST NP 1,000 MG, 500 MG INTRAVENOUS SOLUTION <b>DL, LA</b>	4	PA
BUPHENYL 0.94 GRAM/GRAM ORAL POWDER <b>DL</b>	4	
BUPHENYL 500 MG TABLET <b>DL</b>	4	
CERDELGA 84 MG CAPSULE <b>DL</b>	4	PA
CEREZYME 400 UNIT INTRAVENOUS SOLUTION <b>DL</b>	4	PA
CHOLBAM 250 MG, 50 MG CAPSULE <b>DL</b>	4	PA,QL (120 per 30 days)
CREON 12,000-38,000-60,000 UNIT CAPSULE,DELAYED RELEASE; CREON 24,000-76,000-120,000 UNIT CAPSULE,DELAYED RELEASE; CREON 3,000 UNIT-9,500 UNIT-15,000 UNIT CAPSULE,DELAYED RELEASE; CREON 36,000 UNIT-114,000 UNIT-180,000 UNIT CAPSULE,DELAYED RELEASE; CREON 6,000-19,000-30,000 UNIT CAPSULE,DELAYED RELEASE <b>MO</b>	2	
CRYSVITA 10 MG/ML, 20 MG/ML SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA,QL (2 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
CRYSVITA 30 MG/ML SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA,QL (6 per 28 days)
CYSTADANE 1 GRAM/1.7 ML ORAL POWDER <b>DL</b>	4	
CYSTAGON 150 MG, 50 MG CAPSULE <b>MO</b>	3	
ELAPRASE 6 MG/3 ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA
ELELYSO 200 UNIT INTRAVENOUS SOLUTION <b>DL</b>	4	PA
FABRAZYME 35 MG, 5 MG INTRAVENOUS SOLUTION <b>DL</b>	4	PA
GALAFOLD 123 MG CAPSULE <b>DL</b>	4	PA,QL (14 per 28 days)
GLASSIA 1 GRAM/50 ML (2 %) INTRAVENOUS SOLUTION <b>DL, LA</b>	4	PA
KANUMA 2 MG/ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA
KEVEYIS 50 MG TABLET <b>DL</b>	4	PA,QL (120 per 30 days)
KUVAN 100 MG SOLUBLE TABLET <b>DL</b>	4	PA
KUVAN 100 MG, 500 MG ORAL POWDER PACKET <b>DL</b>	4	PA
LUMIZYME 50 MG INTRAVENOUS SOLUTION <b>DL</b>	4	PA
MEPSEVII 2 MG/ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA
<i>miglustat 100 mg capsule</i> <b>DL</b>	4	PA,QL (90 per 30 days)
NAGLAZYME 5 MG/5 ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA
<i>nitisinone 10 mg, 2 mg, 5 mg capsule</i> <b>DL</b>	4	
NITYR 10 MG, 2 MG, 5 MG TABLET <b>DL</b>	4	
ORFADIN 10 MG, 2 MG, 20 MG, 5 MG CAPSULE <b>DL</b>	4	
ORFADIN 4 MG/ML ORAL SUSPENSION <b>DL</b>	4	
PALYNZIQ 10 MG/0.5 ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA,QL (15 per 30 days)
PALYNZIQ 2.5 MG/0.5 ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA,QL (4 per 28 days)
PALYNZIQ 20 MG/ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA,QL (30 per 30 days)
PANCREAZE 10,500 UNIT-35,500 UNIT-61,500 UNIT CAPSULE,DELAYED RELEASE; PANCREAZE 16,800 UNIT-56,800 UNIT-98,400 UNIT CAPSULE,DELAYED RELEASE; PANCREAZE 2,600 UNIT-6,200 UNIT-10,850 UNIT CAPSULE,DELAYED RELEASE; PANCREAZE 21,000 UNIT-54,700 UNIT-83,900 UNIT CAPSULE,DELAYED RELEASE; PANCREAZE 4,200 UNIT-14,200 UNIT-24,600 UNIT CAPSULE,DELAYED RELEASE <b>DL</b>	4	ST
PERTZYE 16,000 UNIT-57,500 UNIT-60,500 UNIT CAPSULE,DELAYED RELEASE; PERTZYE 24,000-86,250-90,750 UNIT CAPSULE,DELAYED RELEASE; PERTZYE 4,000 UNIT-14,375 UNIT-15,125 UNIT CAPSULE,DELAYED RELEASE; PERTZYE 8,000 UNIT-28,750 UNIT-30,250 UNIT CAPSULE,DELAYED RELEASE <b>DL</b>	4	ST
PROCYSBI 25 MG CAPSULE,DELAYED RELEASE SPRINKLE <b>DL</b>	4	PA,QL (120 per 30 days)
PROCYSBI 300 MG ORAL DR GRANULES IN PACKET <b>DL</b>	4	PA,QL (210 per 30 days)
PROCYSBI 75 MG CAPSULE,DELAYED RELEASE SPRINKLE <b>DL</b>	4	PA,QL (780 per 30 days)
PROCYSBI 75 MG ORAL DR GRANULES IN PACKET <b>DL</b>	4	PA,QL (780 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
PROLASTIN-C 1,000 MG (+-)/20 ML INTRAVENOUS SOLUTION; PROLASTIN-C 1,000 MG, 1,000 MG (+-)/20 ML INTRAVENOUS POWDER FOR SOLUTION <b>DL, LA</b>	4	PA
RAVICTI 1.1 GRAM/ML ORAL LIQUID <b>DL</b>	4	PA,QL (525 per 30 days)
REVOVI 2.4 MG/1.5 ML (1.6 MG/ML) INTRAMUSCULAR SOLUTION <b>DL</b>	4	
<i>sodium phenylbutyrate 500mg tb</i> <b>DL</b>	4	
<i>sodium phenylbutyrate powder</i> <b>DL</b>	4	
STRENSIQ 18 MG/0.45 ML, 28 MG/0.7 ML, 40 MG/ML, 80 MG/0.8 ML SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA
SUCRAID 8,500 UNIT/ML ORAL SOLUTION <b>DL</b>	4	
TEGSEDI 284 MG/1.5 ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA,QL (6 per 28 days)
VIOKACE 10,440 UNIT-39,150 UNIT-39,150 UNIT TABLET; VIOKACE 20,880 UNIT-78,300 UNIT-78,300 UNIT TABLET <b>DL</b>	4	ST
VPRIV 400 UNIT INTRAVENOUS SOLUTION <b>DL</b>	4	PA
VYNDAMAX 61 MG CAPSULE <b>DL</b>	4	PA,QL (30 per 30 days)
VYNDAREL 20 MG CAPSULE <b>DL</b>	4	PA,QL (120 per 30 days)
VYONDYS-53 50 MG/ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA
XURIDEN 2 GRAM ORAL GRANULES IN PACKET <b>DL</b>	4	PA,QL (120 per 30 days)
ZAVESCA 100 MG CAPSULE <b>DL</b>	4	PA,QL (90 per 30 days)
ZEMAIRA 1,000 MG INTRAVENOUS SOLUTION <b>DL, LA</b>	4	PA
ZENPEP 10,000 UNIT-32,000 UNIT-42,000 UNIT CAPSULE, DELAYED RELEASE; ZENPEP 15,000 UNIT-47,000 UNIT-63,000 UNIT CAPSULE, DELAYED RELEASE; ZENPEP 20,000 UNIT-63,000 UNIT-84,000 UNIT CAPSULE, DELAYED RELEASE; ZENPEP 25,000 UNIT-79,000 UNIT-105,000 UNIT CAPSULE, DELAYED RELEASE; ZENPEP 3,000 UNIT-10,000 UNIT-14,000 UNIT CAPSULE, DELAYED RELEASE; ZENPEP 40,000 UNIT-126,000 UNIT-168,000 UNIT CAPSULE, DELAYED RELEASE; ZENPEP 5,000 UNIT-17,000 UNIT-24,000 UNIT CAPSULE, DELAYED RELEASE <b>MO</b>	3	
<b>Genitourinary Agents</b>		
<i>alfuzosin hcl er 10 mg tablet</i> <b>MO</b>	1	
AVODART 0.5 MG CAPSULE <b>MO</b>	3	PA,QL (30 per 30 days)
<i>bethanechol 10 mg, 25 mg, 5 mg, 50 mg tablet</i> <b>MO</b>	1	
CIALIS 2.5 MG, 5 MG TABLET <b>MO</b>	3	PA
<i>darifenacin er 15 mg, 7.5 mg tablet</i> <b>MO</b>	1	ST,QL (30 per 30 days)
DETROL 1 MG, 2 MG TABLET <b>MO</b>	3	PA,QL (60 per 30 days)
DETROL LA 2 MG, 4 MG CAPSULE, EXTENDED RELEASE <b>MO</b>	3	PA,QL (30 per 30 days)
DITROPAN XL 10 MG, 5 MG TABLET, EXTENDED RELEASE <b>MO</b>	3	PA,QL (60 per 30 days)
<i>dutasteride 0.5 mg capsule</i> <b>MO</b>	1	QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>dutasteride-tamsulosin 0.5-0.4</i> <b>MO</b>	1	QL (30 per 30 days)
ELMIRON 100 MG CAPSULE <b>DL</b>	4	QL (90 per 30 days)
ENABLEX 15 MG, 7.5 MG TABLET <b>MO</b>	3	ST,QL (30 per 30 days)
<i>finasteride 5 mg tablet</i> <b>MO</b>	1	QL (30 per 30 days)
<i>flavoxate hcl 100 mg tablet</i> <b>MO</b>	1	
FLOMAX 0.4 MG CAPSULE <b>MO</b>	3	
GELNIQUE 10 % (100 MG/GRAM), 100 MG/GRAM (10 %) TRANSDERMAL GEL PACKET; GELNIQUE 10% GEL PUMP <b>MO</b>	3	ST,QL (30 per 30 days)
JALYN 0.5 MG-0.4 MG CAPSULE, EXTENDED RELEASE <b>MO</b>	3	PA,QL (30 per 30 days)
MYRBETRIQ 25 MG, 50 MG TABLET,EXTENDED RELEASE <b>MO</b>	2	QL (30 per 30 days)
<i>oxybutynin 5 mg tablet</i> <b>MO</b>	1	
<i>oxybutynin 5 mg/5 ml syrup</i> <b>MO</b>	1	
<i>oxybutynin cl er 10 mg, 15 mg, 5 mg tablet</i> <b>MO</b>	1	QL (60 per 30 days)
OXYTROL 3.9 MG/24 HR TRANSDERMAL PATCH <b>MO</b>	3	ST,QL (8 per 28 days)
PROSCAR 5 MG TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
RAPAFLO 4 MG, 8 MG CAPSULE <b>MO</b>	3	PA,QL (30 per 30 days)
<i>silodosin 4 mg, 8 mg capsule</i> <b>MO</b>	1	QL (30 per 30 days)
<i>solifenacin 10 mg, 5 mg tablet</i> <b>MO</b>	1	QL (30 per 30 days)
<i>tadalafil 2.5 mg, 5 mg tablet</i> <b>MO</b>	1	PA
<i>tamsulosin hcl 0.4 mg capsule</i> <b>MO</b>	1	
THIOLA 100 MG TABLET <b>DL</b>	4	
THIOLA EC 100 MG, 300 MG TABLET,DELAYED RELEASE <b>DL</b>	4	
<i>tolterodine tart er 2 mg, 4 mg cap</i> <b>MO</b>	1	QL (30 per 30 days)
<i>tolterodine tartrate 1 mg, 2 mg tab</i> <b>MO</b>	1	QL (60 per 30 days)
TOVIAZ 4 MG, 8 MG TABLET,EXTENDED RELEASE <b>MO</b>	2	QL (30 per 30 days)
<i>tropium chloride 20 mg tablet</i> <b>MO</b>	1	
<i>tropium chloride er 60 mg cap</i> <b>MO</b>	1	QL (30 per 30 days)
URECHOLINE 10 MG, 25 MG, 5 MG, 50 MG TABLET <b>MO</b>	1	PA
UROXATRAL 10 MG TABLET,EXTENDED RELEASE <b>MO</b>	3	
VESICARE 10 MG, 5 MG TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
<b>Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal)</b>		
<i>a-hydrocort 100 mg solution for injection</i> <b>MO</b>	1	
ACTHAR 80 UNIT/ML INJECTION GEL <b>DL, LA</b>	4	PA,QL (30 per 30 days)
ARISTOSPAN INTRA-ARTICULAR 20 MG/ML SUSPENSION FOR INJECTION <b>MO</b>	3	
ARISTOSPAN INTRALESIONAL 5 MG/ML SUSPENSION FOR INJECTION <b>MO</b>	3	
<i>betamethasone sp-ac 30 mg/5 ml</i> <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
CELESTONE SOLUSPAN 6 MG/ML SUSPENSION FOR INJECTION <sup>MO</sup>	3	
cortisone 25 mg tablet <sup>MO</sup>	1	
decadron 0.5 mg, 0.75 mg, 4 mg, 6 mg tablet <sup>MO</sup>	1	
decadron 0.5 mg/5 ml elixir <sup>MO</sup>	1	
DEPO-MEDROL 20 MG/ML, 40 MG/ML, 80 MG/ML SUSPENSION FOR INJECTION <sup>MO</sup>	3	
dexabliss 1.5 mg (39 tabs) tablets in a dose pack <sup>MO</sup>	1	
dexamethasone 0.5 mg, 0.75 mg, 1 mg, 1.5 mg, 1.5 mg (21 tabs), 1.5 mg (35 tabs), 1.5 mg (51 tabs), 2 mg, 4 mg, 6 mg tablet; dexamethasone 10 day 1.5 mg tb; dexamethasone 13 day 1.5 mg tb; dexamethasone 6 day 1.5 mg tab <sup>MO</sup>	1	
dexamethasone 0.5 mg/5 ml elx <sup>MO</sup>	1	
dexamethasone 0.5 mg/5 ml liq <sup>MO</sup>	1	
dexamethasone intensol 1 mg/ml drops (concentrate) <sup>MO</sup>	1	
dexamethasone 10 mg/ml syringe <sup>MO</sup>	1	
dexamethasone 10 mg/ml vial <sup>MO</sup>	1	
dexamethasone 10 mg/ml, 4 mg/ml vial <sup>MO</sup>	1	
dexamethasone 4 mg/ml syringe <sup>MO</sup>	1	
DEXPAK 10 DAY 1.5 MG TABLET <sup>MO</sup>	1	
DEXPAK 13 DAY 1.5 MG TABLET <sup>MO</sup>	1	
DEXPAK 6 DAY 1.5 MG TABLET <sup>MO</sup>	1	
DXEVO 1.5 MG (39 TABS) TABLETS IN A DOSE PACK <sup>MO</sup>	1	
EMFLAZA 18 MG, 30 MG, 36 MG, 6 MG TABLET <sup>DL</sup>	4	PA
EMFLAZA 22.75 MG/ML ORAL SUSPENSION <sup>DL</sup>	4	PA
fludrocortisone 0.1 mg tablet <sup>MO</sup>	1	
HEMADY 20 MG TABLET <sup>MO</sup>	3	PA, QL (24 per 28 days)
hidex 1.5 mg (21 tabs) tablets in a dose pack <sup>MO</sup>	1	
KENALOG 0.147 MG/GRAM TOPICAL AEROSOL <sup>MO</sup>	3	QL (200 per 30 days)
KENALOG 10 MG/ML, 40 MG/ML SUSPENSION FOR INJECTION <sup>MO</sup>	3	
KENALOG-80 80 MG/ML SUSPENSION FOR INJECTION <sup>MO</sup>	3	
MEDROL 16 MG, 2 MG, 32 MG, 4 MG, 8 MG TABLET <sup>MO</sup>	3	B vs D
MEDROL (PAK) 4 MG TABLETS IN A DOSE PACK <sup>MO</sup>	3	
methylprednisolone 16 mg, 32 mg, 4 mg, 8 mg tab; methylprednisolone 16 mg, 32 mg, 4 mg, 8 mg tablet <sup>MO</sup>	1	B vs D
methylprednisolone 4 mg dosepk <sup>MO</sup>	1	
methylprednisolone 40 mg/ml, 80 mg/ml vl <sup>MO</sup>	1	
methylprednisolone ss 1 gm vl; methylprednisolone ss 1,000 mg, 125 mg, 40 mg, 500 mg; methylprednisolone ss 1,000 mg, 125 mg, 40 mg, 500 mg vl <sup>MO</sup>	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>micort hc 2.5% cream</i> <sup>MO</sup>	1	
MICORT-HC 2.5% CREAM <sup>MO</sup>	1	
<i>millipred 5 mg tablet</i> <sup>MO</sup>	1	B vs D
<i>millipred dp 5 mg (21 tabs), 5 mg (48 tabs) tablets in a dose pack</i> <sup>MO</sup>	1	
ORAPRED ODT 10 MG, 15 MG, 30 MG DISINTEGRATING TABLET <sup>MO</sup>	3	
PEDIAPRED 5 MG BASE/5 ML (6.7 MG/5 ML) ORAL SOLUTION <sup>MO</sup>	3	
<i>prednisolone 15 mg/5 ml soln</i> <sup>MO</sup>	1	
<i>prednisolone 10 mg/5 ml, 15 mg/5 ml (3 mg/ml), 20 mg/5 ml (4 mg/ml), 25 mg/5 ml (5 mg/ml), 5 mg base/5 ml (6.7 mg/5 ml) soln; prednisolone 15 mg/5 ml soln; prednisolone 20 mg/5 ml soln; prednisolone 5 mg/5 ml soln;</i> <i>prednisolone sod ph 25 mg/5 ml</i> <sup>MO</sup>	1	
<i>prednisolone odt 10 mg, 15 mg, 30 mg tablet</i> <sup>MO</sup>	1	
<i>prednisone 1 mg, 10 mg, 2.5 mg, 20 mg, 5 mg, 50 mg tablet</i> <sup>MO</sup>	1	B vs D
<i>prednisone 10 mg, 5 mg tab dose pack</i> <sup>MO</sup>	1	
<i>prednisone 5 mg/5 ml solution</i> <sup>MO</sup>	1	B vs D
<i>prednisone intensol 5 mg/ml oral concentrate</i> <sup>MO</sup>	1	B vs D
RAYOS 1 MG, 2 MG, 5 MG TABLET, DELAYED RELEASE <sup>DL</sup>	4	B vs D
SOLU-CORTEF 100 MG SOLUTION FOR INJECTION <sup>MO</sup>	3	
SOLU-CORTEF ACT-O-VIAL (PF) 1,000 MG/8 ML, 100 MG/2 ML, 250 MG/2 ML, 500 MG/4 ML SOLUTION FOR INJECTION <sup>MO</sup>	3	
SOLU-MEDROL 1,000 MG, 2 GRAM, 500 MG INTRAVENOUS SOLUTION <sup>MO</sup>	3	
SOLU-MEDROL (PF) 1,000 MG/8 ML, 125 MG/2 ML, 40 MG/ML, 500 MG/4 ML INTRAVENOUS SOLUTION; SOLU-MEDROL (PF) 1,000 MG/8 ML, 125 MG/2 ML, 40 MG/ML, 500 MG/4 ML SOLUTION FOR INJECTION <sup>MO</sup>	3	
<i>taperdex 1.5 mg (21 tabs), 1.5 mg (27 tabs), 1.5 mg (49 tabs) tablets in a dose pack</i> <sup>MO</sup>	1	
<i>triamcinolone 0.025% cream; triamcinolone 0.1% cream; triamcinolone 0.5% cream</i> <sup>MO</sup>	1	
<i>triamcinolone 0.025% lotion; triamcinolone 0.1% lotion</i> <sup>MO</sup>	1	
<i>triamcinolone 0.025% oint; triamcinolone 0.1% ointment; triamcinolone 0.5% ointment</i> <sup>MO</sup>	1	
<i>triamcinolone 0.05% ointment</i> <sup>DL</sup>	4	
<i>triamcinolone 0.147 mg/g spray</i> <sup>MO</sup>	1	QL (200 per 30 days)
<i>triamcinolone acet 40 mg/ml vl</i> <sup>MO</sup>	1	
<i>trianex 0.05 % topical ointment</i> <sup>DL</sup>	4	
<i>triderm 0.1 %, 0.5 % topical cream</i> <sup>MO</sup>	1	
VERIPRED 20 20 MG/5 ML (4 MG/ML) ORAL SOLUTION <sup>MO</sup>	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ZCORT 1.5 MG (25 TABS) TABLETS IN A DOSE PACK <b>MO</b>	1	
ZILRETTA 32 MG INTRA-ARTICULAR SUSPENSION,EXTENDED RELEASE <b>MO</b>	3	PA
<b>Hormonal Agents, Stimulant/Replacement/Modifying (Pituitary)</b>		
CHORIONIC GONAD 10,000 UNIT VL <b>DL</b>	4	PA
DDAVP 0.01% NASAL SPRAY <b>MO</b>	3	PA,QL (25 per 30 days)
DDAVP 0.1 MG TABLET <b>DL</b>	4	PA,QL (180 per 30 days)
DDAVP 0.1 MG/ML (REFRIGERATE), 4 MCG/ML INJECTION SOLUTION; DDAVP 0.1 MG/ML (REFRIGERATE), 4 MCG/ML NASAL SOLUTION <b>MO</b>	3	PA
DDAVP 0.2 MG TABLET <b>DL</b>	4	PA
<i>desmopressin 0.01% solution; desmopressin 10 mcg/0.1 ml spr</i> <b>MO</b>	1	QL (25 per 30 days)
<i>desmopressin ac 4 mcg/ml vial</i> <b>MO</b>	1	
<i>desmopressin acetate 0.1 mg tb</i> <b>MO</b>	1	QL (180 per 30 days)
<i>desmopressin acetate 0.2 mg tb</i> <b>MO</b>	1	
EGRIFTA 1 MG VIAL <b>DL</b>	4	PA,QL (60 per 30 days)
EGRIFTA SV 2 MG SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA,QL (30 per 30 days)
GENOTROPIN 12 MG/ML (36 UNIT/ML), 5 MG/ML (15 UNIT/ML) SUBCUTANEOUS CARTRIDGE <b>DL</b>	4	PA
GENOTROPIN MINIQUICK 0.2 MG/0.25 ML, 0.4 MG/0.25 ML, 0.6 MG/0.25 ML, 0.8 MG/0.25 ML, 1 MG/0.25 ML, 1.2 MG/0.25 ML, 1.4 MG/0.25 ML, 1.6 MG/0.25 ML, 1.8 MG/0.25 ML, 2 MG/0.25 ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA
HUMATROPE 12 MG (36 UNIT), 24 MG (72 UNIT), 6 MG (18 UNIT) INJECTION CARTRIDGE <b>DL</b>	4	PA
HUMATROPE 5 MG (15 UNIT) SOLUTION FOR INJECTION <b>DL</b>	4	PA
INCRELEX 10 MG/ML SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA
NOCDURNA (MEN) 55.3 MCG DISINTEGRATING TABLET,SUBLINGUAL <b>MO</b>	3	PA,QL (30 per 30 days)
NOCDURNA (WOMEN) 27.7 MCG DISINTEGRATING TABLET,SUBLINGUAL <b>MO</b>	3	PA,QL (30 per 30 days)
NORDITROPIN FLEXPRO 10 MG/1.5 ML (6.7 MG/ML), 15 MG/1.5 ML (10 MG/ML), 30 MG/3 ML (10 MG/ML), 5 MG/1.5 ML (3.3 MG/ML) SUBCUTANEOUS PEN INJECTOR <b>DL</b>	4	PA
NOVAREL 10,000 UNIT, 5,000 UNIT INTRAMUSCULAR SOLUTION <b>MO</b>	3	PA
NUTROPIN AQ NUSPIN 10 MG/2 ML (5 MG/ML), 20 MG/2 ML (10 MG/ML), 5 MG/2 ML (2.5 MG/ML) SUBCUTANEOUS PEN INJECTOR <b>DL</b>	4	PA
OMNITROPE 10 MG/1.5 ML (6.7 MG/ML), 5 MG/1.5 ML (3.3 MG/ML) SUBCUTANEOUS CARTRIDGE <b>DL</b>	4	PA
OMNITROPE 5.8 MG SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA
PREGNYL 10,000 UNIT INTRAMUSCULAR SOLUTION <b>MO</b>	3	PA
SAIZEN 5 MG SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA,QL (28 per 28 days)
SAIZEN 8.8 MG SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
SAIZEN SAIZENPREP 8.8 MG/1.51 ML (FINAL CONC.) SUBCUTANEOUS CARTRIDGE <b>DL</b>	4	PA
SEROSTIM 4 MG, 5 MG, 6 MG SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA,QL (28 per 28 days)
STIMATE 1.5 MG/ML NASAL SPRAY <b>DL</b>	4	
ZOMACTON 10 MG SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA
ZOMACTON 5 MG SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA,QL (28 per 28 days)
ZORBTIVE 8.8 MG SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA
<b>Hormonal Agents, Stimulant/Replacement/Modifying (Prostaglandins)</b>		
<i>carboprost 250 mcg/ml vial</i> <b>MO</b>	1	
HEMABATE 250 MCG/ML INTRAMUSCULAR SOLUTION <b>MO</b>	3	
<b>Hormonal Agents, Stimulant/Replacement/Modifying (Sex Hormones/Modifiers)</b>		
ACTIVELLA 0.5-0.1 MG, 1-0.5 MG TABLET; ACTIVELLA 1 MG-0.5 MG TABLET <b>MO</b>	3	
<i>afirmelle 0.1 mg-20 mcg tablet</i> <b>MO</b>	1	
ALORA 0.025 MG/24 HR, 0.05 MG/24 HR, 0.075 MG/24 HR, 0.1 MG/24 HR TRANSDERMAL PATCH <b>MO</b>	3	QL (8 per 28 days)
<i>altavera (28) 0.15 mg-0.03 mg tablet</i> <b>MO</b>	1	
<i>alyacen 1/35 (28) 1 mg-35 mcg tablet</i> <b>MO</b>	1	
<i>alyacen 7/7/7 (28) 0.5 mg/0.75 mg/1 mg-35 mcg tablet</i> <b>MO</b>	1	
<i>amabelz 0.5 mg-0.1 mg tablet; amabelz 1 mg-0.5 mg tablet</i> <b>MO</b>	1	
<i>amethia 0.15 mg-30 mcg (84)/10 mcg(7) tablets,3 month dose pack</i> <b>MO</b>	1	QL (91 per 90 days)
<i>amethia lo 0.10 mg-20 mcg (84)/10 mcg(7) tablets,3 month dose pack</i> <b>MO</b>	1	QL (91 per 90 days)
<i>amethyst (28) 90 mcg-20 mcg tablet</i> <b>MO</b>	1	
ANADROL-50 50 MG TABLET <b>DL</b>	4	
ANDRODERM 2 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH <b>MO</b>	3	PA,QL (90 per 30 days)
ANDRODERM 4 MG/24 HR TRANSDERMAL 24 HOUR PATCH <b>MO</b>	3	PA,QL (30 per 30 days)
ANDROGEL 1 % (25 MG/2.5 GRAM) TRANSDERMAL GEL PACKET; ANDROGEL 1 % (25 MG/2.5GRAM), 1 % (50 MG/5 GRAM) TRANSDERMAL GEL PACKET <b>DL</b>	4	PA,QL (300 per 30 days)
ANDROGEL 1.62 % (20.25 MG/1.25 GRAM) TRANSDERMAL GEL PACKET <b>DL</b>	4	PA,QL (37.5 per 30 days)
ANDROGEL 1.62 % (40.5 MG/2.5 GRAM) TRANSDERMAL GEL PACKET <b>DL</b>	4	PA,QL (150 per 30 days)
ANDROGEL 20.25 MG/1.25 GRAM (1.62 %) TRANSDERMAL GEL PUMP <b>MO</b>	3	PA,QL (150 per 30 days)
ANDROID 10 MG CAPSULE <b>DL</b>	4	
ANGELIQ 0.25 MG-0.5 MG TABLET; ANGELIQ 0.5 MG-1 MG TABLET <b>MO</b>	3	
ANNOVERA 0.15 MG-0.013 MG/24 HR VAGINAL RING <b>MO</b>	3	QL (1 per 365 days)
<i>apri 0.15 mg-0.03 mg tablet</i> <b>MO</b>	1	
<i>aranelle (28) 0.5 mg/1 mg/0.5 mg-35 mcg tablet</i> <b>MO</b>	1	
<i>ashlyna 0.15 mg-30 mcg (84)/10 mcg(7) tablets,3 month dose pack</i> <b>MO</b>	1	QL (91 per 90 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>aubra</i> 0.1 mg-20 mcg tablet <b>MO</b>	1	
<i>aubra eq</i> 0.1 mg-20 mcg tablet <b>MO</b>	1	
<i>aurovela</i> 1.5/30 (21) 1.5 mg-30 mcg tablet <b>MO</b>	1	
<i>aurovela</i> 1/20 (21) 1 mg-20 mcg tablet <b>MO</b>	1	
<i>aurovela</i> 24 fe 1 mg-20 mcg (24)/75 mg (4) tablet <b>MO</b>	1	
<i>aurovela fe</i> 1-20 (28) 1 mg-20 mcg (21)/75 mg (7) tablet <b>MO</b>	1	
<i>aurovela fe</i> 1.5/30 (28) 1.5 mg-30 mcg (21)/75 mg (7) tablet <b>MO</b>	1	
AVEED 750 MG/3 ML (250MG/ML) INTRAMUSCULAR SOLUTION <b>DL</b>	4	PA,QL (3 per 70 days)
<i>aviane</i> 0.1 mg-20 mcg tablet <b>MO</b>	1	
AXIRON 30 MG/ACTUATION SOLN <b>MO</b>	3	PA,QL (180 per 30 days)
AYGESTIN 5 MG TABLET <b>MO</b>	1	
<i>ayuna</i> 0.15 mg-0.03 mg tablet <b>MO</b>	1	
<i>azurette</i> (28) 0.15 mg-0.02 mg (21)/0.01 mg (5) tablet <b>MO</b>	1	
BALCOLTRA 0.1 MG-0.02 MG(21)/36.5 MG(7) TABLET <b>MO</b>	3	
<i>balziva</i> (28) 0.4 mg-35 mcg tablet <b>MO</b>	1	
<i>bekyree</i> (28) 0.15 mg-0.02 mg (21)/0.01 mg (5) tablet <b>MO</b>	1	
BEYAZ (28) 3 MG-0.02 MG-0.451 MG (24)/0.451 MG (4) TABLET <b>MO</b>	3	
BIJUVA 1 MG-100 MG CAPSULE <b>MO</b>	3	QL (30 per 30 days)
<i>blisovi</i> 24 fe 1 mg-20 mcg (24)/75 mg (4) tablet <b>MO</b>	1	
<i>blisovi fe</i> 1.5/30 (28) 1.5 mg-30 mcg (21)/75 mg (7) tablet <b>MO</b>	1	
<i>blisovi fe</i> 1/20 (28) 1 mg-20 mcg (21)/75 mg (7) tablet <b>MO</b>	1	
<i>briellyn</i> 0.4 mg-35 mcg tablet <b>MO</b>	1	
<i>camila</i> 0.35 mg tablet <b>MO</b>	1	
<i>camrese</i> 0.15 mg-30 mcg (84)/10 mcg(7) tablets,3 month dose pack <b>MO</b>	3	QL (91 per 90 days)
<i>camrese lo</i> 0.10 mg-20 mcg (84)/10 mcg(7) tablets,3 month dose pack <b>MO</b>	1	QL (91 per 90 days)
<i>caziant</i> (28) 0.1 mg/0.125 mg/0.15 mg-25 mcg tablet <b>MO</b>	1	
<i>charlotte</i> 24 fe 1 mg-20 mcg (24)/75 mg (4) chewable tablet <b>MO</b>	1	
<i>chateal</i> (28) 0.15 mg-0.03 mg tablet <b>MO</b>	1	
<i>chateal eq</i> (28) 0.15 mg-0.03 mg tablet <b>MO</b>	1	
CLIMARA 0.025 MG/24 HR, 0.0375 MG/24 HR, 0.05 MG/24 HR, 0.06 MG/24 HR, 0.075 MG/24 HR, 0.1 MG/24 HR TRANSDERMAL PATCH <b>MO</b>	3	QL (4 per 28 days)
CLIMARA PRO 0.045 MG-0.015 MG/24 HR TRANSDERMAL PATCH <b>MO</b>	3	QL (4 per 28 days)
COMBIPATCH 0.05 MG-0.14 MG/24 HR TRANSDERMAL; COMBIPATCH 0.05 MG-0.25 MG/24 HR TRANSDERMAL <b>MO</b>	3	QL (8 per 28 days)
CRINONE 4 %, 8 % VAGINAL GEL <b>MO</b>	3	
<i>cryselle</i> (28) 0.3 mg-30 mcg tablet <b>MO</b>	1	
<i>cyclafem</i> 1/35 (28) 1 mg-35 mcg tablet <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>cyclafem 7/7/7 (28) 0.5 mg/0.75 mg/1 mg-35 mcg tablet</i> <sup>MO</sup>	1	
<i>cyred 0.15 mg-0.03 mg tablet</i> <sup>MO</sup>	1	
<i>cyred eq 0.15 mg-0.03 mg tablet</i> <sup>MO</sup>	1	
<i>danazol 100 mg, 200 mg, 50 mg capsule</i> <sup>MO</sup>	1	
<i>dasetta 1/35 (28) 1 mg-35 mcg tablet</i> <sup>MO</sup>	1	
<i>dasetta 7/7/7 (28) 0.5 mg(7)/0.75 mg(7)/1 mg(7)-35 mcg tablet</i> <sup>MO</sup>	1	
<i>daysee 0.15 mg-30 mcg (84)/10 mcg(7) tablets,3 month dose pack</i> <sup>MO</sup>	1	QL (91 per 90 days)
<i>deblitane 0.35 mg tablet</i> <sup>MO</sup>	1	
DELESTROGEN 10 MG/ML, 20 MG/ML, 40 MG/ML INTRAMUSCULAR OIL <sup>MO</sup>	3	
DEPO-ESTRADIOL 5 MG/ML INTRAMUSCULAR OIL <sup>MO</sup>	1	QL (5 per 30 days)
DEPO-PROVERA 150 MG/ML INTRAMUSCULAR SUSPENSION <sup>MO</sup>	3	QL (1 per 90 days)
DEPO-PROVERA 150 MG/ML INTRAMUSCULAR SYRINGE <sup>MO</sup>	3	QL (1 per 90 days)
DEPO-PROVERA 400 MG/ML INTRAMUSCULAR SUSPENSION <sup>MO</sup>	3	
DEPO-SUBQ PROVERA 104 104 MG/0.65 ML SUBCUTANEOUS SYRINGE <sup>MO</sup>	3	QL (0.65 per 90 days)
DEPO-TESTOSTERONE 100 MG/ML, 200 MG/ML INTRAMUSCULAR OIL <sup>MO</sup>	1	
<i>desogestr-eth estrad eth estra</i> <sup>MO</sup>	1	
<i>desogest-eth estra 0.15-0.03mg</i> <sup>MO</sup>	1	
DIVIGEL 0.25 MG/0.25 GRAM (0.1 %), 0.5 MG/0.5 GRAM (0.1 %), 0.75 MG/0.75 GRAM (0.1%), 1 MG/GRAM (0.1 %), 1.25 MG/1.25 GRAM (0.1 %) TRANSDERMAL GEL PACKET <sup>MO</sup>	3	
<i>dotti 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr transdermal patch</i> <sup>MO</sup>	1	QL (8 per 28 days)
<i>dros-ee-levomef 3-0.02-0.451; dros-ee-levomef 3-0.03-0.451</i> <sup>MO</sup>	1	
<i>drosiprone-ee 3-0.02 mg, 3-0.03 mg tab</i> <sup>MO</sup>	1	
DUAVEE 0.45 MG-20 MG TABLET <sup>MO</sup>	3	PA,QL (30 per 30 days)
ELESTRIN 0.87 GRAM/ACTUATION (0.06%) TRANSDERMAL GEL PUMP <sup>MO</sup>	3	QL (52 per 30 days)
<i>elinest 0.3 mg-30 mcg tablet</i> <sup>MO</sup>	1	
ELLA 30 MG TABLET <sup>MO</sup>	2	QL (1 per 30 days)
<i>eluryng 0.12 mg-0.015 mg/24 hr vaginal ring</i> <sup>MO</sup>	1	QL (1 per 28 days)
<i>emoquette 0.15 mg-0.03 mg tablet</i> <sup>MO</sup>	1	
ENDOMETRIN 100 MG VAGINAL INSERT <sup>DL</sup>	4	
<i>enpresse 50-30 (6)/75-40(5)/125-30(10) tablet</i> <sup>MO</sup>	1	
<i>enskyce 0.15 mg-0.03 mg tablet</i> <sup>MO</sup>	1	
<i>errin 0.35 mg tablet</i> <sup>MO</sup>	1	
<i>estarylla 0.25 mg-35 mcg tablet</i> <sup>MO</sup>	1	
ESTRACE 0.01% (0.1 MG/GRAM) VAGINAL CREAM <sup>MO</sup>	3	PA
ESTRACE 0.5 MG, 1 MG, 2 MG TABLET <sup>MO</sup>	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>estradiol 0.01% cream</i> <b>MO</b>	1	
<i>estradiol 0.025 mg patch(1/wk); estradiol 0.0375mg patch(1/wk); estradiol 0.05 mg patch (1/wk); estradiol 0.06 mg patch (1/wk); estradiol 0.075 mg patch(1/wk); estradiol 0.1 mg patch (1/wk)</i> <b>MO</b>	1	QL (4 per 28 days)
<i>estradiol 0.025 mg patch(2/wk); estradiol 0.0375mg patch(2/wk); estradiol 0.05 mg patch (2/wk); estradiol 0.075 mg patch(2/wk); estradiol 0.1 mg patch (2/wk)</i> <b>MO</b>	1	QL (8 per 28 days)
<i>estradiol 0.5 mg, 1 mg, 10 mcg, 2 mg tablet; estradiol 0.5 mg, 1 mg, 10 mcg, 2 mg vaginal insrt</i> <b>MO</b>	1	
<i>estradiol valerate 100 mg/5 ml; estradiol valerate 200 mg/5 ml</i> <b>MO</b>	1	
<i>estradiol-noreth 0.5-0.1 mg, 1-0.5 mg tab; estradiol-noreth 0.5-0.1 mg, 1-0.5 mg tb</i> <b>MO</b>	1	
<i>ESTRING 2 MG (7.5 MCG/24 HOUR) VAGINAL RING</i> <b>MO</b>	3	QL (1 per 90 days)
<i>ESTROGEL 1.25 GRAM/ACTUATION (0.06%) TRANSDERMAL GEL PUMP</i> <b>MO</b>	3	
<i>ESTROSTEP FE-28 1-20 (5)/1-30(7)/1MG-35MCG(9) TABLET</i> <b>MO</b>	3	
<i>ethynodiol-eth estra 1mg-35mcg; ethynodiol-eth estra 1mg-50mcg</i> <b>MO</b>	1	
<i>etonogestrel-ee vaginal ring</i> <b>MO</b>	1	QL (1 per 28 days)
<i>EVAMIST 1.53 MG/SPRAY (1.7 %) TRANSDERMAL SPRAY</i> <b>MO</b>	3	
<i>EVISTA 60 MG TABLET</i> <b>MO</b>	3	PA,QL (30 per 30 days)
<i>falmina (28) 0.1 mg-20 mcg tablet</i> <b>MO</b>	1	
<i>fayosim 0.15 mg-20 mcg/0.15 mg-25 mcg tablets,3 month dose pack</i> <b>MO</b>	1	QL (91 per 90 days)
<i>FEMHRT LOW DOSE 0.5 MG-2.5 MCG TABLET</i> <b>MO</b>	3	
<i>FEMRING 0.05 MG/24 HR, 0.1 MG/24 HR VAGINAL</i> <b>MO</b>	3	QL (1 per 90 days)
<i>femynor 0.25 mg-35 mcg tablet</i> <b>MO</b>	1	
<i>FORTESTA 10 MG/0.5 GRAM/ACTUATION TRANSDERMAL GEL PUMP</i> <b>MO</b>	3	PA,QL (120 per 30 days)
<i>fyavolv 0.5 mg-2.5 mcg tablet; fyavolv 1 mg-5 mcg tablet</i> <b>MO</b>	1	
<i>GENERESS FE 0.8 MG-25 MCG (24)/75 MG (4) CHEWABLE TABLET</i> <b>MO</b>	3	
<i>gianvi (28) 3 mg-0.02 mg tablet</i> <b>MO</b>	1	
<i>hailey 1.5 mg-30 mcg tablet</i> <b>MO</b>	1	
<i>hailey 24 fe 1 mg-20 mcg (24)/75 mg (4) tablet</i> <b>MO</b>	1	
<i>hailey fe 1.5/30 (28) 1.5 mg-30 mcg (21)/75 mg (7) tablet</i> <b>MO</b>	1	
<i>hailey fe 1/20 (28) 1 mg-20 mcg (21)/75 mg (7) tablet</i> <b>MO</b>	1	
<i>heather 0.35 mg tablet</i> <b>MO</b>	1	
<i>hydroxyprogest 250 mg/ml vial</i> <b>DL</b>	4	PA
<i>hydroxyprogest 1,250 mg/5 ml</i> <b>DL</b>	4	PA
<i>hydroxyprogesterone 1.25 g/5ml</i> <b>DL</b>	4	PA
<i>incassia 0.35 mg tablet</i> <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
introvale 0.15 mg-30 mcg (91) tablets,3 month dose pack <sup>MO</sup>	1	QL (91 per 90 days)
isibloom 0.15 mg-0.03 mg tablet <sup>MO</sup>	1	
jaimiess 0.15 mg-30 mcg (84)/10 mcg(7) tablets,3 month dose pack <sup>MO</sup>	1	QL (91 per 90 days)
jasmiel (28) 3 mg-0.02 mg tablet <sup>MO</sup>	1	
jencycla 0.35 mg tablet <sup>MO</sup>	1	
jevantique lo 0.5 mg-2.5 mcg <sup>MO</sup>	3	
jinteli 1 mg-5 mcg tablet <sup>MO</sup>	1	
jolessa 0.15 mg-30 mcg (91) tablets,3 month dose pack <sup>MO</sup>	1	QL (91 per 90 days)
jolivette tablet <sup>MO</sup>	1	
juleber 0.15 mg-0.03 mg tablet <sup>MO</sup>	1	
junel 1.5/30 (21) 1.5 mg-30 mcg tablet <sup>MO</sup>	1	
junel 1/20 (21) 1 mg-20 mcg tablet <sup>MO</sup>	1	
junel fe 1.5/30 (28) 1.5 mg-30 mcg (21)/75 mg (7) tablet <sup>MO</sup>	1	
junel fe 1/20 (28) 1 mg-20 mcg (21)/75 mg (7) tablet <sup>MO</sup>	1	
junel fe 24 1 mg-20 mcg (24)/75 mg (4) tablet <sup>MO</sup>	1	
kaitlib fe 0.8 mg-25 mcg (24)/75 mg (4) chewable tablet <sup>MO</sup>	1	
kalliga 0.15 mg-0.03 mg tablet <sup>MO</sup>	1	
kariva (28) 0.15 mg-0.02 mg (21)/0.01 mg (5) tablet <sup>MO</sup>	1	
kelnor 1-50 1 mg-50 mcg tablet <sup>MO</sup>	1	
kelnor 1/35 (28) 1 mg-35 mcg tablet <sup>MO</sup>	1	
kurvelo (28) 0.15 mg-0.03 mg tablet <sup>MO</sup>	1	
levono-e estrad 0.15-0.03-0.01; levonor-e estrad 0.1-0.02-0.01; levonorg 0.15mg-ee 20-25-30mcg <sup>MO</sup>	1	QL (91 per 90 days)
larin 1.5/30 (21) 1.5 mg-30 mcg tablet <sup>MO</sup>	1	
larin 1/20 (21) 1 mg-20 mcg tablet <sup>MO</sup>	1	
larin 24 fe 1 mg-20 mcg (24)/75 mg (4) tablet <sup>MO</sup>	1	
larin fe 1.5/30 (28) 1.5 mg-30 mcg (21)/75 mg (7) tablet <sup>MO</sup>	1	
larin fe 1/20 (28) 1 mg-20 mcg (21)/75 mg (7) tablet <sup>MO</sup>	1	
larissia 0.1 mg-20 mcg tablet <sup>MO</sup>	1	
LAYOLIS FE 0.8 MG-25 MCG (24)/75 MG (4) CHEWABLE TABLET <sup>MO</sup>	3	
leena 28 0.5 mg/1 mg/0.5 mg-35 mcg tablet <sup>MO</sup>	1	
lessina 0.1 mg-20 mcg tablet <sup>MO</sup>	1	
levonest (28) 50-30 (6)/75-40(5)/125-30(10) tablet <sup>MO</sup>	1	
levonor-eth estrad triphasic <sup>MO</sup>	1	
levonor-eth estra 0.09-0.02 mg; levonor-eth estrad 0.1-0.02 mg; levonor-eth estrad 0.15-0.03 <sup>MO</sup>	1	
levonor-eth estrad 0.15-0.03 <sup>MO</sup>	1	QL (91 per 90 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
levora-28 0.15 mg-0.03 mg tablet <b>MO</b>	1	
lillow (28) 0.15 mg-0.03 mg tablet <b>MO</b>	1	
LO LOESTRIN FE 1 MG-10 MCG (24)/10 MCG (2) TABLET <b>MO</b>	3	
lo-zumandimine (28) 3 mg-0.02 mg tablet <b>MO</b>	1	
LOESTRIN 1.5/30 (21) 1.5 MG-30 MCG TABLET <b>MO</b>	1	
LOESTRIN 1/20 (21) 1 MG-20 MCG TABLET <b>MO</b>	1	
LOESTRIN FE 1.5/30 (28-DAY) 1.5 MG-30 MCG (21)/75 MG (7) TABLET <b>MO</b>	1	
LOESTRIN FE 1/20 (28-DAY) 1 MG-20 MCG (21)/75 MG (7) TABLET <b>MO</b>	1	
lojaimiess 0.10 mg-20 mcg (84)/10 mcg(7) tablets,3 month dose pack <b>MO</b>	1	QL (91 per 90 days)
lopreeza 0.5 mg-0.1 mg tablet; lopreeza 1 mg-0.5 mg tablet <b>MO</b>	1	
loryna (28) 3 mg-0.02 mg tablet <b>MO</b>	1	
LOSEASONIQUE 0.10 MG-20 MCG (84)/10 MCG(7) TABLETS,3 MONTH DOSE PACK <b>MO</b>	3	QL (91 per 90 days)
low-ogestrel (28) 0.3 mg-30 mcg tablet <b>MO</b>	1	
lutera (28) 0.1 mg-20 mcg tablet <b>MO</b>	1	
lyza 0.35 mg tablet <b>MO</b>	1	
MAKENA 250 MG/ML, 250 MG/ML (1 ML) INTRAMUSCULAR OIL <b>DL</b>	4	PA
MAKENA (PF) 275 MG/1.1 ML SUBCUTANEOUS AUTO-INJECTOR <b>DL</b>	4	PA
marlissa (28) 0.15 mg-0.03 mg tablet <b>MO</b>	1	
medroxyprogesterone 10 mg, 2.5 mg, 5 mg tab <b>MO</b>	1	
medroxyprogesterone 150 mg/ml <b>MO</b>	1	QL (1 per 90 days)
MEGACE ES 625 MG/5 ML SUSP <b>MO</b>	3	
megestrol 20 mg, 40 mg tablet <b>MO</b>	1	
megestrol 625 mg/5 ml susp; megestrol acet 40 mg/ml susp; megestrol acet 400 mg/10 ml <b>MO</b>	1	
melodetta 24 fe 1 mg-20 mcg (24)/75 mg (4) chewable tablet <b>MO</b>	1	
MENEST 0.3 MG, 0.625 MG, 1.25 MG TABLET <b>MO</b>	1	
MENOSTAR 14 MCG/24 HR TRANSDERMAL PATCH <b>MO</b>	3	QL (8 per 28 days)
METHITEST 10 MG TABLET <b>DL</b>	4	
methyltestosterone 10 mg cap <b>DL</b>	4	
mibelas 24 fe 1 mg-20 mcg (24)/75 mg (4) chewable tablet <b>MO</b>	1	
microgestin 1.5/30 (21) 1.5 mg-30 mcg tablet <b>MO</b>	1	
microgestin 1/20 (21) 1 mg-20 mcg tablet <b>MO</b>	1	
MICROGESTIN 24 FE 1 MG-20 MCG <b>MO</b>	3	
microgestin fe 1.5/30 (28) 1.5 mg-30 mcg (21)/75 mg (7) tablet <b>MO</b>	1	
microgestin fe 1/20 (28) 1 mg-20 mcg (21)/75 mg (7) tablet <b>MO</b>	1	
mili 0.25 mg-35 mcg tablet <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>mimvey 1 mg-0.5 mg tablet</i> <sup>MO</sup>	1	
<i>mimvey lo 0.5-0.1 mg tablet</i> <sup>MO</sup>	1	
MINASTRIN 24 FE 1 MG-20 MCG (24)/75 MG (4) CHEWABLE TABLET <sup>MO</sup>	3	
MINIVELLE 0.025 MG/24 HR, 0.0375 MG/24 HR, 0.05 MG/24 HR, 0.075 MG/24 HR, 0.1 MG/24 HR TRANSDERMAL PATCH <sup>MO</sup>	3	QL (8 per 28 days)
MIRCETTE (28) 0.15 MG-0.02 MG (21)/0.01 MG (5) TABLET <sup>MO</sup>	1	
<i>mono-lynyah 0.25 mg-35 mcg tablet</i> <sup>MO</sup>	1	
<i>mononessa 28 tablet</i> <sup>MO</sup>	1	
<i>myzilra-28 tablet</i> <sup>MO</sup>	1	
NATAZIA 3 MG/2 MG-2 MG/2 MG-3 MG/1 MG TABLET <sup>MO</sup>	3	
NATESTO 5.5 MG/0.122 GRAM PER ACTUATION NASAL GEL PUMP <sup>MO</sup>	3	PA,QL (21.96 per 30 days)
<i>necon 0.5/35 (28) 0.5 mg-35 mcg tablet</i> <sup>MO</sup>	1	
<i>nikki (28) 3 mg-0.02 mg tablet</i> <sup>MO</sup>	1	
<i>nora-be 0.35 mg tablet</i> <sup>MO</sup>	1	
<i>noret-estr-fe 0.4-0.035(21)-75; norethin-estra-fe 0.8-0.025 mg</i> <sup>MO</sup>	1	
<i>norethindrone 0.35 mg tablet</i> <sup>MO</sup>	1	
<i>norethin-ee 1.5-0.03 mg(21) tb; norethin-eth estrad 1 mg-5 mcg; norethind-eth estrad 0.5-2.5; norethind-eth estrad 1-0.02 mg</i> <sup>MO</sup>	1	
<i>norethindrone 5 mg tablet</i> <sup>MO</sup>	1	
<i>noreth-ee-fe 1.5-0.03mg(21)-75; noreth-estrad-fe 1-0.02(21)-75; noreth-estrad-fe 1-0.02(24)-75</i> <sup>MO</sup>	1	
<i>noreth-estrad-fe 1-0.02(24)-75</i> <sup>MO</sup>	1	
<i>norg-ee 0.18-0.215-0.25/0.025; norg-ee 0.18-0.215-0.25/0.035; norg-ethin estra 0.25-0.035 mg</i> <sup>MO</sup>	1	
<i>norlyda 0.35 mg tablet</i> <sup>MO</sup>	1	
<i>nortrel 0.5/35 (28) 0.5 mg-35 mcg tablet</i> <sup>MO</sup>	1	
<i>nortrel 1/35 (21) 1 mg-35 mcg tablet</i> <sup>MO</sup>	1	
<i>nortrel 1/35 (28) 1 mg-35 mcg tablet</i> <sup>MO</sup>	1	
<i>nortrel 7/7/7 (28) 0.5 mg/0.75 mg/1 mg-35 mcg tablet</i> <sup>MO</sup>	1	
NUVARING 0.12 MG-0.015 MG/24 HR VAGINAL <sup>MO</sup>	3	QL (1 per 28 days)
<i>ocella 3 mg-0.03 mg tablet</i> <sup>MO</sup>	1	
<i>ogestrel tablet</i> <sup>MO</sup>	1	
<i>orsythia 0.1 mg-20 mcg tablet</i> <sup>MO</sup>	1	
ORTHO MICRONOR 0.35 MG TABLET <sup>MO</sup>	3	
ORTHO TRI-CYCLEN (28) 0.18 MG(7)/0.215 MG(7)/0.25 MG(7)-35 MCG TABLET <sup>MO</sup>	3	
ORTHO TRI-CYCLEN LO TABLET <sup>MO</sup>	3	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ORTHO-CYCLLEN 28 TABLET <b>MO</b>	3	
ORTHO-NOVUM 1/35 (28) 1 MG-35 MCG TABLET <b>MO</b>	3	
ORTHO-NOVUM 7/7/7 (28) 0.5 MG/0.75 MG/1 MG-35 MCG TABLET <b>MO</b>	3	
OSPHENA 60 MG TABLET <b>MO</b>	2	PA
oxandrolone 10 mg tablet <b>DL</b>	4	PA,QL (60 per 30 days)
oxandrolone 2.5 mg tablet <b>MO</b>	1	PA,QL (120 per 30 days)
philit 0.4 mg-35 mcg tablet <b>MO</b>	1	
pimtra (28) 0.15 mg-0.02 mg (21)/0.01 mg (5) tablet <b>MO</b>	1	
pirmella 0.5/0.75/1 mg-35 mcg tablet; pirmella 1 mg-35 mcg tablet <b>MO</b>	1	
portia 28 0.15 mg-0.03 mg tablet <b>MO</b>	1	
PREFEST 1 MG (15)/1 MG-0.09 MG (15) TABLET <b>MO</b>	1	
PREMARIN 0.3 MG, 0.45 MG, 0.625 MG, 0.9 MG, 1.25 MG TABLET <b>MO</b>	3	
PREMARIN 0.625 MG/GRAM VAGINAL CREAM <b>MO</b>	2	
PREMARIN 25 MG SOLUTION FOR INJECTION <b>MO</b>	3	
PREMPHASE 0.625 MG(14)/0.625 MG-5MG(14) TABLET <b>MO</b>	3	
PREMPRO 0.3 MG-1.5 MG TABLET; PREMPRO 0.45 MG-1.5 MG TABLET; PREMPRO 0.625 MG-2.5 MG TABLET; PREMPRO 0.625 MG-5 MG TABLET <b>MO</b>	3	
previfem 0.25 mg-35 mcg tablet <b>MO</b>	1	
progesterone 500 mg/10 ml vial <b>MO</b>	1	
progesterone 100 mg, 200 mg capsule <b>MO</b>	1	
PROMETRIUM 100 MG, 200 MG CAPSULE <b>DL</b>	4	
PROVERA 10 MG, 2.5 MG, 5 MG TABLET <b>MO</b>	3	
QUARTETTE 0.15 MG-20 MCG/0.15 MG-25 MCG TABLETS,3 MONTH DOSE PACK <b>MO</b>	3	QL (91 per 90 days)
quasense 0.15-0.03 mg tablet <b>MO</b>	1	QL (91 per 90 days)
rajani 28 tablet <b>MO</b>	1	
raloxifene hcl 60 mg tablet <b>MO</b>	1	QL (30 per 30 days)
reclipsen (28) 0.15 mg-0.03 mg tablet <b>MO</b>	1	
rivelsa 0.15 mg-20 mcg/0.15 mg-25 mcg tablets,3 month dose pack <b>MO</b>	1	QL (91 per 90 days)
SAFYRAL 3 MG-0.03 MG-0.451 MG (21)/0.451 MG (7) TABLET <b>MO</b>	3	
SEASONIQUE 0.15 MG-30 MCG (84)/10 MCG(7) TABLETS,3 MONTH DOSE PACK <b>MO</b>	3	QL (91 per 90 days)
setlakin 0.15 mg-30 mcg (91) tablets,3 month dose pack <b>MO</b>	1	QL (91 per 90 days)
sharobel 0.35 mg tablet <b>MO</b>	1	
simliya (28) 0.15 mg-0.02 mg (21)/0.01 mg (5) tablet <b>MO</b>	1	
simpesse 0.15 mg-30 mcg (84)/10 mcg(7) tablets,3 month dose pack <b>MO</b>	1	QL (91 per 90 days)
SLYND 4 MG (28) TABLET <b>MO</b>	3	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
sprintec (28) 0.25 mg-35 mcg tablet <b>MO</b>	1	
sronyx 0.1 mg-20 mcg tablet <b>MO</b>	1	
STRIANT 30 MG MUCOADHESIVE <b>DL</b>	4	PA
syeda 3 mg-0.03 mg tablet <b>MO</b>	1	
tarina 24 fe 1 mg-20 mcg (24)/75 mg (4) tablet <b>MO</b>	1	
tarina fe 1-20 eq (28) 1 mg-20 mcg (21)/75 mg (7) tablet <b>MO</b>	1	
tarina fe 1/20 (28) 1 mg-20 mcg (21)/75 mg (7) tablet <b>MO</b>	1	
TAYTULLA 1 MG-20 MCG (24)/75 MG (4) CAPSULE <b>MO</b>	3	
TESTIM 50 MG/5 GRAM (1 %) TRANSDERMAL GEL <b>MO</b>	3	PA,QL (300 per 30 days)
testosterone 1.62% (2.5 g) pkt; testosterone 1.62% gel pump <b>MO</b>	1	PA,QL (150 per 30 days)
testosterone 1.62%(1.25 g) pkt <b>MO</b>	1	PA,QL (37.5 per 30 days)
testosterone 10 mg gel pump <b>MO</b>	3	PA,QL (120 per 30 days)
testosterone 12.5 mg/1.25 gram; testosterone 25 mg/2.5 gm pkt; testosterone 50 mg/5 gram gel; testosterone 50 mg/5 gram pkt <b>MO</b>	3	PA,QL (300 per 30 days)
testosterone 30 mg/1.5 ml pump <b>MO</b>	3	PA,QL (180 per 30 days)
testosteron cyp 1,000 mg/10 ml; testosterone cyp 100 mg/ml, 200 mg/ml <b>MO</b>	1	
testosteron enan 1,000 mg/5 ml <b>MO</b>	1	QL (24 per 90 days)
TESTRED 10 MG CAPSULE <b>DL</b>	4	
tilia fe 1-20 (5)/1-30(7)/1mg-35mcg(9) tablet <b>MO</b>	1	
tri femynor (28) 0.18 mg(7)/0.215 mg(7)/0.25 mg(7)-35 mcg tablet <b>MO</b>	1	
tri-estarylla (28) 0.18 mg(7)/0.215 mg(7)/0.25 mg(7)-35 mcg tablet <b>MO</b>	1	
tri-legest fe 1-20 (5)/1-30(7)/1mg-35mcg(9) tablet <b>MO</b>	1	
tri-linyah (28) 0.18 mg(7)/0.215 mg(7)/0.25 mg(7)-35 mcg tablet <b>MO</b>	1	
tri-lo-estarylla 0.18 mg/0.215 mg/0.25 mg-25 mcg tablet <b>MO</b>	1	
tri-lo-marzia 0.18 mg/0.215 mg/0.25 mg-25 mcg tablet <b>MO</b>	1	
tri-lo-mili 0.18/0.215/0.25 mg-25 mcg tablet <b>MO</b>	1	
tri-lo-sprintec 0.18 mg/0.215 mg/0.25 mg-25 mcg tablet <b>MO</b>	1	
tri-mili (28) 0.18 mg(7)/0.215 mg(7)/0.25 mg(7)-35 mcg tablet <b>MO</b>	1	
TRI-NORINYL 28 TABLET <b>MO</b>	3	
tri-previfem (28) 0.18 mg(7)/0.215 mg(7)/0.25 mg(7)-35 mcg tablet <b>MO</b>	1	
tri-sprintec (28) 0.18 mg(7)/0.215 mg(7)/0.25 mg(7)-35 mcg tablet <b>MO</b>	1	
tri-vylibra (28) 0.18 mg(7)/0.215 mg(7)/0.25 mg(7)-35 mcg tablet <b>MO</b>	1	
tri-vylibra lo 0.18/0.215/0.25 mg-25 mcg tablet <b>MO</b>	1	
trinessa tablet <b>MO</b>	1	
trinessa lo tablet <b>MO</b>	1	
trivora (28) 50-30 (6)/75-40(5)/125-30(10) tablet <b>MO</b>	1	
tulana 0.35 mg tablet <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
tydemy 3 mg-0.03 mg-0.451 mg (21)(7) tablet <b>MO</b>	1	
VAGIFEM 10 MCG VAGINAL TABLET <b>MO</b>	3	PA
velivet triphasic regimen (28) 0.1 mg/0.125 mg/0.15 mg-25 mcg tablet <b>MO</b>	1	
vienva 0.1 mg-20 mcg tablet <b>MO</b>	1	
viorele (28) 0.15 mg-0.02 mg (21)/0.01 mg (5) tablet <b>MO</b>	1	
VIVELLE-DOT 0.025 MG/24 HR, 0.0375 MG/24 HR, 0.05 MG/24 HR, 0.075 MG/24 HR, 0.1 MG/24 HR TRANSDERMAL PATCH <b>MO</b>	3	QL (8 per 28 days)
VOGELXO 1 % (50 MG/5 GRAM), 12.5 MG/ 1.25 GRAM (1 %), 50 MG/5 GRAM (1 %) TRANSDERMAL GEL; VOGELXO 1 % (50 MG/5 GRAM), 12.5 MG/ 1.25 GRAM (1 %), 50 MG/5 GRAM (1 %) TRANSDERMAL GEL PACKET; VOGELXO 12.5 MG/1.25 GRAM PER PUMP ACTUATION (1 %) TRANSDERMAL GEL <b>MO</b>	3	PA,QL (300 per 30 days)
volnea (28) 0.15 mg-0.02 mg (21)/0.01 mg (5) tablet <b>MO</b>	1	
vyfemla (28) 0.4 mg-35 mcg tablet <b>MO</b>	1	
vylibra 0.25 mg-35 mcg tablet <b>MO</b>	1	
wera (28) 0.5 mg-35 mcg tablet <b>MO</b>	1	
wymzya fe 0.4 mg-35 mcg (21)/75 mg (7) chewable tablet <b>MO</b>	1	
xulane 150 mcg-35 mcg/24 hr transdermal patch <b>MO</b>	1	QL (3 per 28 days)
XYOSTED 100 MG/0.5 ML, 50 MG/0.5 ML, 75 MG/0.5 ML SUBCUTANEOUS AUTO-INJECTOR <b>MO</b>	3	PA,QL (2 per 28 days)
YASMIN (28) 3 MG-0.03 MG TABLET <b>MO</b>	3	
YAZ (28) 3 MG-0.02 MG TABLET <b>MO</b>	3	
yuvafem 10 mcg vaginal tablet <b>MO</b>	1	
zarah 3 mg-0.03 mg tablet <b>MO</b>	1	
zovia 1/35e (28) 1 mg-35 mcg tablet <b>MO</b>	1	
zumandimine (28) 3 mg-0.03 mg tablet <b>MO</b>	1	
<b>HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (THYROID)</b>		
ARMOUR THYROID 120 MG, 15 MG, 180 MG, 240 MG, 30 MG, 300 MG, 60 MG, 90 MG TABLET <b>MO</b>	2	
CYTOMEL 25 MCG, 5 MCG, 50 MCG TABLET <b>MO</b>	3	
EUTHYROX 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 50 MCG, 75 MCG, 88 MCG TABLET <b>MO</b>	1	
LEVO-T 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 300 MCG, 50 MCG, 75 MCG, 88 MCG TABLET <b>MO</b>	2	
levothyroxine 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 25 mcg, 300 mcg, 50 mcg, 75 mcg, 88 mcg tablet <b>MO</b>	1	
levothyroxine 100 mcg, 200 mcg, 500 mcg vial <b>MO</b>	1	
levothyroxine 100 mcg/5 ml vl; levothyroxine 200 mcg/5 ml vl; levothyroxine 500 mcg/5 ml vl <b>DL</b>	4	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
LEVOXYL 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 50 MCG, 75 MCG, 88 MCG TABLET <b>MO</b>	1	
<i>liothyronine sod 10 mcg/ml vl</i> <b>MO</b>	1	
<i>liothyronine sod 25 mcg, 5 mcg, 50 mcg tab</i> <b>MO</b>	1	
SYNTHROID 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 300 MCG, 50 MCG, 75 MCG, 88 MCG TABLET <b>MO</b>	2	
THYROLAR-1 12.5 MCG-50 MCG TABLET <b>MO</b>	1	
THYROLAR-1/2 6.25 MCG-25 MCG TABLET <b>MO</b>	1	
THYROLAR-1/4 3.1 MCG-12.5 MCG TABLET <b>MO</b>	1	
THYROLAR-2 25 MCG-100 MCG TABLET <b>MO</b>	1	
THYROLAR-3 37.5 MCG-150 MCG TABLET <b>MO</b>	1	
TIROSINT 100 MCG, 112 MCG, 125 MCG, 13 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 50 MCG, 75 MCG, 88 MCG CAPSULE <b>MO</b>	3	
TIROSINT-SOL 100 MCG/ML, 112 MCG/ML, 125 MCG/ML, 13 MCG/ML, 137 MCG/ML, 150 MCG/ML, 175 MCG/ML, 200 MCG/ML, 25 MCG/ML, 50 MCG/ML, 75 MCG/ML, 88 MCG/ML ORAL SOLUTION <b>MO</b>	3	
TRIOSTAT 10 MCG/ML INTRAVENOUS SOLUTION <b>MO</b>	3	
UNITHROID 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 300 MCG, 50 MCG, 75 MCG, 88 MCG TABLET <b>MO</b>	2	
<b>Hormonal Agents, Suppressant (Adrenal)</b>		
LYSODREN 500 MG TABLET <b>DL</b>	4	
<b>Hormonal Agents, Suppressant (Pituitary)</b>		
BYNFEZIA 2,500 MCG/ML SUBCUTANEOUS PEN INJECTOR <b>DL</b>	4	PA
<i>cabergoline 0.5 mg tablet</i> <b>MO</b>	1	QL (16 per 28 days)
ELIGARD 7.5 MG (1 MONTH) SUBCUTANEOUS SYRINGE <b>MO</b>	3	PA
ELIGARD 22.5 MG (3 MONTH) SUBCUTANEOUS SYRINGE <b>MO</b>	3	PA
ELIGARD 30 MG (4 MONTH) SUBCUTANEOUS SYRINGE <b>MO</b>	3	PA
ELIGARD 45 MG (6 MONTH) SUBCUTANEOUS SYRINGE <b>MO</b>	3	PA
FENSOLVI 45 MG SUBCUTANEOUS SYRINGE <b>MO</b>	4	PA,QL (1 per 180 days)
FIRMAGON 120 MG SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA
FIRMAGON KIT WITH DILUENT SYRINGE 120 MG SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA
FIRMAGON KIT WITH DILUENT SYRINGE 80 MG SUBCUTANEOUS SOLUTION <b>MO</b>	3	PA
<i>leuprolide 2wk 14 mg/2.8 ml kt</i> <b>MO</b>	1	B vs D
LUPANETA PACK (1 MONTH) 3.75 MG IM SYRINGE AND 5 MG (30) TABLETS,KIT <b>DL</b>	4	PA,QL (1 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
LUPANETA PACK (3 MONTH) 11.25 MG IM SYRINGE AND 5 MG (90) TABLETS, KIT <b>MO</b>	4	PA, QL (1 per 90 days)
LUPRON DEPOT 3.75 MG INTRAMUSCULAR SYRINGE KIT <b>MO</b>	3	PA, QL (1 per 30 days)
LUPRON DEPOT 7.5 MG INTRAMUSCULAR SYRINGE KIT <b>DL</b>	4	PA, QL (1 per 30 days)
LUPRON DEPOT 11.25 MG, 22.5 MG (3 MONTH) INTRAMUSCULAR SYRINGE KIT <b>MO</b>	3	PA, QL (1 per 90 days)
LUPRON DEPOT 30 MG (4 MONTH) INTRAMUSCULAR SYRINGE KIT <b>MO</b>	3	PA, QL (1 per 112 days)
LUPRON DEPOT (6 MONTH) 45 MG INTRAMUSCULAR SYRINGE KIT <b>MO</b>	4	PA, QL (1 per 168 days)
LUPRON DEPOT-PED 11.25 MG, 15 MG, 7.5 MG (PED) INTRAMUSCULAR KIT <b>DL</b>	4	PA, QL (1 per 28 days)
LUPRON DEPOT-PED 11.25 MG, 30 MG (3 MONTH) INTRAMUSCULAR SYRINGE KIT <b>MO</b>	4	PA, QL (1 per 90 days)
MYCAPSSA 20 MG CAPSULE, DELAYED RELEASE <b>DL</b>	4	PA, QL (112 per 28 days)
octreotide 1,000 mcg/ml, 100 mcg/ml, 200 mcg/ml, 50 mcg/ml, 500 mcg/ml vial; octreotide acet 0.05 mg/ml v; octreotide acet 1,000 mcg/ml, 100 mcg/ml, 200 mcg/ml, 50 mcg/ml, 500 mcg/ml v <b>MO</b>	1	PA
octreotide acet 100 mcg/ml syr; octreotide acet 50 mcg/ml syr; octreotide acet 500 mcg/ml syr <b>MO</b>	1	PA
ORILISSA 150 MG TABLET <b>DL</b>	4	PA, QL (28 per 28 days)
ORILISSA 200 MG TABLET <b>DL</b>	4	PA, QL (56 per 28 days)
SANDOSTATIN 100 MCG/ML, 50 MCG/ML, 500 MCG/ML INJECTION SOLUTION <b>DL</b>	4	PA
SANDOSTATIN LAR DEPOT 10 MG, 20 MG, 30 MG INTRAMUSCULAR SUSP, EXTENDED RELEASE <b>DL</b>	4	PA
SIGNIFOR 0.3 MG/ML (1 ML), 0.6 MG/ML (1 ML), 0.9 MG/ML (1 ML) SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA, QL (60 per 30 days)
SOMATULINE DEPOT 120 MG/0.5 ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA, QL (0.5 per 28 days)
SOMATULINE DEPOT 60 MG/0.2 ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA, QL (0.2 per 28 days)
SOMATULINE DEPOT 90 MG/0.3 ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA, QL (0.3 per 28 days)
SOMAVERT 10 MG, 15 MG, 20 MG SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA, QL (60 per 30 days)
SOMAVERT 25 MG, 30 MG SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA, QL (30 per 30 days)
SYNAREL 2 MG/ML NASAL SPRAY <b>DL</b>	4	
TRELSTAR 11.25 MG, 22.5 MG INTRAMUSCULAR SUSPENSION <b>MO</b>	4	PA
TRELSTAR 3.75 MG INTRAMUSCULAR SUSPENSION <b>DL</b>	4	PA
TRIPTODUR 22.5 MG INTRAMUSCULAR SUSPENSION <b>MO</b>	4	PA, QL (1 per 168 days)
ZOLADEX 10.8 MG SUBCUTANEOUS IMPLANT <b>MO</b>	3	PA, QL (1 per 84 days)
ZOLADEX 3.6 MG SUBCUTANEOUS IMPLANT <b>MO</b>	3	PA, QL (1 per 28 days)
<b>Hormonal Agents, Suppressant (Thyroid)</b>		
methimazole 10 mg, 5 mg tablet <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>propylthiouracil 50 mg tablet</i> <b>MO</b>	1	
TAPAZOLE 10 MG, 5 MG TABLET <b>MO</b>	1	
<b>IMMUNOLOGICAL AGENTS</b>		
ACTEMRA 162 MG/0.9 ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA,QL (3.6 per 28 days)
ACTEMRA ACTPEN 162 MG/0.9 ML SUBCUTANEOUS PEN INJECTOR <b>DL</b>	4	PA,QL (3.6 per 28 days)
ACTHIB (PF) 10 MCG/0.5 ML INTRAMUSCULAR SOLUTION <b>DL</b>	3	
ACTIMMUNE 100 MCG (2 MILLION UNIT)/0.5 ML SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA
ADACEL (TDAP ADOLESN/ADULT)(PF)2 LF-(2.5-5-3-5)-5 LF/0.5 ML IM SYRINGE <b>DL</b>	2	
ADACEL (TDAP ADOLESN/ADULT)(PF)2LF-(2.5-5-3-5MCG)-5 LF/0.5 ML IM SUSP <b>DL</b>	2	
ARAVA 10 MG, 20 MG TABLET <b>DL</b>	4	PA,QL (30 per 30 days)
ARCALYST 220 MG SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA
ASCENIV 10 % INTRAVENOUS SOLUTION <b>DL</b>	4	PA
ASTAGRAF XL 0.5 MG, 1 MG, 5 MG CAPSULE,EXTENDED RELEASE <b>MO</b>	3	B vs D
ATGAM 50 MG/ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA
AVSOLA 100 MG INTRAVENOUS SOLUTION <b>DL</b>	4	PA
AZASAN 100 MG, 75 MG TABLET <b>MO</b>	1	B vs D
<i>azathioprine 50 mg tablet</i> <b>MO</b>	1	B vs D
<i>azathioprine sod 100 mg vial</i> <b>MO</b>	1	B vs D
BCG VACCINE (TICE STRAIN) VIAL <b>DL</b>	3	
BENLYSTA 120 MG INTRAVENOUS SOLUTION <b>DL</b>	4	PA,QL (20 per 28 days)
BENLYSTA 200 MG/ML SUBCUTANEOUS AUTO-INJECTOR <b>DL</b>	4	PA,QL (4 per 28 days)
BENLYSTA 200 MG/ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA,QL (4 per 28 days)
BENLYSTA 400 MG INTRAVENOUS SOLUTION <b>DL</b>	4	PA,QL (6 per 28 days)
BERINERT 500 UNIT (10 ML) INTRAVENOUS KIT <b>DL</b>	4	PA,QL (15 per 30 days)
BERINERT 500 UNIT (10 ML) INTRAVENOUS SOLUTION <b>DL</b>	4	PA,QL (15 per 30 days)
BEXSERO 50 MCG-50 MCG-50 MCG-25 MCG/0.5 ML INTRAMUSCULAR SYRINGE <b>DL</b>	3	
BIVIGAM 10 % INTRAVENOUS SOLUTION <b>DL</b>	4	PA
BOOSTRIX TDAP 2.5 LF UNIT-8 MCG-5 LF/0.5 ML INTRAMUSCULAR SUSPENSION <b>DL</b>	2	
BOOSTRIX TDAP 2.5 LF UNIT-8 MCG-5 LF/0.5 ML INTRAMUSCULAR SYRINGE <b>DL</b>	2	
CELLCEPT 200 MG/ML ORAL SUSPENSION <b>DL</b>	4	B vs D
CELLCEPT 250 MG CAPSULE <b>DL</b>	4	B vs D

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
CELLCEPT 500 MG TABLET <b>DL</b>	4	B vs D
CELLCEPT INTRAVENOUS 500 MG INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D
CIMZIA 400 MG/2 ML (200 MG/ML X 2) SUBCUTANEOUS SYRINGE KIT <b>DL</b>	4	PA,QL (3 per 30 days)
CIMZIA POWDER FOR RECON 400 MG (200 MG X 2 VIALS) SUBCUTANEOUS KIT <b>DL</b>	4	PA,QL (3 per 30 days)
CIMZIA STARTER KIT 400 MG/2 ML (200 MG/ML X2) SUBCUTANEOUS SYRINGE KIT <b>DL</b>	4	PA,QL (3 per 30 days)
CINRYZE 500 UNIT (5 ML) INTRAVENOUS SOLUTION <b>DL</b>	4	PA,QL (20 per 30 days)
COSENTYX 150 MG/ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA,QL (4 per 28 days)
COSENTYX 300 MG/2 SYRINGES (150 MG/ML) SUBCUTANEOUS <b>DL</b>	4	PA,QL (4 per 28 days)
COSENTYX PEN 150 MG/ML SUBCUTANEOUS <b>DL</b>	4	PA,QL (4 per 28 days)
COSENTYX PEN 300 MG/2 PENS (150 MG/ML) SUBCUTANEOUS <b>DL</b>	4	PA,QL (4 per 28 days)
CUTAQUIG 16.5 % SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA
<i>cyclosporine 100 mg, 25 mg capsule</i> <b>MO</b>	1	B vs D
<i>cyclosporine modified 100 mg, 25 mg, 50 mg</i> <b>MO</b>	1	B vs D
<i>cyclosporine modified 100mg/ml</i> <b>MO</b>	1	B vs D
CYTOGAM 50 MG/ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA
DAPTACEL (DTAP PEDIATRIC) (PF) 15 LF UNIT-10 MCG-5 LF/0.5 ML IM SUSP <b>DL</b>	3	
DUPIXENT 300 MG/2 ML SUBCUTANEOUS PEN INJECTOR <b>DL</b>	4	PA,QL (6 per 28 days)
DUPIXENT 200 MG/1.14 ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA,QL (3.42 per 28 days)
DUPIXENT 300 MG/2 ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA,QL (6 per 28 days)
ENBREL 25 MG (1 ML), 25 MG/0.5 ML SUBCUTANEOUS POWDER FOR SOLUTION; ENBREL 25 MG (1 ML), 25 MG/0.5 ML SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA,QL (8 per 28 days)
ENBREL 25 MG/0.5 ML (0.5 ML) SUBCUTANEOUS SYRINGE; ENBREL 25 MG/0.5 ML (0.5), 50 MG/ML (1 ML) SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA,QL (8 per 28 days)
ENBREL MINI 50 MG/ML (1 ML) SUBCUTANEOUS CARTRIDGE <b>DL</b>	4	PA,QL (8 per 28 days)
ENBREL SURECLICK 50 MG/ML (1 ML) SUBCUTANEOUS PEN INJECTOR <b>DL</b>	4	PA,QL (8 per 28 days)
ENGERIX-B (PF) 20 MCG/ML INTRAMUSCULAR SUSPENSION <b>DL</b>	3	B vs D
ENGERIX-B (PF) 20 MCG/ML INTRAMUSCULAR SYRINGE <b>DL</b>	3	B vs D
ENGERIX-B PEDIATRIC (PF) 10 MCG/0.5 ML INTRAMUSCULAR SYRINGE <b>DL</b>	3	B vs D
ENSPRYNG 120 MG/ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA,QL (2 per 28 days)
ENTYVIO 300 MG INTRAVENOUS SOLUTION <b>DL</b>	4	PA,QL (8 per 365 days)
ENVARUSUS XR 0.75 MG, 1 MG, 4 MG TABLET,EXTENDED RELEASE <b>MO</b>	3	PA
<i>everolimus 0.25 mg tablet</i> <b>MO</b>	4	B vs D,QL (60 per 30 days)
<i>everolimus 0.5 mg tablet</i> <b>DL</b>	4	B vs D,QL (120 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
everolimus 0.75 mg tablet <b>DL</b>	4	B vs D,QL (60 per 30 days)
FIRAZYR 30 MG/3 ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA,QL (9 per 30 days)
FLEBOGAMMA DIF 10 %, 5 % INTRAVENOUS SOLUTION <b>DL</b>	4	PA
GAMASTAN 15 %-18 % RANGE INTRAMUSCULAR SOLUTION <b>DL</b>	4	PA
GAMASTAN S/D 15 %-18 % RANGE INTRAMUSCULAR SOLUTION <b>DL</b>	4	PA
GAMMAGARD LIQUID 10 % INJECTION SOLUTION <b>DL</b>	4	PA
GAMMAGARD S-D (IGA &LT; 1 MCG/ML) 10 GRAM, 5 GRAM INTRAVENOUS SOLUTION <b>DL</b>	4	PA
GAMMAKED 1 GRAM/10 ML (10 %), 10 GRAM/100 ML (10 %), 2.5 GRAM/25 ML (10 %), 20 GRAM/200 ML (10 %), 5 GRAM/50 ML (10 %) INJECTION SOLUTION; GAMMAKED 2.5 GRAM/25 ML VIAL <b>DL</b>	4	PA
GAMMAPLEX 10 % INTRAVENOUS SOLUTION <b>DL</b>	4	PA
GAMMAPLEX (WITH SORBITOL) 5 % INTRAVENOUS SOLUTION <b>DL</b>	4	PA
GAMUNEX-C 1 GRAM/10 ML (10 %), 10 GRAM/100 ML (10 %), 2.5 GRAM/25 ML (10 %), 20 GRAM/200 ML (10 %), 40 GRAM/400 ML (10 %), 5 GRAM/50 ML (10 %) INJECTION SOLUTION <b>DL</b>	4	PA
GARDASIL 9 (PF) 0.5 ML INTRAMUSCULAR SUSPENSION <b>DL</b>	3	QL (1.5 per 365 days)
GARDASIL 9 (PF) 0.5 ML INTRAMUSCULAR SYRINGE <b>DL</b>	3	QL (1.5 per 365 days)
gengraf 100 mg, 25 mg capsule <b>MO</b>	1	B vs D
gengraf 100 mg/ml oral solution <b>MO</b>	1	B vs D
HAEGARDA 2,000 UNIT, 3,000 UNIT SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA,QL (24 per 28 days)
HAVRIX (PF) 1,440 ELISA UNIT/ML, 720 ELISA UNIT/0.5 ML INTRAMUSCULAR SUSPENSION; HAVRIX 720 UNITS/0.5 ML VIAL <b>DL</b>	3	
HAVRIX (PF) 1,440 ELISA UNIT/ML, 720 ELISA UNIT/0.5 ML INTRAMUSCULAR SYRINGE <b>DL</b>	3	
HIBERIX (PF) 10 MCG/0.5 ML INTRAMUSCULAR SOLUTION <b>DL</b>	3	
HIZENTRA 1 GRAM/5 ML (20 %), 10 GRAM/50 ML (20 %), 2 GRAM/10 ML (20 %), 4 GRAM/20 ML (20 %) SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA
HIZENTRA 1 GRAM/5 ML (20 %), 2 GRAM/10 ML (20 %), 4 GRAM/20 ML (20 %) SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA
HUMIRA 10 MG/0.2 ML SUBCUTANEOUS SYRINGE KIT <b>DL</b>	4	PA,QL (2 per 28 days)
HUMIRA 20 MG/0.4 ML, 40 MG/0.8 ML SUBCUTANEOUS SYRINGE KIT <b>DL</b>	4	PA,QL (6 per 28 days)
HUMIRA PEDI CROHN 40 MG/0.8 ML <b>DL</b>	4	PA,QL (6 per 28 days)
HUMIRA PEN 40 MG/0.8 ML SUBCUTANEOUS KIT <b>DL</b>	4	PA,QL (6 per 28 days)
HUMIRA PEN CROHN'S-ULC COLITIS-HID SUP STARTER 40 MG/0.8 ML SUBCUT KIT <b>DL</b>	4	PA,QL (6 per 28 days)
HUMIRA PEN PSORIASIS-UVEITIS-ADOL HID SUP START 40 MG/0.8 ML SUBCUT KT <b>DL</b>	4	PA,QL (6 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
HUMIRA(CF) 10 MG/0.1 ML SUBCUTANEOUS SYRINGE KIT <b>DL</b>	4	PA,QL (2 per 28 days)
HUMIRA(CF) 20 MG/0.2 ML, 40 MG/0.4 ML SUBCUTANEOUS SYRINGE KIT <b>DL</b>	4	PA,QL (6 per 28 days)
HUMIRA(CF) PEDI CROHN'S START 80 MG/0.8 ML, 80 MG/0.8 ML-40 MG/0.4 ML SUBCUT SYR KIT; HUMIRA(CF) PEDIATRIC CROHN'S STARTER 80 MG/0.8 ML, 80 MG/0.8 ML-40 MG/0.4 ML SUBCUT SYRINGE KIT <b>DL</b>	4	PA,QL (6 per 28 days)
HUMIRA(CF) PEN 40 MG/0.4 ML, 80 MG/0.8 ML SUBCUTANEOUS KIT <b>DL</b>	4	PA,QL (6 per 28 days)
HUMIRA(CF) PEN CROHN'S-ULC COLITIS-HID SUP STRT 80 MG/0.8 ML SUBCUT KT <b>DL</b>	4	PA,QL (6 per 28 days)
HUMIRA(CF) PEN PS-UV-ADOL HS 80 MG/0.8 ML(1)-40 MG/0.4 ML(2)SUBCUT KIT <b>DL</b>	4	PA,QL (6 per 28 days)
HYPERRAB (PF) 300 UNIT/ML INTRAMUSCULAR SOLUTION <b>DL</b>	4	B vs D
HYPERRAB S/D (PF) 150 UNIT/ML INTRAMUSCULAR SOLUTION <b>DL</b>	4	B vs D
HYPERTET S/D (PF) 250 UNIT INTRAMUSCULAR SYRINGE <b>MO</b>	3	B vs D
<i>icatibant 30 mg/3 ml syringe</i> <b>DL</b>	4	PA,QL (9 per 30 days)
ILUMYA 100 MG/ML SUBCUTANEOUS SYRINGE <b>MO</b>	4	PA,QL (6 per 365 days)
IMOGAM RABIES-HT (PF) 150 UNIT/ML INTRAMUSCULAR SOLUTION <b>MO</b>	3	B vs D
IMOVAX RABIES VACCINE (PF) 2.5 UNIT INTRAMUSCULAR SOLUTION <b>DL</b>	2	B vs D
IMURAN 50 MG TABLET <b>MO</b>	3	PA
INFANRIX (DTAP) (PF) 25 LF UNIT-58 MCG-10 LF/0.5ML INTRAMUSCULAR SUSP <b>DL</b>	3	
INFANRIX (DTAP)(PF) 25 LF UNIT-58MCG-10 LF/0.5ML INTRAMUSCULAR SYRINGE <b>DL</b>	3	
INFLECTRA 100 MG INTRAVENOUS SOLUTION <b>DL</b>	4	PA
INTRON A 10 MILLION UNIT (1 ML), 18 MILLION UNIT (1 ML), 50 MILLION UNIT (1 ML) SOLUTION FOR INJECTION <b>MO</b>	3	PA
INTRON A 10 MILLION UNIT/ML, 6 MILLION UNIT/ML INJECTION SOLUTION <b>DL</b>	4	PA
IPOL 40 UNIT-8 UNIT-32 UNIT/0.5 ML SUSPENSION FOR INJECTION <b>DL</b>	3	
IXIARO (PF) 6 MCG/0.5 ML INTRAMUSCULAR SYRINGE <b>DL</b>	3	
KEDRAB (PF) 150 UNIT/ML INTRAMUSCULAR SOLUTION <b>DL</b>	4	B vs D
KEVZARA 150 MG/1.14 ML, 200 MG/1.14 ML SUBCUTANEOUS PEN INJECTOR <b>DL</b>	4	PA,QL (2.28 per 28 days)
KEVZARA 150 MG/1.14 ML, 200 MG/1.14 ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA,QL (2.28 per 28 days)
KINERET 100 MG/0.67 ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA,QL (20.1 per 30 days)
KINRIX (PF) 25 LF-58 MCG-10 LF/0.5 ML INTRAMUSCULAR SUSPENSION <b>DL</b>	3	
KINRIX (PF) 25 LF-58 MCG-10 LF/0.5 ML INTRAMUSCULAR SYRINGE <b>DL</b>	3	
<i>leflunomide 10 mg, 20 mg tablet</i> <b>MO</b>	1	QL (30 per 30 days)
M-M-R II (PF) 1,000-12,500 TCID50/0.5 ML SUBCUTANEOUS SOLUTION <b>DL</b>	3	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
MENACTRA (PF) 4 MCG/0.5 ML INTRAMUSCULAR SOLUTION <b>DL</b>	3	
MENVEO A-C-Y-W-135-DIP (PF) 10 MCG-5 MCG/0.5 ML INTRAMUSCULAR KIT <b>DL</b>	3	
<i>methotrexate 2.5 mg tablet</i> <b>MO</b>	1	B vs D
<i>methotrexate 50 mg/2 ml vial</i> <b>MO</b>	1	
<i>methotrexate 1 gm vial; methotrexate 50 mg/2 ml vial</i> <b>MO</b>	1	
MONJUVI 200 MG INTRAVENOUS SOLUTION <b>DL</b>	4	PA
<i>mycophenolate 200 mg/ml susp</i> <b>MO</b>	1	B vs D
<i>mycophenolate 250 mg capsule</i> <b>MO</b>	1	B vs D
<i>mycophenolate 500 mg tablet</i> <b>MO</b>	1	B vs D
<i>mycophenolate 500 mg vial</i> <b>MO</b>	1	B vs D
<i>mycophenolic acid dr 180 mg, 360 mg tb</i> <b>MO</b>	1	B vs D
MYFORTIC 180 MG TABLET, DELAYED RELEASE <b>MO</b>	3	B vs D
MYFORTIC 360 MG TABLET, DELAYED RELEASE <b>DL</b>	4	B vs D
NEORAL 100 MG, 25 MG CAPSULE <b>MO</b>	3	B vs D
NEORAL 100 MG/ML ORAL SOLUTION <b>MO</b>	3	B vs D
OCTAGAM 10 %, 5 % INTRAVENOUS SOLUTION <b>DL</b>	4	PA
OLUMIANT 1 MG, 2 MG TABLET <b>DL</b>	4	PA, QL (30 per 30 days)
ORENCIA 125 MG/ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA, QL (4 per 28 days)
ORENCIA 50 MG/0.4 ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA, QL (1.6 per 28 days)
ORENCIA 87.5 MG/0.7 ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA, QL (2.8 per 28 days)
ORENCIA CLICKJECT 125 MG/ML SUBCUTANEOUS AUTO-INJECTOR <b>DL</b>	4	PA, QL (4 per 28 days)
OTREXUP (PF) 10 MG/0.4 ML, 12.5 MG/0.4 ML, 15 MG/0.4 ML, 17.5 MG/0.4 ML, 20 MG/0.4 ML, 22.5 MG/0.4 ML, 25 MG/0.4 ML SUBCUTANEOUS AUTO-INJECTOR <b>DL</b>	4	PA, QL (1.6 per 28 days)
PANZYGA 10 % INTRAVENOUS SOLUTION <b>DL</b>	4	PA
PEDIARIX (PF) 10 MCG-25 LF-25 MCG-10 LF/0.5 ML INTRAMUSCULAR SYRINGE <b>DL</b>	3	
PEDVAX HIB (PF) 7.5 MCG/0.5 ML INTRAMUSCULAR SOLUTION <b>DL</b>	3	
PEGASYS 180 MCG/0.5 ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA, QL (2 per 28 days)
PEGASYS 180 MCG/ML SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA, QL (4 per 28 days)
PEGASYS PROCLICK 135 MCG/0.5; PEGASYS PROCLICK 180 MCG/0.5 <b>DL</b>	4	PA, QL (2 per 28 days)
PEGINTRON 50 MCG/0.5 ML SUBCUTANEOUS KIT <b>DL</b>	4	PA, QL (4 per 28 days)
PENTACEL (PF) 15 LF UNIT-20 MCG-5 LF /0.5 ML INTRAMUSCULAR KIT; PENTACEL (PF) 15 LF-48 MCG-62 DU-10 MCG/0.5 ML INTRAMUSCULAR KIT <b>DL</b>	3	
PRIVIGEN 10 % INTRAVENOUS SOLUTION <b>DL</b>	4	PA
PROGRAF 0.2 MG, 1 MG ORAL GRANULES IN PACKET <b>MO</b>	3	B vs D

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
PROGRAF 0.5 MG, 1 MG, 5 MG CAPSULE <b>MO</b>	3	B vs D
PROQUAD (PF) 10EXP3-4.3-3-3.99TCID50/0.5ML SUBCUTANEOUS SUSPENSION <b>DL</b>	3	
QUADRACEL (PF) 15 LF-48 MCG-5 LF UNIT/0.5 ML INTRAMUSCULAR SUSPENSION <b>DL</b>	3	
RABAVERT (PF) 2.5 UNIT INTRAMUSCULAR SUSPENSION <b>DL</b>	2	B vs D
RAPAMUNE 0.5 MG, 1 MG, 2 MG TABLET <b>DL</b>	4	B vs D
RAPAMUNE 1 MG/ML ORAL SOLUTION <b>DL</b>	4	B vs D
RASUVO (PF) 10 MG/0.2 ML SUBCUTANEOUS AUTO-INJECTOR <b>MO</b>	3	PA,QL (0.8 per 28 days)
RASUVO (PF) 12.5 MG/0.25 ML SUBCUTANEOUS AUTO-INJECTOR <b>MO</b>	3	PA,QL (1 per 28 days)
RASUVO (PF) 15 MG/0.3 ML SUBCUTANEOUS AUTO-INJECTOR <b>MO</b>	3	PA,QL (1.2 per 28 days)
RASUVO (PF) 17.5 MG/0.35 ML SUBCUTANEOUS AUTO-INJECTOR <b>MO</b>	3	PA,QL (1.4 per 28 days)
RASUVO (PF) 20 MG/0.4 ML SUBCUTANEOUS AUTO-INJECTOR <b>MO</b>	3	PA,QL (1.6 per 28 days)
RASUVO (PF) 22.5 MG/0.45 ML SUBCUTANEOUS AUTO-INJECTOR <b>MO</b>	3	PA,QL (1.8 per 28 days)
RASUVO (PF) 25 MG/0.5 ML SUBCUTANEOUS AUTO-INJECTOR <b>MO</b>	3	PA,QL (2 per 28 days)
RASUVO (PF) 30 MG/0.6 ML SUBCUTANEOUS AUTO-INJECTOR <b>MO</b>	3	PA,QL (2.4 per 28 days)
RASUVO (PF) 7.5 MG/0.15 ML SUBCUTANEOUS AUTO-INJECTOR <b>MO</b>	3	PA,QL (0.6 per 28 days)
RECOMBIVAX HB (PF) 10 MCG/ML, 40 MCG/ML, 5 MCG/0.5 ML INTRAMUSCULAR SUSPENSION <b>DL</b>	3	B vs D
RECOMBIVAX HB (PF) 10 MCG/ML, 5 MCG/0.5 ML INTRAMUSCULAR SYRINGE <b>DL</b>	3	B vs D
REMICADE 100 MG INTRAVENOUS SOLUTION <b>DL</b>	4	PA
RENFLIXIS 100 MG INTRAVENOUS SOLUTION <b>DL</b>	4	PA
RHOPHYLAC 1,500 UNIT (300 MCG)/2 ML INJECTION SYRINGE <b>DL</b>	4	
RIDAURA 3 MG CAPSULE <b>DL</b>	4	
RINVOQ 15 MG TABLET,EXTENDED RELEASE <b>DL</b>	4	PA,QL (30 per 30 days)
ROTARIX 10EXP6 CCID50/ML SUSPENSION <b>DL</b>	3	
ROTATEQ VACCINE 2 ML ORAL SOLUTION <b>DL</b>	3	
RUCONEST 2,100 UNIT INTRAVENOUS SOLUTION <b>DL</b>	4	PA,QL (8 per 28 days)
SANDIMMUNE 100 MG, 25 MG CAPSULE <b>MO</b>	3	B vs D
SANDIMMUNE 100 MG/ML ORAL SOLUTION <b>MO</b>	3	B vs D
SHINGRIX (PF) 50 MCG/0.5 ML INTRAMUSCULAR SUSPENSION, KIT <b>DL</b>	2	QL (2 per 999 days)
SILIQ 210 MG/1.5 ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA,QL (4.5 per 28 days)
SIMPONI 100 MG/ML SUBCUTANEOUS PEN INJECTOR <b>DL</b>	4	PA,QL (3 per 28 days)
SIMPONI 100 MG/ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA,QL (3 per 28 days)
SIMPONI 50 MG/0.5 ML SUBCUTANEOUS PEN INJECTOR <b>DL</b>	4	PA,QL (0.5 per 30 days)
SIMPONI 50 MG/0.5 ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA,QL (0.5 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
SIMPONI ARIA 12.5 MG/ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA,QL (20 per 28 days)
SIMULECT 10 MG, 20 MG INTRAVENOUS SOLUTION <b>DL</b>	4	B vs D
<i>sirolimus 0.5 mg, 1 mg, 2 mg tablet</i> <b>MO</b>	1	B vs D
<i>sirolimus 1 mg/ml solution</i> <b>MO</b>	1	B vs D
SKYRIZI 150 MG/1.66 ML(75 MG/0.83 ML X 2) SUBCUTANEOUS SYRINGE KIT <b>MO</b>	4	PA,QL (6 per 365 days)
SKYRIZI 75 MG/0.83 ML SUBCUTANEOUS SYRINGE <b>MO</b>	4	PA,QL (9.96 per 365 days)
STELARA 130 MG/26 ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA,QL (104 per 30 days)
STELARA 45 MG/0.5 ML SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA,QL (1.5 per 84 days)
STELARA 45 MG/0.5 ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA,QL (1.5 per 84 days)
STELARA 90 MG/ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA,QL (3 per 84 days)
SYLATRON 200 MCG, 300 MCG, 600 MCG KIT; SYLATRON 200 MCG, 300 MCG, 600 MCG SUBCUTANEOUS KIT <b>DL</b>	4	PA,QL (4 per 28 days)
SYLVANT 100 MG, 400 MG INTRAVENOUS SOLUTION <b>DL</b>	4	PA
<i>tacrolimus 0.5 mg, 1 mg, 5 mg capsule</i> <b>MO</b>	1	B vs D
TAKHZYRO 300 MG/2 ML (150 MG/ML) SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA,QL (4 per 28 days)
TALTZ AUTOINJECTOR 80 MG/ML SUBCUTANEOUS <b>DL</b>	4	PA,QL (4 per 28 days)
TALTZ AUTOINJECTOR (2 PACK) 80 MG/ML SUBCUTANEOUS <b>DL</b>	4	PA,QL (4 per 28 days)
TALTZ AUTOINJECTOR (3 PACK) 80 MG/ML SUBCUTANEOUS <b>DL</b>	4	PA,QL (4 per 28 days)
TALTZ SYRINGE 80 MG/ML SUBCUTANEOUS <b>DL</b>	4	PA,QL (4 per 28 days)
TDVAX 2 LF UNIT-2 LF UNIT/0.5 ML INTRAMUSCULAR SUSPENSION <b>DL</b>	3	
TENIVAC (PF) 5 LF UNIT-2 LF UNIT/0.5 ML INTRAMUSCULAR SUSPENSION <b>DL</b>	3	
TENIVAC (PF) 5 LF UNIT-2 LF UNIT/0.5 ML INTRAMUSCULAR SYRINGE <b>DL</b>	3	
DIPHTHERIA-TETANUS TOXOIDS-PED <b>DL</b>	3	
THYMOGLOBULIN 25 MG INTRAVENOUS SOLUTION <b>MO</b>	3	PA
TREMFYA 100 MG/ML SUBCUTANEOUS AUTO-INJECTOR <b>DL</b>	4	PA,QL (8 per 365 days)
TREMFYA 100 MG/ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA,QL (8 per 365 days)
TREXALL 10 MG, 15 MG, 5 MG, 7.5 MG TABLET <b>MO</b>	1	B vs D
TRUMENBA 120 MCG/0.5 ML INTRAMUSCULAR SYRINGE <b>DL</b>	3	
TWINRIX (PF) 720 ELISA UNIT-20 MCG/ML INTRAMUSCULAR SYRINGE <b>DL</b>	3	
TYPHIM VI 25 MCG/0.5 ML INTRAMUSCULAR SOLUTION <b>DL</b>	3	
TYPHIM VI 25 MCG/0.5 ML INTRAMUSCULAR SYRINGE <b>DL</b>	3	
VAQTA (PF) 25 UNIT/0.5 ML, 50 UNIT/ML INTRAMUSCULAR SUSPENSION <b>DL</b>	3	
VAQTA (PF) 25 UNIT/0.5 ML, 50 UNIT/ML INTRAMUSCULAR SYRINGE <b>DL</b>	3	
VARIVAX (PF) 1,350 UNIT/0.5 ML SUBCUTANEOUS SUSPENSION <b>DL</b>	2	
VARIZIG 125 UNIT/1.2 ML INTRAMUSCULAR SOLUTION <b>DL</b>	4	PA,QL (12 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
WINRHO SDF 1,500 UNIT (300 MCG)/1.3 ML, 15000 UNIT(3000 MCG)/13 ML, 2,500 UNIT (500 MCG)/2.2 ML, 5,000 UNIT(1000 MCG)/4.4 ML INJECTION SOLUTION; WINRHO SDF 15,000 UNIT (3,000 MCG)/13 ML INJECTION SOLUTION; WINRHO SDF 5,000 UNIT (1,000 MCG)/4.4 ML INJECTION SOLUTION <b>DL</b>	4	B vs D
XATMEP 2.5 MG/ML ORAL SOLUTION <b>MO</b>	3	PA
XELJANZ 10 MG, 5 MG TABLET <b>DL</b>	4	PA,QL (60 per 30 days)
XELJANZ XR 11 MG, 22 MG TABLET,EXTENDED RELEASE <b>DL</b>	4	PA,QL (30 per 30 days)
XEMBIFY 1 GRAM/5 ML (20 %), 10 GRAM/50 ML (20 %), 2 GRAM/10 ML (20 %), 4 GRAM/20 ML (20 %) SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA
XOLAIR 150 MG SUBCUTANEOUS SOLUTION <b>DL, LA</b>	4	PA,QL (6 per 28 days)
XOLAIR 150 MG/ML SUBCUTANEOUS SYRINGE <b>DL, LA</b>	4	PA,QL (6 per 28 days)
XOLAIR 75 MG/0.5 ML SUBCUTANEOUS SYRINGE <b>DL, LA</b>	4	PA,QL (3 per 28 days)
YF-VAX (PF) 10 EXP4.74 UNIT/0.5 ML SUBCUTANEOUS SUSPENSION <b>DL</b>	3	
ZORTRESS 0.25 MG, 0.75 MG, 1 MG TABLET <b>DL</b>	4	B vs D,QL (60 per 30 days)
ZORTRESS 0.5 MG TABLET <b>DL</b>	4	B vs D,QL (120 per 30 days)
ZOSTAVAX (PF) 19,400 UNIT/0.65 ML SUBCUTANEOUS SUSPENSION <b>DL</b>	3	QL (1 per 365 days)
<b>Inflammatory Bowel Disease Agents</b>		
APRISO 0.375 GRAM CAPSULE,EXTENDED RELEASE <b>MO</b>	3	ST,QL (120 per 30 days)
ASACOL HD 800 MG TABLET,DELAYED RELEASE <b>DL</b>	4	ST,QL (180 per 30 days)
AZULFIDINE 500 MG TABLET <b>MO</b>	3	
AZULFIDINE EN-TABS 500 MG TABLET,DELAYED RELEASE <b>MO</b>	3	
<i>balsalazide disodium 750 mg cp</i> <b>MO</b>	1	
<i>budesonide ec 3 mg capsule</i> <b>MO</b>	1	PA
<i>budesonide er 9 mg tablet</i> <b>DL</b>	4	PA,QL (30 per 30 days)
CANASA 1,000 MG RECTAL SUPPOSITORY <b>DL</b>	4	ST,QL (30 per 30 days)
COLAZAL 750 MG CAPSULE <b>DL</b>	4	PA
<i>colocort 100 mg/60 ml enema</i> <b>MO</b>	1	
CORTENEMA 100 MG/60 ML <b>MO</b>	3	
CORTIFOAM 10 % (80 MG) RECTAL <b>MO</b>	3	
DELZICOL 400 MG CAPSULE (DR TABLETS INSIDE) <b>MO</b>	3	ST,QL (180 per 30 days)
DIPENTUM 250 MG CAPSULE <b>DL</b>	4	ST,QL (120 per 30 days)
ENTOCORT EC 3 MG CAPSULE,DELAYED,EXTENDED RELEASE <b>DL</b>	4	PA
<i>hydrocortisone 100 mg/60 ml</i> <b>MO</b>	1	
LIALDA 1.2 GRAM TABLET,DELAYED RELEASE <b>MO</b>	3	ST,QL (120 per 30 days)
<i>mesalamine 1,000 mg supp</i> <b>MO</b>	1	ST,QL (30 per 30 days)
<i>mesalamine 4 gm/60 ml enema</i> <b>MO</b>	1	QL (1800 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
mesalamine 800 mg dr tablet <sup>MO</sup>	1	ST,QL (180 per 30 days)
mesalamine dr 1.2 gm tablet <sup>MO</sup>	1	QL (120 per 30 days)
mesalamine dr 400 mg capsule <sup>MO</sup>	1	ST,QL (180 per 30 days)
mesalamine er 0.375 gram cap <sup>MO</sup>	1	ST,QL (120 per 30 days)
ORTIKOS 6 MG, 9 MG CAPSULE,EXTENDED RELEASE <sup>DL</sup>	4	PA,QL (30 per 30 days)
PENTASA 250 MG CAPSULE,CONTROLLED RELEASE <sup>DL</sup>	4	ST,QL (150 per 30 days)
PENTASA 500 MG CAPSULE,CONTROLLED RELEASE <sup>DL</sup>	4	ST,QL (300 per 30 days)
PROCTOFOAM HC 1 %-1 % <sup>MO</sup>	1	
ROWASA 4 GRAM/60 ML ENEMA <sup>MO</sup>	3	QL (1800 per 30 days)
SFROWASA 4 GRAM/60 ML ENEMA <sup>MO</sup>	3	QL (1800 per 30 days)
sulfasalazine 500 mg tablet; sulfasalazine dr 500 mg tab <sup>MO</sup>	1	
UCERIS 2 MG/ACTUATION RECTAL FOAM <sup>DL</sup>	4	PA
UCERIS 9 MG TABLET, EXTENDED RELEASE <sup>DL</sup>	4	PA,QL (30 per 30 days)
<b>METABOLIC BONE DISEASE AGENTS</b>		
ACTONEL 150 MG TABLET <sup>MO</sup>	3	PA,QL (1 per 30 days)
ACTONEL 35 MG TABLET <sup>MO</sup>	3	PA,QL (4 per 28 days)
ACTONEL 5 MG TABLET <sup>MO</sup>	3	PA,QL (30 per 30 days)
alendronate sod 70 mg/75 ml <sup>MO</sup>	1	QL (300 per 30 days)
alendronate sodium 10 mg, 40 mg, 5 mg tab; alendronate sodium 10 mg, 40 mg, 5 mg tablet <sup>MO</sup>	1	QL (30 per 30 days)
alendronate sodium 35 mg, 70 mg tab <sup>MO</sup>	1	QL (4 per 28 days)
ATELVIA 35 MG TABLET,DELAYED RELEASE <sup>MO</sup>	3	PA,QL (4 per 28 days)
BINOSTO 70 MG EFFERVESCENT TABLET <sup>MO</sup>	3	ST,QL (4 per 28 days)
BONIVA 150 MG TABLET <sup>MO</sup>	3	PA,QL (1 per 28 days)
BONIVA 3 MG/3 ML INTRAVENOUS SYRINGE <sup>MO</sup>	3	PA,QL (3 per 90 days)
calcitonin-salmon 200 units sp <sup>MO</sup>	1	QL (3.7 per 28 days)
calcitriol 0.25 mcg, 0.5 mcg capsule <sup>MO</sup>	1	
calcitriol 1 mcg/ml ampul; calcitriol 1 mcg/ml solution <sup>MO</sup>	1	
cinacalcet hcl 30 mg, 60 mg tablet <sup>MO</sup>	1	QL (60 per 30 days)
cinacalcet hcl 90 mg tablet <sup>MO</sup>	1	QL (120 per 30 days)
doxercalciferol 0.5 mcg, 1 mcg, 2.5 mcg cap; doxercalciferol 0.5 mcg, 1 mcg, 2.5 mcg capsule <sup>MO</sup>	1	
doxercalciferol 4 mcg/2 ml vl <sup>MO</sup>	1	
etidronate disodium 200 mg, 400 mg tab <sup>MO</sup>	1	
EVENITY 105 MG/1.17 ML, 210MG/2.34ML ( 105MG/1.17MLX2) SUBCUTANEOUS SYRINGE; EVENITY 210 MG/2.34 ML (105 MG/1.17 ML X 2) SUBCUTANEOUS SYRINGE <sup>DL</sup>	4	PA,QL (2.34 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
FORTEO 20 MCG/DOSE (600 MCG/2.4 ML) SUBCUTANEOUS PEN INJECTOR <b>MO</b>	3	PA,QL (2.4 per 28 days)
FOSAMAX 70 MG TABLET <b>MO</b>	3	PA,QL (4 per 28 days)
FOSAMAX PLUS D 70 MG-2,800 UNIT TABLET; FOSAMAX PLUS D 70 MG-5,600 UNIT TABLET <b>MO</b>	3	ST,QL (4 per 28 days)
HECTOROL 2 MCG/ML INTRAVENOUS SOLUTION <b>MO</b>	2	
HECTOROL 4 MCG/2 ML INTRAVENOUS SOLUTION <b>MO</b>	3	
<i>ibandronate 3 mg/3 ml syringe</i> <b>MO</b>	1	PA,QL (3 per 90 days)
<i>ibandronate 3 mg/3 ml vial</i> <b>MO</b>	1	PA,QL (3 per 90 days)
<i>ibandronate sodium 150 mg tab</i> <b>MO</b>	1	QL (1 per 28 days)
MIACALCIN 200 UNIT/ML INJECTION SOLUTION <b>DL</b>	4	
NATPARA 100 MCG/DOSE, 25 MCG/DOSE, 50 MCG/DOSE, 75 MCG/DOSE SUBCUTANEOUS CARTRIDGE <b>DL</b>	4	PA,QL (2 per 28 days)
<i>pamidronate 30 mg/10 ml vial</i> <b>MO</b>	1	B vs D,QL (30 per 21 days)
<i>pamidronate 60 mg/10 ml vial; pamidronate 90 mg/10 ml vial</i> <b>MO</b>	1	B vs D,QL (10 per 21 days)
<i>paricalcitol 1 mcg, 2 mcg capsule</i> <b>MO</b>	1	QL (30 per 30 days)
<i>paricalcitol 2 mcg/ml vial</i> <b>MO</b>	1	QL (24 per 30 days)
<i>paricalcitol 4 mcg capsule</i> <b>MO</b>	1	QL (12 per 30 days)
<i>paricalcitol 5 mcg/ml vial</i> <b>MO</b>	1	QL (48 per 28 days)
PROLIA 60 MG/ML SUBCUTANEOUS SYRINGE <b>MO</b>	3	B vs D,QL (1 per 180 days)
RAYALDEE 30 MCG CAPSULE,EXTENDED RELEASE <b>DL, LA</b>	4	PA,QL (60 per 30 days)
RECLAST 5 MG/100 ML INTRAVENOUS PIGGYBACK <b>MO</b>	3	PA,QL (100 per 365 days)
<i>risedronate sod dr 35 mg tab; risedronate sodium 35 mg tab</i> <b>MO</b>	1	QL (4 per 28 days)
<i>risedronate sodium 150 mg tab</i> <b>MO</b>	1	QL (1 per 30 days)
<i>risedronate sodium 30 mg, 5 mg tab; risedronate sodium 30 mg, 5 mg tablet</i> <b>MO</b>	1	QL (30 per 30 days)
ROCALTROL 0.25 MCG, 0.5 MCG CAPSULE <b>MO</b>	3	
ROCALTROL 1 MCG/ML ORAL SOLUTION <b>MO</b>	3	
SENSIPAR 30 MG, 60 MG TABLET <b>DL</b>	4	PA,QL (60 per 30 days)
SENSIPAR 90 MG TABLET <b>DL</b>	4	PA,QL (120 per 30 days)
TYMLOS 80 MCG/DOSE (3,120 MCG/1.56 ML) SUBCUTANEOUS PEN INJECTOR <b>DL</b>	4	PA,QL (1.56 per 30 days)
XGEVA 120 MG/1.7 ML (70 MG/ML) SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA,QL (1.7 per 28 days)
ZEMPLAR 1 MCG, 2 MCG CAPSULE <b>MO</b>	3	QL (30 per 30 days)
ZEMPLAR 2 MCG/ML INTRAVENOUS SOLUTION <b>DL</b>	4	QL (24 per 30 days)
ZEMPLAR 5 MCG/ML INTRAVENOUS SOLUTION <b>DL</b>	4	QL (48 per 28 days)
<i>zoledronic acid 4 mg/100 ml</i> <b>MO</b>	1	B vs D,QL (300 per 21 days)
<i>zoledronic acid 4 mg vial</i> <b>MO</b>	1	B vs D

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
zoledronic acid 4 mg/5 ml vial <b>MO</b>	1	B vs D,QL (15 per 21 days)
zoledronic acid 4 mg/100 ml <b>MO</b>	1	B vs D,QL (300 per 21 days)
zoledronic acid 5 mg/100 ml <b>MO</b>	1	PA,QL (100 per 365 days)
ZOMETA 4 MG/100 ML INJECTION <b>DL</b>	4	B vs D,QL (300 per 21 days)
ZOMETA 4 MG/5 ML VIAL <b>DL</b>	4	B vs D,QL (15 per 21 days)
<b>MISCELLANEOUS THERAPEUTIC AGENTS</b>		
1ST TIER UNIFINE PENTIPS 29 GAUGE X 1/2", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 5/32" NEEDLE <b>MO</b>	1	
1ST TIER UNIFINE PENTIPS PLUS 29 GAUGE X 1/2", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 5/32" NEEDLE <b>MO</b>	1	
ABOUTTIME PEN NEEDLE 30 GAUGE X 5/16", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 5/32" <b>MO</b>	1	
ACETADOTE 200 MG/ML (20 %) INTRAVENOUS SOLUTION <b>MO</b>	3	
acetic acid 0.25% irrig soln <b>MO</b>	1	
acetylcysteine 6 gram/30 ml vial <b>MO</b>	1	
ADAKVEO 10 MG/ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA
ADVOCATE PEN NEEDLE 29 GAUGE X 1/2", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 33 GAUGE X 5/32" <b>MO</b>	1	
ADVOCATE SYRINGES 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16; ADVOCATE SYRINGES 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16" <b>MO</b>	1	
ALCOHOL PADS <b>MO</b>	1	
ALCOHOL PREP PADS <b>MO</b>	1	
ALCOHOL SWAB <b>MO</b>	1	
ALCOHOL WIPES <b>MO</b>	1	
AMMONUL 10 %-10 % INTRAVENOUS SOLUTION <b>DL</b>	4	
ASSURE ID DUO-SHIELD 30 GAUGE X 3/16", 30 GAUGE X 5/16" NEEDLE <b>MO</b>	1	
ASSURE ID INSULIN SAFETY 0.5 ML 29 GAUGE X 1/2", 0.5 ML 31 GAUGE X 15/64", 1 ML 29 GAUGE X 1/2", 1 ML 31 GAUGE X 15/64" SYRINGE <b>MO</b>	1	
ASSURE ID PEN NEEDLE 30 GAUGE X 3/16", 30 GAUGE X 5/16", 31 GAUGE X 3/16" <b>MO</b>	1	
AUTOJECT 2 INJECTION DEVICE SUBCUTANEOUS INSULIN PEN <b>MO</b>	1	
AUTOPEN 1 TO 21 UNITS SUBCUTANEOUS <b>MO</b>	1	
AUTOPEN 2 TO 42 UNITS SUBCUTANEOUS <b>MO</b>	1	
BAL IN OIL 100 MG/ML INTRAMUSCULAR SOLUTION <b>MO</b>	3	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
BAND-AID GAUZE PADS 2" X 2" BANDAGE <b>MO</b>	1	
BD ALCOHOL SWABS <b>MO</b>	1	
BD AUTOSHIELD DUO PEN NEEDLE 30 GAUGE X 3/16" <b>MO</b>	1	
BD ECLIPSE LUER-LOK 1 ML 30 GAUGE X 1/2" SYRINGE <b>MO</b>	1	
BD INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.5 ML 29 GAUGE X 1/2", 1 ML 25 GAUGE X 5/8", 1 ML 25 X 1", 1 ML 26 X 1/2", 1 ML 27 GAUGE X 1/2", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2" <b>MO</b>	1	
BD INSULIN SYRINGE HALF UNIT ULTRA-FINE 0.3 ML 31 GAUGE X 5/16" <b>MO</b>	1	
BD INSULIN SYRINGE MICRO-FINE 1 ML 28 GAUGE X 1/2" <b>MO</b>	1	
BD INSULIN SYRINGE SAFETY-LOK 1 ML 29 GAUGE X 1/2" <b>MO</b>	1	
BD INSULIN SYRINGE SLIP TIP 1 ML <b>MO</b>	1	
BD INSULIN SYRINGE U-500 1/2 ML 31 GAUGE X 15/64" <b>MO</b>	1	
BD INSULIN SYRINGE ULTRA-FINE 0.3 ML 30 GAUGE X 1/2", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 1/2", 1 ML 31 GAUGE X 5/16"; BD INSULIN SYRINGE ULTRA-FINE 0.3 ML 30 GAUGE X 1/2", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 1/2", 1 ML 31 GAUGE X 5/16" <b>MO</b>	1	
BD LO-DOSE MICRO-FINE IV 1/2 ML 28 GAUGE X 1/2" SYRINGE <b>MO</b>	1	
BD LO-DOSE ULTRA-FINE 0.5 ML 29 GAUGE X 1/2" SYRINGE <b>MO</b>	1	
BD NANO 2ND GEN PEN NEEDLE 32 GAUGE X 5/32" <b>MO</b>	1	
BD SAFETYGLIDE INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 31 GAUGE X 15/64", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 15/64", 1 ML 29 GAUGE X 1/2", 1 ML 31 GAUGE X 15/64" <b>MO</b>	1	
BD SAFETYGLIDE SYRINGE 1 ML 27 GAUGE X 5/8" <b>MO</b>	1	
BD ULTRA-FINE MICRO PEN NEEDLE 32 GAUGE X 1/4" <b>MO</b>	1	
BD ULTRA-FINE MINI PEN NEEDLE 31 GAUGE X 3/16" <b>MO</b>	1	
BD ULTRA-FINE NANO PEN NEEDLE 32 GAUGE X 5/32" <b>MO</b>	1	
BD ULTRA-FINE ORIGINAL PEN NEEDLE 29 GAUGE X 1/2" <b>MO</b>	1	
BD ULTRA-FINE SHORT PEN NEEDLE 31 GAUGE X 5/16" <b>MO</b>	1	
BD VEO INSULIN SYRINGE HALF UNIT ULTRA-FINE 0.3 ML 31 GAUGE X 15/64" <b>MO</b>	1	
BD VEO INSULIN SYRINGE ULTRA-FINE 0.3 ML 31 GAUGE X 15/64", 1 ML 31 GAUGE X 15/64", 1/2 ML 31 GAUGE X 15/64" <b>MO</b>	1	
BORDERED GAUZE 2" X 2" BANDAGE <b>MO</b>	1	
CAFCIT 60 MG/3 ML (20 MG/ML) INTRAVENOUS SOLUTION <b>MO</b>	3	
<i>caffeine cit 60 mg/3 ml oral; caffeine cit 60 mg/3 ml vial</i> <b>MO</b>	1	
<i>calcium disodium versenate 200 mg/ml injection solution</i> <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
CAREFINE PEN NEEDLE 29 GAUGE X 1/2", 30 GAUGE X 5/16", 31 GAUGE X 1/4", 31 GAUGE X 5/16", 32 GAUGE X 1/4", 32 GAUGE X 3/16", 32 GAUGE X 5/32" <b>MO</b>	1	
CARETOUCH ALCOHOL PREP PAD TOPICAL PADS <b>MO</b>	1	
CARETOUCH INSULIN SYRINGE 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 X 5/16", 1 ML 29 GAUGE X 5/16, 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16; CARETOUCH INSULIN SYRINGE 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 X 5/16", 1 ML 29 GAUGE X 5/16, 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16"; CARETOUCH INSULIN SYRINGE 1 ML 28 GAUGE X 5/16" <b>MO</b>	1	
CARETOUCH PEN NEEDLE 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 3/16", 32 GAUGE X 5/32" <b>MO</b>	1	
CERVIDIL 10 MG VAGINAL INSERT, CONTROLLED RELEASE <b>MO</b>	3	
CINVANTI 7.2 MG/ML INTRAVENOUS EMULSION <b>MO</b>	3	PA, QL (36 per 28 days)
CLARINEX-D 12 HOUR 2.5 MG-120 MG TABLET, EXTENDED RELEASE <b>MO</b>	3	ST, QL (60 per 30 days)
CLICKFINE PEN NEEDLE 31 GAUGE X 1/4", 31 GAUGE X 5/16", 32 GAUGE X 5/32" <b>MO</b>	1	
COMFORT EZ INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE X 1/2"; COMFORT EZ INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE X 1/2" <b>MO</b>	1	
COMFORT EZ PEN NEEDLES 29 GAUGE X 1/2", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 1/4", 32 GAUGE X 3/16", 32 GAUGE X 5/16", 32 GAUGE X 5/32", 33 GAUGE X 1/4", 33 GAUGE X 3/16", 33 GAUGE X 5/16", 33 GAUGE X 5/32" <b>MO</b>	1	
CURITY ALCOHOL SWABS <b>MO</b>	1	
CURITY GAUZE 2" X 2" BANDAGE <b>MO</b>	1	
DEFITELIO 80 MG/ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA
DERMACEA 2" X 2" BANDAGE <b>MO</b>	1	
DOJOLVI 8.3 KCAL/ML ORAL LIQUID <b>DL</b>	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
DROPLET INSULIN SYRINGE HALF UNIT 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 15/64", 0.5 ML 31 GAUGE X 5/16", 0.5ML 30 GAUGE X 15/64"; DROPLET INSULIN SYRINGE HALF UNIT 0.5 ML 30 GAUGE X 15/64" <b>MO</b>	1	
DROPLET INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 1/2", 0.3 ML 30 GAUGE X 15/64", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 15/64", 0.3 ML 31 GAUGE X 5/16", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 15/64", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 15/64", 1 ML 31 GAUGE X 5/16; DROPLET INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 1/2", 0.3 ML 30 GAUGE X 15/64", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 15/64", 0.3 ML 31 GAUGE X 5/16", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 15/64", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 15/64", 1 ML 31 GAUGE X 5/16" <b>MO</b>	1	
DROPLET MICRON PEN NEEDLE 34 GAUGE X 9/64" <b>MO</b>	1	
DROPLET PEN NEEDLE 29 GAUGE X 1/2", 29 GAUGE X 3/8", 30 GAUGE X 5/16", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 1/4", 32 GAUGE X 3/16", 32 GAUGE X 5/16", 32 GAUGE X 5/32" <b>MO</b>	1	
DROPSAFE PEN NEEDLE 31 GAUGE X 1/4", 31 GAUGE X 5/16" <b>MO</b>	1	
DROXIA 200 MG, 300 MG, 400 MG CAPSULE <b>MO</b>	2	
EASY COMFORT ALCOHOL PAD TOPICAL PADS <b>MO</b>	1	
EASY COMFORT INSULIN SYRINGE 0.3 ML 30 GAUGE X 5/16", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16, 1 ML 32 GAUGE X 5/16", 1/2 ML 32 GAUGE X 5/16"; EASY COMFORT INSULIN SYRINGE 0.3 ML 30 GAUGE X 5/16", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16, 1 ML 32 GAUGE X 5/16", 1/2 ML 32 GAUGE X 5/16" <b>MO</b>	1	
EASY COMFORT PEN NEEDLES 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 5/32", 33 GAUGE X 1/4", 33 GAUGE X 3/16", 33 GAUGE X 5/32" <b>MO</b>	1	
EASY GLIDE INSULIN SYRINGE 0.3 ML 31 GAUGE X 15/64", 1 ML 31 GAUGE X 15/64", 1/2 ML 31 GAUGE X 15/64" <b>MO</b>	1	
EASY GLIDE PEN NEEDLE 33 GAUGE X 5/32" <b>MO</b>	1	
EASY TOUCH 29 GAUGE X 1/2", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 1/4", 32 GAUGE X 3/16", 32 GAUGE X 5/32" NEEDLE <b>MO</b>	1	
EASY TOUCH ALCOHOL PREP PADS <b>MO</b>	1	
EASY TOUCH FLIPLOCK INSULIN 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16", 1 ML 31 GAUGE X 5/16" SYRINGE; EASY TOUCH FLIPLOCK INSULIN SYRINGE 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16", 1 ML 31 GAUGE X 5/16" <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
EASY TOUCH INSULIN SAFETY SYRINGE 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2" <b>MO</b>	1	
EASY TOUCH INSULIN SYRINGE 0.3 ML 30 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 27 GAUGE X 1/2", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16, 1/2 ML 27 GAUGE X 1/2", 1/2 ML 28 GAUGE X 1/2"; EASY TOUCH INSULIN SYRINGE 0.3 ML 30 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 27 GAUGE X 1/2", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16, 1/2 ML 27 GAUGE X 1/2", 1/2 ML 28 GAUGE X 1/2" <b>MO</b>	1	
EASY TOUCH LUER LOCK INSULIN 1 ML SYRINGE <b>MO</b>	1	
EASY TOUCH PEN NEEDLE 30 GAUGE X 5/16" <b>MO</b>	1	
EASY TOUCH SAFETY PEN NEEDLE 29 GAUGE X 3/16", 30 GAUGE X 3/16" <b>MO</b>	1	
EASY TOUCH SHEATHLOCK INSULIN 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16", 1 ML 31 GAUGE X 5/16" SYRINGE; EASY TOUCH SHEATHLOCK INSULIN SYRINGE 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16", 1 ML 31 GAUGE X 5/16" <b>MO</b>	1	
EASY TOUCH UNI-SLIP 1 ML SYRINGE <b>MO</b>	1	
EXEL INSULIN 0.3 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 1 ML 30 GAUGE X 5/16, 1/2 ML 28 GAUGE X 1/2" SYRINGE; EXEL INSULIN 0.3 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 1 ML 30 GAUGE X 5/16, 1/2 ML 28 GAUGE X 1/2" SYRINGE <b>MO</b>	1	
<i>flumazenil 0.5 mg/5 ml vial</i> <b>MO</b>	1	
<i>fomepizole 1.5 gm/1.5 ml vial</i> <b>MO</b>	1	
FREESTYLE PRECISION 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16 SYRINGE; FREESTYLE PRECISION 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16" SYRINGE <b>MO</b>	1	
GAUZE PADS 2"X2" <b>MO</b>	1	
GAUZE PAD 2" X 2" BANDAGE <b>MO</b>	1	
GIVLAARI 189 MG/ML SUBCUTANEOUS SOLUTION <b>DL</b>	4	PA
HEALTHWISE INSULIN SYRINGE 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16; HEALTHWISE INSULIN SYRINGE 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16" <b>MO</b>	1	
HEALTHWISE PEN NEEDLE 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 5/32" <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
HEALTHY ACCENTS UNIFINE PENTIP 29 GAUGE X 1/2", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 5/32" NEEDLE <b>MO</b>	1	
HUMAPEN LUXURA HD <b>MO</b>	1	
INCONTROL ALCOHOL PADS <b>MO</b>	1	
INCONTROL PEN NEEDLE 29 GAUGE X 1/2", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 5/32" <b>MO</b>	1	
INSULIN SYR 0.3ML 31GX1/4(1/2) <b>MO</b>	1	
INSULIN SYRINGE 0.5 ML 29 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2" <b>MO</b>	1	
INSULIN SYRINGE MICROFINE 1 ML 27 GAUGE X 5/8", 1/2 ML 28 GAUGE X 1/2" <b>MO</b>	1	
BD LUER-LOK SYRINGE 1 ML <b>MO</b>	1	
BD INSULIN SYR 1 ML 28GX1/2"; INSULIN 1 ML SYRINGE; INSULIN 1/2 ML SYRINGE; INSULIN 3/10 ML SYRINGE; INSULIN SYRIN 0.3 ML 30GX1/2"; INSULIN SYRIN 0.3 ML 31GX5/16"; INSULIN SYRIN 0.5 ML 30GX1/2"; INSULIN SYRING 0.5 ML 27GX1/2"; INSULIN SYRINGE 0.3 ML 31GX1/4; INSULIN SYRINGE 0.5 ML 31GX1/4; INSULIN SYRINGE 1 ML 27GX1/2"; INSULIN SYRINGE 1 ML 30GX1/2"; INSULIN SYRINGE 1 ML 31GX1/4"; INSULIN SYRINGE 1 ML 31GX5/16"; KMART VALU PLUS SYR 1/2 ML; PREFERRED PLUS SYRINGE 0.5 ML; PREFERRED PLUS SYRINGE 1 ML; RELI-ON INSULIN 0.3 ML SYR; RELI-ON INSULIN 1 ML SYR; RELION INS SYR 0.3 ML 31GX6MM; RELION INS SYR 0.5 ML 31GX6MM; RELION INS SYR 1 ML 31GX15/64"; TERUMO INS SYRINGE U100-1 ML; ULTICARE INS SYR 1 ML 29GX1/2"; ULTICARE SYR 0.3 ML 30GX5/16"; ULTICARE SYR 0.5 ML 29GX1/2"; ULTICARE SYR 0.5 ML 30GX5/16"; ULTICARE SYR 0.5 ML 31GX5/16"; ULTICARE SYR 1 ML 30GX5/16"; ULTICARE SYRIN 0.3 ML 29GX1/2"; ULTICARE SYRIN 0.5 ML 28GX1/2" <b>MO</b>	1	
INSUPEN 29 GAUGE X 1/2", 30 GAUGE X 5/16", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 1/4", 32 GAUGE X 5/16", 32 GAUGE X 5/32", 33 GAUGE X 5/32" NEEDLE <b>MO</b>	1	
ISTURISA 1 MG TABLET <b>DL</b>	4	PA,QL (240 per 30 days)
ISTURISA 10 MG TABLET <b>DL</b>	4	PA,QL (180 per 30 days)
ISTURISA 5 MG TABLET <b>DL</b>	4	PA,QL (60 per 30 days)
IV PREP WIPES MEDICATED <b>MO</b>	1	
KORLYM 300 MG TABLET <b>DL</b>	4	PA,QL (120 per 30 days)
<i>lactated ringers irrigation</i> <b>MO</b>	1	
LITE TOUCH INSULIN PEN NEEDLES 29 GAUGE X 1/2", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16" <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
LITE TOUCH INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 GAUGE, 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE, 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 30 GAUGE X 7/16", 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE, 1/2 ML 28 GAUGE X 1/2", 1/2 ML 30 GAUGE; LITE TOUCH INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 GAUGE, 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE, 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 30 GAUGE X 7/16", 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE, 1/2 ML 28 GAUGE X 1/2", 1/2 ML 30 GAUGE"; LITE TOUCH INSULIN SYRINGE 1/2 ML 29 <b>MO</b>	1	
LITHOSTAT 250 MG TABLET <b>DL</b>	4	
MAGELLAN INSULIN SAFETY SYRINGE 0.3 ML 29 X 1/2", 0.5 ML 29 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16" <b>MO</b>	1	
MAGELLAN SYRINGE 0.3 ML 30 X 5/16", 0.5 ML 30 GAUGE X 5/16" <b>MO</b>	1	
MAXI-COMFORT INSULIN SYRINGE 1 ML 28 GAUGE X 1/2", 1/2 ML 28 GAUGE X 1/2" <b>MO</b>	1	
MAXICOMFORT II PEN NEEDLE 31 GAUGE X 1/4" <b>MO</b>	1	
MAXICOMFORT INSULIN SYRINGE 1 ML 27 GAUGE X 1/2", 1/2 ML 27 GAUGE X 1/2" <b>MO</b>	1	
MAXICOMFORT SAFETY PEN NEEDLE 29 GAUGE X 3/16", 29 GAUGE X 5/16" <b>MO</b>	1	
<i>methergine 0.2 mg tablet</i> <b>DL</b>	4	
<i>methylergonovine 0.2 mg tablet</i> <b>MO</b>	1	
<i>methylergonovine 0.2 mg/ml amp</i> <b>MO</b>	1	
MICRODOT INSULIN PEN NEEDLE 31 GAUGE X 1/4", 32 GAUGE X 5/32", 33 GAUGE X 5/32" <b>MO</b>	1	
MINI ULTRA-THIN II 31 GAUGE X 3/16" NEEDLE <b>MO</b>	1	
MONOJECT INSULIN SAFETY SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 29 GAUGE X 1/2" <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
MONOJECT INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 25 GAUGE X 5/8", 1 ML 27 GAUGE X 1/2", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE X 1/2"; MONOJECT INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 25 GAUGE X 5/8", 1 ML 27 GAUGE X 1/2", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE X 1/2"; MONOJECT INSULIN SYRINGE 1 ML <b>MO</b>	1	
MONOJECT SYRINGE 1/2 ML 28 GAUGE <b>MO</b>	1	
MONOJECT ULTRA COMFORT INSULIN 1/2 ML 28 GAUGE SYRINGE <b>MO</b>	1	
neomy-polymyxin b 40 mg/ml amp <b>MO</b>	1	
NOVOFINE 32 32 GAUGE X 1/4" NEEDLE <b>MO</b>	1	
NOVOFINE AUTOCOVER 30 GAUGE X 1/3" NEEDLE <b>MO</b>	1	
NOVOFINE PLUS 32 GAUGE X 1/6" NEEDLE <b>MO</b>	1	
NOVOPEN ECHO SUBCUTANEOUS <b>MO</b>	1	
NOVOTWIST 32 GAUGE X 1/5" NEEDLE <b>MO</b>	1	
NURTEC ODT 75 MG DISINTEGRATING TABLET <b>DL</b>	4	PA,QL (8 per 30 days)
OMNIPOD DASH 5 PACK INSULIN POD SUBCUTANEOUS CARTRIDGE <b>MO</b>	2	
OMNIPOD INSULIN MANAGEMENT <b>MO</b>	2	
OMNIPOD INSULIN REFILL SUBCUTANEOUS CARTRIDGE <b>MO</b>	2	
ORIAHNN 300-1-0.5 MG(AM)/300 MG(PM) CAPSULES <b>DL</b>	4	PA,QL (56 per 28 days)
OXBRYTA 500 MG TABLET <b>DL</b>	4	PA,QL (90 per 30 days)
oxytocin 10 unit/ml vial <b>MO</b>	1	
PEN NEEDLE 29 GAUGE X 1/2", 30 GAUGE X 5/16", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 5/32" <b>MO</b>	1	
COMFORT POINT PEN NDL 31GX1/3"; COMFORT POINT PEN NDL 31GX1/6"; FIFTY50 PEN 31G X 3/16" NEEDLE; FIFTY50 PEN NEEDLE 32G X 1/4"; KRO PEN NEEDLE 4MM X 33G; PEN NEEDLE 12MM 29G; PEN NEEDLE 30G X 8MM; PEN NEEDLE 32G X 3/16"; PEN NEEDLE 32G X 5/32"; PEN NEEDLE 8MM 31G; PEN NEEDLES 6MM 31G <b>MO</b>	1	
PENTIPS 29 GAUGE X 1/2", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 5/32" NEEDLE <b>MO</b>	1	
PHYSIOLYTE 140 MEQ-5 MEQ-3 MEQ-98 MEQ/L IRRIGATION SOLUTION <b>MO</b>	1	
PHYSIOSOL IRRIGATION 140 MEQ-5 MEQ-3 MEQ-98 MEQ/L SOLUTION <b>MO</b>	1	
PITOCIN 10 UNIT/ML INJECTION SOLUTION <b>MO</b>	3	
PREVENT DROPSAFE PEN NEEDLE 31 GAUGE X 1/4", 31 GAUGE X 5/16" <b>MO</b>	1	
PRIALT 100 MCG/ML, 25 MCG/ML INTRATHECAL SOLUTION <b>DL</b>	4	PA

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
PRO COMFORT ALCOHOL PADS <b>MO</b>	1	
PRO COMFORT INSULIN SYRINGE 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16; PRO COMFORT INSULIN SYRINGE 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16" <b>MO</b>	1	
PRO COMFORT PEN NEEDLE 31 GAUGE X 5/16", 32 GAUGE X 1/4", 32 GAUGE X 3/16", 32 GAUGE X 5/32" <b>MO</b>	1	
PRODIGY INSULIN SYRINGE 0.3 ML 31 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 GAUGE X 1/2" <b>MO</b>	1	
<i>promethazine vc 6.25 mg-5 mg/5 ml oral syrup</i> <b>MO</b>	1	
<i>promethazine-phenylephrine syr</i> <b>MO</b>	1	
<i>protamine 250 mg/25 ml vial</i> <b>MO</b>	1	
PURE COMFORT ALCOHOL PADS <b>MO</b>	1	
PURE COMFORT PEN NEEDLE 32 GAUGE X 1/4", 32 GAUGE X 3/16", 32 GAUGE X 5/16", 32 GAUGE X 5/32" <b>MO</b>	1	
RECTIV 0.4 % (W/W) OINTMENT <b>MO</b>	3	QL (30 per 30 days)
RELION NEEDLES 31 GAUGE X 1/4" <b>MO</b>	1	
RELION PEN NEEDLES 32 GAUGE X 5/32" <b>MO</b>	1	
RENACIDIN 1980.6 MG-59.4MG-980.4MG/30ML IRRIGATION SOLUTION <b>MO</b>	3	
<i>ribavirin 6 gm inhalation vial</i> <b>DL</b>	4	B vs D
RIMSO-50 50 % INTRAVESICAL SOLUTION <b>DL</b>	4	
<i>ringers irrigation solution</i> <b>MO</b>	1	
SAFESNAP INSULIN SYRINGE 0.3 ML 30 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2" <b>MO</b>	1	
SAFETY PEN NEEDLE 31 GAUGE X 3/16" <b>MO</b>	1	
SEMPREX-D 8 MG-60 MG CAPSULE <b>MO</b>	3	
SIKLOS 1,000 MG TABLET <b>DL</b>	4	PA
SIKLOS 100 MG TABLET <b>MO</b>	3	PA
<i>sod phenylacet-sod benzoate vl</i> <b>DL</b>	4	
<i>sodium chloride 0.9% irrig.</i> <b>MO</b>	1	
<i>sorbitol-mannitol irrig</i> <b>MO</b>	1	
SURE COMFORT ALCOHOL PREP PADS <b>MO</b>	1	
SURE COMFORT INSULIN SYRINGE U-100 0.5 ML 29 GAUGE X 1/2" <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
SURE COMFORT INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 1/4", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 1/4", 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE X 1/2", 1/2 ML 31 GAUGE X 1/4"; SURE COMFORT INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 1/4", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 1/4", 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE X 1/2", 1/2 ML 31 GAUGE X 1/4" <b>MO</b>	1	
SURE COMFORT PEN NEEDLE 29 GAUGE X 1/2", 30 GAUGE X 5/16", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 1/4", 32 GAUGE X 5/32" <b>MO</b>	1	
SURE-FINE PEN NEEDLES 29 GAUGE X 1/2", 31 GAUGE X 3/16", 31 GAUGE X 5/16" <b>MO</b>	1	
SURE-JECT INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE X 1/2"; SURE-JECT INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE X 1/2" <b>MO</b>	1	
SURE-PREP ALCOHOL PREP PADS <b>MO</b>	1	
SYNAGIS 100 MG/ML, 50 MG/0.5 ML INTRAMUSCULAR SOLUTION <b>DL</b>	4	PA
TECHLITE INSULIN SYRINGE HALF UNIT 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 15/64", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 15/64", 0.5 ML 31 GAUGE X 5/16" <b>MO</b>	1	
TECHLITE INSULIN SYRINGE 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 15/64", 1 ML 31 GAUGE X 5/16; TECHLITE INSULIN SYRINGE 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 15/64", 1 ML 31 GAUGE X 5/16" <b>MO</b>	1	
TECHLITE PEN NEEDLE 29 GAUGE X 1/2", 29 GAUGE X 3/8", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 1/4", 32 GAUGE X 5/16", 32 GAUGE X 5/32" <b>MO</b>	1	
TEPEZZA 500 MG INTRAVENOUS SOLUTION <b>DL</b>	4	PA
TERUMO INSULIN SYRINGE 0.3 ML 30 X 3/8", 0.5 ML 29 GAUGE X 1/2", 1 ML 27 GAUGE X 1/2", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1/2 ML 27 GAUGE X 1/2", 1/2 ML 28 GAUGE X 1/2", 1/2 ML 30 X 3/8" <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
THINPRO INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 X 3/8", 0.3 ML 31 X 3/8", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 31 X 3/8", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 3/8", 1 ML 31 X 3/8", 1/2 ML 28 GAUGE X 1/2", 1/2 ML 30 X 3/8" <b>MO</b>	1	
TOPCARE CLICKFINE 31 GAUGE X 1/4", 31 GAUGE X 5/16" NEEDLE <b>MO</b>	1	
TOPCARE ULTRA COMFORT 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16 SYRINGE; TOPCARE ULTRA COMFORT 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16" SYRINGE <b>MO</b>	1	
TRUE COMFORT ALCOHOL PADS <b>MO</b>	1	
TRUE COMFORT INSULIN SYRINGE 0.5 ML 31 GAUGE X 5/16", 1 ML 31 GAUGE X 5/16; TRUE COMFORT INSULIN SYRINGE 0.5 ML 31 GAUGE X 5/16", 1 ML 31 GAUGE X 5/16" <b>MO</b>	1	
TRUE COMFORT PEN NEEDLE 31 GAUGE X 1/4", 31 GAUGE X 3/16", 32 GAUGE X 5/32" <b>MO</b>	1	
TRUEPLUS INSULIN 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE X 1/2" SYRINGE; TRUEPLUS INSULIN 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE X 1/2" SYRINGE <b>MO</b>	1	
TRUEPLUS PEN NEEDLE 29 GAUGE X 1/2", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 5/32" <b>MO</b>	1	
UBRELVY 100 MG, 50 MG TABLET <b>DL</b>	4	PA,QL (8 per 30 days)
ULTICARE 0.3 ML 30 GAUGE X 1/2", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 1/2", 1 ML 31 GAUGE X 5/16 SYRINGE; ULTICARE 0.3 ML 30 GAUGE X 1/2", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 1/2", 1 ML 31 GAUGE X 5/16" SYRINGE <b>MO</b>	1	
ULTICARE INSULIN SYRINGE HALF UNIT 0.3 ML 31 GAUGE X 1/4" <b>MO</b>	1	
ULTICARE INSULIN SYRINGE 0.3 ML 31 GAUGE X 1/4", 1 ML 31 GAUGE X 1/4", 1/2 ML 31 GAUGE X 1/4" <b>MO</b>	1	
ULTICARE PEN NEEDLE 29 GAUGE X 1/2", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 1/4", 32 GAUGE X 5/32" <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ULTIGUARD SAFE PACK 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 1/4", 32 GAUGE X 5/32" NEEDLE <b>MO</b>	1	
ULTILET ALCOHOL SWAB <b>MO</b>	1	
ULTILET INSULIN SYRINGE 0.3 ML 29 GAUGE, 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 29 GAUGE, 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16; ULTILET INSULIN SYRINGE 0.3 ML 29 GAUGE, 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 29 GAUGE, 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16"; ULTILET INSULIN SYRINGE 1/2 ML 29 <b>MO</b>	1	
ULTILET PEN NEEDLE 29 GAUGE, 32 GAUGE X 5/32" <b>MO</b>	1	
ULTRA COMFORT INSULIN SYRINGE HALF UNIT 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16" <b>MO</b>	1	
ULTRA COMFORT INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30, 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 GAUGE, 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE, 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 30 GAUGE X 7/16", 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE, 1/2 ML 28 GAUGE X 1/2", 1/2 ML 30 GAUGE; ULTRA COMFORT INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30, 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 28 GAUGE, 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE, 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 30 GAUGE X 7/16", 1 ML 31 GAUGE X 5/16, 1/2 ML 28 GAUGE, 1/2 ML 28 GAUGE X 1/2", 1/2 ML 30 GAUGE"; ULTRA COMFORT INSULIN SYRINGE 1/2 ML 29 <b>MO</b>	1	
ULTRA FLO INSULIN SYRINGE 0.3 ML 29 GAUGE X 1/2" <b>MO</b>	1	
ULTRA FLO PEN NEEDLE 29 GAUGE X 1/2", 31 GAUGE X 3/16" <b>MO</b>	1	
ULTRA THIN PEN NEEDLE 32 GAUGE X 5/32" <b>MO</b>	1	
ULTRA-THIN II (SHORT) INSULIN SYRINGE 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16; ULTRA-THIN II (SHORT) INSULIN SYRINGE 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16" <b>MO</b>	1	
ULTRA-THIN II (SHORT) PEN NDL 31 GAUGE X 5/16" NEEDLE <b>MO</b>	1	
ULTRA-THIN II INSULIN PEN NEEDLES 29 GAUGE X 1/2" <b>MO</b>	1	
ULTRA-THIN II INSULIN SYRINGE 0.5 ML 29 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2" <b>MO</b>	1	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ULTRACARE INSULIN SYRINGE 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16; ULTRACARE INSULIN SYRINGE 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16" <b>MO</b>	1	
ULTRACARE PEN NEEDLE 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 1/4", 32 GAUGE X 3/16", 32 GAUGE X 5/32", 33 GAUGE X 5/32" <b>MO</b>	1	
UNIFINE PENTIPS 29 GAUGE, 29 GAUGE X 1/2", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 1/4", 32 GAUGE X 5/32", 33 GAUGE X 5/32" NEEDLE <b>MO</b>	1	
UNIFINE PENTIPS MAXFLOW 30 GAUGE X 3/16" NEEDLE <b>MO</b>	1	
UNIFINE PENTIPS PLUS 29 GAUGE X 1/2", 31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 5/32", 33 GAUGE X 5/32" NEEDLE <b>MO</b>	1	
UNIFINE PENTIPS PLUS MAXFLOW 30 GAUGE X 3/16" NEEDLE <b>MO</b>	1	
UNIFINE SAFECONTROL 30 GAUGE X 3/16", 30 GAUGE X 5/16" NEEDLE <b>MO</b>	1	
V-GO 20 DEVICE <b>MO</b>	2	
V-GO 30 DEVICE <b>MO</b>	2	
V-GO 40 DEVICE <b>MO</b>	2	
VANISHPOINT INSULIN SYRINGE 1 ML 30 GAUGE X 3/16" <b>MO</b>	1	
VANISHPOINT SYRINGE 0.5 ML 30 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2" <b>MO</b>	1	
VERIFINE PEN NEEDLE 31 GAUGE X 1/4", 31 GAUGE X 5/16", 32 GAUGE X 3/16", 32 GAUGE X 5/32" <b>MO</b>	1	
VIRAZOLE 6 GRAM SOLUTION FOR INHALATION <b>DL</b>	4	B vs D
<i>sterile water for irrigation</i> <b>MO</b>	1	
WEBCOL TOPICAL PADS <b>MO</b>	1	
XENICAL 120 MG CAPSULE <b>MO</b>	3	PA
<b>OPHTHALMIC AGENTS</b>		
ACULAR 0.5 % EYE DROPS <b>MO</b>	3	ST
ACULAR LS 0.4 % EYE DROPS <b>MO</b>	3	ST
ACUVAIL (PF) 0.45 % EYE DROPS IN A DROPPERETTE <b>MO</b>	3	ST
<i>ak-poly-bac 500 unit-10,000 unit/gram eye ointment</i> <b>MO</b>	1	
AKTEN (PF) 3.5 % EYE GEL <b>MO</b>	3	
ALCAINE 0.5 % EYE DROPS <b>MO</b>	1	
ALOCRIL 2 % EYE DROPS <b>MO</b>	3	
ALOMIDE 0.1 % EYE DROPS <b>MO</b>	3	
ALPHAGAN P 0.1 % EYE DROPS <b>MO</b>	2	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ALPHAGAN P 0.15 % EYE DROPS <sup>MO</sup>	3	PA
ALREX 0.2 % EYE DROPS,SUSPENSION <sup>MO</sup>	3	ST
apraclonidine hcl 0.5% drops <sup>MO</sup>	1	
atropine 1% eye drops <sup>MO</sup>	1	
AZASITE 1 % EYE DROPS <sup>MO</sup>	3	ST,QL (2.5 per 25 days)
azelastine hcl 0.05% drops <sup>MO</sup>	1	
AZOPT 1 % EYE DROPS,SUSPENSION <sup>MO</sup>	3	ST,QL (10 per 28 days)
BACIGUENT 500 UNIT/GRAM EYE OINTMENT <sup>MO</sup>	1	
bacitracin 500 unit/gm ophth <sup>MO</sup>	1	
bacitracin-polymyxin eye oint <sup>MO</sup>	1	
balanced salt intraocular solution <sup>MO</sup>	1	
BEPREVE 1.5 % EYE DROPS <sup>MO</sup>	3	ST,QL (5 per 25 days)
BESIVANCE 0.6 % EYE DROPS,SUSPENSION <sup>MO</sup>	3	ST
BETADINE OPHTHALMIC PREP 5 % SOLUTION <sup>MO</sup>	3	
betaxolol hcl 0.5% eye drop <sup>MO</sup>	1	
BETIMOL 0.25 %, 0.5 % EYE DROPS <sup>MO</sup>	3	ST
BETOPTIC S 0.25 % EYE DROPS,SUSPENSION <sup>MO</sup>	3	ST
bimatoprost 0.03% eye drops <sup>MO</sup>	1	QL (2.5 per 25 days)
BLEPH-10 10 % EYE DROPS <sup>MO</sup>	1	
BLEPHAMIDE 10 %-0.2 % EYE DROPS,SUSPENSION <sup>MO</sup>	3	
BLEPHAMIDE S.O.P. 10 %-0.2 % EYE OINTMENT <sup>MO</sup>	1	
brimonidine 0.2% eye drop; brimonidine tartrate 0.15% drp <sup>MO</sup>	1	
bromfenac sodium 0.09% eye drp <sup>MO</sup>	1	QL (1.7 per 30 days)
BROMSITE 0.075 % EYE DROPS <sup>MO</sup>	3	ST,QL (5 per 30 days)
BSS INTRAOCULAR SOLUTION <sup>MO</sup>	3	
BSS PLUS INTRAOCULAR SOLUTION <sup>MO</sup>	3	
carteolol hcl 1% eye drops <sup>MO</sup>	1	
CEQUA 0.09 % EYE DROPS IN A DROPPERETTE <sup>MO</sup>	3	PA,QL (60 per 30 days)
CILOXAN 0.3 % EYE DROPS <sup>MO</sup>	3	
CILOXAN 0.3 % EYE OINTMENT <sup>MO</sup>	3	
ciprofloxacin 0.3% eye drop <sup>MO</sup>	1	
COMBIGAN 0.2 %-0.5 % EYE DROPS <sup>MO</sup>	2	QL (5 per 25 days)
COSOPT 22.3 MG-6.8 MG/ML EYE DROPS <sup>MO</sup>	3	ST,QL (10 per 30 days)
COSOPT (PF) 2 %-0.5 % EYE DROPS IN A DROPPERETTE <sup>MO</sup>	3	ST,QL (60 per 30 days)
cromolyn 4% eye drops <sup>MO</sup>	1	
CYSTARAN 0.44 % EYE DROPS <sup>DL</sup>	4	PA,QL (60 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>dexamethasone 0.1% eye drop</i> <b>MO</b>	1	
DEXTENZA 0.4 MG INTRACANALICULAR INSERT <b>MO</b>	3	B vs D,QL (1 per 30 days)
<i>diclofenac 0.1% eye drops</i> <b>MO</b>	1	
<i>dorzolamide hcl 2% eye drops</i> <b>MO</b>	1	QL (10 per 30 days)
<i>dorzolamide-timolol eye drops</i> <b>MO</b>	1	QL (10 per 30 days)
<i>dorzolamide-timolol 2%-0.5%</i> <b>MO</b>	1	ST,QL (60 per 30 days)
DUREZOL 0.05 % EYE DROPS <b>MO</b>	2	
DURYSTA 10 MCG INTRACAMERAL IMPLANT <b>DL</b>	4	PA,QL (2 per 365 days)
ELESTAT 0.05% EYE DROPS <b>MO</b>	3	ST,QL (5 per 25 days)
EMADINE 0.05% EYE DROPS <b>MO</b>	3	ST
<i>epinastine hcl 0.05% eye drops</i> <b>MO</b>	1	ST,QL (5 per 25 days)
<i>erythromycin 0.5% eye ointment</i> <b>MO</b>	1	
FLAREX 0.1 % EYE DROPS,SUSPENSION <b>MO</b>	3	ST
<i>fluorometholone 0.1% drops</i> <b>MO</b>	1	
<i>flurbiprofen 0.03% eye drop</i> <b>MO</b>	1	
FML FORTE 0.25 % EYE DROPS,SUSPENSION <b>MO</b>	3	ST
FML LIQUIFILM 0.1 % EYE DROPS,SUSPENSION <b>MO</b>	3	ST
FML S.O.P. 0.1 % EYE OINTMENT <b>MO</b>	3	ST
<i>gatifloxacin 0.5% eye drops</i> <b>MO</b>	1	QL (2.5 per 25 days)
<i>gentak 0.3 % (3 mg/gram) eye ointment</i> <b>MO</b>	1	
<i>gentamicin 3 mg/ml eye drop</i> <b>MO</b>	1	
ILEVRO 0.3 % EYE DROPS,SUSPENSION <b>MO</b>	2	QL (3 per 30 days)
INVELTYS 1 % EYE DROPS,SUSPENSION <b>MO</b>	3	ST
IOPIDINE 0.5% EYE DROPS <b>MO</b>	3	PA
IOPIDINE 1 % EYE DROPS IN A DROPPERETTE <b>MO</b>	3	
ISOPTO CARPINE 1 %, 2 %, 4 % EYE DROPS <b>MO</b>	3	
ISTALOL 0.5 % EYE DROPS <b>MO</b>	3	
<i>ketorolac 0.4% ophth solution; ketorolac 0.5% ophth solution</i> <b>MO</b>	1	
LACRISERT 5 MG EYE INSERTS <b>MO</b>	3	
LASTACFT 0.25 % EYE DROPS <b>MO</b>	3	ST
<i>latanoprost 0.005% eye drops</i> <b>MO</b>	1	QL (5 per 25 days)
<i>levobunolol 0.5% eye drops</i> <b>MO</b>	1	
<i>levofloxacin 0.5% eye drops</i> <b>MO</b>	1	
LOTEMAX 0.5 % EYE DROPS,SUSPENSION; LOTEMAX 0.5 % EYE GEL DROPS <b>MO</b>	3	ST
LOTEMAX 0.5 % EYE OINTMENT <b>MO</b>	3	ST
LOTEMAX SM 0.38 % EYE GEL DROPS <b>MO</b>	3	

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
loteprednol etabonate 0.5% drp <sup>MO</sup>	1	ST
LUMIGAN 0.01 % EYE DROPS <sup>MO</sup>	2	QL (2.5 per 25 days)
MAXIDEX 0.1 % EYE DROPS,SUSPENSION <sup>MO</sup>	3	ST
MAXITROL 3.5 MG/G-10,000 UNIT/G-0.1 % EYE OINTMENT <sup>MO</sup>	3	
MAXITROL 3.5 MG/ML-10,000 UNIT/ML-0.1% EYE DROPS,SUSPENSION <sup>MO</sup>	1	
metipranolol 0.3% eye drops <sup>MO</sup>	1	
MIOSTAT 0.01 % INTRAOCULAR SOLUTION <sup>MO</sup>	3	
MOXEZA 0.5 % EYE DROPS <sup>MO</sup>	3	ST
moxifloxacin 0.5% eye drops <sup>MO</sup>	1	
moxifloxacin 0.5% eye drops <sup>MO</sup>	1	ST
NATACYN 5 % EYE DROPS,SUSPENSION <sup>MO</sup>	3	
neo-polycin 3.5 mg-400 unit-10,000 unit/g eye ointment <sup>MO</sup>	1	
neo-polycin hc 3.5 mg-400-10,000 unit/g-1 % eye ointment <sup>MO</sup>	1	
neo-bacit-poly-hc eye ointment <sup>MO</sup>	1	
neomyc-bacit-polymix eye oint <sup>MO</sup>	1	
neomyc-polym-dexamet eye ointm <sup>MO</sup>	1	
neomyc-polym-dexameth eye drop <sup>MO</sup>	1	
neomyc-polym-gramicid eye drop <sup>MO</sup>	1	
neomycin-poly-hc eye drops <sup>MO</sup>	1	
NEVANAC 0.1 % EYE DROPS,SUSPENSION <sup>MO</sup>	3	ST
OCUFLOX 0.3 % EYE DROPS <sup>MO</sup>	3	
ofloxacin 0.3% eye drops <sup>MO</sup>	1	
olopatadine hcl 0.1% eye drops <sup>MO</sup>	1	ST
olopatadine hcl 0.2% eye drop <sup>MO</sup>	1	
OMNIPRED 1% EYE DROPS <sup>MO</sup>	3	ST
OXERVATE 0.002 % EYE DROPS <sup>DL</sup>	4	PA,QL (112 per 365 days)
PATADAY 0.2 % EYE DROPS <sup>MO</sup>	3	ST
PATANOL 0.1% EYE DROPS <sup>MO</sup>	3	ST
PAZEO 0.7 % EYE DROPS <sup>MO</sup>	2	QL (2.5 per 25 days)
PHOSPHOLINE IODIDE 0.125 % EYE DROPS <sup>MO</sup>	3	
<sup>MO</sup> pilocarpine 1% eye drops; pilocarpine 2% eye drops; pilocarpine 4% eye drops	1	
polycin 500 unit-10,000 unit/gram eye ointment <sup>MO</sup>	1	
polymyxin b-tmp eye drops <sup>MO</sup>	1	
POLYTRIM 10,000 UNIT-1 MG/ML EYE DROPS <sup>MO</sup>	3	
PRED FORTE 1 % EYE DROPS,SUSPENSION <sup>MO</sup>	3	ST
PRED MILD 0.12 % EYE DROPS,SUSPENSION <sup>MO</sup>	3	ST

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
PRED-G 0.3 %-1 % EYE DROPS,SUSPENSION <sup>MO</sup>	3	
PRED-G S.O.P. 0.3 %-0.6 % EYE OINTMENT <sup>MO</sup>	3	
<i>prednisolone ac 1% eye drop</i> <sup>MO</sup>	1	
<i>prednisolone sod 1% eye drop</i> <sup>MO</sup>	1	
PROLENSA 0.07 % EYE DROPS <sup>MO</sup>	3	ST,QL (3 per 30 days)
<i>proparacaine 0.5% eye drops</i> <sup>MO</sup>	1	
RESTASIS 0.05 % EYE DROPS IN A DROPPERETTE <sup>MO</sup>	2	QL (60 per 30 days)
RESTASIS MULTIDOSE 0.05 % EYE DROPS <sup>MO</sup>	2	QL (5.5 per 25 days)
RHOPRESSA 0.02 % EYE DROPS <sup>MO</sup>	2	ST,QL (2.5 per 25 days)
ROCKLATAN 0.02 %-0.005 % EYE DROPS <sup>MO</sup>	2	ST,QL (2.5 per 25 days)
SIMBRINZA 1 %-0.2 % EYE DROPS,SUSPENSION <sup>MO</sup>	3	ST,QL (16 per 30 days)
<i>sulfacetamide 10% eye drops</i> <sup>MO</sup>	1	
<i>sulf-pred 10-0.23% eye drops</i> <sup>MO</sup>	1	
<i>timolol 0.25% gfs gel-solution; timolol 0.5% gfs gel-solution</i> <sup>MO</sup>	1	
<i>timolol 0.5% eye drop; timolol maleate 0.25% eye drop; timolol maleate 0.5% eye drops</i> <sup>MO</sup>	1	
TIMOPTIC 0.25 %, 0.5 % EYE DROPS <sup>MO</sup>	3	ST
TIMOPTIC OCUDOSE (PF) 0.25 %, 0.5 % EYE DROPS IN A DROPPERETTE <sup>MO</sup>	3	ST
TIMOPTIC-XE 0.25 %, 0.5 % EYE GEL <sup>MO</sup>	3	PA
TOBRADEX 0.3 %-0.1 % EYE DROPS,SUSPENSION <sup>MO</sup>	3	
TOBRADEX 0.3 %-0.1 % EYE OINTMENT <sup>MO</sup>	3	
TOBRADEX ST 0.3 %-0.05 % EYE DROPS,SUSPENSION <sup>MO</sup>	3	
<i>tobramycin 0.3% eye drop</i> <sup>MO</sup>	1	
<i>tobramycin-dexameth ophth susp</i> <sup>MO</sup>	1	
TOBREX 0.3 % EYE DROPS <sup>MO</sup>	3	
TOBREX 0.3 % EYE OINTMENT <sup>MO</sup>	3	
TRAVATAN Z 0.004 % EYE DROPS <sup>MO</sup>	3	ST,QL (2.5 per 25 days)
<i>travoprost 0.004% eye drop</i> <sup>MO</sup>	1	QL (2.5 per 25 days)
<i>trifluridine 1% eye drops</i> <sup>MO</sup>	1	
TRUSOPT 2 % EYE DROPS <sup>MO</sup>	3	QL (10 per 30 days)
VIGAMOX 0.5 % EYE DROPS <sup>MO</sup>	3	PA
VYZULTA 0.024 % EYE DROPS <sup>MO</sup>	3	QL (5 per 30 days)
XALATAN 0.005 % EYE DROPS <sup>MO</sup>	3	PA,QL (5 per 25 days)
XELPROS 0.005 % EYE DROP EMULSION <sup>MO</sup>	3	ST,QL (2.5 per 25 days)
XIIDRA 5 % EYE DROPS IN A DROPPERETTE <sup>MO</sup>	3	PA,QL (60 per 30 days)
ZERVIAE 0.24 % EYE DROPS IN A DROPPERETTE <sup>MO</sup>	3	ST,QL (60 per 30 days)
ZIOPTAN (PF) 0.0015 % EYE DROPS IN A DROPPERETTE <sup>MO</sup>	3	ST,QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
ZYLET 0.3 %-0.5 % EYE DROPS,SUSPENSION <b>MO</b>	3	
ZYMAXID 0.5 % EYE DROPS <b>MO</b>	3	ST,QL (2.5 per 25 days)
<b>Otic Agents</b>		
CIPRO HC 0.2 %-1 % EAR DROPS,SUSPENSION <b>MO</b>	3	
CIPRODEX 0.3 %-0.1 % EAR DROPS,SUSPENSION <b>MO</b>	3	
<i>ciprofloxacin 0.2% otic soln</i> <b>MO</b>	1	
<i>ciproflox-dexameth otic susp</i> <b>MO</b>	1	
<i>ciproflox-fluocinoln 0.3-0.025%</i> <b>MO</b>	3	
COLY-MYCIN S OTIC SUSP DROP <b>MO</b>	3	
CORTISPORIN-TC 3.3 MG-3 MG-10 MG-0.5 MG/ML EAR DROPS,SUSPENSION <b>MO</b>	3	
DERMOTIC OIL 0.01 % EAR DROPS <b>MO</b>	3	
<i>flac otic (ear) oil 0.01 % drops</i> <b>MO</b>	1	
<i>fluocinolone oil 0.01% ear drp</i> <b>MO</b>	1	
<i>hydrocortison-acetic acid soln</i> <b>MO</b>	1	
<i>neomycin-polymyxin-hc ear soln</i> <b>MO</b>	1	
<i>neomycin-polymyxin-hc ear susp</i> <b>MO</b>	1	
<i>ofloxacin 0.3% ear drops</i> <b>MO</b>	1	
OTOVEL 0.3 %-0.025 % (0.25 ML) EAR SOLUTION <b>MO</b>	3	
<b>Respiratory Tract/Pulmonary Agents</b>		
ACCOLATE 10 MG, 20 MG TABLET <b>MO</b>	3	PA,QL (60 per 30 days)
<i>acetylcysteine 10% vial; acetylcysteine 20% vial</i> <b>MO</b>	1	B vs D
ADCIRCA 20 MG TABLET <b>DL</b>	4	PA,QL (60 per 30 days)
ADEMPAS 0.5 MG, 1 MG, 1.5 MG, 2 MG, 2.5 MG TABLET <b>DL</b>	4	PA,QL (90 per 30 days)
ADRENALIN 1 MG/ML, 1 MG/ML (1 ML) INJECTION SOLUTION <b>MO</b>	3	
ADVAIR DISKUS 100 MCG-50 MCG/DOSE POWDER FOR INHALATION; ADVAIR DISKUS 250 MCG-50 MCG/DOSE POWDER FOR INHALATION; ADVAIR DISKUS 500 MCG-50 MCG/DOSE POWDER FOR INHALATION <b>MO</b>	2	QL (60 per 30 days)
ADVAIR HFA 115 MCG-21 MCG/ACTUATION AEROSOL INHALER; ADVAIR HFA 230 MCG-21 MCG/ACTUATION AEROSOL INHALER; ADVAIR HFA 45 MCG-21 MCG/ACTUATION AEROSOL INHALER <b>MO</b>	2	QL (12 per 30 days)
AIRDUO DIGIHALER 113 MCG-14 MCG/ACTUATION, 232-14 MCG/ACTUATION, 55-14 MCG/ACTUATION BREATH ACT,POWDER SENSOR; AIRDUO DIGIHALER 232 MCG-14 MCG/ACTUATION BREATH ACT,POWDER SENSOR; AIRDUO DIGIHALER 55 MCG-14 MCG/ACTUATION BREATH ACT,POWDER SENSOR <b>MO</b>	3	ST,QL (1 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
AIRDUO RESPICLICK 113 MCG-14 MCG/ACTUATION BREATH ACTIVATED; AIRDUO RESPICLICK 232 MCG-14 MCG/ACTUATION BREATH ACTIVATED; AIRDUO RESPICLICK 55 MCG-14 MCG/ACTUATION BREATH ACTIVATED <sup>MO</sup>	3	ST,QL (1 per 30 days)
albuterol 0.63 mg/3 ml, 1.25 mg/3 ml, 2.5 mg /3 ml (0.083 %), 2.5 mg/0.5 ml, 5 mg/ml sol; albuterol 0.63 mg/3 ml, 1.25 mg/3 ml, 2.5 mg /3 ml (0.083 %), 2.5 mg/0.5 ml, 5 mg/ml solution; albuterol sul 0.63 mg/3 ml, 1.25 mg/3 ml, 2.5 mg /3 ml (0.083 %), 2.5 mg/0.5 ml, 5 mg/ml sol; albuterol sul 2.5 mg/3 ml soln <sup>MO</sup>	1	B vs D
albuterol hfa 90 mcg inhaler <sup>MO</sup>	1	QL (36 per 30 days)
albuterol sulf 2 mg/5 ml syrup <sup>MO</sup>	1	
albuterol sulfate 2 mg tab <sup>MO</sup>	1	QL (120 per 30 days)
albuterol sulfate 4 mg tab <sup>MO</sup>	1	
albuterol sulfate er 4 mg, 8 mg tab <sup>MO</sup>	1	
ALVESCO 160 MCG/ACTUATION, 80 MCG/ACTUATION AEROSOL INHALER <sup>MO</sup>	3	ST,QL (18.3 per 28 days)
alyq 20 mg tablet <sup>MO</sup>	1	PA,QL (60 per 30 days)
ambrisentan 10 mg, 5 mg tablet <sup>DL</sup>	4	PA,QL (30 per 30 days)
aminophylline 250 mg/10 ml, 500 mg/20 ml vial <sup>MO</sup>	1	
ANORO ELLIPTA 62.5 MCG-25 MCG/ACTUATION POWDER FOR INHALATION <sup>MO</sup>	3	PA,QL (60 per 30 days)
ARCAPTA NEOHALER 75 MCG CAPSULE WITH INHALATION DEVICE <sup>MO</sup>	3	PA,QL (30 per 30 days)
ARMONAIR RESPICLICK 113 MCG; ARMONAIR RESPICLICK 113 MCG/ACTUATION, 232 MCG/ACTUATION, 55 MCG/ACTUATION BREATH ACTIVATED POWDER INHALER <sup>MO</sup>	3	ST,QL (1 per 30 days)
ARNUIITY ELLIPTA 100 MCG/ACTUATION, 200 MCG/ACTUATION, 50 MCG/ACTUATION POWDER FOR INHALATION <sup>MO</sup>	2	QL (30 per 30 days)
ASMANEX HFA 100 MCG/ACTUATION, 200 MCG/ACTUATION, 50 MCG/ACTUATION AEROSOL INHALER <sup>MO</sup>	3	ST,QL (13 per 30 days)
ASMANEX TWISTHALER 110 MCG/ACTUATION(30 DOSES) BREATH ACTIVATED INHALR; ASMANEX TWISTHALER 220 MCG/ACTUATION(120 DOSES) BREATH ACTIVATED INHLR; ASMANEX TWISTHALER 220 MCG/ACTUATION(14 DOSES) BREATH ACTIVATED INHALR; ASMANEX TWISTHALER 220 MCG/ACTUATION(30 DOSES) BREATH ACTIVATED INHALR; ASMANEX TWISTHALER 220 MCG/ACTUATION(60 DOSES) BREATH ACTIVATED INHALR <sup>MO</sup>	3	ST,QL (1 per 28 days)
ATROVENT HFA 17 MCG/ACTUATION AEROSOL INHALER <sup>MO</sup>	3	QL (25.8 per 30 days)
azelastine 0.1% (137 mcg) spry <sup>MO</sup>	1	QL (30 per 25 days)
azelastine 0.15% nasal spray <sup>MO</sup>	1	QL (30 per 25 days)
azelastin-flutic 137-50mcg spr <sup>MO</sup>	1	ST,QL (23 per 28 days)
BECONASE AQ 42 MCG (0.042 %) NASAL SPRAY <sup>MO</sup>	3	ST,QL (50 per 30 days)
BEVESPI AEROSPHERE 9 MCG-4.8 MCG HFA AEROSOL INHALER <sup>MO</sup>	3	QL (10.7 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>bosentan 125 mg, 62.5 mg tablet</i> <b>DL</b>	4	PA,QL (60 per 30 days)
BREO ELLIPTA 100 MCG-25 MCG/DOSE POWDER FOR INHALATION; BREO ELLIPTA 200 MCG-25 MCG/DOSE POWDER FOR INHALATION <b>MO</b>	2	QL (60 per 30 days)
BREZTRI AEROSPHERE 160 MCG-9MCG-4.8MCG/ACTUATION HFA AEROSOL INHALER <b>MO</b>	2	QL (10.7 per 30 days)
BROVANA 15 MCG/2 ML SOLUTION FOR NEBULIZATION <b>DL</b>	4	PA,QL (120 per 30 days)
<i>budesonide 0.25 mg/2 ml, 0.5 mg/2 ml, 1 mg/2 ml inh susp; budesonide 0.25 mg/2 ml, 0.5 mg/2 ml, 1 mg/2 ml susp</i> <b>MO</b>	1	B vs D
<i>carbinoxamine 4 mg/5 ml liquid</i> <b>MO</b>	1	
<i>carbinoxamine maleate 4 mg tab</i> <b>MO</b>	1	
<i>carbinoxamine maleate 6 mg tab</i> <b>MO</b>	1	QL (120 per 30 days)
CAYSTON 75 MG/ML SOLUTION FOR NEBULIZATION <b>DL</b>	4	PA,QL (84 per 28 days)
<i>cetirizine hcl 1 mg/ml soln</i> <b>MO</b>	1	QL (300 per 30 days)
CINQAIR 10 MG/ML INTRAVENOUS SOLUTION <b>DL</b>	4	PA
CLARINEX 0.5 MG/ML (2.5 MG/5) <b>MO</b>	3	ST,QL (300 per 30 days)
CLARINEX 5 MG TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
<i>clemastine fum 2.68 mg tab</i> <b>MO</b>	1	
COMBIVENT RESPIMAT 20 MCG-100 MCG/ACTUATION SOLUTION FOR INHALATION <b>MO</b>	3	QL (4 per 20 days)
<i>cromolyn 100 mg/5 ml oral conc</i> <b>MO</b>	1	
<i>cromolyn 20 mg/2 ml neb soln</i> <b>DL</b>	4	B vs D
<i>cyproheptadine 2 mg/5 ml syrup</i> <b>MO</b>	1	
<i>cyproheptadine 4 mg tablet</i> <b>MO</b>	1	
DALIRESP 250 MCG TABLET <b>MO</b>	2	QL (28 per 365 days)
DALIRESP 500 MCG TABLET <b>MO</b>	2	QL (30 per 30 days)
<i>desloratadine 2.5 mg, 5 mg odt</i> <b>MO</b>	1	ST,QL (30 per 30 days)
<i>desloratadine 5 mg tablet</i> <b>MO</b>	1	QL (30 per 30 days)
<i>dexchlorpheniramine 2 mg/5 ml</i> <b>MO</b>	1	PA
<i>diphen 12.5 mg/5 ml oral elixir</i> <b>MO</b>	1	
<i>diphenhydramine 12.5 mg/5 ml</i> <b>MO</b>	1	
<i>diphenhydramine 50 mg/ml syrng</i> <b>MO</b>	1	
<i>diphenhydramine 50 mg/ml vial</i> <b>MO</b>	1	
DOPRAM 20 MG/ML INTRAVENOUS SOLUTION <b>MO</b>	3	
DUAKLIR PRESSAIR 400 MCG-12 MCG/ACTUATION BREATH ACTIVATED <b>DL</b>	4	PA,QL (1 per 30 days)
DULERA 100 MCG-5 MCG/ACTUATION HFA AEROSOL INHALER; DULERA 200 MCG-5 MCG/ACTUATION HFA AEROSOL INHALER; DULERA 50 MCG-5 MCG/ACTUATION HFA AEROSOL INHALER <b>MO</b>	3	ST,QL (13 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
DYMISTA 137 MCG-50 MCG/SPRAY NASAL SPRAY <b>MO</b>	3	ST,QL (23 per 28 days)
ELIXOPHYLLIN 80 MG/15 ML ORAL ELIXIR <b>MO</b>	1	
<i>epinephrine 0.15 mg auto-inject; epinephrine 0.3 mg auto-inject</i> <b>MO</b>	1	QL (4 per 30 days)
EPIPEN 0.3 MG/0.3 ML INJECTION, AUTO-INJECTOR <b>MO</b>	3	PA,QL (4 per 30 days)
EPIPEN 2-PAK 0.3 MG/0.3 ML INJECTION, AUTO-INJECTOR <b>MO</b>	3	PA,QL (4 per 30 days)
EPIPEN JR 0.15 MG/0.3 ML INJECTION,AUTO-INJECTOR <b>MO</b>	3	PA,QL (4 per 30 days)
EPIPEN JR 2-PAK 0.15 MG/0.3 ML INJECTION,AUTO-INJECTOR <b>MO</b>	3	PA,QL (4 per 30 days)
<i>epoprostenol sodium 0.5 mg, 1.5 mg v1</i> <b>DL</b>	4	PA
ESBRIET 267 MG CAPSULE <b>DL, LA</b>	4	PA,QL (270 per 30 days)
ESBRIET 267 MG TABLET <b>DL, LA</b>	4	PA,QL (270 per 30 days)
ESBRIET 801 MG TABLET <b>DL, LA</b>	4	PA,QL (90 per 30 days)
FASENRA 30 MG/ML SUBCUTANEOUS SYRINGE <b>DL</b>	4	PA,QL (1 per 28 days)
FASENRA PEN 30 MG/ML SUBCUTANEOUS AUTO-INJECTOR <b>DL</b>	4	PA,QL (1 per 28 days)
FLOVENT DISKUS 100 MCG/ACTUATION, 250 MCG/ACTUATION, 50 MCG/ACTUATION POWDER FOR INHALATION <b>MO</b>	2	QL (60 per 30 days)
FLOVENT HFA 110 MCG/ACTUATION, 220 MCG/ACTUATION AEROSOL INHALER <b>MO</b>	2	QL (24 per 30 days)
FLOVENT HFA 44 MCG/ACTUATION AEROSOL INHALER <b>MO</b>	2	QL (10.6 per 30 days)
<i>flunisolide 0.025% spray</i> <b>MO</b>	1	QL (50 per 30 days)
<i>fluticasone-salmeterol 100-50; fluticasone-salmeterol 250-50;</i>	1	QL (60 per 30 days)
<i>fluticasone-salmeterol 500-50</i> <b>MO</b>		
<i>fluticasone-salmeterol 113-14; fluticasone-salmeterol 232-14;</i>	2	QL (1 per 30 days)
<i>fluticasone-salmeterol 55-14</i> <b>MO</b>		
<i>fluticasone prop 50 mcg spray</i> <b>MO</b>	1	QL (16 per 30 days)
GASTROCROM 100 MG/5 ML ORAL CONCENTRATE <b>DL</b>	4	
GRASTEK 2,800 BAU SUBLINGUAL TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
<i>hydroxyzine pam 100 mg, 25 mg, 50 mg cap</i> <b>MO</b>	1	
INCRUSE ELLIPTA 62.5 MCG/ACTUATION POWDER FOR INHALATION <b>MO</b>	3	PA,QL (30 per 30 days)
<i>ipratropium 0.03% spray</i> <b>MO</b>	1	QL (30 per 30 days)
<i>ipratropium 0.06% spray</i> <b>MO</b>	1	QL (45 per 30 days)
<i>ipratropium br 0.02% soln</i> <b>MO</b>	1	B vs D
<i>iprat-albut 0.5-3(2.5) mg/3 ml</i> <b>MO</b>	1	B vs D
KALYDECO 150 MG TABLET <b>DL</b>	4	PA,QL (60 per 30 days)
KALYDECO 25 MG, 50 MG, 75 MG ORAL GRANULES IN PACKET <b>DL</b>	4	PA,QL (56 per 28 days)
KARBINAL ER 4 MG/5 ML ORAL SUSPENSION,EXTENDED RELEASE <b>MO</b>	3	
LETAIRIS 10 MG, 5 MG TABLET <b>DL</b>	4	PA,QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
levalbuterol 0.31 mg/3 ml, 0.63 mg/3 ml, 1.25 mg/0.5 ml, 1.25 mg/3 ml sol; levalbuterol conc 1.25 mg/0.5 <sup>MO</sup>	1	B vs D
levalbuterol tar hfa 45mcg inh <sup>MO</sup>	1	ST,QL (30 per 30 days)
levocetirizine 2.5 mg/5 ml sol <sup>MO</sup>	1	QL (300 per 30 days)
levocetirizine 5 mg tablet <sup>MO</sup>	1	QL (30 per 30 days)
LONHALA MAGNAIR REFILL 25 MCG/ML SOLUTION FOR NEBULIZATION <sup>DL</sup>	4	PA,QL (60 per 30 days)
LONHALA MAGNAIR STARTER 25 MCG/ML SOLUTION FOR NEBULIZATION <sup>DL</sup>	4	PA,QL (60 per 365 days)
metaproterenol 10 mg, 20 mg tablet <sup>MO</sup>	1	
metaproterenol 10 mg/5 ml syr <sup>MO</sup>	1	
mometasone furoate 50 mcg spry <sup>MO</sup>	1	ST,QL (34 per 30 days)
montelukast sod 10 mg tablet <sup>MO</sup>	1	QL (30 per 30 days)
montelukast sod 4 mg granules <sup>MO</sup>	1	QL (30 per 30 days)
montelukast sod 4 mg, 5 mg tab chew <sup>MO</sup>	1	QL (30 per 30 days)
NASONEX 50 MCG/ACTUATION SPRAY <sup>MO</sup>	3	ST,QL (34 per 30 days)
NUCALA 100 MG, 100 MG/ML SUBCUTANEOUS AUTO-INJECTOR; NUCALA 100 MG, 100 MG/ML SUBCUTANEOUS SOLUTION <sup>DL</sup>	4	PA,QL (3 per 28 days)
NUCALA 100 MG/ML SUBCUTANEOUS SYRINGE <sup>DL</sup>	4	PA,QL (3 per 28 days)
ODACTRA 12 SQ-HDM SUBLINGUAL TABLET <sup>MO</sup>	3	PA,QL (30 per 30 days)
OFEV 100 MG, 150 MG CAPSULE <sup>DL, LA</sup>	4	PA,QL (60 per 30 days)
olopatadine 665 mcg nasal spry <sup>MO</sup>	1	ST,QL (30.5 per 30 days)
OMNARIS 50 MCG NASAL SPRAY <sup>MO</sup>	3	ST,QL (12.5 per 30 days)
OPSUMIT 10 MG TABLET <sup>DL</sup>	4	PA,QL (30 per 30 days)
ORALAIR 100 INDEX OF REACTIVITY SUBLINGUAL TABLET; ORALAIR 100 INDEX OF REACTIVITY(3)/300 IDX REACT.(6) SUBLINGUAL TABLET; ORALAIR 300 IR SUBLINGUAL TABLET <sup>MO</sup>	3	PA,QL (30 per 30 days)
ORENITRAM 0.125 MG TABLET,EXTENDED RELEASE <sup>DL</sup>	4	PA,QL (1000 per 30 days)
ORENITRAM 0.25 MG TABLET,EXTENDED RELEASE <sup>DL</sup>	4	PA,QL (500 per 30 days)
ORENITRAM 1 MG TABLET,EXTENDED RELEASE <sup>DL</sup>	4	PA,QL (720 per 30 days)
ORENITRAM 2.5 MG TABLET,EXTENDED RELEASE <sup>DL</sup>	4	PA,QL (300 per 30 days)
ORENITRAM 5 MG TABLET, EXTENDED RELEASE <sup>DL</sup>	4	PA,QL (150 per 30 days)
ORKAMBI 100 MG-125 MG ORAL GRANULES IN PACKET; ORKAMBI 150 MG-188 MG ORAL GRANULES IN PACKET <sup>DL</sup>	4	PA,QL (56 per 28 days)
ORKAMBI 100 MG-125 MG TABLET; ORKAMBI 200 MG-125 MG TABLET <sup>DL</sup>	4	PA,QL (112 per 28 days)
PATANASE 0.6 % NASAL SPRAY <sup>MO</sup>	3	ST,QL (30.5 per 30 days)
PERFORMIST 20 MCG/2 ML SOLUTION FOR NEBULIZATION <sup>MO</sup>	3	PA,QL (120 per 30 days)
PROAIR DIGIHALER 90 MCG/ACTUATION AEROSOL POWDER BREATH ACT, SENSOR <sup>MO</sup>	3	ST,QL (2 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
PROAIR HFA 90 MCG/ACTUATION AEROSOL INHALER <b>MO</b>	3	ST,QL (36 per 30 days)
PROAIR RESPICLICK 90 MCG/ACTUATION BREATH ACTIVATED <b>MO</b>	3	ST,QL (2 per 30 days)
PROVENTIL HFA 90 MCG/ACTUATION AEROSOL INHALER <b>MO</b>	3	ST,QL (36 per 30 days)
PULMICORT 0.25 MG/2 ML, 0.5 MG/2 ML, 1 MG/2 ML SUSPENSION FOR NEBULIZATION <b>MO</b>	3	B vs D
PULMICORT FLEXHALER 180 MCG/ACTUATION, 90 MCG/ACTUATION BREATH ACTIVATED <b>MO</b>	3	ST,QL (2 per 30 days)
PULMOZYME 1 MG/ML SOLUTION FOR INHALATION <b>DL</b>	4	B vs D
QNASL 40 MCG/ACTUATION NASAL AEROSOL SPRAY <b>MO</b>	3	ST,QL (6.8 per 30 days)
QNASL 80 MCG/ACTUATION NASAL AEROSOL SPRAY <b>MO</b>	3	ST,QL (10.6 per 30 days)
QUZYTIR 10 MG/ML INTRAVENOUS SOLUTION <b>MO</b>	3	B vs D
QVAR REDHALER 40 MCG/ACTUATION HFA BREATH ACTIVATED AEROSOL <b>MO</b>	3	ST,QL (10.6 per 30 days)
QVAR REDHALER 80 MCG/ACTUATION HFA BREATH ACTIVATED AEROSOL <b>MO</b>	3	ST,QL (21.2 per 30 days)
RAGWITEK 12 AMB A 1 UNIT SUBLINGUAL TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
REMODULIN 1 MG/ML, 10 MG/ML, 2.5 MG/ML, 5 MG/ML INJECTION SOLUTION <b>DL</b>	4	PA
REVATIO 10 MG/ML ORAL SUSPENSION <b>DL</b>	4	PA,QL (180 per 30 days)
REVATIO 20 MG TABLET <b>DL</b>	4	PA,QL (90 per 30 days)
RYCLORA 2 MG/5 ML ORAL SOLUTION <b>MO</b>	1	
RYVENT 6 MG TABLET <b>MO</b>	1	QL (120 per 30 days)
SEEBRI NEOHALER 15.6 MCG CAPSULE WITH INHALATION DEVICE <b>MO</b>	3	PA,QL (60 per 30 days)
SEREVENT DISKUS 50 MCG/DOSE POWDER FOR INHALATION <b>MO</b>	3	PA,QL (60 per 30 days)
<i>sildenafil 10 mg/ml oral susp</i> <b>DL</b>	4	PA,QL (180 per 30 days)
<i>sildenafil 20 mg tablet</i> <b>MO</b>	1	PA,QL (90 per 30 days)
SINGULAIR 10 MG TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
SINGULAIR 4 MG ORAL GRANULES IN PACKET <b>MO</b>	3	PA,QL (30 per 30 days)
SINGULAIR 4 MG, 5 MG CHEWABLE TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
SPIRIVA RESPIMAT 1.25 MCG/ACTUATION, 2.5 MCG/ACTUATION SOLUTION FOR INHALATION <b>MO</b>	2	QL (4 per 28 days)
SPIRIVA WITH HANDHALER 18 MCG AND INHALATION CAPSULES <b>MO</b>	2	QL (30 per 30 days)
STIOLTO RESPIMAT 2.5 MCG-2.5 MCG/ACTUATION SOLUTION FOR INHALATION <b>MO</b>	2	QL (4 per 28 days)
STRIVERDI RESPIMAT 2.5 MCG/ACTUATION SOLUTION FOR INHALATION <b>MO</b>	2	QL (4 per 30 days)
SYMBICORT 160 MCG-4.5 MCG/ACTUATION HFA AEROSOL INHALER; SYMBICORT 80 MCG-4.5 MCG/ACTUATION HFA AEROSOL INHALER <b>MO</b>	2	QL (10.2 per 30 days)
SYMDEKO 100 MG-150 MG (DAY)/150 MG (NIGHT) TABLETS; SYMDEKO 50 MG-75 MG (DAY)/75 MG (NIGHT) TABLETS <b>DL</b>	4	PA,QL (56 per 28 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
SYMJEPI 0.15 MG/0.3 ML, 0.3 MG/0.3 ML INJECTION SYRINGE; SYMJEPI 0.15 MG/0.3 ML, 0.3 MG/0.3 ML INJECTION SYRINGE (FOR 33 LB TO 66 LB PATIENTS) <b>MO</b>	2	QL (4 per 30 days)
tadalafil 20 mg tablet <b>MO</b>	1	PA,QL (60 per 30 days)
terbutaline sulf 1 mg/ml vial <b>DL</b>	4	
terbutaline sulfate 2.5 mg, 5 mg tab <b>MO</b>	1	
THEO-24 100 MG, 200 MG, 300 MG, 400 MG CAPSULE,EXTENDED RELEASE <b>MO</b>	1	
theophylline 80 mg/15 ml soln <b>MO</b>	1	
theophylline er 100 mg, 200 mg, 300 mg tab; theophylline er 100 mg, 200 mg, 300 mg tablet <b>MO</b>	1	
theophylline er 400 mg, 600 mg tablet <b>MO</b>	1	
theophylline er 450 mg tab <b>MO</b>	1	QL (30 per 30 days)
theophylline 200 mg/100 ml, 200 mg/50 ml, 400 mg/250 ml, 400 mg/500 ml, 800 mg/250 ml d5w <b>MO</b>	1	
TOBI PODHALER 28 MG CAPSULE WITH INHALATION DEVICE; TOBI PODHALER 28 MG INHALE CAP <b>DL</b>	4	PA,QL (224 per 28 days)
TRACLEER 125 MG, 62.5 MG TABLET <b>DL</b>	4	PA,QL (60 per 30 days)
TRACLEER 32 MG TABLET FOR ORAL SUSPENSION <b>DL</b>	4	PA,QL (120 per 30 days)
TRELEGY ELLIPTA 100 MCG-62.5 MCG-25 MCG POWDER FOR INHALATION <b>MO</b>	2	QL (60 per 30 days)
treprostinil 100 mg/20 ml vial; treprostinil 20 mg/20 ml vial; treprostinil 200 mg/20 ml vial; treprostinil 50 mg/20 ml vial <b>DL</b>	4	PA
TRIKAFTA 100-50-75 MG (D)/150 MG (N) TABLETS <b>DL</b>	4	PA,QL (84 per 28 days)
TUDORZA PRESSAIR 400 MCG/ACTUATION BREATH ACTIVATED <b>MO</b>	3	PA,QL (1 per 30 days)
TYVASO 1.74 MG/2.9 ML (0.6 MG/ML) SOLUTION FOR NEBULIZATION <b>DL</b>	4	PA
TYVASO INSTITUTIONAL STARTER KIT 1.74 MG/2.9 ML SOLN FOR NEBULIZATION <b>DL</b>	4	PA
TYVASO REFILL KIT 1.74 MG/2.9 ML (0.6 MG/ML) SOLUTION FOR NEBULIZATION <b>DL</b>	4	PA
TYVASO STARTER KIT 1.74 MG/2.9 ML SOLUTION FOR NEBULIZATION <b>DL</b>	4	PA
UPTRAVI 1,000 MCG, 1,200 MCG, 1,400 MCG, 1,600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG TABLET <b>DL</b>	4	PA,QL (60 per 30 days)
UPTRAVI 200 MCG (140)-800 MCG (60) TABLETS IN A DOSE PACK <b>DL</b>	4	PA,QL (200 per 30 days)
UTIBRON NEOHALER 27.5 MCG-15.6 MCG CAPSULE WITH INHALATION DEVICE <b>MO</b>	3	PA,QL (60 per 30 days)
VELETRI 0.5 MG, 1.5 MG INTRAVENOUS SOLUTION <b>DL</b>	4	PA
VENTAVIS 10 MCG/ML SOLUTION FOR NEBULIZATION <b>DL</b>	4	PA,QL (150 per 30 days)
VENTAVIS 20 MCG/ML SOLUTION FOR NEBULIZATION <b>DL</b>	4	PA,QL (90 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
VENTOLIN HFA 90 MCG/ACTUATION AEROSOL INHALER <b>MO</b>	2	QL (36 per 30 days)
VISTARIL 25 MG, 50 MG CAPSULE <b>MO</b>	3	
wixela inhub 100 mcg-50 mcg/dose powder for inhalation; wixela inhub 250 mcg-50 mcg/dose powder for inhalation; wixela inhub 500 mcg-50 mcg/dose powder for inhalation <b>MO</b>	1	QL (60 per 30 days)
XHANCE 93 MCG/ACTUATION BREATH ACTIVATED AEROSOL <b>MO</b>	3	PA,QL (32 per 30 days)
XOPENEX 0.31 MG/3 ML, 0.63 MG/3 ML, 1.25 MG/3 ML SOLUTION FOR NEBULIZATION <b>MO</b>	3	B vs D
XOPENEX CONCENTRATE 1.25 MG/0.5 ML SOLUTION FOR NEBULIZATION <b>MO</b>	3	B vs D
XOPENEX HFA 45 MCG/ACTUATION AEROSOL INHALER <b>MO</b>	3	ST,QL (30 per 30 days)
YUPELRI 175 MCG/3 ML SOLUTION FOR NEBULIZATION <b>DL</b>	4	PA,QL (90 per 30 days)
zafirlukast 10 mg, 20 mg tablet <b>MO</b>	1	QL (60 per 30 days)
ZETONNA 37 MCG/ACTUATION NASAL HFA INHALER <b>MO</b>	3	ST,QL (6.1 per 28 days)
zileuton er 600 mg tablet <b>DL</b>	4	ST,QL (120 per 30 days)
ZYFLO 600 MG TABLET <b>DL</b>	4	ST,QL (120 per 30 days)
ZYFLO CR 600 MG TABLET <b>DL</b>	4	ST,QL (120 per 30 days)
<b>SKELETAL MUSCLE RELAXANTS</b>		
AMRIX 15 MG, 30 MG CAPSULE,EXTENDED RELEASE <b>DL</b>	4	ST,QL (21 per 30 days)
carisoprodol 250 mg, 350 mg tablet <b>MO</b>	1	QL (120 per 30 days)
carisoprodol-aspirin 200-325 mg <b>MO</b>	1	
carisoprodol-aspirin-codein tb <b>DL</b>	1	QL (360 per 30 days)
chlorzoxazone 250 mg tablet <b>MO</b>	1	ST,QL (360 per 30 days)
chlorzoxazone 375 mg, 750 mg tablet <b>MO</b>	1	ST,QL (120 per 30 days)
chlorzoxazone 500 mg tablet <b>MO</b>	1	ST
cyclobenzaprine 10 mg, 5 mg tablet <b>MO</b>	1	
cyclobenzaprine 7.5 mg tablet <b>MO</b>	1	QL (90 per 30 days)
cyclobenzaprine er 15 mg, 30 mg cap <b>MO</b>	1	ST,QL (21 per 30 days)
FEXMID 7.5 MG TABLET <b>MO</b>	1	ST,QL (90 per 30 days)
LORZONE 375 MG, 750 MG TABLET <b>MO</b>	1	ST,QL (120 per 30 days)
metaxall 800 mg tablet <b>MO</b>	1	QL (120 per 30 days)
metaxalone 400 mg, 800 mg tablet <b>MO</b>	1	QL (120 per 30 days)
methocarbamol 1,000 mg/10 ml <b>MO</b>	1	
methocarbamol 500 mg, 750 mg tablet <b>MO</b>	1	
NORGESIC FORTE 50 MG-770 MG-60 MG TABLET <b>DL</b>	4	PA,QL (120 per 30 days)
orphenadrine 30 mg/ml vial <b>MO</b>	1	
orphenadrine er 100 mg tablet <b>MO</b>	1	
orphenad-asa-caff 50-770-60 mg <b>DL</b>	4	PA,QL (120 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<i>orphengesic forte 50 mg-770 mg-60 mg tablet</i> <b>DL</b>	4	PA,QL (120 per 30 days)
ROBAXIN 100 MG/ML INJECTION SOLUTION <b>DL</b>	4	
ROBAXIN 500 MG TABLET <b>MO</b>	3	
ROBAXIN-750 750 MG TABLET <b>MO</b>	3	
SKELAXIN 800 MG TABLET <b>DL</b>	4	PA,QL (120 per 30 days)
SOMA 250 MG TABLET <b>DL</b>	4	PA,QL (120 per 30 days)
SOMA 350 MG TABLET <b>MO</b>	3	PA,QL (120 per 30 days)
<i>vanadom 350 mg tablet</i> <b>MO</b>	1	QL (120 per 30 days)
<b>SLEEP DISORDER AGENTS</b>		
AMBIEN 10 MG, 5 MG TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
AMBIEN CR 12.5 MG, 6.25 MG TABLET,EXTENDED RELEASE <b>MO</b>	3	PA,QL (30 per 30 days)
<i>armodafinil 150 mg, 200 mg, 250 mg tablet</i> <b>MO</b>	1	PA,QL (30 per 30 days)
<i>armodafinil 50 mg tablet</i> <b>MO</b>	1	PA,QL (60 per 30 days)
BELSOMRA 10 MG TABLET <b>MO</b>	2	QL (60 per 30 days)
BELSOMRA 15 MG, 20 MG TABLET <b>MO</b>	2	QL (30 per 30 days)
BELSOMRA 5 MG TABLET <b>MO</b>	2	QL (120 per 30 days)
DAYVIGO 10 MG, 5 MG TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
<i>doxepin hcl 3 mg, 6 mg tablet</i> <b>MO</b>	1	QL (30 per 30 days)
EDLUAR 10 MG SUBLINGUAL TABLET <b>MO</b>	3	
EDLUAR 5 MG SUBLINGUAL TABLET <b>MO</b>	3	QL (30 per 30 days)
<i>estazolam 1 mg, 2 mg tablet</i> <b>DL</b>	1	QL (30 per 30 days)
<i>eszopiclone 1 mg, 2 mg, 3 mg tablet</i> <b>MO</b>	1	QL (30 per 30 days)
<i>flurazepam 15 mg capsule</i> <b>DL</b>	1	QL (60 per 30 days)
<i>flurazepam 30 mg capsule</i> <b>DL</b>	1	QL (30 per 30 days)
HALCION 0.25 MG TABLET <b>DL</b>	3	PA,QL (30 per 30 days)
HETLIOZ 20 MG CAPSULE <b>DL</b>	4	PA,QL (30 per 30 days)
INTERMEZZO 1.75 MG, 3.5 MG SUBLINGUAL TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
LUNESTA 1 MG, 2 MG, 3 MG TABLET <b>MO</b>	3	PA,QL (30 per 30 days)
<i>modafinil 100 mg, 200 mg tablet</i> <b>MO</b>	1	PA,QL (60 per 30 days)
NUVIGIL 150 MG, 200 MG, 250 MG TABLET <b>DL</b>	4	PA,QL (30 per 30 days)
NUVIGIL 50 MG TABLET <b>DL</b>	4	PA,QL (60 per 30 days)
PROVIGIL 100 MG, 200 MG TABLET <b>DL</b>	4	PA,QL (60 per 30 days)
<i>ramelteon 8 mg tablet</i> <b>MO</b>	1	ST,QL (30 per 30 days)
RESTORIL 15 MG, 22.5 MG, 30 MG, 7.5 MG CAPSULE <b>DL</b>	4	PA,QL (30 per 30 days)
ROZEREM 8 MG TABLET <b>MO</b>	3	ST,QL (30 per 30 days)
SILENOR 3 MG, 6 MG TABLET <b>MO</b>	3	QL (30 per 30 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
SONATA 10 MG, 5 MG CAPSULE <b>MO</b>	3	PA,QL (30 per 30 days)
SUNOSI 150 MG, 75 MG TABLET <b>DL</b>	4	PA,QL (30 per 30 days)
<i>temazepam 15 mg, 22.5 mg, 30 mg, 7.5 mg capsule</i> <b>DL</b>	1	QL (30 per 30 days)
<i>triazolam 0.125 mg, 0.25 mg tablet</i> <b>DL</b>	1	QL (30 per 30 days)
WAKIX 17.8 MG, 4.45 MG TABLET <b>DL</b>	4	PA,QL (60 per 30 days)
XYREM 500 MG/ML ORAL SOLUTION <b>DL</b>	4	PA,QL (540 per 30 days)
<i>zaleplon 10 mg, 5 mg capsule</i> <b>MO</b>	1	QL (30 per 30 days)
<i>zolpidem tart 1.75 mg, 10 mg, 12.5 mg, 3.5 mg, 5 mg, 6.25 mg tab sl;</i> <i>zolpidem tart 1.75 mg, 10 mg, 12.5 mg, 3.5 mg, 5 mg, 6.25 mg tablet sl;</i> <i>zolpidem tart er 1.75 mg, 10 mg, 12.5 mg, 3.5 mg, 5 mg, 6.25 mg tab;</i> <i>zolpidem tartrate 1.75 mg, 10 mg, 12.5 mg, 3.5 mg, 5 mg, 6.25 mg tablet</i> <b>MO</b>	1	QL (30 per 30 days)
ZOLPIMIST 5 MG/SPRAY (0.1 ML) ORAL SPRAY <b>MO</b>	3	QL (23.1 per 365 days)

Need more information about the indicators displayed by the drug names? Please go to page 9.

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

## Humana Group Medicare Plan Coverage of Additional Prescription Drugs

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<b>COUGH/COLD</b>		
benzonatate 100 mg, 150 mg, 200 mg capsule <b>MO</b>	1	
bromfed dm 2 mg-30 mg-10 mg/5 ml oral syrup <b>MO</b>	1	
bromphen-pse-dm 2-30-10 mg/5ml <b>MO</b>	1	
hydrocodone-chlorphen er susp <b>MO</b>	1	
hydrocod-cpm-pseudoep 5-4-60/5 <b>MO</b>	1	
hydrocodone-guaif 2.5-200 mg/5 , <b>DL</b>	3	
hydrocodone-homatropine 5-1.5 <b>MO</b>	1	
hydrocodone-homatropine syrup <b>MO</b>	1	
hydromet 5 mg-1.5 mg/5 ml oral syrup <b>MO</b>	1	
OBREDON 2.5 MG-200 MG/5 ML ORAL SOLUTION <b>MO</b>	3	
promethazine vc-codeine syrup <b>MO</b>	1	
promethazine-codeine syrup <b>MO</b>	1	
promethazine-dm syrup <b>MO</b>	1	
promethazine-pe-codeine syrup <b>MO</b>	1	
RESPA-AR 8 MG-90 MG-0.24 MG TABLET,EXTENDED RELEASE <b>MO</b>	3	
TESSALON PERLES 100 MG CAPSULE <b>MO</b>	3	
TUSSICAPS 10 MG-8 MG CAPSULE,EXTENDED RELEASE; TUSSICAPS 5 MG-4 MG CAPSULE <b>MO</b>	1	
TUSSIONEX PENNKINETIC SUSP <b>MO</b>	3	
TUZISTRA XR 14.7 MG-2.8 MG/5 ML ORAL SUSPENSION,EXTENDED RELEASE <b>MO</b>	3	
<b>FERTILITY</b>		
CETROTIDE 0.25 MG SUBCUTANEOUS KIT <b>MO</b>	3	
clomiphene citrate 50 mg tab <b>MO</b>	1	
FOLLISTIM AQ 300 UNIT/0.36 ML, 600 UNIT/0.72 ML, 900 UNIT/1.08 ML SUBCUTANEOUS CARTRIDGE <b>MO</b>	3	

Your Humana Group Medicare Plan plan has additional coverage of some drugs. These drugs aren't normally covered under Medicare Part D. These drugs aren't subject to the Medicare appeals process. The amount you pay when you fill a prescription for these drugs does not count toward your total drug costs (in other words, the amount you pay does not help you qualify for catastrophic coverage).

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
 MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<b>FERTILITY</b>		
GANIRELIX ACET 250 MCG/0.5 ML <b>MO</b>	3	
GONAL-F 1,050 UNIT, 450 UNIT SUBCUTANEOUS SOLUTION <b>MO</b>	3	
GONAL-F RFF 75 UNIT SUBCUTANEOUS SOLUTION <b>MO</b>	3	
GONAL-F RFF REDI-JECT 300 UNIT/0.5 ML SUBCUTANEOUS PEN INJECTOR; GONAL-F RFF REDI-JECT 450 UNIT/0.75 ML SUBCUTANEOUS PEN INJECTOR; GONAL-F RFF REDI-JECT 900 UNIT/1.5 ML SUBCUTANEOUS PEN INJECTOR <b>MO</b>	3	
MENOPUR 75 UNIT SUBCUTANEOUS SOLUTION <b>MO</b>	3	
OVIDREL 250 MCG/0.5 ML SUBCUTANEOUS SYRINGE <b>MO</b>	3	
SEROPHENE 50 MG TABLET <b>MO</b>	3	
<b>VITAMINS/MINERALS</b>		
ascorbic acid 500 mg/ml vial <b>MO</b>	1	
b complex 100 100 mg-2 mg-100 mg-2mg-2mg/ml injectable solution <b>MO</b>	1	
b-complex 100 mg-2 mg-100 mg-2mg-2mg/ml injection solution <b>MO</b>	1	
cyanocobalamin 1,000 mcg/ml <b>MO</b>	1	
DRISDOL 1,250 MCG (50,000 UNIT) CAPSULE <b>MO</b>	3	
vitamin d2 1.25mg(50,000 unit) <b>MO</b>	1	
folic acid 1 mg tablet <b>MO</b>	1	
folic acid 5 mg/ml vial <b>MO</b>	1	
hydroxocobalamin 1,000 mcg/ml <b>MO</b>	1	
INFUVITE ADULT 3300 UNIT-150 MCG/10 ML INTRAVENOUS SOLUTION <b>MO</b>	3	
INFUVITE PEDIATRIC 80 MG-400 UNIT-200 MCG/5 ML INTRAVENOUS SOLUTION <b>MO</b>	3	
M.V.I. ADULT 3,300 UNIT-150 MCG/10 ML INTRAVENOUS SOLUTION <b>MO</b>	3	
M.V.I. PEDIATRIC 80 MG-400 UNIT-200 MCG INTRAVENOUS SOLUTION <b>MO</b>	3	
M.V.I.-12 (WITHOUT VIT K) 3,300 UNIT-200 UNIT/10 ML INTRAVENOUS SOLN <b>MO</b>	3	
MEPHYTON 5 MG TABLET <b>MO</b>	3	

Your Humana Group Medicare Plan plan has additional coverage of some drugs. These drugs aren't normally covered under Medicare Part D. These drugs aren't subject to the Medicare appeals process. The amount you pay when you fill a prescription for these drugs does not count toward your total drug costs (in other words, the amount you pay does not help you qualify for catastrophic coverage).

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access



DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<b>VITAMINS/MINERALS</b>		
NASCOBAL 500 MCG/SPRAY NASAL SPRAY <b>MO</b>	3	
phytonadione 1 mg/0.5 ml syr <b>MO</b>	1	
phytonadione 10 mg/ml ampul <b>MO</b>	1	
phytonadione 5 mg tablet <b>MO</b>	1	
pnv-dha 27 mg iron-1 mg-300 mg capsule <b>MO</b>	1	
pnv-omega 28 mg-1 mg-300 mg capsule <b>MO</b>	1	
POTABA 500 MG CAPSULE <b>MO</b>	3	
prenatal-u 106.5 mg-1 mg capsule <b>MO</b>	1	
pyridoxine 100 mg/ml vial <b>MO</b>	1	
thiamine 200 mg/2 ml vial <b>MO</b>	1	
vitamin d2 1,250 mcg (50,000 unit) capsule <b>MO</b>	1	
vitamin k 1 mg/0.5 ml injection solution <b>MO</b>	1	
vitamin k1 10 mg/ml injection solution <b>MO</b>	1	
zatean-pn dha 27 mg iron-1 mg-300 mg capsule <b>MO</b>	1	
zatean-pn plus 28 mg-1 mg-300 mg capsule <b>MO</b>	1	
zingiber 1.2 mg-40 mg-124.1 mg-100 mg tablet <b>MO</b>	1	
<b>WEIGHT LOSS</b>		
adipex-p 37.5 mg capsule <b>MO</b>	1	
ADIPEX-P 37.5 MG TABLET <b>MO</b>	1	
benzphetamine hcl 25 mg, 50 mg tablet <b>MO</b>	1	
CONTRAVE 8 MG-90 MG TABLET,EXTENDED RELEASE <b>MO</b>	3	QL (120 per 30 days)
diethylpropion 25 mg tablet <b>MO</b>	1	
diethylpropion er 75 mg tablet <b>MO</b>	1	
lomaira 8 mg tablet <b>MO</b>	1	
phendimetrazine 35 mg tablet <b>MO</b>	1	

Your Humana Group Medicare Plan plan has additional coverage of some drugs. These drugs aren't normally covered under Medicare Part D. These drugs aren't subject to the Medicare appeals process. The amount you pay when you fill a prescription for these drugs does not count toward your total drug costs (in other words, the amount you pay does not help you qualify for catastrophic coverage).

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD – Maintenance Drug • DL – Dispensing Limit • LA – Limited Access

DRUG NAME	TIER	UTILIZATION MANAGEMENT REQUIREMENTS
<b>WEIGHT LOSS</b>		
<i>phendimetrazine er 105 mg cap</i> <b>MO</b>	3	
<i>phentermine 15 mg, 30 mg, 37.5 mg capsule</i> <b>MO</b>	1	
<i>phentermine 37.5 mg tablet</i> <b>MO</b>	1	
QSYMIA 11.25 MG-69 MG CAPSULE, EXTENDED RELEASE; QSYMIA 15 MG-92 MG CAPSULE, EXTENDED RELEASE; QSYMIA 3.75 MG-23 MG CAPSULE, EXTENDED RELEASE; QSYMIA 7.5 MG-46 MG CAPSULE, EXTENDED RELEASE <b>MO</b>	3	QL (30 per 30 days)
REGIMEX 25 MG TABLET <b>MO</b>	1	
SAXENDA 3 MG/0.5 ML (18 MG/3 ML) SUBCUTANEOUS PEN INJECTOR <b>MO</b>	3	

Your Humana Group Medicare Plan plan has additional coverage of some drugs. These drugs aren't normally covered under Medicare Part D. These drugs aren't subject to the Medicare appeals process. The amount you pay when you fill a prescription for these drugs does not count toward your total drug costs (in other words, the amount you pay does not help you qualify for catastrophic coverage).

ST - Step Therapy • QL - Quantity Limit • PA - Prior Authorization • B vs D - Part B versus Part D  
MD - Maintenance Drug • DL - Dispensing Limit • LA - Limited Access

# Index

## A

- a-hydrocort... 124
- abacavir... 65
- abacavir-lamivudine... 65
- abacavir-lamivudine-zidovudine... 66
- ABELCET... 42
- ABILIFY MAINTENA... 62
- ABILIFY MYCITE... 62
- ABILIFY... 61
- abiraterone... 48
- ABOUTTIME PEN NEEDLE... 150
- ABRAXANE... 48
- ABSORICA LD... 101, 102
- ABSORICA... 101
- ABSTRAL... 10
- acamprosate... 20
- ACANYA... 102
- acarbose... 72
- ACCOLATE... 167
- ACCUPRIL... 82
- ACCURETIC... 82
- acebutolol... 82
- ACETADOTE... 150
- acetaminophen-caff-dihydrocod... 10
- acetaminophen-codeine... 10
- acetazolamide sodium... 82
- acetazolamide... 82
- acetic acid... 21, 150
- acetylcysteine... 150, 167
- ACIPHEX SPRINKLE... 117
- ACIPHEX... 117
- acitretin... 102
- ACTEMRA ACTPEN... 140
- ACTEMRA... 140
- ACTHAR... 124
- ACTHIB (PF)... 140
- ACTICLATE... 21
- ACTIGALL... 118
- ACTIMMUNE... 140
- ACTIQ... 10
- ACTIVELLA... 128
- ACTONEL... 148
- ACTOPLUS MET XR... 72
- ACTOPLUS MET... 72
- ACTOS... 72
- ACULAR LS... 162
- ACULAR... 162
- ACUVAIL (PF)... 162
- acyclovir sodium... 66
- acyclovir... 66
- ACZONE... 102
- ADACEL(TDAP ADOLESN/ADULT)(PF)... 140
- ADAGEN... 121
- ADAKVEO... 150
- ADALAT CC... 82
- adapalene... 102
- adapalene-benzoyl peroxide... 102
- ADCETRIS... 48
- ADCIRCA... 167
- ADDERALL XR... 96
- ADDERALL... 96
- adefovir... 66
- ADEMPAS... 167
- adenosine... 82
- adipex-p... 179
- ADLYXIN... 72
- ADMELOG SOLOSTAR U-100 INSULIN... 72
- ADMELOG U-100 INSULIN LISPRO... 72
- ADRENALIN... 167
- adriamycin... 48
- adrucil... 48
- ADVAIR DISKUS... 167
- ADVAIR HFA... 167
- ADVOCATE PEN NEEDLE... 150
- ADVOCATE SYRINGES... 150

ADZENYS ER... 97	albendazole... 58	ALOPRIM... 45
ADZENYS XR-ODT... 97	ALBENZA... 59	ALORA... 128
AEMCOLO... 118	albuterol sulfate... 168	alosetron... 118
afeditab cr... 82	ALCAINE... 162	ALPHAGAN P... 162, 163
AFINITOR DISPERZ... 48	alclometasone... 102	alprazolam intensol... 71
AFINITOR... 48	ALCOHOL PADS... 150	alprazolam... 71
afirmelle... 128	ALCOHOL PREP PADS... 150	ALREX... 163
AFREZZA... 73	ALCOHOL SWABS... 150	ALTABAX... 102
AGGRASTAT CONCENTRATE... 78	ALCOHOL WIPES... 150	ALTACE... 83
AGGRASTAT IN SODIUM CHLORIDE... 78	ALDACTAZIDE... 82	altavera (28)... 128
AGGRENOX... 78	ALDACTONE... 83	ALTOPREV... 83
AGRYLIN... 78	ALDARA... 102	ALTRENO... 102
AIMOVIG AUTOINJECTOR (2 PACK)... 45	ALDURAZYME... 121	ALUNBRIG... 48
AIMOVIG AUTOINJECTOR... 45	ALECENSA... 48	ALVESCO... 168
AIRDUO DIGIHALER... 167	alendronate... 148	alyacen 1/35 (28)... 128
AIRDUO RESPICLICK... 168	alfuzosin... 123	alyacen 7/7/7 (28)... 128
AJOVY AUTOINJECTOR... 45	ALIMTA... 48	alyq... 168
AJOVY SYRINGE... 45	ALINIA... 59	amabelz... 128
ak-poly-bac... 162	ALIQOPA... 48	amantadine hcl... 59, 60
AKLIEF... 102	aliskiren... 83	AMARYL... 73
AKTEN (PF)... 162	ALKERAN (AS HCL)... 48	AMBIEN CR... 175
AKTIPAK... 102	ALKERAN... 48	AMBIEN... 175
AKYNZEO (FOSNETUPITANT)... 40	allopurinol sodium... 45	AMBISOME... 42
AKYNZEO (NETUPITANT)... 41	allopurinol... 45	ambrisentan... 168
ALA-CORT... 102	ALLZITAL... 10	amcinonide... 102
ALA-SCALP... 102	almotriptan malate... 46	AMERGE... 46
	ALOCRIL... 162	amethia lo... 128
	ALOMIDE... 162	amethia... 128

amethyst (28)... 128	amitriptyline-chlordiazepoxide... 37	anastrozole... 48
AMICAR... 78	amlodipine... 83	ANCOBON... 42
amifostine crystalline... 48	amlodipine-atorvastatin... 83	ANDRODERM... 128
amikacin... 22	amlodipine-benazepril... 83	ANDROGEL... 128
amiloride... 83	amlodipine-olmesartan... 83	ANDROID... 128
amiloride-hydrochlorothiazide... 83	amlodipine-valsartan... 83	ANGELIQ... 128
aminocaproic acid... 78, 79	amlodipine-valsartan-hcthiazyd... 83	ANNOVERA... 128
aminophylline... 168	ammonium lactate... 102	ANORO ELLIPTA... 168
AMINOSYN II 10 %... 111	AMMONUL... 150	ANTABUSE... 20
AMINOSYN II 15 %... 111	amnesteem... 102	ANTARA... 83
AMINOSYN II 7 %... 111	amoxapine... 37	anusol-hc... 102
AMINOSYN II 8.5 %... 111	amoxicil-clarithromy-lansopraz... 118	ANZEMET... 41
AMINOSYN II 8.5 %-ELECTROLYTES... 111	amoxicillin... 22	apexicon e... 102
AMINOSYN M 3.5 %... 111	amoxicillin-pot clavulanate... 22	APIDRA SOLOSTAR U-100 INSULIN... 73
AMINOSYN 10 %... 110	amphetamine sulfate... 97	APIDRA U-100 INSULIN... 73
AMINOSYN 7 % WITH ELECTROLYTES... 110	amphetamine... 97	APLENZIN... 37
AMINOSYN 8.5 %... 110	amphotericin b... 42	APOKYN... 60
AMINOSYN 8.5 %-ELECTROLYTES... 110	ampicillin sodium... 22	apraclonidine... 163
AMINOSYN-HBC 7%... 111	ampicillin... 22	aprepitant... 41
AMINOSYN-PF 10 %... 111	ampicillin-sulbactam... 22	apri... 128
AMINOSYN-PF 7 % (SULFITE-FREE)... 111	AMPYRA... 97	APRISO... 147
AMINOSYN-RF 5.2 %... 111	AMRIX... 174	APTENSIO XR... 97
amiodarone... 83	AMZEEQ... 102	APTIOM... 31
AMITIZA... 118	ANADROL-50... 128	APTIVUS (WITH VITAMIN E)... 66
amitriptyline... 37	ANAFRANIL... 37	APTIVUS... 66
	anagrelide... 79	ARALAST NP... 121
	ANAPROX DS... 10	aranelle (28)... 128

ARANESP (IN POLYSORBATE)... 79	ascomp with codeine... 10	aubra eq... 129
ARAVA... 140	ascorbic acid (vitamin c)... 178	aubra... 129
ARAZLO... 102	ashlyna... 128	AUGMENTIN ES-600... 22
ARCALYST... 140	ASMANEX HFA... 168	AUGMENTIN XR... 22
ARCAPTA NEOHALER... 168	ASMANEX TWISTHALER... 168	AUGMENTIN... 22
ARICEPT... 36	ASPARLAS... 48	aurovela fe 1.5/30 (28)... 129
ARIKAYCE... 22	aspirin-dipyridamole... 79	aurovela fe 1-20 (28)... 129
ARIMIDEX... 48	ASSURE ID DUO-SHIELD... 150	aurovela 1.5/30 (21)... 129
aripiprazole... 62	ASSURE ID INSULIN SAFETY... 150	aurovela 1/20 (21)... 129
ARISTADA INITIO... 62	ASSURE ID PEN NEEDLE... 150	aurovela 24 fe... 129
ARISTADA... 62	ASTAGRAF XL... 140	AURYXIA... 111
ARISTOSPAN INTRA-ARTICULAR... 124	ATACAND HCT... 83	AUSTEDO... 97
ARISTOSPAN INTRALESIONAL... 124	ATACAND... 83	AUTOJECT 2 INJECTION DEVICE... 150
ARIXTRA... 79	atazanavir... 66	AUTOPEN 1 TO 21 UNITS... 150
armodafinil... 175	ATELVIA... 148	AUTOPEN 2 TO 42 UNITS... 150
ARMONAIR RESPICLICK... 168	atenolol... 83	AVALIDE... 83
ARMOUR THYROID... 137	atenolol-chlorthalidone... 83	AVANDIA... 73
ARNUITY ELLIPTA... 168	ATGAM... 140	AVAPRO... 83
AROMASIN... 48	ATIVAN... 71	AVASTIN... 48
ARRANON... 48	atomoxetine... 97	AVC VAGINAL... 22
arsenic trioxide... 48	atorvastatin... 83	AVEED... 129
ARTHROTEC 50... 10	atovaquone... 59	AVELOX IN NACL (ISO-OSMOTIC)... 22
ARTHROTEC 75... 10	atovaquone-proguanil... 59	AVELOX... 22
ARYMO ER... 10	ATRALIN... 102	aviane... 129
ARZERRA... 48	ATRIPLA... 66	avidoxy... 22
ASACOL HD... 147	atropine... 118, 163	AVITA... 102
ASCENIV... 140	ATROVENT HFA... 168	
	AUBAGIO... 97	



AVODART... 123	azurette (28)... 129	BAXDELA... 23
AVONEX (WITH ALBUMIN)... 97	<b>B</b>	BCG VACCINE, LIVE (PF)... 140
AVONEX... 97	b complex 100... 178	BD ALCOHOL SWABS... 151
AVSOLA... 140	b-complex injection... 178	BD AUTOSHIELD DUO PEN NEEDLE... 151
AVYCAZ... 22	BACIGUENT... 163	BD ECLIPSE LUER-LOK... 151
AXIRON... 129	baciim... 23	BD INSULIN SYRINGE HALF UNIT... 151
AYGESTIN... 129	bacitracin... 23, 163	BD INSULIN SYRINGE MICRO-FINE... 151
ayuna... 129	bacitracin-polymyxin b... 163	BD INSULIN SYRINGE SAFETY-LOK... 151
AYVAKIT... 48	baclofen... 65	BD INSULIN SYRINGE SLIP TIP... 151
azacitidine... 49	BACTRIM DS... 23	BD INSULIN SYRINGE U-500... 151
AZACTAM IN DEXTROSE (ISO-OSM)... 22	BACTRIM... 23	BD INSULIN SYRINGE ULTRA-FINE... 151
AZACTAM... 22	BACTROBAN NASAL... 103	BD INSULIN SYRINGE... 151
AZASAN... 140	BACTROBAN... 102	BD LO-DOSE MICRO-FINE IV... 151
AZASITE... 163	BAFIERTAM... 97	BD LO-DOSE ULTRA-FINE... 151
azathioprine sodium... 140	BAL IN OIL... 150	BD NANO 2ND GEN PEN NEEDLE... 151
azathioprine... 140	bal-care dha... 111	BD SAFETYGLIDE INSULIN SYRINGE... 151
azelaic acid... 102	balanced salt... 163	BD SAFETYGLIDE SYRINGE... 151
azelastine... 163, 168	BALCOLTRA... 129	BD ULTRA-FINE MICRO PEN NEEDLE... 151
azelastine-fluticasone... 168	balsalazide... 147	BD ULTRA-FINE MINI PEN NEEDLE... 151
AZELEX... 102	BALVERSA... 49	BD ULTRA-FINE NANO PEN NEEDLE... 151
AZILECT... 60	balziva (28)... 129	
azithromycin... 22	BAND-AID GAUZE PADS... 151	
AZOPT... 163	BANZEL... 31	
AZOR... 83	BAQSIMI... 73	
aztreonam... 23	BARACLUDGE... 66	
AZULFIDINE EN-TABS... 147	BASAGLAR KWIKPEN U-100 INSULIN... 73	
AZULFIDINE... 147	BAVENCIO... 49	

BD ULTRA-FINE ORIG PEN NEEDLE... 151	BESIVANCE... 163	BILTRICIDE... 59
BD ULTRA-FINE SHORT PEN NEEDLE... 151	BESPONSA... 49	bimatoprost... 163
BD VEO INSULIN SYR HALF UNIT... 151	BETADINE OPHTHALMIC PREP... 163	BINOSTO... 148
BD VEO INSULIN SYRINGE UF... 151	betamethasone acet,sod phos... 124	BIORPHEN... 84
BECONASE AQ... 168	betamethasone dipropionate... 103	bisoprolol fumarate... 84
bekyree (28)... 129	betamethasone valerate... 103	bisoprolol-hydrochlorothiazide... 84
BELBUCA... 10	betamethasone, augmented... 103	BIVIGAM... 140
BELEODAQ... 49	BETAPACE AF... 84	BLENREP... 49
BELSOMRA... 175	BETAPACE... 84	bleomycin... 49
benazepril... 83	BETASERON... 97	BLEPH-10... 163
benazepril-hydrochlorothiazide... 83	betaxolol... 84, 163	BLEPHAMIDE S.O.P.... 163
BENDEKA... 49	bethanechol chloride... 123	BLEPHAMIDE... 163
BENICAR HCT... 84	BETHKIS... 23	blisovi fe 1.5/30 (28)... 129
BENICAR... 83	BETIMOL... 163	blisovi fe 1/20 (28)... 129
BENLYSTA... 140	BETOPTIC S... 163	blisovi 24 fe... 129
BENTYL... 118	BEVESPI AEROSPHERE... 168	BONIVA... 148
BENZAACLIN PUMP... 103	BEVYXXA... 79	BONJESTA... 41
BENZAACLIN... 103	bexarotene... 49	BOOSTRIX TDAP... 140
BENZAMYCIN... 103	BEXSERO... 140	BORDERED GAUZE... 151
benznidazole... 59	BEYAZ... 129	bortezomib... 49
benzonatate... 177	bicalutamide... 49	bosentan... 169
benzphetamine... 179	BICILLIN C-R... 23	BOSULIF... 49
benztropine... 60	BICILLIN L-A... 23	BRAFTOVI... 49
BEPREVE... 163	BICNU... 49	BREO ELLIPTA... 169
BERINERT... 140	BIDIL... 84	bretylium tosylate... 84
besser... 103	BIJUVA... 129	BREVIBLOC IN NACL (ISO-OSM)... 84
	BIKTARVY... 66	BREVIBLOC... 84
		BREZTRI AEROSPHERE... 169

briellyn... 129	BUPRENEX... 10	CADUET... 84
BRILINTA... 79	buprenorphine hcl... 10, 21	CAFCIT... 151
brimonidine... 163	buprenorphine... 10	CAFERGOT... 46
BRISDELLE... 37	buprenorphine-naloxone... 21	caffeine citrate... 151
BRIVIACT... 31	bupropion hcl (smoking deter)... 21	CALAN SR... 84
bromfed dm... 177	bupropion hcl... 37	CALAN... 84
bromfenac... 163	buspirone... 71	calcipotriene... 103
bromocriptine... 60	busulfan... 49	calcipotriene-betamethasone... 103
brompheniramine-pseudoeph-dm... 177	BUSULFEX... 49	calcitonin (salmon)... 148
BROMSITE... 163	butalbital compound w/codeine... 10	calcitrene... 103
BROVANA... 169	butalbital-acetaminop-caf-cod... 10	calcitriol... 103, 148
BRUKINSA... 49	butalbital-acetaminophen... 10	calcium acetate(phosphat bind)... 111
BRYHALI... 103	butalbital-acetaminophen-caff... 10	calcium chloride... 111
BSS PLUS... 163	butalbital-aspirin-caffeine... 10	calcium disodium versenate... 151
BSS... 163	butorphanol... 10, 11	calcium gluc in nacl, iso-osm... 111
budesonide... 147, 169	BUTRANS... 11	calcium gluconate... 111
bumetanide... 84	BYDUREON BCISE... 73	CALDOLOR... 11
BUNAVAIL... 21	BYDUREON... 73	CALQUENCE... 49
bupap... 10	BYETTA... 73	CAMBIA... 11
BUPHENYL... 121	BYNFEZIA... 138	camila... 129
bupivacaine (pf)... 19	BYSTOLIC... 84	CAMPTOSAR... 49
bupivacaine... 19	BYVALSON... 84	camrese lo... 129
bupivacaine-dextrose-water(pf)... 19	<b>C</b>	camrese... 129
bupivacaine-epinephrine (pf)... 19	c-nate dha... 111	CANASA... 147
bupivacaine-epinephrine bitart... 19	cabergoline... 138	CANCIDAS... 42
bupivacaine-epinephrine... 19	CABLIVI... 79	candesartan... 84
	CABOMETYX... 49	

candesartan-hydrochlorothiazid... 84	CAREFINE PEN NEEDLE... 152	cefazolin... 23
CAPASTAT... 47	CARETOUCH ALCOHOL PREP PAD... 152	cefdinir... 23
CAPEX... 103	CARETOUCH INSULIN SYRINGE... 152	cefepime in dextrose 5 %... 23
CAPLYTA... 62	CARETOUCH PEN NEEDLE... 152	cefepime in dextrose,iso-osm... 23
CAPRELSA... 49	carisoprodol... 174	cefepime... 23
captopril... 84	carisoprodol-aspirin... 174	cefixime... 23
captopril-hydrochlorothiazide... 84	carisoprodol-aspirin-codeine... 174	CEFOTAN... 23
CARAC... 103	carmustine... 49	cefotaxime... 23
CARAFATE... 118	CARNITOR (SUGAR-FREE)... 111	cefotetan in dextrose, iso-osm... 23
CARBAGLU... 111	CARNITOR... 111	cefotetan... 23
carbamazepine... 31	CAROSPIR... 85	cefoxitin in dextrose, iso-osm... 23
CARBATROL... 31	carteolol... 163	cefoxitin... 23
carbidopa... 60	cartia xt... 85	cefpodoxime... 24
carbidopa-levodopa... 60	carvedilol phosphate... 85	cefprozil... 24
carbidopa-levodopa-entacapone... 60	carvedilol... 85	ceftazidime in d5w... 24
carbinoxamine maleate... 169	CASODEX... 49	ceftazidime... 24
CARBOCAINE (PF)... 19	caspofungin... 42	ceftriaxone in dextrose,iso-os... 24
CARBOCAINE WITH NEO-COBEFRIN... 19	CATAPRES... 85	ceftriaxone... 24
CARBOCAINE... 19	CATAPRES-TTS-1... 85	cefuroxime axetil... 24
carboplatin... 49	CATAPRES-TTS-2... 85	cefuroxime sodium... 24
carboprost tromethamine... 128	CATAPRES-TTS-3... 85	CELEBREX... 11
CARDIZEM CD... 84	CAYSTON... 169	celecoxib... 11
CARDIZEM LA... 85	caziant (28)... 129	CELESTONE SOLUSPAN... 125
CARDIZEM... 84	cefaclor... 23	CELEXA... 37, 38
CARDURA XL... 85	cefadroxil... 23	CELLCEPT INTRAVENOUS... 141
CARDURA... 85	cefazolin in dextrose (iso-os)... 23	CELLCEPT... 140, 141
		CELONTIN... 31
		CENTANY... 103

cephalexin... 24	chlorpropamide... 73	ciprofloxacin (mixture)... 24
CEQUA... 163	chlorthalidone... 85	ciprofloxacin hcl... 24, 163, 167
CERDELGA... 121	chlorzoxazone... 174	ciprofloxacin in 5 % dextrose... 24
CEREBYX... 31	CHOLBAM... 121	ciprofloxacin... 24
CEREZYME... 121	cholestyramine (with sugar)... 85	ciprofloxacin-dexamethasone... 167
CERVIDIL... 152	cholestyramine light... 85	ciprofloxacin-fluocinolone... 167
CESAMET... 41	CHORIONIC GONADOTROPIN, HUMAN... 127	cisplatin... 49
cetirizine... 169	CIALIS... 123	citalopram... 38
CETROTIDE... 177	ciclodan... 42	CITRANATAL B-CALM (FE GLUC)... 111
cevimeline... 101	ciclopirox... 42, 43	cladribine... 49
CHANTIX CONTINUING MONTH BOX... 21	cidofovir... 66	CLAFORAN... 24
CHANTIX STARTING MONTH BOX... 21	cilostazol... 79	claravis... 103
CHANTIX... 21	CILOXAN... 163	CLARINEX... 169
charlotte 24 fe... 129	CIMDUO... 66	CLARINEX-D 12 HOUR... 152
chateal (28)... 129	cimetidine hcl... 118	clarithromycin... 24
chateal eq (28)... 129	cimetidine... 118	clemastine... 169
CHEMET... 111	CIMZIA POWDER FOR RECONST... 141	CLENPIQ... 118
CHENODAL... 118	CIMZIA STARTER KIT... 141	CLEOCIN HCL... 24
chloramphenicol sod succinate... 24	CIMZIA... 141	CLEOCIN IN 5 % DEXTROSE... 25
chlordiazepoxide hcl... 71	cinacalcet... 148	CLEOCIN PEDIATRIC... 25
chlorhexidine gluconate... 101	CINQAIR... 169	CLEOCIN T... 103
chlorprocaine (pf)... 19	CINRYZE... 141	CLEOCIN... 24
chloroquine phosphate... 59	CINVANTI... 152	CLEVIPREX... 85
chlorothiazide sodium... 85	CIPRO HC... 167	CLICKFINE PEN NEEDLE... 152
chlorothiazide... 85	CIPRO... 24	CLIMARA PRO... 129
chlorpromazine... 62	CIPRODEX... 167	CLIMARA... 129

clindacin etz... 103	CLINIMIX 4.25%-D20W SULF-FREE... 111	clopidogrel... 79
clindacin p... 103	CLINIMIX 4.25%-D25W SULF-FREE... 111	clorazepate dipotassium... 71
CLINDAGEL... 103	CLINIMIX 4.25%/D10W SULF FREE... 111	COLOROTEKAL... 19
clindamycin hcl... 25	CLINIMIX 4.25%/D5W SULFIT FREE... 112	clotrimazole... 43
clindamycin in 0.9 % sod chlor... 25	CLINIMIX 5%-D20W(SULFITE-FREE)... 112	clotrimazole-betamethasone... 43
clindamycin in 5 % dextrose... 25	CLINIMIX 5%/D15W SULFITE FREE... 111	clovique... 112
clindamycin palmitate hcl... 25	CLINIMIX 5%/D25W SULFITE-FREE... 111	clozapine... 62
clindamycin pediatric... 25	CLINISOL SF 15 %... 112	CLOZARIL... 62
clindamycin phosphate... 25, 104	CLINOLIPID... 112	COARTEM... 59
clindamycin-benzoyl peroxide... 104	clobazam... 32	codeine sulfate... 11
clindamycin-tretinoin... 104	clobetasol... 104	codeine-butalbital-asa-caff... 11
CLINDESSE... 25	clobetasol-emollient... 104	COGENTIN... 60
CLINIMIX E 2.75%/D10W SUL FREE... 112	CLOBEX... 104	COLAZAL... 147
CLINIMIX E 2.75%/D5W SULF FREE... 112	clodan... 104	colesevelam... 85
CLINIMIX E 4.25%/D10W SUL FREE... 112	CLODERM... 104	COLESTID FLAVORED... 85
CLINIMIX E 4.25%/D25W SUL FREE... 112	clofarabine... 49	COLESTID... 85
CLINIMIX E 4.25%/D5W SULF FREE... 112	CLOLAR... 49	colestipol... 85
CLINIMIX E 5%/D15W SULFIT FREE... 112	clomiphene citrate... 177	colistin (colistimethate na)... 25
CLINIMIX E 5%/D20W SULFIT FREE... 112	clomipramine... 38	colocort... 147
CLINIMIX E 5%/D25W SULFIT FREE... 112	clonazepam... 71	COLY-MYCIN M PARENTERAL... 25
CLINIMIX 2.75%/D5W SULFIT FREE... 111	clonidine hcl... 85, 97	COLY-MYCIN S... 167
	clonidine... 85	COLYTE WITH FLAVOR PACKS... 118
		COMBIGAN... 163
		COMBIPATCH... 129
		COMBIVENT RESPIMAT... 169
		COMBIVIR... 66
		COMETRIQ... 49, 50



COMFORT EZ INSULIN SYRINGE... 152  
 COMFORT EZ PEN NEEDLES... 152  
 COMPAZINE... 41  
 COMPLERA... 66  
 complete natal dha... 112  
 compro... 41  
 COMTAN... 60  
 CONCERTA... 97  
 CONDYLOX... 104  
 constulose... 118  
 CONTRAVE... 179  
 CONZIP... 11  
 COPAXONE... 97  
 COPIKTRA... 50  
 CORDRAN TAPE LARGE ROLL... 104  
 CORDRAN... 104  
 COREG CR... 85  
 COREG... 85  
 coremino... 25  
 CORGARD... 85  
 CORLANOR... 86  
 CORLOPAM... 86  
 cormax... 104  
 CORTEF... 104  
 CORTENEMA... 147  
 CORTIFOAM... 147  
 cortisone... 125  
 CORTISPORIN... 104  
 CORTISPORIN-TC... 167  
 CORVERT... 86  
 CORZIDE... 86  
 COSENTYX (2 SYRINGES)... 141  
 COSENTYX PEN (2 PENS)... 141  
 COSENTYX PEN... 141  
 COSENTYX... 141  
 COSMEGEN... 50  
 COSOPT (PF)... 163  
 COSOPT... 163  
 COTELLIC... 50  
 COTEMPLA XR-ODT... 97  
 COUMADIN... 79  
 COZAAR... 86  
 CREON... 121  
 CRESEMBA... 43  
 CRESTOR... 86  
 CRINONE... 129  
 CRIXIVAN... 66  
 cromolyn... 163, 169  
 crotan... 104  
 cryselle (28)... 129  
 CRYSVITA... 121, 122  
 CUBICIN RF... 25  
 CUBICIN... 25  
 CUPRIMINE... 112  
 CURITY ALCOHOL SWABS... 152  
 CURITY GAUZE... 152  
 CUTAQUIG... 141  
 CUTIVATE... 105  
 CUVPOSA... 118  
 cyanocobalamin (vitamin b-12)... 178  
 cyclofem 1/35 (28)... 129  
 cyclofem 7/7/7 (28)... 130  
 cyclobenzaprine... 174  
 cyclophosphamide... 50  
 cycloserine... 47  
 CYCLOSET... 73  
 cyclosporine modified... 141  
 cyclosporine... 141  
 CYKLOKAPRON... 79  
 CYMBALTA... 38  
 cyproheptadine... 169  
 CYRAMZA... 50  
 cyred eq... 130  
 cyred... 130  
 CYSTADANE... 122  
 CYSTAGON... 122  
 CYSTARAN... 163  
 cytarabine (pf)... 50  
 cytarabine... 50  
 CYTOGAM... 141  
 CYTOMEL... 137  
 CYTOTEC... 118

CYTOVENE... 66	DAYVIGO... 175	DERMA-SMOOTH/FS BODY OIL... 105
<b>D</b>	DDAVP... 127	DERMA-SMOOTH/FS SCALP OIL... 105
D.H.E.45... 46	deblitane... 130	DERMACEA... 152
dacarbazine... 50	decadron... 125	DERMATOP... 105
DACOGEN... 50	decitabine... 50	DERMOTIC OIL... 167
dactinomycin... 50	deferasirox... 112	DESCOVY... 66
DAKLINZA... 66	deferoramine... 112	DESFERAL... 112
dalfampridine... 97	DEFITELIO... 152	desipramine... 38
DALIRESP... 169	DELESTROGEN... 130	desloratadine... 169
DALVANCE... 25	DELSTRIGO... 66	desmopressin... 127
danazol... 130	DELZICOL... 147	desog-e.estradiol/e.estradiol... 130
DANTRIUM... 65	DEMADEX... 86	desogestrel-ethinyl estradiol... 130
dantrolene... 65	demeclocycline... 25	DESONATE... 105
dapsone... 47, 105	DEMEROL (PF)... 11	desonide... 105
DAPTACEL (DTAP PEDIATRIC) (PF)... 141	DEMEROL... 11	DESOWEN... 105
daptomycin... 25	DEMSE... 86	desoximetasone... 105
DARAPRIM... 59	DENAVIR... 66	DESOXYN... 97
darifenacin... 123	DEPACON... 32	desvenlafaxine succinate... 38
DARZALEX FASPRO... 50	DEPAKENE... 32	desvenlafaxine... 38
DARZALEX... 50	DEPAKOTE ER... 32	DETROL LA... 123
dasetta 1/35 (28)... 130	DEPAKOTE SPRINKLES... 32	DETROL... 123
dasetta 7/7/7 (28)... 130	DEPAKOTE... 32	dexabliss... 125
daunorubicin... 50	DEPEN TITRATABS... 112	dexamethasone intensol... 125
DAURISMO... 50	DEPO-ESTRADIOL... 130	dexamethasone sodium phos (pf)... 125
DAYPRO... 11	DEPO-MEDROL... 125	dexamethasone sodium phosphate... 125, 164
daysee... 130	DEPO-PROVERA... 130	
DAYTRANA... 97	DEPO-SUBQ PROVERA 104... 130	
	DEPO-TESTOSTERONE... 130	

dexamethasone... 125	dextrose 5%-0.3 % sod.chloride... 113	dihydroergotamine... 46
dexchlorpheniramine maleate... 169	dextrose 50 % in water (d50w)... 113	DILANTIN EXTENDED... 32
DEXEDRINE SPANSULE... 97	dextrose 70 % in water (d70w)... 113	DILANTIN INFATABS... 32
DEXILANT... 118	DIASTAT ACUDIAL... 32	DILANTIN... 32
dexmethylphenidate... 97	DIASTAT... 32	DILANTIN-125... 32
DEXPAK 10 DAY... 125	diazepam intensol... 71	DILATRATE-SR... 86
DEXPAK 13 DAY... 125	diazepam... 32, 71	DILAUDID... 11
DEXPAK 6 DAY... 125	diazoxide... 73	dilt-xr... 86
dexrazoxane hcl... 50	DIBENZYLIN... 86	diltiazem hcl... 86
DEXTENZA... 164	DICLEGIS... 41	dimenhydrinate... 41
dextroamphetamine... 98	diclofenac epolamine... 11	DIOVAN HCT... 86
dextroamphetamine-amphetamine... 98	diclofenac potassium... 11	DIOVAN... 86
dextrose 10 % and 0.2 % nacl... 112	diclofenac sodium... 11, 105, 164	DIPENTUM... 147
dextrose 10 % in water (d10w)... 112	diclofenac-misoprostol... 11	diphen... 169
dextrose 20 % in water (d20w)... 112	dicloxacillin... 25	diphenhydramine hcl... 169
dextrose 25 % in water (d25w)... 112	dicyclomine... 118	diphenoxylate-atropine... 118
dextrose 30 % in water (d30w)... 112	didanosine... 66	DIPROLENE... 105
dextrose 40 % in water (d40w)... 112	diethylpropion... 179	dipyridamole... 79
dextrose 5 % in water (d5w)... 113	DIFFERIN... 105	disopyramide phosphate... 86
dextrose 5 %-lactated ringers... 113	DIFICID... 25	disulfiram... 21
dextrose 5%-0.2 % sod chloride... 113	diflorasone... 105	DITROPAN XL... 123
	DIFLUCAN... 43	DIURIL IV... 86
	diflunisal... 11	DIURIL... 86
	digitek... 86	divalproex... 32
	digox... 86	DIVIGEL... 130
	digoxin... 86	dobutamine in d5w... 86
		dobutamine... 86
		DOCEFREZ... 50

docetaxel... 50	doxycycline hyclate... 25, 26	DURAGESIC... 12
dofetilide... 87	doxycycline monohydrate... 26	DURAMORPH (PF)... 12
DOJOLVI... 152	doxylamine-pyridoxine (vit b6)... 41	DUREZOL... 164
DOLOPHINE... 12	DRISDOL... 178	DURYSTA... 164
donepezil... 36	DRIZALMA SPRINKLE... 38	dutasteride... 123
dopamine in 5 % dextrose... 87	dronabinol... 41	dutasteride-tamsulosin... 124
dopamine... 87	droperidol... 62	DUTOPROL... 87
DOPRAM... 169	DROPLET INSULIN SYR HALF UNIT... 153	DUZALLO... 45
DOPTELET (10 TAB PACK)... 79	DROPLET INSULIN SYRINGE... 153	dvorah... 12
DOPTELET (15 TAB PACK)... 79	DROPLET MICRON PEN NEEDLE... 153	DXEVO... 125
DOPTELET (30 TAB PACK)... 79	DROPLET PEN NEEDLE... 153	DYANAVEL XR... 98
doripenem... 25	DROPSAFE PEN NEEDLE... 153	DYAZIDE... 87
DORYX MPC... 25	DROPSAFE PEN NEEDLE... 153	DYMISTA... 170
DORYX... 25	drosiprenone-e.estradiol-lm.fa... 130	DYRENIUM... 87
dorzolamide... 164	drosiprenone-ethinyl estradiol... 130	d10 %-0.45 % sodium chloride... 112
dorzolamide-timolol (pf)... 164	DROXIA... 153	d2.5 %-0.45 % sodium chloride... 112
dorzolamide-timolol... 164	DUAKLIR PRESSAIR... 169	d5 % and 0.9 % sodium chloride... 112
dothelle dha... 113	DUAVEE... 130	d5 %-0.45 % sodium chloride... 112
dotti... 130	DUET DHA WITH OMEGA-3... 113	
DOVATO... 66	DUETACT... 73	<b>E</b>
DOVONEX... 105	DUEXIS... 12	E.E.S. GRANULES... 26
doxazosin... 87	DULERA... 169	E.E.S. 400... 26
doxepin... 71, 105, 175	duloxetine... 38	EASY COMFORT ALCOHOL PAD... 153
doxercalciferol... 148	DUOBRII... 105	EASY COMFORT INSULIN SYRINGE... 153
DOXIL... 50	DUOPA... 60	EASY COMFORT PEN NEEDLES... 153
doxorubicin... 50	DUPIXENT PEN... 141	EASY GLIDE INSULIN SYRINGE... 153
doxorubicin, peg-liposomal... 50	DUPIXENT SYRINGE... 141	
doxy-100... 25		

EASY GLIDE PEN NEEDLE... 153	EGATEN... 59	EMBEDA... 12
EASY TOUCH ALCOHOL PREP PADS... 153	EGRIFTA SV... 127	EMCYT... 50
EASY TOUCH FLIPLOCK INSULIN... 153	EGRIFTA... 127	EMEND (FOSAPREPITANT)... 41
EASY TOUCH INSULIN SAFETY SYR... 154	ELAPRASE... 122	EMEND... 41
EASY TOUCH INSULIN SYRINGE... 154	electrolyte-48 in d5w... 113	EMFLAZA... 125
EASY TOUCH LUER LOCK INSULIN... 154	ELELYSO... 122	EMGALITY PEN... 46
EASY TOUCH PEN NEEDLE... 154	ELESTAT... 164	EMGALITY SYRINGE... 46
EASY TOUCH SAFETY PEN NEEDLE... 154	ELESTRIN... 130	emoquette... 130
EASY TOUCH SHEATHLOCK INSULIN... 154	eletriptan... 46	EMPLICITI... 50
EASY TOUCH UNI-SLIP... 154	ELIDEL... 105	EMSAM... 38
EASY TOUCH... 153	ELIGARD (3 MONTH)... 138	EMTRIVA... 66, 67
EC-NAPROSYN... 12	ELIGARD (4 MONTH)... 138	emverm... 59
ec-naproxen... 12	ELIGARD (6 MONTH)... 138	ENABLEX... 124
econazole... 43	ELIGARD... 138	enalapril maleate... 87
EDARBI... 87	ELIMITE... 105	enalapril-hydrochlorothiazide... 87
EDARBYCLOR... 87	elinest... 130	enalaprilat... 87
EDECIN... 87	ELIQUIS DVT-PE TREAT 30D START... 80	ENBREL MINI... 141
EDLUAR... 175	ELIQUIS... 79, 80	ENBREL SURECLICK... 141
EDURANT... 66	ELITEK... 50	ENBREL... 141
efavirenz... 66	ELIXOPHYLLIN... 170	ENDARI... 118
EFFEXOR XR... 38	ELLA... 130	endocet... 12
EFFIENT... 79	ELLENCE... 50	ENDOMETRIN... 130
EFUDEX... 105	ELMIRON... 124	ENGERIX-B (PF)... 141
	ELOCON... 105	ENGERIX-B PEDIATRIC (PF)... 141
	eluryng... 130	ENHERTU... 51
	ELZONRIS... 50	enoxaparin... 80
	EMADINE... 164	enpresse... 130
		enskyce... 130

ENSPRYNG... 141	eprosartan... 87	erythromycin-benzoyl peroxide... 106
ENSTILAR... 105	eptifibatide... 80	ESBRIET... 170
entacapone... 60	EPZICOM... 67	escitalopram oxalate... 38
entecavir... 67	EQUETRO... 32	ESGIC... 12
ENTOCORT EC... 147	ERAXIS(WATER DILUENT)... 43	esmolol in nacl (iso-osm)... 87
ENTRESTO... 87	ERBITUX... 51	esmolol... 87
ENTYVIO... 141	ergocalciferol (vitamin d2)... 178	esomeprazole magnesium... 118
enulose... 118	ergoloid... 36	esomeprazole sodium... 118
ENVARUS XR... 141	ERGOMAR... 46	esomeprazole strontium... 118
EPANED... 87	ergotamine-caffeine... 46	estarylla... 130
EPCLUSA... 67	ERIVEDGE... 51	estazolam... 175
EPIDIOLEX... 32	ERLEADA... 51	ESTRACE... 130
EPIDUO FORTE... 106	erlotinib... 51	estradiol valerate... 131
EPIDUO... 106	errin... 130	estradiol... 131
EPIFOAM... 106	ERTACZO... 43	estradiol-norethindrone acet... 131
epinastine... 164	ertapenem... 26	ESTRING... 131
epinephrine... 170	ERWINAZE... 51	ESTROGEL... 131
EPIPEN JR 2-PAK... 170	ery pads... 106	ESTROSTEP FE-28... 131
EPIPEN JR... 170	ERY-TAB... 26	eszopiclone... 175
EPIPEN 2-PAK... 170	ERYGEL... 106	ethacrynate sodium... 87
EPIPEN... 170	ERYPED 200... 26	ethacrynic acid... 87
epirubicin... 51	ERYPED 400... 26	ethambutol... 47
epitol... 32	ERYTHROCIN (AS STEARATE)... 26	ethosuximide... 32
EPIVIR HBV... 67	ERYTHROCIN... 26	ethynodiol diac-eth estradiol... 131
EPIVIR... 67	erythromycin ethylsuccinate... 26	ETHYOL... 51
eplerenone... 87	erythromycin with ethanol... 106	etidronate disodium... 148
EPOGEN... 80	erythromycin... 26, 164	etodolac... 12
epoprostenol (glycine)... 170		



etonogestrel-ethinyl estradiol... 131	EZALLOR SPRINKLE... 87	femynor... 131
ETOPOPHOS... 51	ezetimibe... 87	fenofibrate micronized... 88
etoposide... 51	ezetimibe-simvastatin... 87	fenofibrate nanocrystallized... 88
EUCRISA... 106	<b>F</b>	fenofibrate... 88
EURAX... 106	FABIOR... 106	fenofibric acid (choline)... 88
EUTHYROX... 137	FABRAZYME... 122	fenofibric acid... 88
EVAMIST... 131	falmina (28)... 131	FENOGLIDE... 88
EVEKEO ODT... 98	famciclovir... 67	fenopropfen... 12
EVEKEO... 98	famotidine (pf)... 118	FENSOLVI... 138
EVENITY... 148	famotidine (pf)-nacl (iso-os)... 118	fentanyl citrate (pf)... 12
everolimus (immunosuppressive)... 141, 142	famotidine... 118	fentanyl citrate... 12
EVISTA... 131	FANAPT... 62	fentanyl... 12
EVOCLIN... 106	FARESTON... 51	FENTORA... 13
EVOMELA... 51	FARXIGA... 73	FERRIPROX (2 TIMES A DAY)... 113
EVOTAZ... 67	FARYDAK... 51	FERRIPROX... 113
EVOXAC... 101	FASENRA PEN... 170	FETROJA... 26
EVZIO... 21	FASENRA... 170	FETZIMA... 38
EXALGO ER... 12	FASLODEX... 51	FEXMID... 174
EXEL INSULIN... 154	fayosim... 131	FIASP FLEXTOUCH U-100 INSULIN... 73
EXELDERM... 43	FAZACLO... 62, 63	FIASP PENFILL U-100 INSULIN... 73
EXELON... 36	febuxostat... 45	FIASP U-100 INSULIN... 73
exemestane... 51	felbamate... 32	FIBRICOR... 88
EXFORGE HCT... 87	FELBATOL... 32	FINACEA... 106
EXFORGE... 87	FELDENE... 12	finasteride... 124
EXJADE... 113	felodipine... 88	FINTEPLA... 32
EXTAVIA... 98	FEMARA... 51	FIORICET WITH CODEINE... 13
EXTINA... 43	FEMHRT LOW DOSE... 131	fioricet... 13
	FEMRING... 131	

FIORINAL... 13	flunisolide... 170	FOCALIN... 98
FIORINAL-CODEINE #3... 13	fluocinolone acetonide oil... 167	folic acid... 178
FIRAZYR... 142	fluocinolone and shower cap... 106	FOLLISTIM AQ... 177
FIRDAPSE... 98	fluocinolone... 106	FOLOTYN... 51
FIRMAGON KIT W DILUENT SYRINGE... 138	fluocinonide... 106	fomepizole... 154
FIRMAGON... 138	fluocinonide-e... 106	fondaparinux... 80
FIRVANQ... 26	fluocinonide-emollient... 106	FORFIVO XL... 38
flac otic oil... 167	fluorometholone... 164	FORTAMET... 73
FLAGYL... 26	FLUOROPLEX... 106	FORTAZ... 26
FLAREX... 164	fluorouracil... 51, 106	FORTEO... 149
flavoxate... 124	fluoxetine... 38	FORTESTA... 131
FLEBOGAMMA DIF... 142	fluphenazine decanoate... 63	FOSAMAX PLUS D... 149
flecainide... 88	fluphenazine hcl... 63	FOSAMAX... 149
FLECTOR... 13	flurandrenolide... 106	fosamprenavir... 67
FLOLIPID... 88	flurazepam... 175	fosaprepitant... 41
FLOMAX... 124	flurbiprofen sodium... 164	FOSCAVIR... 67
FLOVENT DISKUS... 170	flurbiprofen... 13	fosinopril... 88
FLOVENT HFA... 170	flutamide... 51	fosinopril-hydrochlorothiazide... 88
floxuridine... 51	fluticasone propion-salmeterol... 170	fosphenytoin... 32
fluconazole in dextrose(iso-o)... 43	fluticasone propionate... 106, 107, 170	FOSRENOL... 113
fluconazole in nacl (iso-osm)... 43	fluvastatin... 88	FRAGMIN... 80
fluconazole... 43	fluvoxamine... 38	FREAMINE HBC 6.9 %... 113
flucytosine... 43	FML FORTE... 164	FREAMINE III 10 %... 113
fludarabine... 51	FML LIQUIFILM... 164	FREESTYLE PRECISION... 154
fludrocortisone... 125	FML S.O.P.... 164	FROVA... 46
FLUMADINE... 67	FOCALIN XR... 98	frovatriptan... 46
flumazenil... 154		FULPHILA... 80
		fulvestrant... 51

FURADANTIN... 26  
 furosemide... 88  
 FUSILEV... 51  
 FUZEON... 67  
 fyavolv... 131  
 FYCOMPA... 32

**G**

gabapentin... 32, 33  
 GABITRIL... 33  
 GALAFOLD... 122  
 galantamine... 36, 37  
 GAMASTAN S/D... 142  
 GAMASTAN... 142  
 GAMMAGARD LIQUID... 142  
 GAMMAGARD S-D (IGA < 1  
 MCG/ML)... 142  
 GAMMAKED... 142  
 GAMMAPLEX (WITH SORBITOL)...  
 142  
 GAMMAPLEX... 142  
 GAMUNEX-C... 142  
 ganciclovir sodium... 67  
 GANIRELIX... 178  
 GARDASIL 9 (PF)... 142  
 GASTROCROM... 170  
 gatifloxacin... 164  
 GATTEX ONE-VIAL... 118  
 GATTEX 30-VIAL... 118  
 GAUZE BANDAGE... 154

GAUZE PAD... 154  
 gavilyte-c... 119  
 gavilyte-g... 119  
 gavilyte-n... 119  
 GAZYVA... 51  
 GELNIQUE... 124  
 gemcitabine... 51  
 gemfibrozil... 88  
 GEMZAR... 51  
 GENERESS FE... 131  
 generlac... 119  
 gengraf... 142  
 GENOTROPIN MINIQUICK... 127  
 GENOTROPIN... 127  
 gentak... 164  
 gentamicin in nacl (iso-osm)... 26  
 gentamicin sulfate (ped) (pf)... 26  
 gentamicin sulfate (pf)... 26  
 gentamicin... 26, 164  
 GENVOYA... 67  
 GEODON... 63  
 gianvi (28)... 131  
 GILENYA... 98  
 GILOTRIF... 51  
 GIVLAARI... 154  
 GLASSIA... 122  
 glatiramer... 98  
 glatopa... 98

GLEEVEC... 51  
 glimepiride... 73  
 glipizide... 73  
 glipizide-metformin... 73  
 GLOPERBA... 45  
 GLUCAGEN HYPOKIT... 73  
 GLUCAGON (HCL) EMERGENCY KIT...  
 73  
 GLUCAGON EMERGENCY KIT  
 (HUMAN)... 73  
 GLUCOPHAGE XR... 74  
 GLUCOPHAGE... 74  
 GLUCOTROL XL... 74  
 GLUCOTROL... 74  
 GLUMETZA... 74  
 glyburide micronized... 74  
 glyburide... 74  
 glyburide-metformin... 74  
 GLYCAT... 119  
 GLYCOPHOS... 113  
 glycopyrrolate (pf) in water... 119  
 glycopyrrolate... 119  
 glydo... 19  
 GLYNASE... 74  
 GLYSET... 74  
 GLYXAMBI... 74  
 GOCOVRI... 60  
 GOLYTELY... 119

GONAL-F RFF REDI-JECT... 178	HALDOL DECANOATE... 63	HETLIOZ... 175
GONAL-F RFF... 178	HALDOL... 63	HEXALEN... 52
GONAL-F... 178	halobetasol propionate... 107	HIBERIX (PF)... 142
GONITRO... 88	HALOG... 107	hidex... 125
GRALISE 30-DAY STARTER PACK... 98	haloperidol decanoate... 63	HIPREX... 27
GRALISE... 98	haloperidol lactate... 63	HIZENTRA... 142
granisetron (pf)... 41	haloperidol... 63	HORIZANT... 98
granisetron hcl... 41	HARVONI... 67	HUMALOG JUNIOR KWIKPEN U-100... 74
GRANIX... 80	HAVRIX (PF)... 142	HUMALOG KWIKPEN INSULIN... 74
GRASTEK... 170	HEALTHWISE INSULIN SYRINGE... 154	HUMALOG MIX 50-50 INSULN U-100... 74
griseofulvin microsize... 43	HEALTHWISE PEN NEEDLE... 154	HUMALOG MIX 50-50 KWIKPEN... 74
griseofulvin ultramicrosize... 43	HEALTHY ACCENTS UNIFINE PENTIP... 155	HUMALOG MIX 75-25 KWIKPEN... 74
guanfacine... 88, 98	heather... 131	HUMALOG MIX 75-25(U-100)INSULN... 74
guanidine... 47	HECTOROL... 149	HUMALOG U-100 INSULIN... 74
GVOKE HYPOPEN 1-PACK... 74	helidac... 119	HUMAPEN LUXURA HD... 155
GVOKE HYPOPEN 2-PACK... 74	HEMABATE... 128	HUMATROPE... 127
GVOKE PFS 1-PACK SYRINGE... 74	HEMADY... 125	HUMIRA PEDIATRIC CROHNS START... 142
GVOKE PFS 2-PACK SYRINGE... 74	HEMANGEOL... 88	HUMIRA PEN CROHNS-UC-HS START... 142
gynazole-1... 43	hemenatal ob + dha... 113	HUMIRA PEN PSOR-UEVITS-ADOL HS... 142
<b>H</b>	heparin (porcine)... 80	HUMIRA PEN... 142
HAEGARDA... 142	heparin, porcine (pf)... 80	HUMIRA... 142
hailey fe 1.5/30 (28)... 131	HEPATAMINE 8%... 113	HUMIRA(CF) PEDI CROHNS STARTER... 143
hailey fe 1/20 (28)... 131	HEPSERA... 67	
hailey 24 fe... 131	HERCEPTIN HYLECTA... 52	
hailey... 131	HERCEPTIN... 52	
HALAVEN... 51	HERZUMA... 52	
halcinonide... 107		
HALCION... 175		

HUMIRA(CF) PEN CROHNS-UC-HS... 143	hydrocodone-homatropine... 177	<b>I</b>
HUMIRA(CF) PEN PSOR-UV-ADOL HS... 143	hydrocodone-ibuprofen... 13	ibandronate... 149
HUMIRA(CF) PEN... 143	hydrocortisone butyr-emollient... 107	IBRANCE... 52
HUMIRA(CF)... 143	hydrocortisone butyrate... 107	ibu... 14
HUMULIN N NPH INSULIN KWIKPEN... 75	hydrocortisone valerate... 107	IBUDONE... 14
HUMULIN N NPH U-100 INSULIN... 75	hydrocortisone... 107, 147	ibuprofen... 14
HUMULIN R REGULAR U-100 INSULN... 75	hydrocortisone-acetic acid... 167	ibuprofen-oxycodone... 14
HUMULIN R U-500 (CONC) INSULIN... 75	hydrocortisone-min oil-wht pet... 107	ibutilide fumarate... 89
HUMULIN R U-500 (CONC) KWIKPEN... 75	hydromet... 177	icatibant... 143
HUMULIN 70/30 U-100 INSULIN... 74	hydromorphone (pf)... 13	ICLUSIG... 52
HUMULIN 70/30 U-100 KWIKPEN... 75	hydromorphone... 13	IDAMYCIN PFS... 52
HYCAMTIN... 52	hydroxocobalamin... 178	idarubicin... 52
hydralazine... 88	hydroxychloroquine... 59	IDHIFA... 52
HYDREA... 52	hydroxyprogest(pf)(preg presv)... 131	IFEX... 52
hydrochlorothiazide... 88	hydroxyprogesterone cap(ppres)... 131	ifosfamide... 52
hydrocodone bitartrate... 13	hydroxyprogesterone caproate... 131	ILEVRO... 164
hydrocodone-acetaminophen... 13	hydroxyurea... 52	ILUMYA... 143
hydrocodone-chlorpheniramine... 177	hydroxyzine hcl... 71, 72	imatinib... 52
hydrocodone-cpm-pseudoephed... 177	hydroxyzine pamoate... 170	IMBRUVICA... 52
hydrocodone-guaifenesin... 177	HYPERRAB (PF)... 143	IMFINZI... 52
	HYPERRAB S/D (PF)... 143	imipenem-cilastatin... 27
	HYPERTET S/D (PF)... 143	imipramine hcl... 38
	HYSINGLA ER... 13	imipramine pamoate... 38
	HYZAAR... 88	imiquimod... 107
		IMITREX STATDOSE PEN... 46
		IMITREX STATDOSE REFILL... 46
		IMITREX... 46
		IMLYGIC... 52

IMOGAM RABIES-HT (PF)... 143	INSPIRA... 89	INVOKAMET XR... 75
IMOVAX RABIES VACCINE (PF)... 143	INSULIN ASP PRT-INSULIN ASPART... 75	INVOKAMET... 75
IMPAVIDO... 59	INSULIN ASPART U-100... 75	INVOKANA... 75
IMPOYZ... 107	INSULIN LISPRO PROTAMIN-LISPRO... 75	IONOSOL-B IN D5W... 113
IMURAN... 143	INSULIN LISPRO... 75	IONOSOL-MB IN D5W... 113
INBRIJA... 60	INSULIN SYR/NDL U100 HALF MARK... 155	IOPIDINE... 164
incassia... 131	INSULIN SYRINGE MICROFINE... 155	IPOL... 143
INCONTROL ALCOHOL PADS... 155	INSULIN SYRINGE NEEDLELESS... 155	ipratropium bromide... 170
INCONTROL PEN NEEDLE... 155	INSULIN SYRINGE... 155	ipratropium-albuterol... 170
INCRELEX... 127	INSULIN SYRINGE-NEEDLE U-100... 155	irbesartan... 89
INCRUSE ELLIPTA... 170	INSUPEN... 155	irbesartan-hydrochlorothiazide... 89
indapamide... 89	INTEGRILIN... 81	IRESSA... 52
INDERAL LA... 89	INTELENCE... 67	irinotecan... 53
INDOCIN... 14	INTERMEZZO... 175	ISENTRESS HD... 67
indomethacin sodium... 14	INTRALIPID... 113	ISENTRESS... 67
indomethacin... 14	INTRON A... 143	isibloom... 132
INFANRIX (DTAP) (PF)... 143	introvale... 132	isochron... 89
INFLECTRA... 143	INTUNIVER... 98	ISOLYTE S PH 7.4... 113
INFUGEM... 52	INVANZ... 27	ISOLYTE-P IN 5 % DEXTROSE... 113
INFUMORPH P/F... 14	INVEGA SUSTENNA... 63	ISOLYTE-S... 113
INFUVITE ADULT... 178	INVEGA TRINZA... 63	isoniazid... 47
INFUVITE PEDIATRIC... 178	INVEGA... 63	ISOPTO CARPINE... 164
INGREZZA INITIATION PACK... 98	INVELTYS... 164	ISORDIL TITRADOSE... 89
INGREZZA... 98	INVIRASE... 67	ISORDIL... 89
INLYTA... 52		isosorbide dinitrate... 89
INNOPRAN XL... 89		isosorbide mononitrate... 89
INQOVI... 52		isotretinoin... 107
INREBIC... 52		isradipine... 89



ISTALOL... 164	jolivette... 132	KAZANO... 75
ISTODAX... 53	JORNAY PM... 99	KEDRAB (PF)... 143
ISTURISA... 155	JUBLIA... 43	KEFLEX... 27
ISUPREL... 89	juleber... 132	kelnor 1-50... 132
itraconazole... 43	JULUCA... 67	kelnor 1/35 (28)... 132
IV PREP WIPES... 155	junel fe 1.5/30 (28)... 132	KENALOG... 125
ivermectin... 59, 107	junel fe 1/20 (28)... 132	KENALOG-80... 125
IXEMPRA... 53	junel fe 24... 132	KENGREAL... 81
IXIARO (PF)... 143	junel 1.5/30 (21)... 132	KEPIVANCE... 101
<b>J</b>	junel 1/20 (21)... 132	KEPPRA XR... 33
JADENU SPRINKLE... 113	JUXTAPID... 89	KEPPRA... 33
JADENU... 113	JYNARQUE... 113	KERYDIN... 43
jaimiess... 132	<b>K</b>	ketoconazole... 43
JAKAFI... 53	K-TAB... 113	ketodan... 43
JALYN... 124	KABIVEN... 113	ketoprofen... 14
jantoven... 81	KADCYLA... 53	ketorolac... 14, 164
JANUMET XR... 75	KADIAN... 14	KEVEYIS... 122
JANUMET... 75	kaitlib fe... 132	KEVZARA... 143
JANUVIA... 75	KALETRA... 67	KEYTRUDA... 53
JARDIANCE... 75	kalliga... 132	KHAPZORY... 53
jasmiel (28)... 132	KALYDECO... 170	KHEDEZLA... 39
jencycla... 132	KANJINTI... 53	KINERET... 143
JENTADUETO XR... 75	KANUMA... 122	KINRIX (PF)... 143
JENTADUETO... 75	KAPSPARGO SPRINKLE... 89	kionex (with sorbitol)... 114
jevantique lo... 132	KAPVAY... 99	KISQALI FEMARA CO-PACK... 53
JEVTANA... 53	KARBINAL ER... 170	KISQALI... 53
jjinteli... 132	kariva (28)... 132	KITABIS PAK... 27
jolessa... 132	KATERZIA... 89	KLARON... 27

KLONOPIN... 72	LAMICTAL ODT STARTER (ORANGE)... 33	larissia... 132
klor-con m10... 114	LAMICTAL ODT... 33	LARTRUVO... 53
KLOR-CON M15... 114	LAMICTAL STARTER (BLUE) KIT... 33	LASIX... 89
klor-con m20... 114	LAMICTAL STARTER (GREEN) KIT... 33	LASTACAFT... 164
klor-con sprinkle... 114	LAMICTAL STARTER (ORANGE) KIT... 33	latanoprost... 164
KLOR-CON 10... 114	LAMICTAL XR STARTER (BLUE)... 33	LATUDA... 63
KLOR-CON 8... 114	LAMICTAL XR STARTER (GREEN)... 33	LAYOLIS FE... 132
klor-con... 114	LAMICTAL XR STARTER (ORANGE)... 33	LAZANDA... 14
KOMBIGLYZE XR... 75, 76	LAMICTAL XR... 33	ledipasvir-sofosbuvir... 68
KORLYM... 155	LAMICTAL... 33	leena 28... 132
KOSELUGO... 53	lamivudine... 67, 68	leflunomide... 143
KOSHER PRENATAL PLUS IRON... 114	lamivudine-zidovudine... 68	LEMTRADA... 99
KRINTAFEL... 59	lamotrigine... 33	LENVIMA... 53
KRISTALOSE... 119	LANOXIN PEDIATRIC... 89	LESCOL XL... 89
kurvelo (28)... 132	LANOXIN... 89	LESCOL... 89
KUVAN... 122	lansoprazole... 119	lessina... 132
KYNMOBI... 60	lanthanum... 114	LETAIRIS... 170
KYPROLIS... 53	LANTUS SOLOSTAR U-100 INSULIN... 76	letrozole... 53
<b>L</b>	LANTUS U-100 INSULIN... 76	leucovorin calcium... 53
l norgest/e.estradiol-e.estrad... 132	larin fe 1.5/30 (28)... 132	LEUKERAN... 53
labetalol... 89	larin fe 1/20 (28)... 132	LEUKINE... 81
LACRISERT... 164	larin 1.5/30 (21)... 132	leuprolide... 138
lactated ringers... 114, 155	larin 1/20 (21)... 132	levalbuterol hcl... 171
lactulose... 119	larin 24 fe... 132	levalbuterol tartrate... 171
LAMICTAL ODT STARTER (BLUE)... 33		LEVAQUIN... 27
LAMICTAL ODT STARTER (GREEN)... 33		LEVEMIR FLEXTOUCH U-100 INSULN... 76
		LEVEMIR U-100 INSULIN... 76

levetiracetam in nacl (iso-os)... 34	lidocaine in 5 % dextrose (pf)... 90	LITHOBID... 72
levetiracetam... 34	lidocaine viscous... 19	LITHOSTAT... 156
LEVO-T... 137	lidocaine... 19	LIVALO... 90
levobunolol... 164	lidocaine-epinephrine bit... 19	LO LOESTRIN FE... 133
levocarnitine (with sugar)... 114	lidocaine-epinephrine... 19	lo-zumandimine (28)... 133
levocarnitine... 114	lidocaine-prilocaine... 19	LOCOID LIPOCREAM... 107
levocetirizine... 171	LIDODERM... 20	LOCOID... 107
levofloxacin in d5w... 27	lillow (28)... 133	LODINE... 14
levofloxacin... 27, 164	LINCOCIN... 27	LODOSYN... 60
levoleucovorin calcium... 53	lincomycin... 27	LOESTRIN FE 1.5/30 (28-DAY)... 133
levonest (28)... 132	lindane... 107	LOESTRIN FE 1/20 (28-DAY)... 133
levonorg-eth estrad triphasic... 132	linezolid in dextrose 5%... 27	LOESTRIN 1.5/30 (21)... 133
levonorgestrel-ethinyl estrad... 132	linezolid... 27	LOESTRIN 1/20 (21)... 133
LEVOPHED (BITARTRATE)... 89	linezolid-0.9% sodium chloride... 27	lojaimiess... 133
levora-28... 133	LINZESS... 119	LOKELMA... 114
levorphanol tartrate... 14	liothyronine... 138	lomaira... 179
levothyroxine... 137	LIPITOR... 90	LOMOTIL... 119
LEVOXYL... 138	lipodox 50... 54	LONHALA MAGNAIR REFILL... 171
LEVULAN... 53	lipodox... 54	LONHALA MAGNAIR STARTER... 171
LEXAPRO... 39	LIPOFEN... 90	LONSURF... 54
LEXETTE... 107	lisinopril... 90	loperamide... 119
LEXIVA... 68	lisinopril-hydrochlorothiazide... 90	LOPID... 90
LIALDA... 147	LITE TOUCH INSULIN PEN	lopinavir-ritonavir... 68
LIBTAYO... 54	NEEDLES... 155	lopreeza... 133
LICART... 14	LITE TOUCH INSULIN SYRINGE...	LOPRESSOR HCT... 90
lidocaine (pf) in d7.5w... 19	156	LOPRESSOR... 90
lidocaine (pf)... 19, 90	lithium carbonate... 72	LOPROX (AS OLAMINE)... 44
lidocaine hcl... 19	lithium citrate... 72	LOPROX... 44

lorazepam intensol... 72	LUMIZYME... 122	M.V.I.-12 (WITHOUT VITAMIN K)... 178
lorazepam... 72	LUMOXITI... 54	M-M-R II (PF)... 143
LORBRENA... 54	LUNESTA... 175	m-natal plus... 114
lorcet (hydrocodone)... 14	LUPANETA PACK (1 MONTH)... 138	MACROBID... 27
lorcet hd... 14	LUPANETA PACK (3 MONTH)... 139	MACRODANTIN... 27
lorcet plus... 14	LUPRON DEPOT (3 MONTH)... 139	mafenide acetate... 108
lortab elixir... 14	LUPRON DEPOT (4 MONTH)... 139	MAGELLAN INSULIN SAFETY SYRNG... 156
loryna (28)... 133	LUPRON DEPOT (6 MONTH)... 139	MAGELLAN SYRINGE... 156
LORZONE... 174	LUPRON DEPOT... 139	magnesium sulfate in d5w... 114
losartan... 90	LUPRON DEPOT-PED (3 MONTH)... 139	magnesium sulfate in water... 114
losartan-hydrochlorothiazide... 90	LUPRON DEPOT-PED... 139	magnesium sulfate... 114
LOSEASONIQUE... 133	lutera (28)... 133	MAKENA (PF)... 133
LOTEMAX SM... 164	LUXIQ... 107	MAKENA... 133
LOTEMAX... 164	LUZU... 44	MALARONE PEDIATRIC... 59
LOTENSIN HCT... 90	LYNPARZA... 54	MALARONE... 59
LOTENSIN... 90	LYRICA CR... 99	malathion... 108
loteprednol etabonate... 165	LYRICA... 99	mannitol 10 %... 90
LOTREL... 90	LYSODREN... 138	mannitol 20 %... 90
LOTRISONE... 44	LYSTEDA... 81	mannitol 25 %... 90
LOTRONEX... 119	LYUMJEV KWIKPEN U-100 INSULIN... 76	mannitol 5 %... 90
lovastatin... 90	LYUMJEV KWIKPEN U-200 INSULIN... 76	maprotiline... 39
LOVAZA... 90	LYUMJEV U-100 INSULIN... 76	MARCAINE (PF)... 20
LOVENOX... 81	lyza... 133	MARCAINE SPINAL (PF)... 20
low-ogestrel (28)... 133		MARCAINE... 20
loxapine succinate... 63		MARCAINE-EPINEPHRINE (PF)... 20
LUCEMYRA... 21		MARCAINE-EPINEPHRINE... 20
luliconazole... 44		
LUMIGAN... 165		
	<b>M</b>	
	M.V.I. ADULT... 178	
	M.V.I. PEDIATRIC... 178	

MARINOL... 41	MAYZENT... 99	meprobamate... 72
marlissa (28)... 133	meclizine... 41	MEPRON... 59
MARPLAN... 39	meclofenamate... 14	MEPSEVII... 122
MARQIBO... 54	MEDROL (PAK)... 125	mercaptapurine... 54
MATULANE... 54	MEDROL... 125	meropenem... 27
matzim la... 90	medroxyprogesterone... 133	meropenem-0.9% sodium chloride... 27
MAVENCLAD (10 TABLET PACK)... 99	mefenamic acid... 14	MERREM... 27
MAVENCLAD (4 TABLET PACK)... 99	mefloquine... 59	mesalamine... 147, 148
MAVENCLAD (5 TABLET PACK)... 99	MEGACE ES... 133	mesna... 54
MAVENCLAD (6 TABLET PACK)... 99	megestrol... 133	MESNEX... 54
MAVENCLAD (7 TABLET PACK)... 99	MEKINIST... 54	MESTINON TIMESPAN... 47
MAVENCLAD (8 TABLET PACK)... 99	MEKTOVI... 54	MESTINON... 47
MAVENCLAD (9 TABLET PACK)... 99	melodetta 24 fe... 133	metadate er... 99
MAVYRET... 68	meloxicam... 14	metaproterenol... 171
MAXALT... 46	melphalan hcl... 54	metaxall... 174
MAXALT-MLT... 46	melphalan... 54	metaxalone... 174
MAXI-COMFORT INSULIN SYRINGE... 156	memantine... 37	metformin... 76
MAXICOMFORT II PEN NEEDLE... 156	MENACTRA (PF)... 144	methadone intensol... 15
MAXICOMFORT INSULIN SYRINGE... 156	MENEST... 133	methadone... 15
MAXICOMFORT SAFETY PEN NEEDLE... 156	MENOPUR... 178	METHADOSE... 15
MAXIDEX... 165	MENOSTAR... 133	methamphetamine... 99
MAXIPIME... 27	MENTAX... 44	methazolamide... 90
MAXITROL... 165	MENVEO A-C-Y-W-135-DIP (PF)... 144	methenamine hippurate... 27
MAXZIDE... 90	meperidine (pf)... 15	methergine... 156
MAXZIDE-25MG... 90	meperidine... 15	methimazole... 139
MAYZENT STARTER PACK... 99	MEPHYTON... 178	METHITEST... 133
	mepivacaine (pf)... 20	methocarbamol... 174

methotrexate sodium (pf)... 144	metronidazole in nacl (iso-os)... 27	milrinone in 5 % dextrose... 91
methotrexate sodium... 144	metronidazole... 27	milrinone... 91
methoxsalen... 108	metyrosine... 91	mimvey lo... 134
methscopolamine... 119	mexiletine... 91	mimvey... 134
methyclothiazide... 90	MIACALCIN... 149	MINASTRIN 24 FE... 134
methyldopa... 90	mibelas 24 fe... 133	MINI ULTRA-THIN II... 156
methyldopa-hydrochlorothiazide... 90	micafungin... 44	MINIPRESS... 91
methyldopate... 90	MICARDIS HCT... 91	minitran... 91
methylergonovine... 156	MICARDIS... 91	MINIVELLE... 134
METHYLIN... 99	miconazole nitrate-zinc ox-pet... 44	MINOCIN... 27, 28
methylphenidate hcl... 99, 100	miconazole-3... 44	minocycline... 28
methylprednisolone acetate... 125	micort-hc... 126	MINOLIRA ER... 28
methylprednisolone sodium succ... 125	MICRODOT INSULIN PEN NEEDLE... 156	minoxidil... 91
methylprednisolone... 125	microgestin fe 1.5/30 (28)... 133	MIOSTAT... 165
methyltestosterone... 133	microgestin fe 1/20 (28)... 133	MIRAPEX ER... 60
metipranolol... 165	microgestin 1.5/30 (21)... 133	MIRAPEX... 60
metoclopramide hcl... 41	microgestin 1/20 (21)... 133	MIRCERA... 81
metolazone... 90	MICROGESTIN 24 FE... 133	MIRCETTE (28)... 134
metoprolol succinate... 90	MICROZIDE... 91	mirtazapine... 39
metoprolol ta-hydrochlorothiaz... 91	midodrine... 91	MIRVASO... 108
metoprolol tartrate... 91	migergot... 46	misoprostol... 119
METRO I.V.... 27	miglitol... 76	MITIGARE... 45
METROCREAM... 27	miglustat... 122	mitigo (pf)... 15
METROGEL VAGINAL... 27	MIGRANAL... 46	mitomycin... 54
METROGEL... 27	mili... 133	mitoxantrone... 54
METROLOTION... 27	millipred dp... 126	MOBIC... 15
	millipred... 126	modafinil... 175
		moderiba... 68



moexipril... 91  
moexipril-hydrochlorothiazide... 91  
molindone... 63  
mometasone... 108, 171  
mondoxylene nl... 28  
MONJUVI... 144  
mono-linyah... 134  
MONODOX... 28  
MONOJECT INSULIN SAFETY  
SYRING... 156  
MONOJECT INSULIN SYRINGE... 157  
MONOJECT SYRINGE... 157  
MONOJECT ULTRA COMFORT  
INSULIN... 157  
mononessa (28)... 134  
montelukast... 171  
MONUROL... 28  
morgidox... 28  
MORPHABOND ER... 15  
morphine (pf)... 16  
morphine concentrate... 16  
morphine... 15, 16  
MOTEGRITY... 119  
MOTOFEN... 119  
MOVANTIK... 119  
MOVIPREP... 119  
MOXEZA... 165  
moxifloxacin... 28, 165

moxifloxacin-sod.ace,sul-water...  
28  
moxifloxacin-sod.chloride(iso)... 28  
MOZOBIL... 81  
MS CONTIN... 16  
MULPLETA... 81  
MULTAQ... 91  
mupirocin calcium... 108  
mupirocin... 108  
MUSTARGEN... 54  
MUTAMYCIN... 54  
MVASI... 54  
MYALEPT... 119  
MYAMBUTOL... 47  
MYCAMINE... 44  
MYCAPSSA... 139  
MYCOBUTIN... 47  
mycophenolate mofetil (hcl)... 144  
mycophenolate mofetil... 144  
mycophenolate sodium... 144  
MYDAYIS... 100  
MYFORTIC... 144  
MYLOTARG... 54  
myorisan... 108  
MYRBETRIQ... 124  
MYSOLINE... 34  
MYTESI... 119  
myzilra... 134

## N

nabumetone... 16  
nadolol... 91  
nadolol-bendroflumethiazide... 91  
nafcillin in dextrose iso-osm... 28  
nafcillin... 28  
naftifine... 44  
NAFTIN... 44  
NAGLAZYME... 122  
nalbuphine... 16  
NALFON... 16  
nalocet... 16  
naloxone... 21  
naltrexone... 21  
NAMENDA TITRATION PAK... 37  
NAMENDA XR... 37  
NAMENDA... 37  
NAMZARIC... 37  
NAPRELAN CR... 16  
NAPROSYN... 16  
naproxen sodium... 16  
naproxen... 16  
naproxen-esomeprazole... 16  
naratriptan... 46  
NARCAN... 21  
NARDIL... 39  
NAROPIN (PF)... 20  
NASCOBAL... 179

NASONEX... 171	NEORAL... 144	NILANDRON... 54
NATACHEW (FE BIS-GLYCINATE)... 114	NEPHRAMINE 5.4 %... 114	nilutamide... 54
NATACYN... 165	NERLYNX... 54	nimodipine... 92
NATAZIA... 134	NESACAINE... 20	NINLARO... 54
nateglinide... 76	NESACAINE-MPF... 20	NIPENT... 54
NATESTO... 134	NESINA... 76	nisoldipine... 92
NATPARA... 149	neuac... 108	nitisinone... 122
NATRECOR... 91	NEULASTA... 81	NITRO-BID... 92
NATROBA... 108	NEUPOGEN... 81	NITRO-DUR... 92
NAVELBINE... 54	NEUPRO... 60	nitrofurantoin macrocrystal... 28
NAYZILAM... 34	NEURONTIN... 34	nitrofurantoin monohyd/m-cryst... 28
NEBUPENT... 59	NEVANAC... 165	nitrofurantoin... 28
necon 0.5/35 (28)... 134	nevirapine... 68	nitroglycerin in 5 % dextrose... 92
nefazodone... 39	NEXAVAR... 54	nitroglycerin... 92
NEMBUTAL SODIUM... 34	NEXIUM IV... 119	NITROLINGUAL... 92
neo-polycin hc... 165	NEXIUM PACKET... 119	NITROSTAT... 92
neo-polycin... 165	NEXIUM... 119	NITYR... 122
NEO-SYNALAR... 108	NEXLETOL... 91	NIVESTYM... 81
neomycin... 28	NEXLIZET... 91	nizatidine... 119
neomycin-bacitracin-poly-hc... 165	NEXTERONE... 91	NIZORAL... 44
neomycin-bacitracin-polymyxin... 165	niacin... 91	NOCDURNA (MEN)... 127
neomycin-polymyxin b gu... 157	niacor... 91	NOCDURNA (WOMEN)... 127
neomycin-polymyxin b-dexameth... 165	NIASPAN EXTENDED-RELEASE... 91	nolix... 108
neomycin-polymyxin-gramicidin... 165	nicardipine... 91	nora-be... 134
neomycin-polymyxin-hc... 165, 167	NICOTROL NS... 21	NORCO... 16
	NICOTROL... 21	NORDITROPIN FLEXP... 127
	nifedipine... 91, 92	norepinephrine bitartrate... 92
	nikki (28)... 134	

noreth-ethinyl estradiol-iron... 134	NOURIANZ... 60	NUCYNTA ER... 17
norethindrone (contraceptive)... 134	NOVAREL... 127	NUCYNTA... 17
norethindrone ac-eth estradiol... 134	NOVOFINE AUTOCOVER... 157	NUEDEXTA... 100
norethindrone acetate... 134	NOVOFINE PLUS... 157	NULYTELY LEMON-LIME... 120
norethindrone-e.estradiol-iron... 134	NOVOFINE 32... 157	NULYTELY WITH FLAVOR PACKS... 120
NORGESIC FORTE... 174	NOVOLIN N FLEXPEN... 76	NUPLAZID... 63
norgestimate-ethinyl estradiol... 134	NOVOLIN N NPH U-100 INSULIN... 76	NURTEC ODT... 157
NORITATE... 28	NOVOLIN R FLEXPEN... 76	NUTRESTORE... 120
norlyda... 134	NOVOLIN R REGULAR U-100 INSULN... 76	NUTRILIPID... 114
NORMOSOL-M IN 5 % DEXTROSE... 114	NOVOLIN 70-30 FLEXPEN U-100... 76	NUTROPIN AQ NUSPIN... 127
NORMOSOL-R IN 5 % DEXTROSE... 114	NOVOLIN 70/30 U-100 INSULIN... 76	NUVARING... 134
NORMOSOL-R PH 7.4... 114	NOVOLOG FLEXPEN U-100 INSULIN... 76	NUVESSA... 28
NORMOSOL-R... 114	NOVOLOG MIX 70-30 U-100 INSULN... 76	NUVIGIL... 175
NORPACE CR... 92	NOVOLOG MIX 70-30FLEXPEN U-100... 76	NUZYRA (7 DAY WITH LOAD DOSE)... 28
NORPACE... 92	NOVOLOG PENFILL U-100 INSULIN... 76	NUZYRA (7 DAY)... 28
NORPRAMIN... 39	NOVOLOG U-100 INSULIN ASPART... 77	NUZYRA... 28
NORTHERA... 92	NOVOPEN ECHO... 157	nyamyc... 44
nortrel 0.5/35 (28)... 134	NOVOTWIST... 157	NYMALIZE... 92
nortrel 1/35 (21)... 134	NOXAFIL... 44	nystatin... 44
nortrel 1/35 (28)... 134	NUBEQA... 54	nystatin-triamcinolone... 44
nortrel 7/7/7 (28)... 134	NUCALA... 171	nystop... 44
nortriptyline... 39		
NORVASC... 92		
NORVIR... 68		

**O**

O-CAL PRENATAL... 114  
 OB COMPLETE ONE... 114  
 OB COMPLETE PETITE... 114  
 OB COMPLETE PREMIER... 114

OBREDON... 177	OMEGAVEN... 114	OPSUMIT... 171
OICALIVA... 120	omeppi... 120	ORACEA... 28
ocella... 134	omeprazole... 120	ORALAIR... 171
OCREVUS... 100	omeprazole-sodium bicarbonate... 120	oralone... 101
OCTAGAM... 144	OMNARIS... 171	ORAP... 64
octreotide acetate... 139	OMNIPOD DASH 5 PACK POD... 157	ORAPRED ODT... 126
OCUFLOX... 165	OMNIPOD INSULIN MANAGEMENT... 157	ORAVIG... 44
ODACTRA... 171	OMNIPOD INSULIN REFILL... 157	ORBACTIV... 28
ODEFSEY... 68	OMNIPRED... 165	ORENCIA CLICKJECT... 144
ODOMZO... 54	OMNITROPE... 127	ORENCIA... 144
OFEV... 171	ONCASPAR... 55	ORENITRAM... 171
ofloxacin... 28, 165, 167	ondansetron hcl (pf)... 41, 42	ORFADIN... 122
ogestrel (28)... 134	ondansetron hcl... 41	ORIAHNN... 157
OGIVRI... 54	ondansetron... 41	ORILISSA... 139
okebo... 28	ONEXTON... 108	ORKAMBI... 171
olanzapine... 64	ONFI... 34	orphenadrine citrate... 174
olanzapine-fluoxetine... 39	ONGENTYS... 60	orphenadrine-asa-caffeine... 174
olmesartan... 92	ONGLYZA... 77	orphengesic forte... 175
olmesartan-amlodipin-hcthiazyd... 92	ONIVYDE... 55	orsythia... 134
olmesartan-hydrochlorothiazide... 92	ONMEL... 44	ORTHO MICRONOR... 134
olopatadine... 165, 171	ONTRUZANT... 55	ORTHO TRI-CYCLEN (28)... 134
OLUMIANT... 144	ONUREG... 55	ORTHO TRI-CYCLEN LO (28)... 134
OLUX... 108	ONZETRA XSAIL... 46	ORTHO-CYCLEN (28)... 135
OLUX-E... 108	OPANA... 17	ORTHO-NOVUM 1/35 (28)... 135
OMECLAMOX-PAK... 120	OPDIVO... 55	ORTHO-NOVUM 7/7/7 (28)... 135
omega-3 acid ethyl esters... 92	opium tincture... 120	ORTIKOS... 148
		oseltamivir... 68
		OSENI... 77

OSMITROL 10 %... 92	oxycodone... 17	paroxetine mesylate(menop.sym)... 39
OSMITROL 15 %... 93	oxycodone-acetaminophen... 17	PASER... 47
OSMITROL 20 %... 93	oxycodone-aspirin... 17	PATADAY... 165
OSMITROL 5 %... 93	OXYCONTIN... 17	PATANASE... 171
OSMOLEX ER... 60, 61	oxymorphone... 17	PATANOL... 165
OSMOPREP... 120	oxytocin... 157	PAXIL CR... 39
OSPHENA... 135	OXYTROL... 124	PAXIL... 39
OTEZLA STARTER... 108	OZEMPIC... 77	PAZEO... 165
OTEZLA... 108	<b>P</b>	PEDIAPRED... 126
OTOVEL... 167	PACERONE... 93	PEDIARIX (PF)... 144
OTREXUP (PF)... 144	paclitaxel... 55	PEDVAX HIB (PF)... 144
OVIDE... 108	PADCEV... 55	peg 3350-electrolytes... 120
OVIDREL... 178	paliperidone... 64	peg-electrolyte soln... 120
oxacillin in dextrose(iso-osm)... 28	PALYNZIQ... 122	peg-prep... 120
oxacillin... 28	PAMELOR... 39	PEGANONE... 34
oxaliplatin... 55	pamidronate... 149	PEGASYS PROCLICK... 144
oxandrolone... 135	PANCREAZE... 122	PEGASYS... 144
oxaprozin... 17	PANDEL... 108	PEGINTRON... 144
OXAYDO... 17	PANRETIN... 55	PEMAZYRE... 55
oxazepam... 72	pantoprazole... 120	PEN NEEDLE... 157
OXBRYTA... 157	PANZYGA... 144	PEN NEEDLE, DIABETIC... 157
oxcarbazepine... 34	paraplatin... 55	penicillamine... 114
OXERVATE... 165	paricalcitol... 149	penicillin g pot in dextrose... 29
oxiconazole... 44	PARLODEL... 61	penicillin g potassium... 29
OXISTAT... 44	PARNATE... 39	penicillin g procaine... 29
OXSORALEN ULTRA... 108	paroex oral rinse... 101	penicillin g sodium... 29
OXTELLAR XR... 34	paromomycin... 28	penicillin v potassium... 29
oxybutynin chloride... 124	paroxetine hcl... 39	

PENLAC... 44	PHENERGAN... 42	piperacillin-tazobactam... 29
PENNSAID... 17	phenobarbital sodium... 34	PIQRAY... 55
PENTACEL (PF)... 144	phenobarbital... 34	pirmella... 135
PENTAM... 59	phenoxybenzamine... 93	piroxicam... 17
pentamidine... 59	phentermine... 180	PITOCIN... 157
PENTASA... 148	phenylephrine hcl... 93	PLAQUENIL... 59
pentazocine-naloxone... 17	PHENYTEK... 34	PLASMA-LYTE A... 115
PENTIPS... 157	phenytoin sodium extended... 34	PLASMA-LYTE 148... 115
pentobarbital sodium... 34	phenytoin sodium... 34	PLAVIX... 81
pentoxifylline... 93	phenytoin... 34	PLEGRIDY... 100
pepcid... 120	PHESGO... 55	plenamine... 115
PERCOCET... 17	philith... 135	PLENVU... 120
PERFOROMIST... 171	PHOSLYRA... 115	PLIAGLIS... 20
PERIKABIVEN... 115	PHOSPHOLINE IODIDE... 165	plixda... 108
perindopril erbumine... 93	phrenilin forte(with caffeine)... 17	pnv ob+dha... 115
periogard... 101	PHYSIOLYTE... 157	pnv-dha... 179
PERJETA... 55	PHYSIOSOL IRRIGATION... 157	pnv-omega... 179
permethrin... 108	phytonadione (vitamin k1)... 179	podofilox... 108
perphenazine... 64	PICATO... 108	POLIVY... 55
perphenazine-amitriptyline... 39	PIFELTRO... 68	polocaine... 20
PERSERIS... 64	pilocarpine hcl... 101, 165	polocaine-mpf... 20
PERTZYE... 122	pimecrolimus... 108	polycin... 165
PEXEVA... 39	pimozide... 64	polymyxin b sulf-trimethoprim... 165
pfizerpen-g... 29	pimtrea (28)... 135	polymyxin b sulfate... 29
phenadoz... 42	pindolol... 93	POLYTRIM... 165
phendimetrazine tartrate... 179, 180	pioglitazone... 77	POMALYST... 55
phenelzine... 39	pioglitazone-glimepiride... 77	portia 28... 135
	pioglitazone-metformin... 77	



PORTRAZZA... 55	prasugrel... 81	prenatal plus dha... 116
posaconazole... 45	PRAVACHOL... 93	prenatal vitamin plus low iron... 116
POTABA... 179	pravastatin... 93	prenatal-u... 179
potassium acetate... 115	praziquantel... 59	PRENATE ELITE... 116
potassium chlorid-d5-0.45%nacl... 115	prazosin... 93	preplus... 116
potassium chloride in lr-d5... 115	PRECOSE... 77	PREPOPIK... 120
potassium chloride in water... 115	PRED FORTE... 165	PRESTALIA... 93
potassium chloride in 0.9%nacl... 115	PRED MILD... 165	PRETOMANID... 47
potassium chloride in 5 % dex... 115	PRED-G S.O.P.... 166	PREVACID SOLUTAB... 120
potassium chloride... 115	PRED-G... 166	PREVACID... 120
potassium chloride-d5-0.2%nacl... 115	prednicarbate... 108	prevalite... 93
potassium chloride-d5-0.3%nacl... 115	prednisolone acetate... 166	PREVENT DROPSAFE PEN NEEDLE... 157
potassium chloride-d5-0.9%nacl... 115	prednisolone sodium phosphate... 126, 166	previfem... 135
potassium chloride-0.45 % nacl... 115	prednisolone... 126	PREVYMIS... 68
potassium chloride-0.45 % nacl... 115	prednisone intensol... 126	PREZCOBIX... 68
potassium citrate... 115	prednisone... 126	PREZISTA... 68
POTELIGEO... 55	PREFEST... 135	PRIALT... 157
pr natal 400 ec... 115	pregabalin... 100	PRIFTIN... 47
pr natal 400... 115	PREGNYL... 127	PRILOSEC... 120
pr natal 430 ec... 115	PREMARIN... 135	primaquine... 59
pr natal 430... 115	PREMASOL 10 %... 115	PRIMAXIN IV... 29
PRADAXA... 81	PREMASOL 6 %... 115	primidone... 34
PRALUENT PEN... 93	PREMPHASE... 135	primlev... 17
pramipexole... 61	PREMPRO... 135	PRIMSOL... 29
PRANDIN... 77	PRENATA... 115	PRINIVIL... 93
	PRENATABS FA... 115	PRISTIQ... 39
	prenatal plus (calcium carb)... 116	PRIVIGEN... 144

PRO COMFORT ALCOHOL PADS... 158	PROGLYCEM... 77	PROTONIX... 120
PRO COMFORT INSULIN SYRINGE... 158	PROGRAF... 144, 145	PROTOPIC... 109
PRO COMFORT PEN NEEDLE... 158	PROLASTIN-C... 123	protriptyline... 39
PROAIR DIGIHALER... 171	prolate... 17	PROVENTIL HFA... 172
PROAIR HFA... 172	PROLENSA... 166	PROVERA... 135
PROAIR RESPICLICK... 172	PROLEUKIN... 55	PROVIGIL... 175
probenecid... 45	PROLIA... 149	PROZAC... 39
probenecid-colchicine... 45	PROMACTA... 81, 82	PRUDOXIN... 109
procainamide... 93	promethazine vc... 158	psorcon... 109
PROCALAMINE 3%... 116	promethazine vc-codeine... 177	PULMICORT FLEXHALER... 172
PROCARDIA XL... 93	promethazine... 42	PULMICORT... 172
PROCARDIA... 93	promethazine-codeine... 177	PULMOZYME... 172
procentra... 100	promethazine-dm... 177	PURE COMFORT ALCOHOL PADS... 158
prochlorperazine edisylate... 42	promethazine-phenyleph-codeine... 177	PURE COMFORT PEN NEEDLE... 158
prochlorperazine maleate... 42	promethazine-phenylephrine... 158	PURIXAN... 55
prochlorperazine... 42	promethegan... 42	PYLERA... 120
PROCRIPT... 81	PROMETRIUM... 135	pyrazinamide... 47
procto-med hc... 108	propafenone... 93	pyridostigmine bromide... 47
procto-pak... 109	propantheline... 120	pyridoxine (vitamin b6)... 179
PROCTOFOAM HC... 148	proparacaine... 166	pyrimethamine... 59
proctosol hc... 109	propranolol... 93	<b>Q</b>
proctozone-hc... 109	propranolol-hydrochlorothiazid... 93	QBRELIS... 93
PROCYSBI... 122	propylthiouracil... 140	QBREXZA... 109
PRODIGY INSULIN SYRINGE... 158	PROQUAD (PF)... 145	QINLOCK... 55
profeno... 17	PROSCAR... 124	QMIIZ ODT... 18
progesterone micronized... 135	PROSOL 20 %... 116	QNASL... 172
progesterone... 135	protamine... 158	QSYMIA... 180

QTERN... 77	ranolazine... 94	RELION NEEDLES... 158
QUADRACEL (PF)... 145	RAPAFLO... 124	RELION PEN NEEDLES... 158
QUALAQUIN... 59	RAPAMUNE... 145	RELISTOR... 120
QUARTETTE... 135	rasagiline... 61	RELPAK... 46
quasense... 135	RASUVO (PF)... 145	REMERON SOLTAB... 39
QUDEXY XR... 34, 35	RAVICTI... 123	REMERON... 39
QUESTRAN LIGHT... 93	RAYALDEE... 149	REMICADE... 145
QUESTRAN... 93	RAYOS... 126	REMODULIN... 172
quetiapine... 64	RAZADYNE ER... 37	RENACIDIN... 158
QUILLICHEW ER... 100	RAZADYNE... 37	RENAGEL... 116
QUILLIVANT XR... 100	REBETOL... 68	RENFLEXIS... 145
quinapril... 93	REBIF (WITH ALBUMIN)... 100	REVELA... 116
quinapril-hydrochlorothiazide... 93	REBIF REBIDOSE... 100	REOPRO... 82
quinidine gluconate... 94	REBIF TITRATION PACK... 100	repaglinide... 77
quinidine sulfate... 94	REBLOZYL... 82	repaglinide-metformin... 77
quinine sulfate... 59	RECARBRIO... 29	REPATHA PUSHTRONEX... 94
QUZYTIR... 172	RECLAST... 149	REPATHA SURECLICK... 94
QVAR REDIHALER... 172	reclipsen (28)... 135	REPATHA SYRINGE... 94
<b>R</b>	RECOMBIVAX HB (PF)... 145	REQUIP XL... 61
RABAVERT (PF)... 145	RECTIV... 158	REQUIP... 61
rabeprazole... 120	REGIMEX... 180	RESCRIPTOR... 68
RADICAVA... 100	REGLAN... 42	RESECTISOL... 94
RAGWITEK... 172	REGONOL... 47	RESPA-AR... 177
rajani... 135	REGRANEX... 109	RESTASIS MULTIDOSE... 166
raloxifene... 135	RELAFEN DS... 18	RESTASIS... 166
ramelteon... 175	RELAFEN... 18	RESTORIL... 175
ramipril... 94	RELENZA DISKHALER... 68	RETACRIT... 82
RANEXA... 94	relexxii... 100	RETEVMO... 55

RETIN-A MICRO PUMP... 109	ringer's... 116, 158	ROTARIX... 145
RETIN-A MICRO... 109	RINVOQ... 145	ROTATEQ VACCINE... 145
RETIN-A... 109	RIOMET ER... 77	ROWASA... 148
RETROVIR... 68, 69	RIOMET... 77	roweepra xr... 35
REVATIO... 172	risedronate... 149	roweepra... 35
REVCОВI... 123	RISPERDAL CONSTA... 64	ROXICODONE... 18
REVLIMID... 55	RISPERDAL... 64	ROXYBOND... 18
revonto... 65	risperidone... 64	ROZEREM... 175
REXULTI... 64	RITALIN LA... 100	ROZLYTREK... 56
REYATAZ... 69	RITALIN... 100	RUBRACA... 56
REYVOW... 46	ritonavir... 69	RUCONEST... 145
RHOFADE... 109	RITUXAN HYCELA... 55	RUKOBIA... 69
RHOPHYLAC... 145	RITUXAN... 55	RUXIENCE... 56
RHOPRESSA... 166	rivastigmine tartrate... 37	RUZURGI... 100
RIASTAP... 82	rivastigmine... 37	RYBELSUS... 77
RIBASPHERE RIBAPAK... 69	rivelsa... 135	RYCLOLA... 172
ribasphere... 69	rizatriptan... 46	RYDAPT... 56
ribavirin... 69, 158	ROBAXIN... 175	RYTARY... 61
RIDAURA... 145	ROBAXIN-750... 175	RYTHMOL SR... 94
rifabutin... 47	ROBINUL FORTE... 121	RYVENT... 172
RIFADIN... 47, 48	ROBINUL... 120	<b>S</b>
RIFAMATE... 48	ROCALTROL... 149	SABRIL... 35
rifampin... 48	ROCKLATAN... 166	SAFESNAP INSULIN SYRINGE... 158
RIFATER... 48	romidepsin... 56	SAFETY PEN NEEDLE... 158
RILUTEK... 100	ropinirole... 61	SAFYRAL... 135
riluzole... 100	ropivacaine (pf)... 20	SAIZEN SAIZENPREP... 128
rimantadine... 69	rosadan... 29	SAIZEN... 127
RIMSO-50... 158	rosuvastatin... 94	SALAGEN (PILOCARPINE)... 101

SAMSCA... 116	SENSIPAR... 149	SIMBRINZA... 166
SANCUSO... 42	SENSORCAINE... 20	simliya (28)... 135
SANDIMMUNE... 145	sensorcaine-epinephrine... 20	simpesse... 135
SANDOSTATIN LAR DEPOT... 139	sensorcaine-mpf spinal... 20	SIMPONI ARIA... 146
SANDOSTATIN... 139	SENSORCAINE-MPF... 20	SIMPONI... 145
SANTYL... 109	sensorcaine-mpf/epinephrine... 20	SIMULECT... 146
SAPHRIS... 64	SEREVENT DISKUS... 172	simvastatin... 94
SARAFEM... 40	SERNIVO... 109	SINEMET CR... 61
SARCLISA... 56	SEROPHENE... 178	SINEMET... 61
SAVAYSA... 82	SEROQUEL XR... 64, 65	SINGULAIR... 172
SAVELLA... 101	SEROQUEL... 64	sirolimus... 146
SAXENDA... 180	SEROSTIM... 128	SIRTURO... 48
scopolamine base... 42	sertraline... 40	SITAVIG... 69
se-natal 19 chewable... 116	setlakin... 135	SIVEXTRO... 29
SEASONIQUE... 135	sevelamer carbonate... 116	SKELAXIN... 175
SECONAL SODIUM... 35	sevelamer hcl... 116	SKLICE... 59
SECUADO... 64	SEYSARA... 29	SKYRIZI... 146
SEEBRI NEOHALER... 172	SFROWASA... 148	SLYND... 135
SEGLUROMET... 77	sharobel... 135	SMOFLIPID... 116
SELECT-OB (FOLIC ACID)... 116	SHINGRIX (PF)... 145	sodium acetate... 116
SELECT-OB + DHA... 116	SIGNIFOR... 139	sodium benzoate-sod phenylacet... 158
SELECT-OB... 116	SIKLOS... 158	sodium bicarbonate... 116
selegiline hcl... 61	sildenafil (pulm.hypertension)... 172	sodium chloride 0.45 %... 116
selenium sulfide... 109	SILENOR... 175	sodium chloride 0.9 %... 116
SELZENTRY... 69	SILIQ... 145	sodium chloride 3 %... 116
SEMGLEE PEN U-100 INSULIN... 77	silodosin... 124	sodium chloride 5 %... 116
SEMGLEE U-100 INSULIN... 77	SILVADENE... 109	sodium chloride... 116, 158
SEMPREX-D... 158	silver sulfadiazine... 109	

SODIUM EDECRIN... 94	sotalol af... 94	STELARA... 146
sodium lactate... 116	sotalol... 94	STIMATE... 128
sodium phenylbutyrate... 123	SOTYLIZE... 94	STIOLTO RESPIMAT... 172
sodium phosphate... 116	SOVALDI... 69	STIVARGA... 56
sodium polystyrene (sorb free)... 116	SPIRIVA RESPIMAT... 172	STRATTERA... 101
sodium polystyrene sulfonate... 116, 117	SPIRIVA WITH HANDIHALER... 172	STRENSIQ... 123
SOLARAZE... 109	spironolacton-hydrochlorothiaz... 94	streptomycin... 29
solifenacin... 124	spironolactone... 94	STRIANT... 136
SOLIQUA 100/33... 77	SPORANOX PULSEPAK... 45	STRIBILD... 69
SOLODYN... 29	SPORANOX... 45	STRIVERDI RESPIMAT... 172
SOLOSEC... 29	sprintec (28)... 136	STROMECTOL... 59
soloxide... 29	SPRITAM... 35	SUBOXONE... 21
SOLTAMOX... 56	SPRIX... 18	SUBSYS... 18
SOLU-CORTEF ACT-O-VIAL (PF)... 126	SPRYCEL... 56	subvenite starter (blue) kit... 35
SOLU-CORTEF... 126	SPS (WITH SORBITOL)... 117	subvenite starter (green) kit... 35
SOLU-MEDROL (PF)... 126	sronyx... 136	subvenite starter (orange) kit... 35
SOLU-MEDROL... 126	SSD... 109	subvenite... 35
SOMA... 175	STALEVO 100... 61	SUCRAID... 123
SOMATULINE DEPOT... 139	STALEVO 125... 61	sucralfate... 121
SOMAVERT... 139	STALEVO 150... 61	SULAR... 94
SONATA... 176	STALEVO 200... 61	sulfacetamide sodium (acne)... 29
SOOLANTRA... 109	STALEVO 50... 61	sulfacetamide sodium... 29, 166
sorbitol-mannitol... 158	STALEVO 75... 61	sulfacetamide-prednisolone... 166
SORIATANE... 109	STARLIX... 77	sulfadiazine... 29
SORILUX... 109	stavudine... 69	sulfamethoxazole-trimethoprim... 29
sorine... 94	STEGLATRO... 77	SULFAMYLON... 109
	STEGLUJAN... 77	sulfasalazine... 148



SULFATRIM... 29	SYMFI LO... 69	TAKHZYRO... 146
sulindac... 18	SYMFI... 69	TALICIA... 121
sumatriptan succinate... 46, 47	SYMJEPI... 173	TALTZ AUTOINJECTOR (2 PACK)... 146
sumatriptan... 46	SYMLINPEN 120... 77	TALTZ AUTOINJECTOR (3 PACK)... 146
sumatriptan-naproxen... 47	SYMLINPEN 60... 77	TALTZ AUTOINJECTOR... 146
SUMAVEL DOSEPRO... 47	SYMPAZAN... 35	TALTZ SYRINGE... 146
SUNOSI... 176	SYMPROIC... 121	TALWIN... 18
SUPRAX... 29	SYMTUZA... 69	TALZENNA... 56
SUPREP BOWEL PREP KIT... 121	SYNAGIS... 159	TAMIFLU... 69
SURE COMFORT ALCOHOL PREP PADS... 158	SYNALAR... 109	tamoxifen... 56
SURE COMFORT INS. SYR. U-100... 158	SYNAREL... 139	tamsulosin... 124
SURE COMFORT INSULIN SYRINGE... 159	SYNDROS... 42	TAPAZOLE... 140
SURE COMFORT PEN NEEDLE... 159	SYNERA... 20	taperdex... 126
SURE-FINE PEN NEEDLES... 159	SYNERCID... 29	TARCEVA... 56
SURE-JECT INSULIN SYRINGE... 159	SYNJARDY XR... 77	TARGADOX... 30
SURE-PREP ALCOHOL PREP PADS... 159	SYNJARDY... 77	TARGRETIN... 56
SURMONTIL... 40	SYNRIBO... 56	tarina fe 1-20 eq (28)... 136
SUSTIVA... 69	SYNTHROID... 138	tarina fe 1/20 (28)... 136
SUTENT... 56	SYPRINE... 117	tarina 24 fe... 136
syeda... 136		TARKA... 94
SYLATRON... 146		TASIGNA... 56
SYLVANT... 146		TASMAR... 61
SYMBICORT... 172		TAVALISSE... 82
SYMBYAX... 40		TAXOTERE... 56
SYMDEKO... 172		TAYTULLA... 136
		tazarotene... 109
	<b>T</b>	
	TABLOID... 56	
	TABRECTA... 56	
	TACLONEX... 109	
	tacrolimus... 109, 146	
	tadalafil (pulm. hypertension)... 173	
	tadalafil... 124	
	TAFINLAR... 56	
	TAGRISSO... 56	

tazicef... 30	tenofovir disoproxil fumarate... 69	THIOLA EC... 124
TAZORAC... 109	TENORETIC 100... 95	THIOLA... 124
taztia xt... 94	TENORETIC 50... 95	thioridazine... 65
TAZVERIK... 56	TENORMIN... 95	thiotepa... 57
TDVAX... 146	TEPEZZA... 159	thiothixene... 65
TECENTRIQ... 56	terazosin... 95	THYMOGLOBULIN... 146
TECFIDERA... 101	terbinafine hcl... 45	THYROLAR-1... 138
TECHLITE INSULIN SYR HALF UNIT... 159	terbutaline... 173	THYROLAR-1/2... 138
TECHLITE INSULIN SYRINGE... 159	terconazole... 45	THYROLAR-1/4... 138
TECHLITE PEN NEEDLE... 159	TERUMO INSULIN SYRINGE... 159	THYROLAR-2... 138
TEFLARO... 30	TESSALON PERLES... 177	THYROLAR-3... 138
TEGRETOL XR... 35	TESTIM... 136	tiadylt er... 95
TEGRETOL... 35	testosterone cypionate... 136	tiagabine... 35
TEGSEDI... 123	testosterone enanthate... 136	TIAZAC... 95
TEKTURNA HCT... 94	testosterone... 136	TIBSOVO... 57
TEKTURNA... 94	TESTRED... 136	TIGAN... 42
telmisartan... 94	TETANUS,DIPHThERIA TOX PED(PF)... 146	tigecycline... 30
telmisartan-amlodipine... 95	tetrabenazine... 101	TIGLUTIK... 101
telmisartan-hydrochlorothiazid... 95	tetracycline... 30	TIKOSYN... 95
temazepam... 176	TEXACORT... 109	tilia fe... 136
TEMIXYS... 69	THALOMID... 56	timolol maleate... 95, 166
TEMODAR... 56	THAM... 117	TIMOPTIC OCUDOSE (PF)... 166
TEMOVATE... 109	THEO-24... 173	TIMOPTIC... 166
temsirolimus... 56	theophylline in dextrose 5 %... 173	TIMOPTIC-XE... 166
tencon... 18	theophylline... 173	TINDAMAX... 30
teniposide... 56	thiamine hcl (vitamin b1)... 179	tinidazole... 30
TENIVAC (PF)... 146	THINPRO INSULIN SYRINGE... 160	TIROSINT... 138
		TIROSINT-SOL... 138

TIVICAY PD... 70	toposar... 57	trazodone... 40
TIVICAY... 69, 70	topotecan... 57	TREANDA... 57
TIVORBEX... 18	TOPROL XL... 95	TRECATOR... 48
tizanidine... 65	toremifene... 57	TRELEGY ELLIPTA... 173
TOBI PODHALER... 173	TORISEL... 57	TRELSTAR... 139
TOBI... 30	torse mide... 95	TREMFYA... 146
TOBRADEX ST... 166	TOSYMRA... 47	treprostinil sodium... 173
TOBRADEX... 166	TOTECT... 57	TRESIBA FLEXTOUCH U-100... 78
tobramycin in 0.225 % nacl... 30	TOUJEO MAX U-300 SOLOSTAR... 78	TRESIBA FLEXTOUCH U-200... 78
tobramycin sulfate... 30	TOUJEO SOLOSTAR U-300 INSULIN... 78	TRESIBA U-100 INSULIN... 78
tobramycin with nebulizer... 30	tovet emollient... 110	TRETIN-X... 110
tobramycin... 166	TOVIAZ... 124	tretinoin (antineoplastic)... 57
tobramycin-dexamethasone... 166	TPN ELECTROLYTES... 117	tretinoin microspheres... 110
TOBEX... 166	TRACLEER... 173	tretinoin... 110
TOFRANIL... 40	TRADJENTA... 78	TREXALL... 146
TOLAK... 110	tramadol... 18	TREXIMET... 47
tolazamide... 78	tramadol-acetaminophen... 18	TREZIX... 18
tolbutamide... 78	trandolapril... 95	tri femynor... 136
tolcapone... 61	trandolapril-verapamil... 95	tri-estarylla... 136
tolmetin... 18	tranexamic acid... 82	tri-legest fe... 136
TOLSURA... 45	TRANSDERM-SCOP... 42	tri-linyah... 136
tolterodine... 124	TRANXENE T-TAB... 72	tri-lo-estarylla... 136
tolvaptan... 117	tranlycypromine... 40	tri-lo-marzia... 136
TOPAMAX... 35	TRAVASOL 10 %... 117	tri-lo-mili... 136
TOPCARE CLICKFINE... 160	TRAVATAN Z... 166	tri-lo-sprintec... 136
TOPCARE ULTRA COMFORT... 160	travoprost... 166	tri-mili... 136
TOPICORT... 110	TRAZIMERA... 57	TRI-NORINYL (28)... 136
topiramate... 35		tri-previfem (28)... 136

tri-sprintec (28)... 136	trinatal rx 1... 117	TRUVADA... 70
tri-vylibra lo... 136	trinessa (28)... 136	TRUXIMA... 57
tri-vylibra... 136	trinessa lo... 136	TUDORZA PRESSAIR... 173
triamcinolone acetonide... 101, 126	TRINTELLIX... 40	TUKYSA... 57
triamterene... 95	TRIOSTAT... 138	tulana... 136
triamterene-hydrochlorothiazid... 95	TRIPTODUR... 139	TURALIO... 57
trianex... 126	TRISENOX... 57	TUSSICAPS... 177
triazolam... 176	TRISTART DHA... 117	TUSSIONEX PENNKINETIC ER... 177
TRIBENZOR... 95	TRIUMEQ... 70	TUZISTRA XR... 177
TRICARE... 117	triveen-duo dha... 117	TWINRIX (PF)... 146
TRICOR... 95	trivora (28)... 136	TWYNSTA... 95
triderm... 126	TRIZIVIR... 70	TYBOST... 70
TRIDESILON... 110	TROGARZO... 70	tydemy... 137
trientine... 117	TROKENDI XR... 35	TYGACIL... 30
trifluoperazine... 65	TROPHAMINE 10 %... 117	TYKERB... 57
trifluridine... 166	TROPHAMINE 6%... 117	TYLENOL-CODEINE #3... 18
TRIGLIDE... 95	trosipium... 124	TYLENOL-CODEINE #4... 18
trihexyphenidyl... 61	TRUE COMFORT ALCOHOL PADS... 160	TYMLOS... 149
TRIJARDY XR... 78	TRUE COMFORT INSULIN SYRINGE... 160	TYPHIM VI... 146
TRIKAFTA... 173	TRUE COMFORT PEN NEEDLE... 160	TYSABRI... 101
triklo... 95	TRUEPLUS INSULIN... 160	TYVASO INSTITUTIONAL START KIT... 173
TRILEPTAL... 35	TRUEPLUS PEN NEEDLE... 160	TYVASO REFILL KIT... 173
TRILIPIX... 95	TRULANCE... 121	TYVASO STARTER KIT... 173
trilyte with flavor packets... 121	TRULICITY... 78	TYVASO... 173
trimethobenzamide... 42	TRUMENBA... 146	
trimethoprim... 30	TRUSOPT... 166	<b>U</b>
trimipramine... 40		UBRELVY... 160
		UCERIS... 148



VAQTA (PF)... 146	VERIFINE PEN NEEDLE... 162	vincristine... 57
VARIVAX (PF)... 146	VERIPRED 20... 126	vinorelbine... 57
VARIZIG... 146	VERSACLOZ... 65	VIOKACE... 123
VARUBI... 42	VERZENIO... 57	viorele (28)... 137
VASCEPA... 95, 96	VESICARE... 124	VIRACEPT... 70
VASERETIC... 96	VFEND IV... 45	VIRAMUNE XR... 70
VASOTEC... 96	VFEND... 45	VIRAMUNE... 70
VAZCULEP... 96	VIBATIV... 30	VIRAZOLE... 162
vecamyl... 96	VIBERZI... 121	VIREAD... 70
VECTIBIX... 57	VIBRAMYCIN... 30	virt-c dha... 117
VECTICAL... 110	vicodin hp... 18	virt-nate dha... 117
VELCADE... 57	vicodin... 18	VISTARIL... 174
VELETRI... 173	VICTOZA 2-PAK... 78	VISTOGARD... 58
velivet triphasic regimen (28)... 137	VICTOZA 3-PAK... 78	VITAFOL FE PLUS... 117
VELPHORO... 117	VIDAZA... 57	VITAFOL GUMMIES... 117
VELTASSA... 117	VIDEX EC... 70	VITAFOL NANO... 117
VELTIN... 110	VIDEX 2 GRAM PEDIATRIC... 70	VITAFOL ULTRA... 117
VEMLIDY... 70	VIDEX 4 GRAM PEDIATRIC... 70	VITAFOL-OB... 117
VENCLEXTA STARTING PACK... 57	VIEKIRA PAK... 70	VITAFOL-OB+DHA... 117
VENCLEXTA... 57	vienva... 137	VITAFOL-ONE... 117
venlafaxine... 40	vigabatrin... 36	VITAMED MD ONE RX... 117
VENTAVIS... 173	vigadrone... 36	vitamin d2... 179
VENTOLIN HFA... 174	VIGAMOX... 166	vitamin k... 179
verapamil... 96	VIIBRYD... 40	vitamin k1... 179
VERDESO... 110	VIMOVO... 18	VITRAKVI... 58
VEREGEN... 110	VIMPAT... 36	vivacaine... 20
VERELAN PM... 96	vinblastine... 57	VIVELLE-DOT... 137
VERELAN... 96	vincasar pfs... 57	VIVITROL... 21



VIVLODEX... 18	<b>W</b>	XEMBIFY... 147
VIZIMPRO... 58	WAKIX... 176	XENAZINE... 101
VOGELXO... 137	warfarin... 82	XENICAL... 162
volnea (28)... 137	water for irrigation, sterile... 162	XENLETA... 31
VOLTAREN... 18	WEBCOL... 162	XEPI... 110
VOLTAREN-XR... 19	WELCHOL... 96	XERAVA... 31
voriconazole... 45	WELLBUTRIN SR... 40	XERESE... 70
VOSEVI... 70	WELLBUTRIN XL... 40	XERMELO... 121
VOTRIENT... 58	wera (28)... 137	XGEVA... 149
VP-PNV-DHA... 117	WINRHO SDF... 147	XHANCE... 174
VPRIV... 123	wixela inhub... 174	XIFAXAN... 121
VRAYLAR... 65	wymzya fe... 137	XIGDUO XR... 78
vtol lq... 19	<b>X</b>	XIIDRA... 166
VUMERITY... 101	XADAGO... 61	XIMINO... 31
VUSION... 45	XALATAN... 166	XOFLUZA... 70
VYEPTI... 47	XALKORI... 58	XOLAIR... 147
vyfemla (28)... 137	XANAX XR... 72	XOLEGEL... 45
vylibra... 137	XANAX... 72	XOPENEX CONCENTRATE... 174
VYNDAMAX... 123	XARELTO DVT-PE TREAT 30D START... 82	XOPENEX HFA... 174
VYNDAQEL... 123	XARELTO... 82	XOPENEX... 174
VYONDYS-53... 123	XATMEP... 147	XOSPATA... 58
VYTORIN 10-10... 96	XCOPRI MAINTENANCE PACK... 36	XPOVIO... 58
VYTORIN 10-20... 96	XCOPRI TITRATION PACK... 36	XTAMPZA ER... 19
VYTORIN 10-40... 96	XCOPRI... 36	XTANDI... 58
VYTORIN 10-80... 96	XELJANZ XR... 147	xulane... 137
VYVANSE... 101	XELJANZ... 147	XULTOPHY 100/3.6... 78
VYXEOS... 58	XELPROS... 166	XURIDEN... 123
VYZULTA... 166		XYOSTED... 137

XYREM... 176

**Y**

YASMIN (28)... 137

YAZ (28)... 137

YERVOY... 58

YF-VAX (PF)... 147

YONDELIS... 58

YONSA... 58

YOSPRALA... 82

YUPELRI... 174

yuvafem... 137

**Z**

zafirlukast... 174

zaleplon... 176

ZALTRAP... 58

ZANAFLEX... 65

ZANOSAR... 58

zarah... 137

ZARONTIN... 36

ZARXIO... 82

zatean-pn dha... 179

zatean-pn plus... 179

ZAVESCA... 123

ZCORT... 127

ZEBUTAL... 19

ZEGERID... 121

ZEJULA... 58

ZELAPAR... 61

ZELBORAF... 58

ZELNORM... 121

ZEMAIRA... 123

ZEMBRACE SYMTOUCH... 47

ZEMDRI... 31

ZEMPLAR... 149

zenatane... 110

ZENPEP... 123

zenzedi... 101

ZEPATIER... 70

ZEPZELCA... 58

ZERBAXA... 31

ZERIT... 70

ZERVIATE... 166

ZESTORETIC... 96

ZESTRIL... 96

ZETIA... 96

ZETONNA... 174

ZIAC... 96

ZIAGEN... 70, 71

ZIANA... 110

zidovudine... 71

ZIEXTENZO... 82

zileuton... 174

ZILRETTA... 127

ZILXI... 110

ZINECARD (AS HCL)... 58

zingiber... 179

ZINPLAVA... 121

ZIOPTAN (PF)... 166

ziprasidone hcl... 65

ziprasidone mesylate... 65

ZIPSOR... 19

ZIRABEV... 58

ZIRGAN... 71

ZITHROMAX TRI-PAK... 31

ZITHROMAX Z-PAK... 31

ZITHROMAX... 31

ZOCOR... 96

ZOFRAN ODT... 42

ZOFRAN... 42

ZOHYDRO ER... 19

ZOLADEX... 139

zoledronic ac-mannitol-0.9nacl...  
149

zoledronic acid... 149, 150

zoledronic acid-mannitol-water...  
150

ZOLINZA... 58

zolmitriptan... 47

ZOLOFT... 40

zolpidem... 176

ZOLPIMIST... 176

ZOMACTON... 128

ZOMETA... 150

ZOMIG ZMT... 47

ZOMIG... 47	ZYPITAMAG... 96
ZONALON... 110	ZYPREXA RELPREV... 65
ZONEGRAN... 36	ZYPREXA ZYDIS... 65
zonisamide... 36	ZYPREXA... 65
ZONTIVITY... 82	ZYTIGA... 58
ZORBTIVE... 128	ZYVOX... 31
ZORTRESS... 147	1ST TIER UNIFINE PENTIPS PLUS... 150
ZORVOLEX... 19	1ST TIER UNIFINE PENTIPS... 150
ZOSTAVAX (PF)... 147	
ZOSYN IN DEXTROSE (ISO-OSM)... 31	
ZOSYN... 31	
zovia 1/35e (28)... 137	
ZOVIRAX... 71	
ZTLIDO... 20	
ZUBSOLV... 21	
ZULRESSO... 40	
zumandimine (28)... 137	
ZUPLENZ... 42	
ZURAMPIC... 45	
ZYBAN... 21	
ZYCLARA... 110	
ZYDELIG... 58	
ZYFLO CR... 174	
ZYFLO... 174	
ZYKADIA... 58	
ZYLET... 167	
ZYLOPRIM... 45	
ZYMAXID... 167	

## Important!

### At Humana, it is important you are treated fairly.

Humana Inc. and its subsidiaries do not discriminate or exclude people because of their race, color, national origin, age, disability, sex, sexual orientation, gender identity, or religion. Discrimination is against the law. Humana and its subsidiaries comply with applicable Federal Civil Rights laws. If you believe that you have been discriminated against by Humana or its subsidiaries, there are ways to get help.

- You may file a complaint, also known as a grievance:  
Discrimination Grievances, P.O. Box 14618, Lexington, KY 40512-4618  
If you need help filing a grievance, call **1-866-396-8810** or if you use a **TTY**, call **711**.
- You can also file a civil rights complaint with the **U.S. Department of Health and Human Services**, Office for Civil Rights electronically through the Office for Civil Rights Complaint Portal, available at <https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>, or by mail or phone at **U.S. Department of Health and Human Services**, 200 Independence Avenue, SW, Room 509F, HHH Building, Washington, DC 20201, **1-800-368-1019, 800-537-7697 (TDD)**.

Complaint forms are available at <https://www.hhs.gov/ocr/office/file/index.html>.

### Auxiliary aids and services, free of charge, are available to you.

1-866-396-8810 (TTY: 711)

Humana provides free auxiliary aids and services, such as qualified sign language interpreters, video remote interpretation, and written information in other formats to people with disabilities when such auxiliary aids and services are necessary to ensure an equal opportunity to participate.

### Language assistance services, free of charge, are available to you.

1-866-396-8810 (TTY: 711)

**Español (Spanish):** Llame al número arriba indicado para recibir servicios gratuitos de asistencia lingüística.

**繁體中文 (Chinese):** 撥打上面的電話號碼即可獲得免費語言援助服務。

**Tiếng Việt (Vietnamese):** Xin gọi số điện thoại trên đây để nhận được các dịch vụ hỗ trợ ngôn ngữ miễn phí.

**한국어 (Korean):** 무료 언어 지원 서비스를 받으려면 위의 번호로 전화하십시오.

**Tagalog (Tagalog – Filipino):** Tawagan ang numero sa itaas upang makatanggap ng mga serbisyo ng tulong sa wika nang walang bayad.

**Русский (Russian):** Позвоните по номеру, указанному выше, чтобы получить бесплатные услуги перевода.

**Kreyòl Ayisyen (French Creole):** Rele nimewo ki pi wo la a, pou resevwa sèvis èd pou lang ki gratis.

**Français (French):** Appelez le numéro ci-dessus pour recevoir gratuitement des services d'aide linguistique.

**Polski (Polish):** Aby skorzystać z bezpłatnej pomocy językowej, proszę zadzwonić pod wyżej podany numer.

**Português (Portuguese):** Ligue para o número acima indicado para receber serviços linguísticos, grátis.

**Italiano (Italian):** Chiamare il numero sopra per ricevere servizi di assistenza linguistica gratuiti.

**Deutsch (German):** Wählen Sie die oben angegebene Nummer, um kostenlose sprachliche Hilfsdienstleistungen zu erhalten.

**日本語 (Japanese):** 無料の言語支援サービスをご要望の場合は、上記の番号までお電話ください。

**فارسی (Farsi)**

برای دریافت تسهیلات زبانی بصورت رایگان با شماره فوق تماس بگیرید.

**Diné Bizaad (Navajo):** Wóda hí béesh bee hani'í bee wolta'ígíí bich'í' hódíílnih éí bee t'áá jiik'eh saad bee áká'ánída'áwo'déé nika'adoowoł.


**العربية (Arabic)**

الرجاء الاتصال بالرقم المبين أعلاه للحصول على خدمات مجانية للمساعدة بلغتك





This formulary was updated on 09/18/2020. For more recent information or other questions, please contact the NC State Health Plan Humana Customer Care Team at 1-888-700-2263 or, for TTY users, 711, or visit [our.humana.com/ncshp](https://our.humana.com/ncshp).



*Dale R. Folwell, CPA*  
STATE TREASURER OF NORTH CAROLINA  
DALE R. FOLWELL, CPA